final programme - EANM 2021 - European Association of ...

FINALPROGRAMME

FI

NA

L P

RO

GR

AM

ME

| T

AB

LE

OF

CO

NT

EN

TE A N M ’21 W O R L D L E A D I N G M E E T I N G

O C T O B E R 2 0 - 2 3 , 2 0 2 1W O R L D L E A D I N G M E E T I N G E A N M ’21

O C T O B E R 2 0 - 2 3 , 2 0 2 1

TA

BL

E O

F C

ON

TE

NT

| FI

NA

L P

RO

GR

AM

ME

32

TABLE OFCONTENTSWELCOME WORDS 4

GENERAL INFORMATION » Board & SP Council 6 » SPC & Session Coordinators 7 » EANM‘21 Reviewers 8 » EANM‘21 Chairpersons 15 » EANM National Societies: Delegates / Deputies 18 » UEMS/EBNM National Societies: Delegates / Deputies 20 » UEMS/EBNM committees 22 » General Information 24 » Committee Interest Group Meetings during EANM’21 26

SCIENTIFIC & TECHNOLOGISTS‘ PROGRAMME » Plenary Sessions 28 » Pre-Congress Symposia 30 » Continuing Medical Education/CME Sessions 32 » Technologists‘ Track 34 » Joint Symposia 36 » Pitfalls & Artefacts Sessions 38 » Teaching Sessions 39 » Special Track 40 » Cutting Edge Science Track 42 » M2M - The 8th “From Molecule to Man” Track 44 » Clinical Oncology Track 45 » Further Oral Presentations 46 » e-Poster Presentations 47 » e-Poster sessions 48 » Programme Overview 52

PRE-CONGRESS SYMPOSIA 60

ORAL PRESENTATIONS 67

E-POSTER PRESENTATIONS 166

E-POSTER SESSIONS 193

INDUSTRY PROGRAMME » Satellite Symposia 215 » Exhibitors & Sponsors 222 » List of Society Booths 223 » Company Profiles 224

USEFUL CONTACTS 258

FI

NA

L P

RO

GR

AM

ME

| L

ET

TE

R O

F I

NV

ITA

TIO

NE A N M ’21 W O R L D L E A D I N G M E E T I N G


O C T O B E R 2 0 - 2 3 , 2 0 2 1

LE

TT

ER

OF

INV

ITA

TIO

N | F

IN

AL

PR

OG

RA

MM

E

54

WELCOMEWORDS

Dear Colleagues, dear Friends,On behalf of the European Association of Nuclear Medicine, it is my honour to invite you to the 34th Annual EANM Congress.The event will run virtually from 20 to 23 October 2021.

Despite the difficult time we are experiencing due to the pandemic, nuclear medicine continues to grow both in diagnostic imaging and therapy. New radiopharmaceuticals which facilitate the study and treatment of new targets are being introduced, more and more protocols which cover unmet clinical needs and new applications are running, and the use of nuclear medicine procedures is increasingly being incorporated into clinical practice and guidelines. This success remains related to that very peculiar characteristic of our specialty, namely, its functional approach to medicine. This is mainly true with respect to imaging, but also for therapy.

In recent years we have proudly celebrated the status of the EANM Congress as the world’s leading meeting for nuclear medicine. In 2019, for example, we reached almost 7000 participants, a truly memorable record. As we all know, the pandemic of 2020 forced all events to move to a virtual format and we did our best to prepare a great event. We succeeded in keeping all of our scientific programmes running with 11 parallel channels and received excellent

feedback from participants. As mentioned, we are unable to return to the live format we are used to and would have all hoped for in 2021. Therefore, we have planned a great event with a full scientific programme once more, but have arranged some significant improvements after the lessons learnt last year. In 2021, pre-congress symposia will run a couple of weeks before the congress, which, as a result, has been shortened by one day. Furthermore, most of the several parallel tracks will not run according to the traditional time sequence but will always be available on demand to facilitate access and productivity for attendees.

In summary, we are working on providing you a congress with superb and comprehensive scientific content as well as a lot of other features to make your participation enjoyable whatever you are looking to achieve.

Stefano Fanti

EANM Congress Chair 2020–2022

STEFANO FANTI

C O N G R E S S C H A I R 2 0 2 0 - 2 0 2 2

BY THE CONGRESS CHAIR

E A N M ’21 W O R L D L E A D I N G M E E T I N GO C T O B E R 2 0 - 2 3 , 2 0 2 1

W O R L D L E A D I N G M E E T I N G E A N M ’21O C T O B E R 2 0 - 2 3 , 2 0 2 1

76

EA

NM

| FI

NA

L P

RO

GR

AM

ME

F

IN

AL

PR

OG

RA

MM

E |

EA

NM

BOARD & SPCOUNCIL

EANM BOARD

President 2021 – 2022 Jolanta Kunikowska (Poland)

President Elect 2021 – 2022 Rudi A.J.O. Dierckx (Netherlands)

Committee Coordinator 2021 – 2022 Roland Hustinx (Belgium)

Congress Chair 2020 – 2022 Stefano Fanti (Italy)

Education Chair 2020 – 2022 Paola A. Erba (Italy)

Secretary/Treasurer 2021 – 2022 Wolfgang Wadsak (Austria)

Scientific Liaison Officer 2021 – 2022 Michael Lassmann (Germany)

SCIENTIFIC PROGRAMME COUNCIL

EANM thanks all Scientific Programme Council Members for their great effort in composing the EANM’21 Virtual Sessions. Congress Chair Stefano Fanti (Italy)

Bone & Joint Committee Salvatore Annunziata (Italy), Tim Van den Wyngaert (Belgium)

Cardiovascular Committee Fabien Hyafil (France), Hein J. Verberne (Netherlands)

Dosimetry Committee Uta Eberlein (Germany), Erik Verburg (Netherlands)

Drug Development Committee Johnny Vercouillie (France), Graham Smith (United Kingdom)

Inflammation & Infection Committee Giorgio Treglia (Switzerland), Andor Glaudemans (Netherlands)

Neuroimaging Committee Henryk Barthel (Germany), Silvia Morbelli (Italy)

Oncology & Theranostics Committee Ken Hermann (Germany), Nicolas Aide (France)

Paediatrics Committee Pinar Kiratli (Turkey), Pietro Zucchetta (Italy)

Physics Committee John Dickson (United Kingdom), Dimitris Visvikis (France)

Radiation Protection Committee Lídia Cunha (Portugal), François Jamar (Belgium)

Radiopharmacy Committee Peter Laverman (Netherlands), Filippo Lodi (Italy)

Technologist Committee Andrea Santos (Portugal), Luca Camoni (Italy)

Thyroid Committee Alfredo Campennì (Italy), Alexis Vrachimis (Cyprus)

Translational Molecular Imaging & Therapy Committee Fijs van Leeuwen (Netherlands), Margret Schottelius (Switzerland)

Aerts, A. (Belgium)

Aide, N. (France)

Albert, N. (Germany)

Aloj, L. (United Kingdom)

Annunziata, S. (Italy)

Attard, M. (Netherlands)

Bacher, K. (Belgium)

Balogová, S. (Slovakia)

Bar Sever, Z. (Israel)

Barthelb, H. (Germany)

Beheshti, M. (Austria)

Brendel, M. (Germany)

Burger, I. (Switzerland)

Camoni, L. (Italy)

Campenni, A. (Italy)

Cecchin, D. (Italy)

Cicone, F. (Italy)

Cunha, L. (Portugal)

de Geus-Oei, L. (Netherlands)

Deandreis, D. (Italy)

Decristoforo, C. (Austria)

Denis-Bacelar, A. (United Kingdom)

Deuther-Conrad, W. (Germany)

Dickson, J. (United Kingdom)

Eberlein, U. (Germany)

Evangelista, L. (Italy)

Fanti, S. (Italy)

Farolfi, A. (Italy)

Geliashvili, T. (Russia)

Glatting, G. (Germany)

Gnanasegaran, G. (United Kingdom)

Goffin, K. (Belgium)

Hatt, M. (France)

Herrmann, K. (Germany)

Jamar, F. (Belgium)

Kobe, C. (Germany)

Konijnenberg, M. (Netherlands)

Koole, M. (Belgium)

Kráčmerová, T. (Czech Republic)

Kreissl, M. C. (Germany)

Lairez, O. (France)

Lauri, C. (Italy)

Leccisotti, L. (Italy)

Lodi, F. (Italy)

Lopci, E. (Italy)

Lubberink, M. (Sweden)

Luporsi, M. (France)

Morbelli, S. (Italy)

Nanni, C. (Italy)

Nappi, C. (Italy)

Noriega-Álvarez, E. (Spain)

Palmedo, H. (Germany)

Pietrzak, A. (Poland)

Rahbar, K. (Germany)

Rbah-Vidal, L. (France)

Rischpler, C. (Germany)

Santos, A. (Portugal)

Saraste, A. (Finland)

Schottelius, M. (Switzerland)

Scott, A. (Australia)

Seimbille, Y. (Netherlands)

Semah, F. (France)

Shi, K. (Switzerland)

Strand Olsen, R. (Denmark)

Taïeb, D. (France)

Terwinghe, C. (Belgium)

Treglia, G. (Switzerland)

van Berckel, B. (Netherlands)

Van den Wyngaert, T. (Belgium)

Verberne, H. (Netherlands)

Visvikis, D. (France)

SESSION COORDINATORS

EANM thanks all Session Coordinators for their huge engagement in organizing the session details and speakers.

SPC & SESSIONCO ORDINATORS

FI

NA

L P

RO

GR

AM

ME

| E

AN

M R

EV

IEW

ER

SE A N M ’21 W O R L D L E A D I N G M E E T I N G


O C T O B E R 2 0 - 2 3 , 2 0 2 1

EA

NM

RE

VIE

WE

RS

| FI

NA

L P

RO

GR

AM

ME

98

EANM’ 21 REVIEWERS

Abbott, B. (United States of America)

Abgral, R. (France)

Acampa, W. (Italy)

Ahmadzadehfar, H. (Germany)

Ak Sivrikoz, I. (Turkey)

Aktolun, C. (Turkey)

Aloj, L. (United Kingdom)

Altini, C. (Italy)

Ambrosini, V. (Italy)

Ametamey, S.M. (Switzerland)

Annunziata, S. (Italy)

Antunovic, L. (Italy)

Artigas, C. (Belgium)

Asenbaum-Nan, S. (Austria)

Atay Kapucu, L.Ö. (Turkey)

Attard, M.C. (Netherlands)

Baldari, S. (Italy)

Balkay, L. (Hungary)

Ballinger, J. (Canada)

Balogova, S. (Slovakia)

Barbet, J. (France)

Bar-Sever, Z. (Israel)

Barthel, H. (Germany)

Bauckneht, M. (Italy)

Beer, A. (Germany)

Behe, M. (Switzerland)

Beheshti, M. (Austria)

Ben-Haim, S. (Israel)

Bergstroem, K. (Finland)

Bernsen, M. (Netherlands)

Bianchi, A. (Italy)

Biassoni, L. (United Kingdom)

Bilgin, B.E. (Turkey)

Bogovic Crncic, T. (Croatia)

Bolch, W. (United States of America)

Booij, J. (Netherlands)

Borbely, K. (Hungary)

Botelho, M.F. R. R. (Portugal)

Bozkurt, M.F. (Turkey)

Brendel, M. (Germany)

Brenner, W. (Germany)

Brian, D. (United Kingdom)

Brouwers, A. (Netherlands)

Bucerius, J. (Germany)

Buchert, R. (Germany)

Buckle, T. (Netherlands)

Burak, Z.E. (Turkey)

Burroni, L. (Italy)

Cai, W. (United States of America)

Camoni, L. (Italy)

Campenni’, A. (Italy)

Cantinho-Lopes, M.G. (Portugal)

Carrilho Vaz, S. (Portugal)

Carrio, I. (Spain)

Castell Conesa, J. (Spain)

Castellucci, P. (Italy)

Cawthorne, C. (Belgium)

Cecchin, D. (Italy)

Ceci, F. (Italy)

Cermik, T.F. (Turkey)

Chakravartty, R. (United Kingdom)

Chiesa, C. (Italy)

Chiti, A. (Italy)

Ciappuccini, R. (France)

Cicone, F. (Italy)

Cook, G.J.R. (United Kingdom)

Cornelissen, B. (United Kingdom)

Costa, G. (Portugal)

Cremonesi, M. (Italy)

Cuocolo, A. (Italy)

Curran, D. (Ireland)

Da Pieve, C. (United Kingdom)

Dalm, S. (Netherlands)

De Bondt, P. (Belgium)

De Geus-Oei, L.-F. (Netherlands)

de Keizer, B. (Netherlands)

De Palma, D. (Italy)

De Swart, J. (Netherlands)

Deandreis, D. (Italy)

Decristoforo, C. (Austria)

Delgado Bolton, R.C. (Spain)

Denis-Bacelar, A. (United Kingdom)

Derlin, T. (Germany)

Deuther-Conrad, W. (Germany)

Dickson, J. (United Kingdom)

Dierickx, L. (France)

Drzezga, A. (Germany)

Duatti, A. (Italy)

Dziuk, M. (Poland)

Eberlein, U. (Germany)

Ekmekcioglu, O. (Turkey)

Ertay, T. (Turkey)

Etchebehere, E. (Brazil)

Evangelista, L. (Italy)

Fani, M. (Switzerland)

Farolfi, A. (Italy)

Farsad, M. (Italy)

Fendler, W. (Germany)

Fernández León, A. (Spain)

Fischer, B. (Denmark)

Flamen, P. (Belgium)

Flotats, A. (Spain)

Flux, G. (United Kingdom)

Forrer, F. (Switzerland)

Fragoso Costa, P. (Germany)

Franceschi, M. (Croatia)

Frangos, S. (Cyprus)

Franzius, C. (Germany)

Gaberscek, S. (Slovenia)

Gabriel, M. (Austria)

Gafita, A. (United States of America)

Gallowitsch, H.-J. (Austria)

FI

NA

L P

RO

GR

AM

ME

| E

AN

M R

EV

IEW

ER



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EA

NM

RE

VIE

WE

RS

| FI

NA

L P

RO

GR

AM

ME

1110

Georgoulias, P. (Greece)

Gheysens, O. (Belgium)

Giammarile, F. (Austria)

Gillings, N. (Denmark)

Gimelli, A. (Italy)

Girotto, N. (Croatia)

Glatting, G. (Germany)

Glaudemans, A. (Netherlands)

Gnanasegaran, G. (United Kingdom)

Goffin, K. (Belgium)

Graf, S. (Austria)

Graham, R. (United Kingdom)

Grana, C.M. (Italy)

Gratz, S. (Germany)

Grimm, J. (United States of America)

Grötzinger, C. (Germany)

Guedj, E. (France)

Guillet, B. (France)

Gulliver, N. (United Kingdom)

Haberkorn, U. (Germany)

Handkiewicz-Junak, D. (Poland)

Hatt, M. (France)

Heijmen, L. (Netherlands)

Hendrikse, H. (Netherlands)

Herholz, K. (United Kingdom)

Herrmann, K. (Germany)

Heskamp, S. (Netherlands)

Hesse, S. (Germany)

Hicks, R. (Australia)

Hindorf, C. (Sweden)

Hofman, M. (Australia)

Holm, S. (Denmark)

Howell, R. (United States of America)

Hubalewska-Dydejczyk, A. (Poland)

Hutton, B.F. (United Kingdom)

Hyafil, F. (France)

Iagaru, A. (United States of America)

Iakovou, I. (Greece)

Jamar, F. (Belgium)

Jarzab, B. (Poland)

Jehanno, N. (France)

Kaya, G.C. (Turkey)

Kedves, A. (Hungary)

Kirac, S.F. (Turkey)

Kirienko, M. (Italy)

Kirjavainen, A. (Finland)

Klett, R. (Germany)

Kobe, C. (Germany)

Kolenc, P. (Slovenia)

Konijnenberg, M. (Netherlands)

Koranda, P. (Czech Republic)

Kostadinova, I.D. (Bulgaria)

Kostkiewicz, M.A. (Poland)

Kotzerke, J. (Germany)

Koutsikos, J. (Greece)

Kracmerova, T. (Czech Republic)

Kraeber-Bodéré, F. (France)

Kramer, S. (Switzerland)

Krause, B.J. (Germany)

Kreissl, M.C. (Germany)

Kresnik, E. (Austria)

Kucuk, N.O. (Turkey)

Kurch, L. (Germany)

Kurth, J. (Germany)

Kuwert, T. (Germany)

Lairez, O. (France)

Lammertsma, A.A. (Netherlands)

Langbein, T. (Germany)

Langsteger, W. (Austria)

Lasnon, C. (France)

Lauri, C. (Italy)

Laverman, P. (Netherlands)

Leccisotti, L. (Italy)

Lemos Pereira, E.A. (Portugal)

Lewington, V. (United Kingdom)

Lodi, F. (Italy)

Lopci, E. (Italy)

Lubberink, M. (Sweden)

Luporsi, M. (France)

Lütje, S. (Germany)

Mada, M. (United Kingdom)

Maes, A. (Belgium)

Maina-Nock, T. (Greece)

Maldonado, A. (Spain)

Manevska, N. (North Macedonia)

Mansi, L. (Italy)

Mapelli, P. (Italy)

Marcassa, C. (Italy)

Marie, P.-Y. (France)

Massalha, S. (Israel)

Mihailovic, J. (Serbia)

Milan, E. (Italy)

Mindt, T.L. (Switzerland)

Minguez Gabiña, P. (Spain)

Minn, H. (Finland)

Mitjavila Casanovas, M. (Spain)

Monteiro, M. (Switzerland)

Morbelli, S. (Italy)

Mottaghy, F.M. (Germany)

Mu, L. (Switzerland)

Nagren, K.A. (Denmark)

Nanni, C. (Italy)

Neels, O. (Germany)

Neglia, D. (Italy)

Niculae, D. (Romania)

Nobili, F.M. (Italy)

Nock, B.A. (Greece)

Nonnekens, J. (Netherlands)

Noriega-Álvarez, E. (Spain)

Olianti, C. (Italy)

Olsen, R. (Denmark)

Oprea-Lager, D.-E. (Netherlands)


FI

NA

L P

RO

GR

AM

ME

| E

AN

M R

EV

IEW

ER



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EA

NM

RE

VIE

WE

RS

| FI

NA

L P

RO

GR

AM

ME

1312

Orlhac, F. (France)

Orlova, A. (Sweden)

Orrù, M.T. (Italy)

Özcan, Z. (Turkey)

Ozgen Kiratli, P. (Turkey)

Paganelli, G. (Italy)

Pagani, M. (Italy)

Palmedo, H. (Germany)

Panagiotidis, E. (Greece)

Papathanasiou, N. (Greece)

Pappata, S. (Italy)

Pascual, T. (Philippines)

Patt, M. (Germany)

Paycha, F. (France)

Payoux, P. (France)

Penuelas, I. (Spain)

Pestean, I.C. (Romania)

Petranovic Ovcaricek, P. (Croatia)

Piciu, D. (Romania)

Pietrzak, A. (Poland)

Pilkington, P. (Spain)

Pirich, C. (Austria)

Poeppel, T. (Germany)

Pruim, J. (Netherlands)

Raavé, R. (Netherlands)

Rabiner, I. (United Kingdom)

Rac, S. (Croatia)

Rajkovaca, Z. (Bosnia and Herzegovina)

Rbah-Vidal, L. (France)

Redondo, F. (Chile)

Resende Geao, A.C. (Portugal)

Rijpkema, M. (Netherlands)

Rischpler, C. (Germany)

Rodríguez-Fraile, M. (Spain)

Roivainen, A.M. (Finland)

Roland, J. (Belgium)

Rominger, A. (Switzerland)

Rossetti, C. (Italy)

Rubí, S. (Spain)

Salaun, P.-Y. (France)

Santos, A.I. (Portugal)

Santos, A. (Portugal)

Saraste, A. (Finland)

Sattler, B. (Germany)

Saxtoft, E.S. (Denmark)

Schäfers, M.A. (Germany)

Schibli, R. (Switzerland)

Schildan, A. (Germany)

Schmidt, E. (Hungary)

Schmidt, M.C. (Germany)

Schwarzenböck, S.M. (Germany)

Sciagra, R. (Italy)

Seimbille, Y. (Netherlands)

Sera, T. (Hungary)

Sestini, S. (Italy)

Shi, K. (Switzerland)

Siclari, G. (Italy)

Signore, A. (Italy)

Slart, R.H.J.A. (Netherlands)

Smith, G. (United Kingdom)

Solbach, C. (Germany)

Sollini, M. (Italy)

Stefanescu, C. (Romania)

Stevens, H. (Netherlands)

Stokke, C. (Norway)

Strobel, K. (Switzerland)

Strömvall, A. (Sweden)

Sunderland, J. (United States of America)

Talbot, J.-N. (France)

Teras, M. (Finland)

Terry, S. (United Kingdom)

Terwinghe, C. (Belgium)

Testanera, G. (United Kingdom)

Todde, S.C. (Italy)

Tolmachev, V. (Sweden)

Treglia, G. (Switzerland)

Treves, T. (United States of America)

Tuncel, M. (Turkey)

Ugrinska, A. (North Macedonia)

Vaccaro, I. (Italy)

Van Dongen, G. A.M.S. (Netherlands)

van Essen, M. (Sweden)

van Lith, S. (Netherlands)

Van Velden, F. (Netherlands)

Van Weehaeghe, D. (Belgium)

Vandenberghe, S. (Belgium)

Vanhove, C. (Belgium)

Varmenot, N. (France)

Veit-Haibach, P. (Canada)

Verberne, H.J. (Netherlands)

Verburg, F. (Netherlands)

Versari, A. (Italy)

Verzijlbergen, F. (Netherlands)

Vidal-Sicart, S. (Spain)

Violante, L. (Portugal)

Vlajkovic, M. (Serbia)

Vrachimis, A. (Cyprus)

Vriens, D. (Netherlands)

Walz, J. (France)

Weber, W. (Germany)

Weiler-Sagie, M. (Israel)

Welch, A. (United Kingdom)

Windhorst, A.D. (Netherlands)

Xavier, C. (Belgium)

Zaletel, K. (Slovenia)

Zambo, K. (Hungary)

Zerizer, I. (United Kingdom)

Zhang-Yin, J. (Belgium)

Zimmer, L. (France)


FI

NA

L P

RO

GR

AM

ME

| C

HA

IRP

ER

SO

NS



1514

CH

AIR

PE

RS

ON

S | F

IN

AL

PR

OG

RA

MM

E

EANM’ 21 CHAIRPERSONS

Adam, J. (Amsterdam)

Aide, N. (Caen)

Al Ibraheem, A. (Amman)

Albert, N. (Munich)

Alessi, A. (Milan)

Aloj, L. (Cambridge)

Armstrong, I. (Manchester)

Attard, MC. (Zwolle)

Balogová, S. (Bratislava)

Bar-Sever, Z. (Petach Tikva)

Barrington, S. (London)

Barthel, H. (Leipzig)

Bauckneht, M. (Genoa)

Beer, A. (Ulm)

Behe, M. (Villigen)

Benesova, M. (Heidelberg)

Boellaard, R. (Amsterdam)

Brendel, M. (Munich)

Camoni, L. (Brescia)

Campenni’, A. (Messina)

Caobelli, F. (Basel)

Castellucci, P. (Bologna)

Cecchin, D. (Padua)

Ceci, F. (Turin)

Cerci, J. (Curitiba)

Cheze Le Rest, C. (Poitiers)

Chiesa, C. (Milan)

Cicone, F. (Catanzaro)

Cleeren, F. (Leuven)

Cunha, L. (Azores)

D’Alessandria, C. (Munich)

De Geus-Oei, L. F. (Leiden)

Deandreis, D. (Turin)

Denis-Bacelar, A. (Teddington)

Deroose, C. (Leuven)

Deuther-Conrad , W. (Leipzig)

Dickson, J. (London)

Eberlein, U. (Würzburg)

Eder, A.C. (Freiburg)

Eiber, M. (Munich)

Ekmekcioglu, O. (Istanbul)

Evangelista, L. (Padua)

Farolfi, A. (Bologna)

Fendler, W. (Essen)

Flux, G. (Sutton)

Garrigue, P. (Marseille)

Gear, J. (London)

Geliashvili, T. (Moscow)

Gheysens, O. (Brussels)

Glatting, G. (Ulm)

Glaudemans, A. W.J.M. (Groningen)

Goffin, K. (Leuven)

Gosewisch, A. (Munich)

Guedj, E. (Marseille)

Guillet, B. (Marseille)

Hartenbach, M. (Vienna)

Hatt, M. (Brest)

Herrmann, K. (Essen)

Heskamp, S. (Nijmegen)

Hindie, E. (Pessac)

Holm, S. (Copenhagen)

Hyafil, F. (Paris)

Israel, O. (Haifa)

Jamar, F. (Brussels)

EANM thanks all reviewers for their invaluable commitment.

Course Programme 2022

Registration for 2022 will open during the EANM 2021 Congress.

Do not forget to visit the ESMIT Booth!

new Online Courses

new Live Webinars4 new

Advanced Courses in Vienna715

Our 2022 programme will include:

In order to make it easier for our community to make the most of their Continuous Medical Education, ESMIT is expanding its

educational o�ers.

… organised in 5 Thematic Tracks:Artificial

Intelligence and Quantification

Clinical Nuclear Medicine Scientific Track Theranostics

Cardiac Amyloidosis.

(EURO-LEARN)


16

FI

NA

L P

RO

GR

AM

ME

| C

HA

IRP

ER

SO

NS

Jonca, B. (Paris)

Kappadath, S. C. (Houston)

Kedves, A. (Kaposvár)

Kobe, C. (Cologne)

Konijnenberg, M. (Rotterdam)

Koole, M. (Leuven)

Kreissl, M. (Magdeburg)

Kunikowska, J. (Warsaw)

Lapa, C. (Augsburg)

Lauri, C. (Rome)

Laverman, P. (Nijmegen)

Lodi, F. (Bologna)

Lopci, E. (Milan)

Lubberink, M. (Uppsala)

Luporsi, M. (Paris)

Luurtsema, G. (Groningen)

Lynch, T. (Belfast)

Massalha, S. (Haifa)

Masukawa, M. (Curitiba)

Minguez Gabiña, P. (Barakaldo)

Morbelli, S. (Genoa)

Mottaghy, F. (Aachen)

Nanni, C. (Bologna)

Nappi, C. (Naples)

Neels, O. (Dresden)

Nekolla, S. G. (Munich)

Noriega-Álvarez, E. (Ciudad Real)

Olianti, C. (Florence)

Oprea-Lager, D. (Amsterdam)

Oyen, W. J. G. (Arnhem)

Palmedo, H. (Bonn)

Panagiotidis, E. (Thessalonik)

Payoux, P. (Toulouse)

Petranović Ovčariček, P. (Zagreb)

Pietrzak, A. (Poznan)

Rbah-Vidal, L. (Nantes)

Rep, S. (Ljubljana)

Reyes-Torres, E. (London)

Rischpler, C. (Essen)

Santos, A. I. (Almada)

Santos, A. (Lisbon)

Saraste, A. (Turku)

Schaarschmidt, B. (Düsseldorf )

Scheidhauer, K. (Munich)

Schottelius, M. (Lausanne)

Schwarzenböck, S. (Rostock)

Seimbille, Y. (Rotterdam)

Shi, K. (Bern)

Smith, A. L. (London)

Sollini, M. (Milan)

Sosabowski, J. (London)

Strand Olsen, R. (Copenhagen)

Strömvall, . L. (Umeå )

Terry, S. (London)

Terwinghe, C. (Leuven)

Tran-Gia, J. (Würzburg)

Traub-Weidinger, T. (Vienna)

Treglia, G. (Bellinzona)

van Berckel, B. (Amsterdam)

Van den Wyngaert, T. (Antwerp)

Vanhove, C. (Ghent)

Verberne, H. J. (Amsterdam)

Verzijlbergen, F. (Nijmegen)

Villar del Moral, J. M. (Granada)

Visvikis, D. (Brest)

Vrachimis, A. (Limassol)

Zacho, H. (Aalborg)

EANM’ 21 CHAIRPERSONS

360°SIZES 16/64

2m

Total Body SPECTTotal Body CT

Total Body SPECT/CT

FI

NA

L P

RO

GR

AM

ME

| E

AN

M N

AT

ION

AL

SO

CIE

TIE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EA

NM

NA

TIO

NA

L S

OC

IET

IES

| FI

NA

L P

RO

GR

AM

ME

1918

EANM NATIONAL SOCIETIES:DELEGATES / DEPUTIES

SOCIETY DELEGATE DEPUTY

Irish Nuclear Medicine Association M. O’Connell R. Killeen

Israeli Society of Nuclear Medicine Z. Bar-Sever Z. Keidar

Italian Society of Nuclear Medicine R. Giubbini M.L. DeRimini

Latvian Society of Nuclear Medicine M. Kalnina J. Kedrova

Lithuanian Society of Nuclear Medicine S. Sediene D. Vajauskas

Luxembourg Society of Nuclear Medicine C. Als J. Zhang-Yin

Maltese Association of Radiologists and

Nuclear Medicine Physicians M.A. Aquilina A. Mallsa

Norwegian Society of Nuclear Medicine T.C. Adamsen R. Sundset

Polish Society of Nuclear Medicine A. Sowa-Staszczak A. Pietrzak

Portuguese Society of Nuclear Medicine A.P. Moreira R. Silva

Romanian Society of Nuclear Medicine D. Piciu C.R. Stolniceanu

Russian Society of Nuclear Medicine P. Rumyantsev V. Sukhov

Serbian Nuclear Medicine Society J. Mihailovic V. Artiko

Slovak Society of Nuclear Medicine L. Kaliska E. Takácsová

Slovenian Society of Nuclear Medicine I. Zagar K. Zaletel

Spanish Society of Nuclear Medicine L. García R. Ruano Perez

Swedish Society of Nuclear Medicine E. Trägårdh A. Larsson Strömvall

Swiss Society of Nuclear Medicine F. Forrer M. Wissmeyer

Turkish Society of Nuclear Medicine Z. Özcan L.Ö. Atay

Ukrainian Society of Nuclear Medicine to be nominated to be nominated

SOCIETY DELEGATE DEPUTY

Armenian Society of Nuclear Medicine V. Barsegian M. Grigoryan

Austrian Society of Nuclear Medicine H.-J. Gallowitsch I. Virgolini

Azerbaijan Society of Nuclear Medicine F. Novruzov A. Aliyev

Belgian Society of Nuclear Medicine F. Jamar N. Withofs

Bosnian Society of Nuclear Medicine Z. Rajkovaca D. Rozic

British Nuclear Medicine Society R. Graham S. Dizdarevic

Bulgarian Society of Nuclear Medicine V. Hadziyska L. Chavdarova

Croatian Society of Nuclear Medicine M. Franceschi D. Šnajder

Cyprus Society of Nuclear Medicine D. Kyprianou R.K. Demetriadou

Czech Society of Nuclear Medicine M. Simanek P. Koranda

Danish Society of Clinical Physiology and

Nuclear Medicine L.T. Jensen P. Hovind

Dutch Society of Nuclear Medicine A. Glaudemans R. Keijsers

Estonian Nuclear Medicine Society S. Nazarenko K. Ulst

Finnish Society of Nuclear Medicine H.Mussalo K. Timonen

Macedonian Society of Nuclear Medicine D. Miladinova A. Ugrinska

French Society of Nuclear Medicine F. Cachin J.-P. Vuillez

German Society of Nuclear Medicine B. Krause K. Herrmann

George de Hevesy Hungarian Society of NM T. Györke L. Pavics

Georgian Nuclear Medicine Specialists Association N. Shengelia K. Shamatava

Hellenic Society of Nuclear Medicine & Biology A. Fotopoulos V.C. Prassopoulos

Icelandic Society of Nuclear Medicine to be nominated to be nominated

FI

NA

L P

RO

GR

AM

ME

| U

EM

S/

EB

NM

CO

MM

ITT

EE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

UE

MS

/E

BN

M C

OM

MIT

TE

ES

| FI

NA

L P

RO

GR

AM

ME

2120

NETHERLANDS D. Wyndaele L. P Arias-Bouda

NORWAY A.R. Midha M. Revheim

POLAND M. Dziuk B. Birkenfeld

PORTUGAL L. Salgado T. Cruz Ferreira

ROMANIA G. Andries R. Mititelu

SERBIA V. Artiko J. Mihailovic

SLOVAKIA A. Vondrak P. Povinec

SLOVENIA S. Gaberscek D. Hrastnik

SPAIN A. Sorriano F. Pons

SWEDEN C. Wassberg E. Trägårdh

SWITZERLAND A. Boubaker G. Goerres

UNITED KINGDOM Y. Du S. Dizdarevic

COUNTRY DELEGATE DEPUTY

AUSTRIA R. Lipp M. Gabriel

BELGIUM K. Spaepen G. Moulin-Romsee

BULGARIA E. Piperkova A. D. Tzonevska

CROATIA D. Huic S. Kusacic Kuna

CYPRUS R. K. Demetriadou

CZECH REPUBLIC O. Lang M. Kaminek

DENMARK S. Hess L. T. Jensen

ESTONIA E. Kelk A. Poksi

FINLAND K. Timonen J. Kemppainen

FRANCE E. Gremillet J. L. Pelletier

GERMANY W. Brenner M. Gotthardt

GREECE S. Koukouraki I. Iakovou

HUNGARY L. Pavics I. Szilvasi

IRELAND S. Skehan R. Mcdermott

ITALY A. Ciarmiello D. Deandreis

LATVIA I. Vevere A. Berzina

LITHUANIA D. Vajauskas N. Jurkiene

LUXEMBOURG P. Paulus C. Picard

MALTA M. A. Aquilina A. Mallia


TURKEY G. Altun Z. Ozcan

nominated from UEMS Associate Member Countries


ISRAEL A. Steinmetz M. Quastel

nominated from UEMS Observer Countries

nominated from full UEMS Member Countries

UEMS/EBNM NATIONAL SOCIETIES:DELEGATES / DEPUTIES

FI

NA

L P

RO

GR

AM

ME

| U

EM

S/

EB

NM

CO

MM

ITT

EE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

UE

MS

/E

BN

M C

OM

MIT

TE

ES

| FI

NA

L P

RO

GR

AM

ME

2322

EXECUTIVE COMMITTEE

President S. Mirzaei (Austria)

Secretary & Treasurer R. Hustinx (Belgium)

Member A. Boubaker (Switzerland)

FELLOWSHIP EXAMINATION

Chair Z. Özcan (Turkey)

Members A. Boubaker (Switzerland)

I. Kulakiene (Lithuania)

S. I. Carrilho Vaz (Portugal)

J. R. García Garzón (Spain)

EDUCATION & SYLLABUS

Chair R. Hustinx (Belgium)

Members J. Darcourt (France)

H. B. Sayman (Turkey)

D. Huic (Croatia)

T. V. Bogsrud (Norway)

P. Castellucci (Italy)

CME ACCREDITATION

Chair M. Farsad (Italy)

Members E. Lopci (Italy)

A. Haug (Austria)

S. Sillanmäki (Finland)

ACCREDITATION OF NUCLEAR MEDICINE DEPARTMENTS & TRAINING CENTRES

Chair J. Prior (Switzerland)

Commitee Members A. García-Burillo (Spain)

N. Mutlukoca (Norway)

P.. Van Boxem (Belgium)

M. L. Hall (United Kingdom)

M. Bajc (Sweden)

Ex officio: S. Mirzaei (Austria)

Corresponding Members: F. Giesel (Germany)

A. Jiménez Heffernan (Spain)

I. Sippo-Tujunen (Finland)

N. G. Hartman (United Kingdom)

S. E. Bouzoucef (Algeria)

A. Ciarmiello (Italy)

L. Torres (Cuba)

UEMS/EBNM COMMIT TEES

Welcome and Introduction

Revealing Gaps in the Advanced Prostate Cancer Treatment Landscape

Precision Medicine: A New Era ofImaging-based Patient Selection

Radiopharmaceuticals in Advanced Prostate Cancer: Past and Future

Panel discussion: Maximising MDTcollaboration in clinical practice

12:00 – 12:05

12:05 – 12:35

12:35 – 12:50

12:50 – 13:00

13:00 – 13:30

EANM’21 Educational Satellite Symposium

Targeting PSMA inadvanced prostate cancer:How will precision medicineevolve patient care?

Pre-recorded symposiumto be streamed on

This symposium may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities

Advanced Accelerator Applications International S.A., Rue de la Tour de l’Ile 4, 1204 Geneva, Switzerland© 2021 AAA, Geneva, Switzerland AAA-NP-GL-0283-21 | August 2021

Joe O’Sullivan (Chair), UK

Noel Clarke, UKElena Castro, Spain

Wim Oyen, The Netherlands

Joe O’Sullivan, UK

Led by Joe O'Sullivan, all

Wednesday 20 October 12:00 – 13:30 CEST

Also available On-Demand

This symposium is not intended for US healthcare professionals



2524

GE

NE

RA

L IN

FO

RM

AT

ION

| FI

NA

L P

RO

GR

AM

ME

F

IN

AL

PR

OG

RA

MM

E |

GE

NE

RA

L I

NF

OR

MA

TIO

N

GENERALINFORMATION

CERTIFICATE OF ATTENDANCECertificates of Attendance will be available in your myEANM Area after the congress.

CLOSING SESSIONThe Congress Closing will be broadcasted on Octo-ber 23, 2021. All registered delegates can join.

CME CREDITSThe EANM’21 Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 24 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

The fourteen EANM’21 CME Sessions have been accredited with 21 European CME credits (ECMEC®s), means 1,5 credits per session.The twelve EANM’21 Pre-Congress Symposia have been accredited with 30 European CME credits (ECMEC®s), means 2,5 credits per session.

CME EVALUATION & CERTIFICATES To acquire CME credits and certificates, attendees are asked to follow the respective session 100%. For CME sessions, as well as the entire congress, an evaluation form must also be completed for each session attended.

CONGRESS E-POSTER AREAAs every year, the e-Poster Area gives you the pos-sibility to read all uploaded e-Posters of EANM’21. You can search for authors, topics and keywords.

CONGRESS LANGUAGEThe congress language is English. No simultaneous translation will be provided.

CONGRESS OFFICEThe congress office will be available during all con-gress days via email, phone and direct chat.

The opening hours are:during the PCS 09:00 to 17:00 CESTduring the Main Congress days 08:00 to 18:00 CEST (on Saturday only until 13:00)

For any questions, please have look at the FAQs first (to be found at the virtual information desk in the congress lobby) as most questions will probably be answered there and then contact us via the info desk in the Lobby of the virtual congress.Contact us viaEmail: [email protected]: +43 1 890 44 27and during the congress days also via the chat option on the info desk in the virtual lobby.

DATES & DEADLINESOctober 4, 2021 Early Registration Deadline October 4-6, 2021 Pre-Congress Symposia 1-6 October 11-13, 2021 Pre-Congress Symposia 7-12 October 20, 2021 Congress Opening October 23, 2021 Congress Closing

DISCLAIMERIn the event the congress has to be cancelled by the organisers because of force majeure, the registration fee, any hotel deposit and any oth-er payments for services ordered through the registration process will be partially refunded or forfeited, which is subject to the commitments of the congress organisers at that time. You may wish to insure yourself directly against such a risk.

EANM MEMBERS’ ASSEMBLYThe Members’ Assembly will be held virtually: EANM Members’ Assembly Saturday, October 16, 2021 16:00–18:00 CEST | online Further details will be provided in due time via e-mail to all eligible participants.

Please note: Only EANM members in good standing (having paid their membership dues for the year 2021) are eligible to attend the Members’ Assembly.

EBAMP ACCREDITATIONEBAMP accredits the EANM’21 Congress and Pre Congress Symposia that will be held on 20-23 of October and 4-6 & 11-13 of October respectively, as on live event, as CPD event for Medical Physicists at EQF Level 8.

The event has been judged according to the EBAMP protocol and it has been assigned: CPD credit points 55.

INSURANCE & LIABILITYNeither the organisers nor the Conference Bureau will assume any responsibility whatsoever for dam-age or injury to persons or property during the con-gress. It is recommended that participants arrange for their personal travel and health insurance.

OPENING CEREMONYAll registered delegates are invited to attend the Congress Opening Wednesday, October 20, 2021 - 08:45-09:10

OPENING CONCERTAt the end of the first congress day, starting at 19:30, there will be the Opening Concert by the party band Bad Powells. During the concert, we in-vite you to discover the chat function and network with your colleagues!

Join us on Wednesday, October 20, 2021 at 19:30-20:30.

SOCIAL MEDIA AND NEWSLETTERFor up-to-date information follow us on our Social Media Channels and subscribe to the Congress Newsletter!

Facebook @officialEANM

Twitter @officialEANM

LinkedIn @officialEANM

YouTube @officialEANM

Newsletter Click here for Subscription

TICKET AVAILABILITYPlease note that the deadline for purchasing a ticket for the main congress is October 23, 2021. This ticket will grant access to the main congress days (October 20-23, 2021) plus access to all on-demand material (including collection of CME credits) for 2 more months (until December 31, 2021).The ticket for all Pre-Congress Symposia (PCS) will also be available for purchase until October 23, 2021. Of course, live interaction will be limited to the specific date and time of broadcasting of each PCS. However, the ticket grants access to the on-demand material of all PCS until December 31, 2021 (including collection of CME credits) as well.

https://www.facebook.com/officialEANM

https://twitter.com/officialEANM

https://www.linkedin.com/company/officialeanm/

https://www.youtube.com/user/officialEANM

https://www.eanm.org/publicpress/newsletter/

FI

NA

L P

RO

GR

AM

ME

| C

OM

MIT

TE

E M

EE

TIN

GS


26

COMMITTEE INTEREST GROUP MEETINGSDURING EANM’21VIRTUAL COMMITTEE INTEREST GROUP MEETINGS

EANM Bone and Joint Committee

T. Van den Wyngaert Tuesday, October 19 14:45-15:30

EANM Dosimetry Committee

J. Gear Monday, October 18 13:45-14:30

EANM Drug Development Committee

J. Vercouillie Tuesday, October 19 10:45-11:30

EANM Infection & Inflammation Committee

O. Gheysens Tuesday, October 19 12:45-13:30

EANM Neuroimaging Committee

S. Morbelli Tuesday, October 19 16:45-17:30

EANM Oncology and Theranostics Committee

K. Herrmann Monday, October 18 15:45-17:30

EANM Paediatrics Committee

P. Zucchetta Tuesday, October 19 15:45-16:30

EANM Physics Committee

D. Visvikis Monday, October 18 11:45-12:30

EANM Radiation Protection Committee

S. Holm Tuesday, October 19 09:45-10:30

EANM Radiopharmacy Committee

M. Patt Monday, October 18 12:45-13:30

EANM Technologists Committee

A. Santos Tuesday, October 19 13:45-14:30

EANM Thyroid Committee

L. Giovanella Monday, October 18 09:45-10:30

AGENDA

Time (CEST) Session Speaker

16:15–16:25 Welcome and introduction Shaunak Navalkissoor

16:25–16:45 Moving towards precision medicine with RLT: Advances in imaging

Vikas Prasad

16:45–17:05 Moving towards precision medicine with RLT: Advances in blood biomarkers

Andrea Frilling

17:05–17:20 Moving towards precision medicine with RLT: Evolving theranostics in and beyond NETs

Shaunak Navalkissoor

17:20–17:40 How can we make the best use of all tools available for optimal patient outcomes?

Panel discussion

17:40–17:45 Summary and conclusion Shaunak Navalkissoor

This symposium is only accessible to healthcare professionals registered to EANM 2021

EANM’21 educational satellite symposium

Advancing towards precision medicine with

theranostics in oncologyWednesday 20 October 2021

16:15–17:45 CESTVirtual satellite symposium

Shaunak Navalkissoor Consultant Nuclear Medicine Physician, Chair of the British Institute of Radiology Nuclear Medicine Subgroup, London, United Kingdom

Vikas PrasadDeputy Director, Department of Nuclear Medicine, University Hospital of Ulm, Ulm, Germany

Andrea FrillingProfessor of Surgery and Chair in Endocrine Surgery, Imperial College London, London, United Kingdom

Information provided in this symposium may contain discussions outside the approved license of medicines or data of medicines not yet approved. This information is not intended to be promoting or recommending any indication, dosage or other claim not covered in the licensed product

information. This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities.

This symposium is organised and funded by Advanced Accelerator Applications, a Novartis Company.AAA-NP-GL-0290-21 August 2021

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM

EE A N M ’21 W O R L D L E A D I N G M E E T I N G


O C T O B E R 2 0 - 2 3 , 2 0 2 1

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

2928

PLENARY SESSIONS

1 Wednesday, October 20, 2021 | 09:10 - 10:00Highlights LecturePresenters: Irene Burger (Switzerland), Nathalie Albert (Germany)

2 Wednesday, October 20, 2021 | 14:40 - 16:10 Theranostics Applications and Challenges (incl. Marie Curie Lecture)Chairpersons: Jolanta Kunikowska (Poland), Benjamin Guillet (France)

» We are Theranostics, Benjamin Guillet (France) » PSMA Theranostics in 2021, Daniela Oprea-Lager (Netherlands) » Marie Curie Lecture: Other New Theranostics, Rodney Hicks (Australia) » Handling Challenges, Laura Evangelista (Italy) » Risk Analysis in Radionuclide Therapy, Rudi Dierckx (Netherlands) » Tech Challenges, Andrea Santos (Portugal) » Reimbursement Challenges, Jolanta Kunikowska (Poland) » Discussion, All Speakers

3 Thursday, October 21, 2021 | 13:30 - 14:50Conventional Nuclear Medicine - Oldies but GoldiesChairpersons: Ora Israel (Israel), Fred Verzijlbergen (Netherlands)

» Why some Scans are Evergreen?, Ora Israel (Israel) » Bone Scan, Gopinath Gnanasegaran (United Kingdom) » Thyroid Scan, Evanthia Giannoula Karamanou (Greece) » Renal Scan, Marika Kalnina (Latvia) » V/Q Scan, Patrick Pilkington (Spain) » Parathyroid Imaging, Petra Petranović Ovčariček (Croatia) » Lessons from the Past, Fred Verzijlbergen (Netherlands) » Discussion, All Speakers

4 Friday, October 22, 2021 | 13:30 -14:45Isotopes’ Past and Future Chairpersons: Jane Sosabowski (United Kingdom), Peter Laverman (Netherlands)

» The Importance of the Isotope, Jane Sosabowski (United Kingdom) » Clinical Applications of Alpha vs Beta, Matthias Eiber (Germany) » New Isotopes on the Blocks, Ulli Köster (France) » Isotopes’ Availability, Verena Pichler (Austria) » Zr and Friends, Daniëlle Vugts (Netherlands) » Beta Emitters for Surface Therapy, Paolo Castellucci (Italy) » The Best has yet to Come, Peter Laverman (Netherlands) » Discussion, All Speakers

PLENARY SESSIONS

PLENARYSESSIONS

The Plenary Sessions are the most prestigious sessions of EANM and organized by the Congress Chair. Each Plenary covers a different topic and will put a spotlight on the different aspects and points of view.

As a novelty for the EANM Congress, the Highlights Session will be the start of the congress – pointing out the most interesting sessions and hot abstracts, thus you do not miss them in the following days.

However, not a novelty is the plan to start all plenaries, once again, with a musical intro.

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM



O C T O B E R 2 0 - 2 3 , 2 0 2 1

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

3130

PRE-CONGRESS SYMPOSIA

1 Monday, October 4, 2021 | 09:00 - 12:00Pre-Clinical Dosimetry and Extrapolations from Animal Models to HumansDosimetry + Translational Molecular Imaging & Therapy Committee

2 Monday, October 4, 2021 | 14:00 - 17:05Signal Quantification in Cardiac SPECT - Dream or Reality?Cardiovascular + Physics Committee

3 Tuesday, October 5, 2021 | 09:00 - 12:00Radiosynoviorthesis - Master Class in Science and PracticeBone & Joint + Oncology & Theranostics + Paediatrics Committee

4 Tuesday, October 5, 2021 | 14:00 - 17:00 Structured Reporting of Oncology PET-CT - Are we Ready for Template-Based Reporting?Oncology & Theranostics Committee

5 Wednesday, October 6, 2021 | 09:00 - 12:10Imaging of Protein Misfolding in Parkinson’s Disease and Related Disorders - Where are we and What do we need?Neuroimaging + Radiopharmacy + Drug Development Committee

6 Wednesday, October 6, 2021 | 14:00 - 17:00Oligocare Concept in Radiation OncologyOncology & Theranostics Committee / ESTRO

7 Monday, October 11, 2021 | 09:00 - 12:00Biokinetic Modelling in Cancer Therapy and Clinical ImpactRadiation Protection + Dosimetry Committee

8 Monday, October 11, 2021 | 14:00 - 17:00Novel Radionuclides for Theranostics on the HorizonRadiopharmacy + Oncology & Theranostics + Drug Development Committee

9 Tuesday, October 12, 2021 | 09:00 - 12:00Nuclear Endocrinology in the Era of Precision MedicineOncology & Theranostics + Thyroid Committee / ESES

10 Tuesday, October 12, 2021 | 14:00 - 17:00Total Body PETPhysics + Dosimetry Committee

11 Wednesday, October 13, 2021 | 09:00 - 12:00Light in the Dark - Hybrid Imaging in Patients with Sepsis/BacteremiaInflammation & Infection Committee

12 Wednesday, October 13, 2021 | 14:00 - 17:15PET/MR - The Cross Path of Morphology and FunctionalityTechnologists Committee


PRE-CONGRESSSYMPOSIADATES: OCT 4-13, 2021

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM



O C T O B E R 2 0 - 2 3 , 2 0 2 1

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

3332

8 Thursday, October 21, 2021 | 16:50 - 18:20 | Channel 1Pregnancy and Breastfeeding in the Context of Nuclear MedicineRadiation Protection + Dosimetry Committee

9 Friday, October 22, 2021 | 09:00 - 10:30 | Channel 1Back to the Future - New Kit-Based Approaches for Labelling Radiopharmaceuticals (68Ga, Al[18F]F,…) Radiopharmacy + Drug Development Committee

10 Friday, October 22, 2021 | 10:45 - 12:15 | Channel 1Radionuclide Therapies - Management of Side Effects and ComplicationsThyroid + Oncology & Theranostics Committee

11 Friday, October 22, 2021 | 15:05 - 16:35 | Channel 1New Concepts for Imaging and Therapy of Bone MetastasesBone & Joint Committee

12 Friday, October 22, 2021 | 16:50 - 18:20 | Channel 1Nuclear Medicine in the Evaluation of Child AbusePaediatrics Committee

13 Saturday, October 23, 2021 | 09:00 - 10:30 | Channel 1ImmunotheranosticsTranslational Molecular Imaging & Therapy + Oncology & Theranostics Committee

14 Saturday, October 23, 2021 | 10:45 - 12:15 | Channel 1Probing Tumour Metabolism - An UpdateDrug Development + Translational Molecular Imaging & Therapy Committee

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

1 Wednesday, October 20, 2021 | 10:15 - 11:45 | Channel 1Prostate Cancer – Greatest HitsOncology & Theranostics Committee

2 Wednesday, October 20, 2021 | 12:00 - 13:30 | Channel 1 AI in RadiomicsPhysics Committee

3 Wednesday, October 20, 2021 | 16:15 - 17:45 | Channel 1The Battle Continues - WBC Scan vs FDG PET/CTInflammation & Infection Committee

4 Wednesday, October 20, 2021 | 18:00 - 19:30 | Channel 1Imaging Neuroinflammation - Everything You Always Wanted to Know, But Were Afraid to AskNeuroimaging + Radiopharmacy Committee

5 Thursday, October 21, 2021 | 09:00 - 10:30 | Channel 1Inflammation, Infection and Infiltrative Cardiovascular Diseases - Think Nuclear!Cardiovascular + Inflammation & Infection Committee

6 Thursday, October 21, 2021| 10:45 - 12:15 | Channel 1Quo Vadis PET/MRI?Oncology & Theranostics Committee

7 Thursday, October 21, 2021 | 15:05 - 16:35 | Channel 1Developments and Challenges in TheranosticsPhysics Committee

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

CMESESSIONS

Continuing Medical Education will span over all days of the EANM’21 main congress days. EANM applied for CME accreditation at EACCME®. The exact number of CME credits granted will be announced after confirmation.

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM



O C T O B E R 2 0 - 2 3 , 2 0 2 1

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

3534

CONTINUING TECHNOLOGIST EDUCATION (CTE) SESSIONS

1 Tech Guide Launch Technologists Committee / SNMMI

2 Managing the Paediatric Patient in Nuclear Medicine DepartmentsTechnologists + Paediatrics Committee

3 PET/CT for RT PlanningTechnologists Committee / ESTRO

4 Cardiac PET/CTTechnologists Committee

5 Update in Inflammation ImagingTechnologists + Inflammation & Infection Committee

6 Radionuclide Therapy ManagementTechnologists Committee

7 Research - Technologist’s InvolvementTechnologists Committee

1 Safety in PET/MRITechnologists Committee

2 Case Studies (PET/CT & PET/MRI)Technologists Committee

3 Case Studies (Conventional Nuclear Medicine)Technologists Committee

IN ADDITION TO THE CTE SESSIONS THE TECHNOLOGISTS’ TRACK INCLUDES 3 MINI COURSES:

TECHNOLOGISTS’TRACKON-DEMAND AVAILABLE FROMOCTOBER 20 - DECEMBER 31, 2021

The Technologists Committee places a massive effort into delivering the most up-to date and highest quality educational initiatives. All sessions of this track are aimed specifically at the technologist audience.



3736

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

F

IN

AL

PR

OG

RA

MM

E |

SC

IEN

TIF

IC P

RO

GR

AM

ME

JOINT SYMPOSIA

1 PET/MRI in MSK - Be Hybrid!Bone & Joint + Inflammation & Infection + Paediatrics Committee / ESSR

2 PET-MPI vs. SPECT-MPI - Is it Worth the Price? Cardiovascular Committee / ASNC

3 MPI after the ISCHEMIA Trial - Still Alive?Cardiovascular Committee / EACVI

4 Biokinetics and Dosimetry in Intraarterial TherapyDosimetry Committee / CIRSE

5 Targeting Cancer with Peptides, Fragments or AntibodiesDrug Development + Radiopharmacy + Oncology & Theranostics Committee / SRS

6 Modifying Radiopharmaceuticals to Alter PharmacokineticsDrug Development + Radiopharmacy + Translational Molecular Imaging & Therapy Committee / SRS

7 My Foot is on Fire - Find the Hot SpotInflammation & Infection Committee / EASD

8 PET/CT and PET/MRI in Patients with Autoimmune DisordersInflammation & Infection + Bone & Joint Committee / EULAR

9 The New ATN Diagnostic Concept in Alzheimer’s DiseaseNeuroimaging Committee / EAN

10 PET/MRI in EpilepsyNeuroimaging Committee / ILAE

11 Advancements in Neuro-OncologyNeuroimaging + Oncology & Theranostics Committee / EANO

12 Nuclear Medicine in Precision OncologyOncology & Theranostics Committee / EORTC

13 Biomarkers in LymphomaOncology & Theranostics Committee / EHA

14 New Therapies in Lymphoma - Is Deauville Still Good Enough?Oncology & Theranostics Committee / EHA

15 Imaging Challenges in Multiple Myeloma - Quo Vadis 2021?Oncology & Theranostics Committee / EHA

16 Combination Treatments - What can Radioligand Therapy be Combined with?Oncology & Theranostics Committee / ESMO

17 What to Do and Not Do in Prostate ImagingOncology & Theranostics Committee / EAU

18 Urological Challenges for Imaging Beyond ProstateOncology & Theranostics Committee / EAU

19 Harmonisation and StandardisationPhysics Committee / EFOMP

20 Artificial Intelligence for Image Processing and QuantificationPhysics Committee / AAPM

21 Numerical and Computer PhantomsPhysics Committee / AAPM

22 The MEDIRAD Project - Impact on Nuclear Medicine PracticeRadiation Protection + Thyroid + Dosimetry Committee / EURAMED

23 Extremity Dosimetry - It’s in Your Hands!Radiation Protection + Technologists Committee / EURADOS

24 Theranostics in Thyroid Cancer Beyond Radioactive IodineThyroid + Oncology & Theranostics Committee / ESMO

25 Global Cost-Effectiveness of Different DTC Management StrategiesThyroid Committee / ESES / ESSO

26 Imaging Mitochondria and Mitochondrial DysfunctionTranslational Molecular Imaging & Therapy Committee / ESMI/WMIS

27 Advances in Molecular Imaging of Neurodegenerative DisordersNeuroimaging Committee / JSNM

28 Lancet Oncology Commission on Medical Imaging and Nuclear MedicineEANM / IAEA

JOINT SYMPOSIA

JOINTSYMPOSIAON-DEMAND AVAILABLE FROMOCTOBER 20 - DECEMBER 31, 2021

EANM is again teaming up with its partner societies to fully reflect the multidisciplinarity of Nuclear Medicine.The preliminary list of planned sessions can be found hereunder.

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM



O C T O B E R 2 0 - 2 3 , 2 0 2 1

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

3938

1 Pitfalls in Cardiovascular ImagingCardiovascular + Physics + Technologists Committee

2 Pseudoprogression and Pseudoresponse in Brain TumoursNeuroimaging + Oncology Committee

3 Challenging Cases in Nuclear NeurologyNeuroimaging Committee

4 Sentinel Lymph Node in Head & Neck, Penile and Gynaecological CancersOncology & Theranostics + Translational Molecular Imaging & Therapy Committee

5 Pitfalls & Pearls in Paediatric MusculoskeletalPaediatrics Committee

6 Pitfalls & Artefacts in Endocrine ImagingThyroid Committee

PITFALLS & ARTEFACTS SESSIONS TEACHING SESSIONS

1 Imaging of Prosthetic Knee Joint Loosening - Spotlight on Quantitative and Multidisciplinary AlgorithmsBone & Joint + Inflammation & Infection Committee / AGA

2 All About Cardiac SPECTCardiovascular Committee

3 Radiobiology as a Missing Link in Improving andUnderstanding Nuclear MedicineDosimetry + Translational Molecular Imaging & Therapy + Radiation Protection Committee

4 Immunotherapy - Assessing Organs and Events on [18F]FDG PET/CTOncology & Theranostics Committee

5 Radiation Detection and MeasurementRadiation Protection + Physics Committee

6 Animal Models - Technical Considerations and RecommendationsTranslational Molecular Imaging & Therapy + Drug Development + Radiopharmacy + Technologists Committee

PITFALLS & ARTEFACTSSESSIONS

This year there will be six Pitfalls & Artefacts Sessions. Renowned specialists will present interesting cases with challenging findings, either pitfalls and/or artefacts to improve your skills.

ON-DEMAND AVAILABLE FROMOCTOBER 20 - DECEMBER 31, 2021

TEACHINGSESSIONS

ON-DEMAND AVAILABLE FROMOCTOBER 20 - DECEMBER 31, 2021This year there are six Teaching Sessions. Specialists will present interesting cases and will guide you from patients’ history through diagnosis to treatment options.

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM



O C T O B E R 2 0 - 2 3 , 2 0 2 1

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

4140

1 Wednesday, October 20, 2021 | 10:15- 10:40 | Channel 2TherapyIrene Virgolini & Stefano Fantie

2 Wednesday, October 20, 2021 | 11:00- 11:20 | Channel 2 Imaging MyelomaCristina Nanni & Paolo Castellucci

3 Wednesday, October 20, 2021 | 12:00 - 12:45 | Channel 2Nuclear Endocrinology

4 Wednesday, October 20, 2021 | 12:45 - 13:30 | Channel 2Neuroimaging

5 Thursday, October 21, 2021 | 09:00 - 09:35 | Channel 2Creating Tracers!Uwe Haberkorn & Stefano Fanti

6 Thursday, October 21, 2021| 09:45 - 10:30 | Channel 2Paediatric NM Today

7 Thursday, October 21, 2021 | 16:50 - 17:35 | Channel 2The Theranostic UnitPhysics Committee

8 Friday, October 22, 2021 | 09:00 - 09:30 | Channel 2Vision TrialBernd Krause & Stefano Fanti

9 Friday, October 22, 2021 | 09:45 - 10:30 | Channel 2The Best Young NM Ken Herrmann & Stefano Fanti

SPECIALTRACKThe Special Track is a new feature within the scientific congress programme. It consists of Interviews with the Experts, Trials Sessions, Case Reports and a Special Talk. Y

10 Friday, October 22, 2021 | 10:45 - 11:30 | Channel 2Running a Preclinical Lab in New York City

11 Friday, October 22, 2021 | 11:30 - 12:15 | Channel 2New PET Tracers in Oncology

12 Friday, October 22, 2021 | 16:50 – 17:25 | Channel 2Radiopharmacy RunningClemens Decristoforo & Stefano Fanti

13 Saturday, October 23, 2021 | 09:00 - 09:45| Channel 2A Life in NM

14 Saturday, October 23, 2021 | 09:45 - 10:30 | Channel 2Prostate Cancer Imaging

15 Saturday, October 23, 2021 | 11:15 - 12:15 | Channel 2Reflections on the Development of PET and Theranostics Downunder – A 25-Year Journey into the Light

INTERVIEW WITH THE EXPERT

THE TOP 3 TRIALS SESSIONS

1 Wednesday, October 20, 2021 | 16:15 – 17:45 | Channel 2Prostate

2 Thursday, October 21, 2021 | 15:05 – 16:35 | Channel 2 Rest of Science

3 Friday, October 22, 2021 | 15:05 – 16:35 | Channel 2Nuclear Endocrinology

CASE REPORTS SESSION

1 Wednesday, October 20, 2021 | 18:00 – 19:30 | Channel 2What’s the Case? Report it Now!

SPECIAL TALK

1 Saturday, October 23, 2021 | 10:45- 11:15 | Channel 2Prostate Cancer along the Yellow Brick RoadDeclan Murphy

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM



O C T O B E R 2 0 - 2 3 , 2 0 2 1

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

4342

209 TROP Session: Radiobiology Meets Dosimetry

309 TROP Session: Dosimetry Methods

509 TROP Session: Lu-177 Dosimetry

609 TROP Session: Clinical Dosimetry and Radioembolisation

809 TROP Session: Diagnostic Dosimetry

909 Featured Session: From Safety Culture to Fieldwork in Radiation Protection

1009 TROP Session: New Imaging Equipment and Techniques

1109 Featured Session: Software Developments in Total Body PET

CUTTING EDGE SCIENCE TRACK

1209 TROP Session: Imaging of Non-Standard Radionuclides

1309 Featured Session: Harmonisation and Standardisation

1409 TROP Session: Data Analysis

1609 Featured Session: PET Reconstructions and Corrections

1709 TROP Session: Data/Image Processing Based on Deep Learning

1809 TROP Session: Artificial Intelligence – Clinical Applications

1909 TROP Session: Radiomics – Methodology and Clinical Applications

CUTTING EDGE SCIENCE TRACK

CUTTING EDGESCIENCE TRACKON-DEMAND AVAILABLE FROMOCTOBER 20 - DECEMBER 31, 2021

The Cutting Edge Science Track (formerly known as the International Symposium on Dosimetry and Molecular Radiotherapy) will take place during the 34th Annual Congress of the European Association of Nuclear Medicine.

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM



O C T O B E R 2 0 - 2 3 , 2 0 2 1

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

4544

M2M TRACK

208 TROP Session: Prostate Cancer Imaging – The Various Angles of Attack

308 TROP Session: It’s the Alpha, not the Beta

508 TROP Session: Theranostics – Various Targets

608 Featured Session: Mapping Brain Structures

808 Featured Session: Functional Brain Imaging

908 TROP Session: Tumour Microenvironment and Immunotherapy

1108 TROP Session: Peptides Only!

1208 TROP Session: Radiochemistry – Cook it or Leave it

1308 TROP Session: Out of the Box Innovations

CLINICAL ONCOLOGY TRACK

210 TROP Session: Head and Neck / Colorectal

310 TROP Session: Breast

510 TROP Session: Lung

610 TROP Session: Gastro-Intestinal

810 TROP Session: Neuroendocrine

910 Featured Session: Radioguided Surgery and Sentinel Lymph Nodes

1110 TROP Session: Prostate Staging

1210 TROP Session: Prostate Varia and Others

1310 TROP Session: Prostate BC Recurrence

1410 TROP Session: Local Radionuclide Therapy and Other Oncological Treatments

1610 Featured Session: Prostate Cancer Therapy

1710 Featured Session: Neuroendocrine Therapy

1810 TROP Session: Lymphoma and Other Hematological Tumours

1910 TROP Session: Gynaecological and Melanoma

M2MTRACK

ON-DEMAND AVAILABLE FROMOCTOBER 20 - DECEMBER 31, 2021M2M - The 8th “From Molecule to Man” Track, covering translational developments in Imaging and Therapy will take place during the 34th Annual Congress of the European Association of Nuclear Medicine.

CLINICAL ONCOLOGYTRACKON-DEMAND AVAILABLE FROMOCTOBER 20 - DECEMBER 31, 2021The Clinical Oncology Track assembles the accepted abstracts which were submitted to the field of Oncology. Oncological diseases represent in average >80% of the daily clinical workload in Nuclear Medicine. Accordingly it is of utmost importance to stay ahead of the curve and be informed what are the most important scientific developments.



4746

SC

IEN

TIF

IC P

RO

GR

AM

ME

| FI

NA

L P

RO

GR

AM

ME

F

IN

AL

PR

OG

RA

MM

E |

SC

IEN

TIF

IC P

RO

GR

AM

ME

FURTHER ORAL PRESENTATIONS e-POSTER PRESENTATIONS

211 Featured Session: Quantification in MPI – A Must!

311 Featured Session: Show me your Heart!

511 Featured Session: New Kids on the Cardiovascular Block!

611 TROP Session: Top of Cardiovascular and Soft Tissue Infection/Inflammation Imaging

811 TROP Session: Top of Nuclear Medicine in COVID-19

911 Featured Session: Molecular Imaging of Alzheimer’s Disease

1111 Featured Session: Molecular Imaging of Movement Disorders

1211 Featured Session: Amino Acid Imaging of Gliomas

1311 Featured Session: Brain Tumor Imaging – More than Amino Acids in Gliomas

1411 Featured Session: Novel Molecular Brain Imaging Applications

1611 TROP Session: Paediatric Nuclear Medicine

1711 TROP Session: General Nuclear Medicine

1811 TROP Session: Nuclear Thyroidologist and Thyroid Cancer Management – Current Update and Future Perspectives

1911 TROP Session: Nuclear Medicine Imaging and Therapy in Thyroid and Parathyroid Disorders

212 e-Poster Presentation Session 1: The Nuclear Cardiovascular World at its Best

312 e-Poster Presentation Session 2: Dosimetry

512 e-Poster Presentation Session 3: More on Infection & Inflammation Imaging and NM in COVID-19

612 e-Poster Presentation Session 4: Radiochemistry

812 e-Poster Presentation Session 5: Theranostics

912 e-Poster Presentation Session 6: Molecular Brain Imaging

1012 e-Poster Presentation Session 7: An Overview on Endocrine Disease

1112 e-Poster Presentation Session 8: Imaging in Recurrent Prostate Cancer

1212 e-Poster Presentation Session 9: Imaging in Primary Prostate Cancer

1312 e-Poster Presentation Session 10: Lymphoma and Other Hematological Diseases

1412 e-Poster Presentation Session 11: Neuroendocrine and Lymphoma

1612 e-Poster Presentation Session 12: Head Neck / Breast / Lung

1712 e-Poster Presentation Session 13: Image Acquisition / Reconstruction / Processing 1

1812 e-Poster Presentation Session 14: Image Acquisition / Reconstruction / Processing 2

1912 e-Poster Presentation Session 15: AI and Radiomics

FURTHER ORALPRESENTATIONS

e-POSTERPRESENTATIONS

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM



O C T O B E R 2 0 - 2 3 , 2 0 2 1

SC

IEN

TIF

IC P

RO

GR

AM

ME

|FI

NA

L P

RO

GR

AM

ME

4948

e-POSTER SESSIONS e-POSTER SESSIONS

01 Preclinical Studies -> Medical Preclinical -> Preclinical Oncology

02 Preclinical Studies -> Medical Preclinical -> Preclinical Therapy

03 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Breast

04 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Lung (including Mesothelioma)

05 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Gastro-Intestinal (including Liver and Non-Endocrine Pancreas)

06 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Neuroendocrine (Pancreatic and Others)

07 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Colorectal

08 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Prostate Other

09 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Thyroid

10 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Gynaecological

11 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Lymphoma

12 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Melanoma

13 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Any Other Malignant (including Primary of Unknown Origin)

14 Imaging Clinical Studies -> Other Oncological Clinical Study -> Radioguided Surgery and Radiation Therapy Planning

15 Imaging Clinical Studies -> Other Oncological Clinical Study -> Sentinel Node

16 Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Perfusion

17 Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Heart Failure (including Sarcoidosis and Amyloidosis)

18 Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Other Cardiovascular Imaging (including Plaque)

19 Imaging Clinical Studies -> Endocrinological Imaging Clinical Study -> Endocrinology (including Thyroid Benign)

20 Imaging Clinical Studies -> Infection and Inflammation -> Vasculitis and Endocarditis

21 Imaging Clinical Studies -> Infection and Inflammation -> Other Infections and Inflammatory Diseases

22 Therapy Clinical Study -> Oncological Therapy Clinical Study -> Neuroendocrine Therapy

23 Therapy Clinical Study -> Oncological Therapy Clinical Study -> Prostate Cancer Therapy

24 Therapy Clinical Study -> Oncological Therapy Clinical Study -> Thyroid Therapy

25 Therapy Clinical Study -> Oncological Therapy Clinical Study -> Other Oncological Treatments

26 Technical Studies -> Radiation Protection -> Radiation Exposure and Protection

e-POSTERSESSIONS

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

PR

OG

RA

MM


O C T O B E R 2 0 - 2 3 , 2 0 2 1 O C T O B E R 2 0 - 2 3 , 2 0 2 1

50

e-POSTER SESSIONS

27 Technical Studies -> Dosimetry and Radiobiology -> Preclinical Dosimetry and Radiobiology

28 Technical Studies -> Dosimetry and Radiobiology -> Clinical Dosimetry

29 Technical Studies -> Radiopharmacy/Radiochemistry -> New Radiopharmaceuticals - SPECT

30 Technical Studies -> Radiopharmacy/Radiochemistry -> New Radiopharmaceuticals - PET

31 Technical Studies -> Radiopharmacy/Radiochemistry -> Radiopharmaceutical Preparation and Quality Control

32 Covid Studies -> Clinical Study

33 Covid Studies -> Other Study (incl. Organisation)

34 Bone & Joint Malignant and Benign Diseases

35 General Isotopic Imaging

36 Technologist Digital ePoster

37 Paediatrics

e-POSTERSESSIONS

earl.eanm.org

We are growing to serve the needs of our community. EARL provides unparallel support for tomorrow’s research needs with today’s molecular imaging data.

EARL PET/CT ACCREDITATION NOW OFFERS 18F STANDARDS 1 & 2, 68GA, 89ZR AND SOON 18F/11C BRAIN PET/CT,HARMONISATION

FI

NA

L P

RO

GR

AM

ME

| P

RO

GR

AM

ME

OV

ER

VIE

WE A N M ’21 W O R L D L E A D I N G M E E T I N G


O C T O B E R 2 0 - 2 3 , 2 0 2 1

PR

OG

RA

MM

E O

VE

RV

IEW

| FI

NA

L P

RO

GR

AM

ME

Time (CEST) Monday, Oct 4, 2021 Tuesday, Oct 5, 2021 Wednesday, Oct 6, 2021 Time (CEST)

09:00 -12:00

Pre-Congress Symposium 1

Dosimetry + Translational Molecular

Imaging & Therapy Committee

Pre-Clinical Dosimetry and Extrapolations from Animal

Models to Humans


Bone & Joint + Oncology & Theranostics +

Paediatrics Committee

Radiosynoviorthesis - Master Class in Science and

Practice


Neuroimaging + Radiopharmacy +

Drug Development Committee

Imaging of Protein Misfolding in Parkinson’s

Disease and Related Disorders - Where are we and

What do we need?

09:00 -12:00

14:00 -17:00


Cardiovascular + Physics Committee

Signal Quantification in Cardiac SPECT – Dream or

Reality?


Oncology & Theranostics Committee

Structured Reporting of Oncology PET-CT – Are we Ready for Template-Based

Reporting?


Oncology & Theranostics Committee / ESTRO

Oligocare Concept in Radiation Oncology

14:00 -17:00

PRE-CONGRESS SYMPOSIAOCTOBER 4-6, 2021

Time (CEST) Monday, Oct 11, 2021 Tuesday, Oct 12, 2021 Wednesday, Oct 13, 2021 Time (CEST)

09:00 -12:00


Radiation Protection + Dosimetry Committee

Biokinetic Modelling in Cancer Therapy and Clinical

Impact


Oncology & Theranostics + Thyroid Committee / ESES

Nuclear Endocrinology in the Era of Precision Medicine


Inflammation & Infection Committee

Light in the Dark - Hybrid Imaging in Patients with

Sepsis/Bacteremia

09:00 -12:00

14:00 -17:00


Radiopharmacy + Oncology & Theranostics +

Drug Development Committee

Novel Radionuclides for Theranostics on the Horizon


Physics + Dosimetry Committee

Total Body PET


Technologists Committee

PET/MR - The Cross Path of Morphology and

Functionality

14:00 -17:00

OCTOBER 11-13, 2021


Plenary Sessions CME Sessions Joint Symposia Technologists’ Track M2M Track Cutting Edge Science Track Pitfalls & Artefacts / Teaching Sessions Clinical Oncology Track Further TROP/Featured Sessions e-Poster Presentation Sessions Special Track Satellite Symposia

SATURDAY OCTOBER 23, 2021FRIDAY OCTOBER 22, 2021

FI

NA

L P

RO

GR

AM

ME

| P

RO

GR

AM

ME

OV

ER

VIE

W



PR

OG

RA

MM

E O

VE

RV

IEW

| FI

NA

L P

RO

GR

AM

ME

Time (CEST) Channel 1 Channel 2 Channel 3

08:45 -09:10 Opening Ceremony

09:10 -10:00

101

Plenary 1

Highlights Lecture

10:15 - 11:00

201

CME 1

Oncology & Theranostics

Committee

Prostate Cancer - Greatest Hits

202-1

Special Track

Interview with the Expert 1

Therapy(10:15 - 10:40)

203-1

Industry Channel

Satellite Symposium by GE Healthcare

11:00 - 11:45

202-2

Special Track


Imaging Myeloma(11:00 - 11:20)

203-2

Industry Channel

Satellite Symposium by Sirtex

12:00 - 12:45

301

CME 2

Physics Committee

AI in Radiomics

302-1

Special Track


Nuclear Endocrinology(12:00 - 12:25)

303

Industry Channel

Satellite Symposium by Advanced Accelerator

Applications, A Novartis Company

12:45 - 13:30

302-2

Special Track


Nuclear Medicine in Neurodegenerative

Diseases

13:30 - 13:50 Awards Ceremony

13:50 - 14:20 Lunch Break Hamburg City

Tour 1

403

Industry Channel

Satellite Symposium by Hermes Medical Solutions

(13:50-14:15)

14:20 - 14:40 Plenary Quiz

14:40 -16:10

401

Plenary 2

incl. Marie Curie LectureTheranostics Applications

and Challenges

16:15 - 17:45

501

CME 3


The Battle Continues - WBC Scan vs FDG PET/CT

502

Special Track

The Top 3 Trials Sessions 1Prostate

503

Industry Channel

Satellite Symposium by Advanced Accelerator

Applications, A Novartis Company

18:00 - 19:30

601

CME 4

Neuroimaging Committee

Imaging Neuroinflammation -

Everything You Always Wanted to Know, But

Were Afraid to Ask

602

Special Track

Case Report Session What’s the Case? Report

it Now!

603

Industry Channel

Satellite Symposium by Telix Pharmaceuticals

19:30 - 20:30

Opening Concert


09:00 - 09:45

801

CME 5

Cardiovascular + Inflammation & Infection

Committee

Infiltration, Infection and Infiltrative Nuclear

Cardiovascular Diseases - Think Nuclear!

802-1

Special Track


Creating Tracers(09:00 - 09:35)

803-1

Industry Channel


09:45-10:30

802-2

Special Track


Paediatric NM Today

803-2

Industry Channel


10:45 - 12:15

901

CME 6Oncology & Theranostics

Committee

Quo vadis PET/MRI?

902

Industry Channel

Satellite Symposium by Siemens Healthineers

903

Industry Channel

Industry Symposium by GE Healthcare

12:15 - 13:10 Lunch Break

Hamburg City Tour 2

(12:30-13:00)


13:30 -14:50

1001

Plenary 3

Conventional Nuclear Medicine - Oldies but

Goldies

15:05 - 16:35

1101

CME 7

Physics + Dosimetry Committee

Developments and Challenges in

Theranostics

1102

Special Track

The Top 3 Trials Sessions 2Rest of the Science

1103

Industry Channel

Satellite Symposium by Terumo Interventional

Systems

16:50 - 17:35

1201

CME 8

Radiation Protection + Dosimetry Committee

Pregnancy and Breastfeeding in the Context of Nuclear

Medicine

1202-1

Special Track


The Theranostic Unit(16:50 - 17:10)

1203

Industry Channel

Satellite Symposium by PeerVoice

17:35 - 18:20


09:00 - 09:45

1301

CME 9

Radiopharmacy + Drug Development Committee

Back to the Future - New Kit-Based

Approaches for Labelling Radiopharmaceuticals

(68Ga, Al[18F]F,...)

1302-1

Special Track


Vision Trial(09:00 - 09:30)

1303-1

Industry Channel


09:45-10:30

1302-2

Special Track


The Best Young NM

1303-2

Industry Channel


10:45 - 11:30

1401

CME 10Thyroid + Oncology &

Theranostics Committee

Radionuclide Therapies - Management of Side

Effects and Complications

1402-1

Special Track


Running a Preclinical Lab in New York City

(10:45 - 11:20)

1403

Industry Channel

Satellite Symposium by Sirtex

11:30 - 12:15

1402-2

Special Track


New PET Tracers in Oncology

12:15 - 13:10 Lunch Break

Hamburg City Tour 3

(12:30-13:00)


13:30 -14:45

1501

Plenary 4

Isotopes‘ Past and Future

15:05 - 16:35

1601

CME 11

Bone & Joint Committee

New Concepts for Imaging and Therapy of

Bone Metastases

1602

Special Track

The Top 3 Trials Sessions 3New Tracers

1603

Industry Channel

Satellite Symposium by Boston Scientific

16:50 - 17:35

1701

CME 12


Nuclear Medicine in the Evaluation of Child Abuse

1702-1

Special Track


Radiopharmacy Running(16:50 - 17:25)

1703

Industry Channel

Satellite Symposium by Spectrum Dynamics

Medical Ltd.

17:35 - 18:20


09:00 - 09:45

1801

CME 13

Translational Molecular Imaging & Therapy +


Immunotheranostics

1802-1

Special Track


The Patient interviews the Doctor - A Roman

Conversation

09:45-10:30

1802-2

Special Track


Prostate Cancer Imaging - Girls Just Want to Have

Fun(ctional) E-PSMA Guidelines

(09:45 - 10:15)

10:45 - 11:27

1901

CME 14

Drug Development + Translational Molecular

Imaging & Therapy Committee

Probing Tumour Metabolism - An Update

1902-1

Special Track

Special Talk by Declan Murphy

Prostate Cancer along the Yellow Brick Road

(10:45- 11:07)

11:27 - 12:13

1902-2

Special Track


Reflections on the Development of PET and Theranostics Downunder - A 25-Year Journey into

the Light

12:13 -12:20

Closing Session

THURSDAY OCTOBER 21, 2021WEDNESDAY OCTOBER 20, 2021

204

Technologists’ Track CTE 1

Technologists Committee / SNMMI

Tech Guide Launch

205

Joint Symposium 1

Bone & Joint + Inflammation & Infection + Paediatrics Committee / ESSR

PET/MRI in MSK - Be Hybrid!

206

Joint Symposium 2

Cardiovascular Committee / ASNC

PET-MPI vs. SPECT-MPI - Is it Worth the Price?

207

Pitfalls & Artefacts 1

Cardiovascular + Physics + Technologists Committee

Pitfalls in Cardiovascular Imaging

208

M2M Track TROP Session

Drug Development + Radiopharmacy +

Translational Molecular Imaging & Therapy

Committee Prostate Cancer Imaging -

The Various Angles of Attack

209

Cutting Edge Science Track TROP Session

Dosimetry Committee

Radiobiology Meets Dosimetry

210

Clinical Oncology Track TROP Session


Head and Neck / Colorectal

211

Featured Session

Cardiovascular Committee

Quantification in MPI - A Must!

212

e-Poster Presentation Session 1


The Nuclear Cardiovascular World at its Best

304


Technologists + Paediatrics Committee

Managing the Paediatric Patient in Nuclear Medicine Departments

305

Joint Symposium 3

Cardiovascular Committee / EACVI

MPI after the ISCHEMIA Trial - Still Alive?

306

Joint Symposium 4

Dosimetry Committee / CIRSE

Biokinetics and Dosimetry in Intraarterial Therapy

307


Neuroimaging + Oncology Committee

Pseudoprogression and Pseudoresponse in Brain Tumours

308


Drug Development + Radiopharmacy + Translational Molecular Imaging & Therapy

Committee

It’s the Alpha, not the Beta

309


Dosimetry Committee

Dosimetry Methods

310



Breast

311

Featured Session


Show me your Heart!

312


Dosimetry Committee

Dosimetry

504


Technologists Committee / ESTRO

PET/CT for RT Planning

505

Joint Symposium 5

Drug Development + Radiopharmacy + Oncology & Theranostics Committee / SRS

Targeting Cancer with Peptides, Fragments or Antibodies

506

Joint Symposium 6


Committee / SRS

Modifying Radiopharmaceuticals to Alter Pharmacokinetics

507



Challenging Cases in Nuclear Neurology

508


Drug Development + Radiopharmacy +

Translational Molecular Imaging & Therapy

Committee

Theranostics - Various Targets

509


Dosimetry Committee

Lu-177 Dosimetry

510



Lung

511

Featured Session


New Kids on the Cardiovascular Block!

512



More on Infection & Inflammation Imaging and NM in COVID-19

604

Technologists’ Track

CTE 4


Cardiac PET/CT

605

Joint Symposium 7

Inflammation & Infection Committee / EASD

My Foot is on Fire - Find the Hot Spot

606

Joint Symposium 8

Inflammation & Infection + Bone & Joint Committee / EULAR

PET/CT and PET/MRI in Patients with Autoimmune Disorders

607


Oncology & Theranostics + Translational Molecular Imaging & Therapy Committee

Sentinel Lymph Node in Head & Neck, Penile and Gynaecological Cancers

608

M2M Track Featured Session


Committee

Mapping Brain Structures

609


Dosimetry Committee

Clinical Dosimetry and Radioembolisation

610



Gastro-Intestinal

611

TROP Session


Top of Cardiovascular and Soft Tissue Infection/Inflammation Imaging

612



Committee

Radiochemistry

804

Technologists’ Track

CTE 5

Technologists + Inflammation & Infection Committee

Update in Inflammation Imaging

805

Joint Symposium 9

Neuroimaging Committee / EAN

The New ATN Diagnostic Concept in Alzheimer’s Disease

806

Joint Symposium 10Neuroimaging Committee / ILAE

PET/MRI in Epilepsy

807



Pitfalls & Pearls in Paediatric Musculoskeletal

808

M2M Track Featured Session


Committee

Functional Brain Imaging

809


Dosimetry Committee

Diagnostic Dosimetry

810



Neuroendocrine

811

TROP Session


Top of Nuclear Medicine in COVID-19

812



Committee

Theranostics

904Technologists’ Track

CTE 6


Radionuclide Therapy Management

905

Joint Symposium 11

Neuroimaging + Oncology & Theranostics Committee / EANO

Advancements in Neuro-Oncology

906

Joint Symposium 12

Oncology & Theranostics Committee / EORTC

Nuclear Medicine in Precision Oncology

907


Thyroid Committee

Pitfalls & Artefacts in Endocrine Imaging

908



Committee

Tumour Microenvironment and Immunotherapy

909

Cutting Edge Science Track Featured Session

Radiation Protection Committee

From Safety Culture to Fieldwork in Radiation Protection

910

Clinical Oncology Track Featured Session


Radioguided Surgery and Sentinel Lymph Nodes

911

Featured Session


Molecular Imaging of Alzheimer’s Disease

912



Molecular Brain Imaging

1009


Physics Committee

New Imaging Equipment and Techniques

1012


Thyroid Committee

An Overview on Endocrine Disease

1104



Research - Technologist’s Involvement

1105

Joint Symposium 13

Oncology & Theranostics Committee / EHA

Biomarkers in Lymphoma

1106

Joint Symposium 14


New Therapies in Lymphoma - Is Deauville Still Good Enough?

1107

Teaching Session 1

Bone & Joint + Inflammation & Infection Committee / AGA

Imaging of Prosthetic Knee Joint Loosening - Spotlight on Quantitative

and Multidisciplinary Algorithms

1108



Committee

Peptides Only!

1109


Physics Committee

Software Developments in Total Body PET

1110



Prostate Staging

1111

Featured Session


Molecular Imaging of Movement Disorders

1112



Imaging in Recurrent Prostate Cancer

FI

NA

L P

RO

GR

AM

ME

| P

RO

GR

AM

ME

OV

ER

VIE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

PR

OG

RA

MM

E O

VE

RV

IEW

| FI

NA

L P

RO

GR

AM

ME

ON-DEMAND CONTENTAVAILABLE FROM OCTOBER 20, 2021 | 09:00

Plenary Sessions CME Sessions Joint Symposia Technologists‘ Track M2M Track Cutting Edge Science Track Pitfalls & Artefacts / Teaching Sessions Clinical Oncology Track Further TROP/Featured Sessions e-Poster Presentation Sessions Special Track Satellite Symposia

1204

Technologists’ Track Technologists’ Oral

Presentations 1


TROP - Sharing Technologist’s Experience 1

1205

Joint Symposium 15


Imaging Challenges in Multiple Myeloma - Quo Vadis 2021?

1206

Joint Symposium 16

Oncology & Theranostics Committee / ESMO

Combination Treatments - What can Radioligand Therapy be Combined

with?

1207

Teaching Session 2


All About Cardiac SPECT

1208



Committee

Radiochemistry - Cook it or Leave it

1209


Physics Committee

Imaging of Non-Standard Radionuclides

1210



Prostate Varia and Others

1211

Featured Session


Amino Acid Imaging of Gliomas

1212



Imaging in Primary Prostate Cancer

1304


Presentations 2



1305

Joint Symposium 17

Oncology & Theranostics Committee / EAU

What to Do and Not Do in Prostate Imaging

1306

Joint Symposium 18

Oncology & Theranostics Committee / EAU

Urological Challenges for Imaging Beyond Prostate

1307

Teaching Session 3

Dosimetry + Translational Molecular Imaging & Therapy + Radiation Protection

Committee

Radiobiology as a Missing Link in Improving and Understanding Nuclear

Medicine

1308



Committee

Out of the Box Innovations

1309


Physics Committee

Harmonisation and Standardisation

1310



Prostate BC Recurrence

1311

Featured Session


Brain Tumor Imaging - More than Amino Acids in Gliomas

1312



Lymphoma and Other Hematological Diseases

1404


Presentations 3



1405

Joint Symposium 19

Physics Committee / EFOMP

Harmonisation and Standardisation

1406

Joint Symposium 20

Physics Committee / AAPM

Artificial Intelligence for Image Processing and Quantification

1407

Teaching Session 4


Immunotherapy - Assessing Organs and Events on [18F]FDG PET/CT

1409

Cutting Edge Science Track

TROP Session

Physics Committee

Data Analysis

1410



Local Radionuclide Therapy and Other Oncological Treatments

1411

Featured Session


Novel Molecular Brain Imaging Applications

1412



Neuroendocrine and Lymphoma

1604

Technologists’ Track Mini Course 1 (60 minutes)


Safety in PET/MRI

1605

Joint Symposium 21

Physics Committee / AAPM

Numerical and Computer Phantoms

1606

Joint Symposium 22

Radiation Protection + Thyroid + Dosimetry Committee / EURAMED

The MEDIRAD Project - Impact on Nuclear Medicine Practice

1607

Teaching Session 5

Radiation Protection + Physics Committee

Radiation Detection and Measurement

1609


Featured Session

Physics Committee

PET Reconstructions and Corrections

1610



Prostate Cancer Therapy

1611

TROP Session


Paediatric Nuclear Medicine

1612



Head Neck / Breast / Lung

1704



Case Studies (PET/CT & PET/MRI)

1705

Joint Symposium 23

Radiation Protection + Technologists Committee / EURADOS

Extremity Dosimetry - It’s in Your Hands!

1706

Joint Symposium 24

Thyroid + Oncology & Theranostics Committee / ESMO

Theranostics in Thyroid Cancer Beyond Radioactive Iodine

1707

Teaching Session 6

Translational Molecular Imaging & Therapy + Drug Development + Radiopharmacy +


Animal Models - Technical Considerations and Recommendations

1709


Physics Committee

Data/Image Processing Based on Deep Learning

1710



Neuroendocrine Therapy

1711

TROP Session


General Nuclear Medicine

1712


Physics Committee

Image Acquisition / Reconstruction / Processing 1

1804



Case Studies (Conventional Nuclear Medicine)

1805

Joint Symposium 25

Thyroid Committee / ESES / ESSO

Global Cost-Effectiveness of Different DTC Management Strategies

1806

Joint Symposium 26

Translational Molecular Imaging & Therapy Committee / ESMI / WMIS

Imaging Mitochondria and Mitochondrial Dysfunction

1809


TROP Session

Physics Committee

Artificial Intelligence - Clinical Applications

1810

Clinical Oncology Track

TROP Session


Lymphoma and Other Hematological Tumours

1811

TROP Session

Thyroid Committee

Nuclear Thyroidologist and Thyroid Cancer Management - Current Update

and Future Perspectives

1812


Physics Committee

Image Acquisition / Reconstruction / Processing 2

1904

Technologists’ Track Technologists’ e-Poster

Presentations


Technologist e-Poster Presentations - Sharing Technologist’s Experience

1905

Joint Symposium 27

Neuroimaging Committee / JSNM

Advances in Molecular Imaging of Neurodegenerative Disorders

1906

Joint Symposium 28

EANM / IAEA

Lancet Oncology Commission on Medical Imaging and Nuclear Medicine

1909


TROP Session

Physics Committee

Radiomics - Methodology and Clinical Applications

1910

Clinical Oncology Track

TROP Session


Gynaecological and Melanoma

1911

TROP Session

Thyroid Committee

Nuclear Medicine Imaging and Therapy in Thyroid and Parathyroid Disorders

1912


Physics Committee

AI and Radiomics

FI

NA

L P

RO

GR

AM

ME

| P

RO

GR

AM

ME

OV

ER

VIE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

PR

OG

RA

MM

E O

VE

RV

IEW

| FI

NA

L P

RO

GR

AM

ME

ON-DEMAND CONTENTAVAILABLE FROM OCTOBER 20, 2021 09:00

Plenary Sessions CME Sessions Joint Symposia Technologists‘ Track M2M Track Cutting Edge Science Track Pitfalls & Artefacts / Teaching Sessions Clinical Oncology Track Further TROP/Featured Sessions e-Poster Presentation Sessions Special Track Satellite Symposia

For more information please contact your Sirtex representative

FLEXdose Delivery Programme Animation

Scan me

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty LtdSirtex Medical Europe GmbH, Joseph-Schumpeter-Allee 33, 53227 Bonn, Germany

www.sirtex.com

APM-EMEA-461 V1 0620

Expedite treatment timelines with SIR-Spheres® during COVID-19

FLEXdose Delivery ProgrammeMultiple delivery options. Any day of the week.

Order – Map – Treat The ability to Map and Treat Same day – Same stay – Same week


60

OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

F

IN

AL

PR

OG

RA

MM

E |

OR

AL

PR

ES

EN

TA

TIO

NS

PCS1

Monday, October 4, 2021, 09:00 - 12:00Channel 1

Pre-Congress-Symposium 1: Pre-Clinical Dosimetry and Extrapolations from Animal Models to Humans

PCS-001Introduction - Preclinical Dosimetry, Challenges and ProspectsF. Cicone; Università degli Studi “Magna Graecia” di Catanzaro, Catanzaro, ITALY.

PCS-003“Clinical” Challenges, Animal Handling and ReproducibilityR. Beck; Technische Universität München, Munich, GERMANY.

PCS-005Building Bridges Between Humans and Animals - Technological DevelopmentsC. Pettinato; Policlinico di Milano, Milan, ITALY.

PCS-007In Vivo Radiobiology and Dose/Response EffectsN. Chouin; LUNAM Université, Oniris, «AMaROC», Nantes, FRANCE.

PCS-006Methodological Aspects of Dose ExtrapolationsS. Gnesin; Institut universitaire de radiophysique appliquée (IRA) - CHUV, Lausanne, SWITZERLAND.

PCS2


Pre-Congress-Symposium 2: Signal Quantification in Cardiac SPECT - Dream or Reality?

PCS-009Clinical Needs for Quantification in Cardiac SPECTH. Verberne; Academic Medical Center, Department of Nuclear Medicine, Amsterdam, NETHERLANDS.

PCS-010Myocardial Blood FlowI. Armstrong; Manchester University NHS Foundation Trust, Nuclear Medicine, Manchester, UNITED KINGDOM.

PCS-011MIBG for Cardiac InnervationK. Prigent; CHU Côte de Nacre, Service de Médecine Nucléaire, Caen, FRANCE.

PCS-013Bone Tracers in AmyloidosisM. Burniston; Burnington, Barts Health NHS Trust, Nuclear Medicine, London, UNITED KINGDOM.

PCS-014Is Whole-Body CZT the Future?L. Imbert; CHRU Nancy, Nuclear Medicine, Nancy, FRANCE.

PCS3

Tuesday, October 5, 2021, 09:00 - 12:00Channel 1

Pre-Congress-Symposium 3: Radiosynoviorthesis - Master Class in Science and Practice

PCS-016Changing Paradigms in (Osteo)Arthritis ManagementL. Terslev; Rigshospitalet Glostrup, Copenhagen Center for Arthritis Research Copenhagen University Hospital, Copenhagen, DENMARK.

PCS-017Challenges in the Management of HaemophiliaT. T. Yee; Royal Free Hospital - University College London, Hematology, London, UNITED KINGDOM.

PCS-020EANM Guideline - Patient Selection, Isotopes, Multidisciplinary CollaborationF. M. van der Zant; Noordwest Ziekenhuisgroep, Nucleaire geneeskunde, Alkmaar, NETHERLANDS.

PCS-021EANM Guideline - Procedural Aspects, Arthrocentesis and Radiation ProtectionW. U. Kampen; Radiologische Allianz Hamburg - Nuklearmedizin Spitalerhof, Hamburg, GERMANY.



6362

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

PCS4


Pre-Congress-Symposium 4: Structured Reporting of Oncology PET-CT - Are we Ready for Template-Based Reporting?

PCS-023Essential Elements of PET-CT Reporting - An OverviewG. Gnanasegaran; Royal Free London NHS Foundation Trust, Department of Nuclear Medicine, London, UNITED KINGDOM.

PCS-024How to Report PET-CT in LymphomaC. Kobe; University of Cologne, Department of Nuclear Medicine, Cologne, GERMANY.

PCS-025How to Report PET-CT in Lung CancerE. Lopci; Nuclear Medicine Unit, IRCCS – Humanitas Research Hospital, Milan, ITALY.

PCS-026How to Report PET-CT in GI and HPB CancerS. Carrilho Vaz; Champalimaud Foundation Centre for the Unkown, Nuclear Medicine, Radiopharmacology, Lisbon, PORTUGAL.

PCS-028How to Report PET-CT in Prostate Cancer K. Rahbar; University Hospital Muenster, Department of Nuclear Medicine, Münster, GERMANY.

PCS-029How to Report PET-CT in Melanoma and MyelomaC. Nanni; Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola, Nuclear Medicine, Bologna, ITALY.

PCS-030How to Report PET-CT in Gynaecological Cancers S. Balogová; Comenius University of Bratislava, St.Elisabeth Oncology Institute, Nuclear medicine, Bratislava, SLOVAKIA.

PCS-031How to Report PET-CT in Neuroendocrine TumourV. Ambrosini; University of Bologna, Policlinico S.Orsola Malpighi Bologna, DIMES, Nuclear Medicine, Bologna, ITALY.

PCS5

Wednesday, October 6, 2021, 09:00 - 12:10Channel 1

Pre-Congress-Symposium 5: Imaging of Protein Misfolding in Parkinson’s Disease and Related Disorders - Where are we and What do we need?

PCS-034Molecular Neuroimaging of PD and Related Disorders - Current StateS. Morbelli; San Martino Hospital, University of Genoa, Nuclear Medicine, Genoa, ITALY.

PCS-035Amyloid and Tau Pathology in PD, DLB, PSP/CBD and MSAG. Kovacs; University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, CANADA.

PCS-036Relevance of Amyloid Imaging in Parkinson’s Disease and Related DisordersN. Bohnen; University of Michigan, Department of Radiology, Michigan, UNITED STATES OF AMERICA.

PCS-038Tau Imaging in PSP/CBD - Ready for Clinical Trials?H. Barthel; University of Leipzig, Department of Nuclear Medicine, Leipzig, GERMANY.

PCS-039Alpha-Syn Pathology in PD, DLB, PSP/CBD and MSAL. Walker; Newcastle University, Institute of Neuroscience, Newcastle, UNITED KINGDOM.

PCS-040Alpha-Syn Imaging in PD, MSA and DLB - Will We Ever Get There?J. Seibyl; Institute for Neurodegenerative Disorders, New Haven, UNITED STATES OF AMERICA.

PCS6


Pre-Congress-Symposium 6 (EANM/ESTRO): Oligocare Concept in Radiation Oncology

PCS-042Oligocare for Tailored MedicineM. Guckenberger; Department of Radiation Oncology, University Hospital Zurich (USZ), Zürich, SWITZERLAND

PCS-043Radiation Oncologist’s Point of ViewM. Scorsetti; Radiotherapy and Radiosurgery Unit, Humanitas University, Pieve Emanuele, ITALY.

PCS-044Targeted Imaging and Therapy in OligometsE. Lopci; Nuclear Medicine Unit, IRCCS – Humanitas Research Hospital, Milan, ITALY.

PCS-046The Future of Imaging in RadiotherapyP. Ost; Department of Radiation Oncology, Iridium Network, Antwerp, BELGIUM.

PCS-047Ongoing Projects and InitiativesY. Lievens; Radiation Oncology Department, Ghent University Hospital and Ghent University, Ghent, BELGIUM.

PCS7


Pre-Congress-Symposium 7: Biokinetic Modelling in Cancer Therapy and Clinical Impact

PCS-049Introduction and OverviewC. Stokke; Oslo University Hospital, Division of Radiology and Nuclear Medicine, Oslo , NORWAY.

PCS-050Biokinetic Modelling and its Clinical Impact for 131I Therapy of Thyroid DiseaseF. Verburg; Erasmus MC, Nuclear Medicine, Rotterdam, NETHERLANDS.

PCS-051Modelling of 177Lu-PRRT Biokinetics and Impact on Clinical DosimetryM. Cremonesi; European Institute of Oncology, Radiation Research Unit, Milan, ITALY.

PCS-053Dosimetry and Treatment Planning for 177Lu-PSMA Using PBPK ModellingG. Glatting; Universität Ulm, Abteilung Nuklearmedizin, Medizinische Strahlenphysik, Ulm, GERMANY.

PCS-054Modelling of 223Ra Biokinetics and its Application for Clinical Dosimetry J. Taprogge; St. George’s University Hospital NHS FT / Royal Marsden Hospital NHS FT, Medical Physics, London, UNITED KINGDOM.

PCS-055Biokinetics of the 212Pb in vivo Alpha Particle Generator and its Radioactive DaughtersN. Zaid; Ulm University, Ulm, GERMANY.

PCS-056Biokinetic Modelling and Dosimetry for Optimizing Treatment using 211At-Labelled AntibodiesS. Palm; University of Gothenburg, Radiation Physics, Gothenburg, SWEDEN.

PCS8


Pre-Congress-Symposium 8: Novel Radionuclides for Theranostics on the Horizon

PCS-059Novel Radionuclides for Theranostics - What for?C. Deroose; University Hospitals Leuven, Nuclear Medicine, Leuven, BELGIUM.

PCS-060PRISMAP - The European Medical Isotope Programme Providing Novel RadionuclidesT. Stora; CERN Geneva, Geneva, SWITZERLAND.

PCS-061Mass Separation Techniques - The Way to High Quality?M. Manzolaro; Istituto Nazionale di Fisica Nucleare, Rome, ITALY.Innsbruck, Innsbruck, AUSTRIA, 3Palacký University Olomouc, Olomouc, CZECH REPUBLIC.



6564

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

PCS-062The Technical Challenges to Provide Novel RadionuclidesR. Mikolajczak; National Centre for Nuclear research-POLATOM, Otwock, POLAND.

PCS-064Novel Radionuclides - Preclinical Proof of ConceptC. Müller; Paul Scherrer Institute, Center for Radiopharmaceutical Sciences, Zürich, SWITZERLAND.

PCS-065Novel Radionuclides - But in Right Quality and for the Right TargetD. Niculae; Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Bucharest, ROMANIA.

PCS-066Novel Radionuclides - What Do We Already Know in Clinical Applications?I. Rauscher; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, GERMANY.

PCS-067Novel Radionuclides - Don’t Forget the Regulatory SideO. Neels; Institute of Radiopharmaceutical Cancer Research Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, GERMANY.

PCS9


Pre-Congress-Symposium 9 (EANM/ESES): Nuclear Endocrinology in the Era of Precision Medicine

PCS-070Precision Medicine in Endocrinology. The Radiopharmacist’s ViewM. Fani; University Hospital Basel, Dept. of Nuclear Medicine, Basel, SWITZERLAND.

PCS-071Functional and Molecular Thyroid ImagingL. Giovanella; Imaging Institute of Southern Switzerland, Clinic for Nuclear Medicine, Bellinzona, SWITZERLAND.

PCS-072Molecular imaging of endocrine neoplasms: a practical approach for well-tailored imaging protocols D. Taïeb; Centre Hospitalo-Universitaire Timone, Médecine Nucléaire, Marseille, FRANCE.

PCS-074Impact of Imaging on Personalized Parathyroidectomy in Primary and Renal HyperparathyroidismP. Petranović Ovčariček; University Hospital Center Sestre milosrdnice, Oncology and nuclear medicine, Zagreb, CROATIA.

PCS-075Integration of Molecular Imaging in the Personalized Approach to Patients with Adrenal MassesM. Raffaelli; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Division of Endocrine and Metabolic Surgery, Department of Medical and Surgical Sciences, Rome, ITALY.

PCS-076Imaging of MEN1, MEN2 and VHL - The Endocrine Surgeon’s ViewF. Sebag; AIc-Marseille university, APHM, Department of Endocrine Surgery, Marseille, FRANCE.

PCS10


Pre-Congress-Symposium 10: Total Body PET

PCS-079Translation of the Technical Innovations of Total Body PET in ClinicL. Nardo; University of California at Davis, Division of Nuclear Medicine, Davis, UNITED STATES OF AMERICA.

PCS-080Clinical Applications of Total Body PET - Bern ExperienceA. Rominger; University of Bern, Department of Nuclear Medicine, Bern, SWITZERLAND.

PCS-081Clinical Applications of Total Body PET - Shanghai ExperienceH. Shi; Zhongshan Hospital of Fudan University, Department of Nuclear Medicine, Shanghai, CHINA.

PCS-082Clinical and Research Benefits of a Long Axial Field-of-View SystemM. Daube-Witherspoon; University of Pennsylvania, Department of Radiology, Philadelphia, UNITED STATES OF AMERICA.

PCS-084Development of Detector for Total Body PETS. Ziegler; University of Munich, Department of Nuclear Medicine, Munich, GERMANY.

PCS-085Instrumentation of Total Body PETS. Vandenberghe; Ghent University, Department of Electronics and Information Systems, Ghent, BELGIUM.

PCS-086Image Reconstruction for Total Body PETD. Visvikis; National Institute of Health and Medical Research (INSERM), Medical Image Processing Lab in Brest, Brest, FRANCE.

PCS11


Pre-Congress-Symposium 11: Light in the Dark - Hybrid Imaging in Patients with Sepsis/Bacteremia

PCS-088Game Intro - Sepsis/Bacteremia and the Questions from Clinicians to NM PhysiciansA. L. Goodman; Centre for Clinical Infection and Diagnostics Research, King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, London, UNITED KINGDOM.

PCS-089Level 1 - Diagnostic Yield of FDG PET/CT in Patients with Sepsis/BacteremiaA. W. J. M. Glaudemans; University Medical Center Groningen, Medical Imaging Center, Groningen, NETHERLANDS.

PCS-090Level 2 - Clinical Impact and Outcome Using FDG PET/CT in Patients with Sepsis/BacteremiaS. Hess; Department of Radiology and Nuclear Medicine, Hospital Southwest Jutland, Esbjerg, DENMARK.

PCS-092Level 3 - Cost-Effectiveness and Proposed Optimal Use of FDG PET/CT in Patients with Sepsis/BacteremiaI. J. Kouijzer; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboudumc, Nijmegen, NETHERLANDS.

PCS-093Bonus Level - Other Tracers Beyond FDGA. Roivainen; Turku PET Centre, University of Turku and Turku University Hospital, Turku, FINLAND.

PCS-094Next Level - Possible Role of FDG PET/MRIP. Veit-Haibach; University Health Network, Joint Dept. Medical Imaging, Toronto, CANADA.

PCS12


Pre-Congress-Symposium 12: PET/MR - The Cross Path of Morphology and Functionality

PCS-096IntroR. Strand Olsen; Bispebjerg and Frederiksberg Hospital, Clinical Physiology; Nuclear Medicine, Copenhagen, DENMARK.

PCS-097The PET/MRT. Lund Andersen; Rigshospitalet, Dept. of Clinical Physiology, Nuclear Medicine and PET, Copenhagen, DENMARK.

PCS-098Performing PET/MRL. Grønnemark; Aarhus University Hospital, Department of Nuclear medicine and PET, Aarhus, DENMARK.

PCS-099Onsite Experience with PET/MRS. Stienaers; University hospitals Leuven, Nuclear Medicine department, Leuven, BELGIUM.

PCS-101PET/MR Motion CorrectionM. Ganz-Benjaminsen; Rigshospitalet, Copenhagen University Hospital, Neurobiology Research Unit, Copenhagen, DENMARK.

PCS-102Interpretation of PET/MRA. Beer; Ulm University Hospital, Department of Nuclear Medicine, Ulm , GERMANY.


67

OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

100


Opening Ceremony

OP-0001Opening CeremonyS. Fanti; EANM Congress Chair, Bologna, ITALY.

101


Plenary 1: Highlights Lecture

OP-0002Highlight LectureI. Burger; Kantonsspital Baden, Nuclear Medicine, Baden, SWITZERLAND.& N. Albert; LMU, Munich, GERMANY.

201


CME 1: Prostate Cancer - Greatest Hits

OP-0004Immunohistochemistry and PET Targeting ProstateSpecific Membrane Antigen - Now You See Me?D. Ferraro; University Hospital Zurich, Department of Nuclear Medicine, Zurich, SWITZERLAND.

OP-0005PSMA PET in Primary Staging - Ready for Prime Time? The Urologist’s PerspectiveO. Ettala; Turku University Hospital, Department of Urology, Turku, FINLAND.

OP-0006PSMA PET After Primary Treatment - Anything New?D. Oprea-Lager; Amsterdam University Medical Centers, Department of Radiology & Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0007PSMA PET for Castration-Resistant Prostate Cancer - How Far Have We Come?W. Fendler; University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

202-1


Interview with the Expert 1 - Therapy

OP-0009Interview - TherapyS. Fanti; University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

OP-0010Interview - TherapyI. Virgolini; Medizinischen Universität Innsbruck, Innsbruck, AUSTRIA.

202-2


Interview with the Expert 2 - Imaging Myeloma

OP-0011Interview - Imaging MyelomaC. Nanni; Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola, Nuclear Medicine, Bologna, ITALY.

OP-0012Interview - Imaging MyelomaP. Castellucci; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine Unit, Bologna, ITALY.

204

Wednesday, October 20 - Saturday, October 23, 2021on-demand pool, release on Wednesday, October 20 at 09:00

CTE 1 (EANM/SNMMI): Tech Guide Launch

OP-0013PET/CT Artefacts and PitfallsJ. T. Middlebrooks; Radiation Safety and Health Physics Consultant, Board Certified in Radiation Safety Medical Imaging Consultants, Benton, UNITED STATES OF AMERICA.

OncoSil™ is delivered directly into the

tumour which is ground breaking. It has been

done experimentally, but nothing of the sort has

been performed and taken to the commercial space.

...what’s significant is the doubling of downstaging

and potential curative surgery to almost 1 in 4 patients from only 12% with standard therapy.

oncosil.com

TRENDS IN NUCLEAR MEDICINE:Dr Zarni Win discusses the increasing

role of oncological therapies in nuclear medicine and the signficance of the

PanCO Study data in the treatment of unresectable pancreatic cancer

The delivery of oncological therapy in nuclear medicine is relatively new; as a nuclear medicine physician, how do you see this evolving in the future? Within the wider community of medicine, the field of radionuclide therapy is very new and innovative, even though it has been around for over half a century. However, the delivery of a radionuclide therapy such as OncoSil™ is very different to what we have been doing in the past. The OncoSil™ device is very different compared to recent therapies like selective internal radiation therapy (SIRT) which is delivered through the artery for liver cancer. OncoSil™ is delivered directly into the tumour which is ground-breaking. It has been done experimentally, but nothing of the sort has been performed and taken to the commercial space, passing through the regulatory phases. This is quite an exciting field of nuclear medicine – mainly because companies like OncoSil and other big companies are coming into the space which has never happened before, and that is really driving forward this field of radionuclide therapy. I think this will be big within the next 5-10-15 years.

What does nuclear medicine bring to the oncological space that the other specialities do not?I think the direct comparison is with oncology radiotherapy, where the radiotherapist is shooting in radiation externally from a machine through the body to where the cancer is. The dose or the activity is limited because it damages the tissues surrounding the tumour, so you will always be limited by the maximum dose of radiation you can deliver with external beam radiotherapy, whether that is super precise or not. Nuclear medicine is way more targeted compared to external beam radiotherapy, and it can deliver significantly higher targeted radiation to the tumour. So that is the biggest advantage of radionuclide therapy compared to other fields of medicine. Nuclear medicine is also a bridge to newer immunotherapies, chemotherapies and radiotherapies – you can target as accurately as you can with immunotherapy but deliver higher doses compared to external beam.

What do you think the PanCO data1 could mean in the future for patients with unresectable locally advanced pancreatic cancer? I find it’s quite significant, and what’s significant is the doubling of downstaging and potential curative surgery to almost 1 in 4 patients from only 12% with standard therapy.

How do you feel about being able to offer this new treatment to patients?It’s very exciting and fills me with optimism – especially as there has not been any significant development for pancreatic patients for over a decade. To me, OncoSil™ offers the patients something new and gives my patients a chance undergo potential curative surgery.

REFERENCES: 1. Ross P et al. ESMO World Congress on Gastrointestinal Cancer; Ann Oncol 2020; 31 (Suppl 3); Abs. O-1 (PanCO study: ClinicalTrials.gov Identifier: NCT03003078) 2. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV in April 2020. OncoSil™ is intended for use in combination with gemcitabine-based chemotherapy. 3. OncoSil™ System Instructions for Use. INTENDED USE/INDICATIONS FOR USE: OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under endoscopic ultrasound guidance. OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. OncoSil™ System is supplied sterile and is intended for single-patient, single-use.This information is intended for healthcare professionals only. All medical treatments carry benefits and risks. For safety related information, please refer to the OncoSil™ System Instructions for Use. OncoSil™ is a registered trademark of OncoSil Medical Ltd. Suite 503, Level 5, 15 Blue Street, North Sydney, NSW 2060 Australia. CO01-E-0821.

Dr Zarni Win is Chief of Service, Nuclear Medicine & Consultant Radiologist at The London Clinic, UK.

• OncoSil Medical was granted CE Marking Approval and breakthrough designation2 for OncoSil™

• OncoSil™ comprises of Phosphorous-32 (32P) microparticles suspended in a specially formulated diluent. The microparticles are a permanent implant which contain Phosphorous-32 (32P), a pure beta-emitter radioisotope with a physical half-life of 14.27 days

• In therapeutic use, 98% of the radiation is delivered within 81 days, which gives an absorbed dose equivalent to 100 Gy3

OncoSil™ is a single-use brachytherapy device

for the treatment of unresectable locally

advanced pancreatic cancer in combination

with chemotherapy



6968

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

208


M2M Track - TROP Session: Prostate Cancer Imaging - The Various Angles of Attack

OP-0032Use of the fibroblast activation protein inhibitor [64Cu]Cu-DOTHA2-FAPI-04 to overcome heterogeneity in prostate cancerO. Bélissant1, V. Dumulon-Perreault2, M. Milot3, I. Ben-Salem1, E. Croteau2, S. Ait-Mohand2, E. Turcotte1, B. Guérin1,2, E. Rousseau1; 1Département de médecine nucléaire et radiobiologie, Université de Sherbrooke, Sherbrooke, QC, CANADA, 2Centre d’imagerie moléculaire de Sherbrooke (CIMS) du CRCHUS, Sherbrooke, QC, CANADA, 3Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-0033Click chemistry-based PSMA ligands for multimodal intraoperative tumor detection of prostate cancerY. Derks1, M. Rijpkema1, H. Amatdjais-Groenen2, A. Kip1, P. Laverman1, S. Lütje3, S. Heskamp1, D. Löwik2; 1Radboud university medical center, Nijmegen, NETHERLANDS, 2Radboud University, Nijmegen, NETHERLANDS, 3University Hospital Bonn, Bonn, GERMANY.

OP-0034Clinical translation of the GRPR antagonist [99mTc]Tc-maSSS-PEG2-RM26 for targeting prostate tumorsA. Abouzayed1, S. S. Rinne1, N. Lushnikova2, A. Rybina2, E. Usynin2, J. Sörensen1, V. Tolmachev1, V. Chernov2, A. Orlova1; 1Uppsala University, Uppsala, SWEDEN, 2Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

OP-003568Ga- versus 18F-PSMA for Cerenkov Luminescence and autoradiography in a prostate cancer mouse modelP. Fragoso Costa1,2, L. Püllen3,2, J. M. Klose1,2, J. Iking1,2, P. Sandach1,2, M. Staniszewska1,2, K. Herrmann1,2, J. P. Radtke3,2, S. Tschirdewahn3,2, B. Hadaschik3,2, W. P. Fendler1,2, C. Darr3,2; 1Clinic for Nuclear Medicine, Essen, GERMANY, 2German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY, 3Department of Urology, Essen, GERMANY.

OP-0036Impact of the specific activity of 18F-PSMA-11 on tumor uptake in a preclinical prostate cancer modelS. Piron1, J. Verhoeven1, B. Descamps1, K. Kersemans2, C. Vanhove1, F. De Vos1; 1Ghent University, Ghent, BELGIUM, 2Ghent University Hospital, Ghent, BELGIUM.

OP-0037Evaluation of the HET-CAM model for biodistribution studies of 18F-siPSMA-14J. Loeffler1,2, C. Hamp2, A. B. Koch2, C. Solbach2, L. Hao1, G. Glatting3, V. Rasche1,4, A. J. Beer2, G. Winter2; 1Center for Translational Imaging, Core Facility Small Animal Imaging, Ulm University, Ulm, GERMANY, 2Department of Nuclear Medicine, Ulm University Medical Faculty, Ulm, GERMANY, 3Department of Nuclear Medicine, Medical Radiation Physics, Ulm University Medical Faculty, Ulm, GERMANY, 4Department of Internal Medicine, Ulm University Medical Faculty, Ulm, GERMANY.

OP-0038Investigation of the Molecular Design of PSMA-targeting Radioligands for Imaging of Prostate CancerF. Lundmark, G. Olanders, S. S. Rinne, A. Abouzayed, A. Orlova, U. Rosenström; Department of Medicinal Chemistry at Uppsala University, Uppsala, SWEDEN.

OP-0039Selection of Optimal Radiolabel Position and Composition in DARPin Ec1 for High-Contrast Imaging of EpCAM Expression in Prostate CancerA. Vorobyeva1,2, T. Xu1, A. Schulga3,2, E. Konovalova3, Y. Liu1, J. Garousi1, S. S. Rinne1, M. Larkina2, H. Ding4, T. Gräslund4, A. Orlova1,2, S. M. Deyev3,2, V. Tolmachev1,2; 1Uppsala University, Uppsala, SWEDEN, 2National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 3Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Moscow, RUSSIAN FEDERATION, 4KTH Royal Institute of Technology, Stockholm, SWEDEN.

OP-0040HER3 targeting 68Ga-labeled affibody provides superior PET imaging contrast compared with 89Zr-labeled antibody and antibody-fragment based tracersS. Rinne1, A. Abouzayed1, C. Dahlsson Leitao2, A. Vorobyeva1, V. Tolmachev1, S. Ståhl2, J. Löfblom2, A. Orlova1; 1Uppsala University, Uppsala, SWEDEN, 2KTH - Royal Institute of Technology, Stockholm, SWEDEN.

OP-0042Synthesis, radiolabelling and in vitro characterisation of a bimodal BODIPY-labelled PSMA-targeting bioconjugate for dual imaging of prostate cancerT. Stemler1, I. Hierlmeier1, S. Maus1, F. Rosar1, F. Khreish1, S. Ezziddin1, E. Krause2, C. Hoffmann3, G. Jung3, M. Bartholomä1; 1Department of Nuclear Medicine, Saarland University – Medical Center, Homburg/Saar, GERMANY, 2Department of Cellular Neurophysiology, Saarland University, Center for Integrative Physiology and Molecular Medicine, Homburg/Saar, GERMANY, 3Department of Biophysical Chemistry, Saarland University, Saarbrücken, GERMANY.

OP-0014New Solutions in OncologyA. Doma; Institute of Oncology Ljubljana, Nuclear Medicine Dep., Ljubljana, SLOVENIA.

OP-0015Advancements in NeuroimagingD. van Weehaeghe; Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Leuven and KU Leuven, Leuven, BELGIUM.

205


Joint Symposium 1 (EANM/ESSR): PET/MRI in MSK - Be Hybrid!

OP-0017MR Protocols for Hybrid PET/MRI in MSKL. Sconfienza; I.R.C.C.S. Istituto Ortopedico Galeazzi, Unit of Diagnostic and Interventional Radiology, Milan, ITALY.

OP-0018PET/MRI in MSK Malignant DiseasesL. Garcia Canamaque; HM Hospitales, Madrid, SPAIN.

OP-0019PET/MRI in MSK Benign ConditionsS. Wan; University College London , London, UNITED KINGDOM.

OP-0020PET/MRI in MSK - Be Hybrid!S. Annunziata; Fondazione Policlinico Gemelli , Rome , ITALY.

206


Joint Symposium 2 (EANM/ASNC): PET-MPI vs. SPECT-MPI - Is it Worth the Price?

OP-0022On Stable Chest Pain?P. Arumugam; Department of Nuclear Medicine, Central Manchester Foundation Trust, Manchester, UNITED KINGDOM.

OP-0023For Detecting Microvessel DiseaseC. Nappi; Federico II University of Naples, Department of Advanced Biomedical Sciences, Naples, ITALY.

OP-0024 For Guiding Coronary Revascularisation R. C. Thompson; University of Missouri - Kansas City, St. Luke’s Mid America Heart Institute, Kansas City, UNITED STATES OF AMERICA.

OP-0025In Inflammatory and Infiltrative DiseasesS. Dorbala; Brigham and Women’s Hospital, Harvard Medical School, Boston, UNITED STATES OF AMERICA.

207


Pitfalls & Artefacts 1: Pitfalls in Cardiovascular Imaging

OP-0027Clinical CasesJ. Diekmann; Hannover Medical School (MHH), Department of Nuclear Medicine, Hanover, GERMANY.

OP-0028Technologist CasesL. Camoni; University of Brescia, Nuclear Medicine and Molecular Imaging Department, Brescia, ITALY.

OP-0029Physics Cases S. G. Nekolla; Technical University of Munich, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY.



7170

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

210


Clinical Oncology Track - TROP Session: Head and Neck / Colorectal

OP-0053Do we know what we’re looking at? Increasing our understanding of 18F-FDG distribution in oncology by direct coregistration of histopathology and autoradiography in malignancies of the head and neckJ. Debacker1,2,3, D. Creytens4,5, Y. D’Asseler5,6, K. De Man6, B. Descamps7,8, V. Keereman8,9, S. Libbrecht4, V. Schelfhout5,6, K. Van de Vijver4,5, C. Vanhove7,8, W. Huvenne1,2; 1Department of Head and Skin, Ghent University, Ghent, BELGIUM, 2Department of Head and Neck Surgery, Ghent University Hospital, Ghent, BELGIUM, 3Department of Nuclear Medicine, University Hospital Brussels, Brussels, BELGIUM, 4Department of Pathology, Ghent University Hospital, Ghent, BELGIUM, 5Department of Diagnostic Sciences, Ghent University, Ghent, BELGIUM, 6Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, 7INFINITY Lab, Ghent University, Ghent, BELGIUM, 8Department of Electronics and Information Systems, Ghent University, Ghent, BELGIUM, 9XEOS Medical, Ghent, BELGIUM.

OP-0054Correlation of FAPI-PET and contrast enhanced T1w / T2w MRI in 12 adenoid cystic carcinomasD. Liew1, M. Röhrich1, L. Loi2, S. Adeberg1, M. Syed1, U. Haberkorn1, D. Paech2; 1University Hospital, Heidelberg, GERMANY, 2German Cancer Research Centre, Heidelberg, GERMANY.

OP-0055Non-invasive Grading of Oropharyngeal Squamous Carcinomas with FDG PET/CT Textural ParametersM. Novikov; LISOD Hospital, Pliuty village, Obuhovskiy district, UKRAINE.

OP-0056Pretreatment metabolic and molecular profiling of locally advanced head and neck cancerH. Minn1,2, A. Silvoniemi3, L. Nissi1, J. Hirvonen4, M. Seppänen5, J. Laine6; 1University of Turku, Turku, FINLAND, 2Department of Oncology, Turku University Hospital, Turku, FINLAND, 3Department of Otorhinolaryngology - Head and Neck Surgery. Turku University Hospital and University of Turku, Turku, FINLAND, 4Department of Radiology. Turku University Hospital and University of Turku, Turku, FINLAND, 5Department of Clinical Physiology, Nuclear Medicine and Turku PET Centre.University of Turku, Turku, FINLAND, 6Department of Pathology. Turku University Hospital and University of Turku, Turku, FINLAND.

OP-0057Monitoring the Response of Radiation Therapy in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with “Full Digital” 18F-FDG-PET/CTM. Mihaylova1, E. Piperkova1, L. Chavdarova1, K. Nikolova1, S. Petrov1, I. Mihaylova2; 1University Specialized Hospital for Active Treatment in Oncology, Clinic of Nuclear Medicine, Sofia, BULGARIA, 2University Specialized Hospital for Active Treatment in Oncology, Department of Radiation Therapy, Sofia, BULGARIA.

OP-0058Molecular Imaging parameters with 18F-FDG PET/CT comparison with MRI in the evaluation of recurrence of nasopharyngeal cancer a Mexican populationS. Medina-Ornelas1, K. Luna-Ortiz1, J. Lopez-Gomez2, J. Altamirano-Garcia1, J. Alegria-Baños1, O. Martinez-Juarez3; 1Instituto Nacional de Cancerologia, Mexico City, MEXICO, 2Hospital Angeles Pedregal, Mexico City, MEXICO, 3Hospital Angeles Lindavista, Mexico City, MEXICO.

OP-0059Disease free and Progression free survivals in metabolic responders and non-responder on follow up FDG PET/CT after chemoradiation in nasopharynx cancer patientsN. Fatima1, M. U. Zaman1, S. Zaman2, A. Zaman3, U. U. Zaman4; 1Aga Khan University, Karachi, PAKISTAN, 2Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN, 3Dr Ruth Pfau (CHK), Karachi, PAKISTAN, 4Sunny Downstate Medical Center, NY, New York, NY, UNITED STATES OF AMERICA.

OP-0060Comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT for the Diagnosis of Lesions in Patients with Colorectal CancerX. Lin, H. Zhu, W. Zhao, Y. Zhang, A. Wu, Z. Yang, X. Wang; Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-0061Combined 18F-FDG PET/CT-based metabolically active tumor volume and dissemination parameter improve outcome prediction in metastatic colorectal cancerE. Woff, G. Critchi, T. Guiot, L. Ameye, A. Hendlisz, P. Flamen; Institut Jules Bordet, Brussels, BELGIUM.

209


Cutting Edge Science Track - TROP Session: Radiobiology Meets Dosimetry

OP-0044Quantitative Ex Vivo Imaging of 225Ac with the iQID Alpha CameraC. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe7,8; 1Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, 2Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 3Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 4Department of Physics and Physical Oceanography, Memorial University of Newfoundland, St. John’s, NL, CANADA, 5Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, UNITED STATES OF AMERICA, 6College of Optical Sciences, University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA, 7PET Functional Imaging, BC Cancer, Vancouver, BC, CANADA, 8Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

OP-0045The Impact of Cell Shape on the Doses Delivered to the Nucleus from 177Lu-labelled RadiotracersC. Miller1,2, G. Chaussé3, J. Brosch-Lenz2,4, F. Bénard3,5,6, A. Rahmim1,2,6, C. Uribe3,6; 1Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, 2Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 3PET Functional Imaging, BC Cancer, Vancouver, BC, CANADA, 4Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, 5Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 6Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

OP-0046A physiologically-based pharmacokinetic model of 212Pb-labelled pharmaceuticals targeting neuroendocrine tumors in miceN. Zaid, P. Kletting, G. Winter, A. Beer, G. Glatting; Ulm University, Ulm, GERMANY.

OP-0047Therapeutic efficacy of heterogeneously distributed radiolabelled peptides: influence of radionuclide choiceG. Tamborino1,2, J. Nonnekens2,3,4, M. De Saint-Hubert1, L. Struelens1, M. De Jong2, M. Konijnenberg2; 1Research in Dosimetric Application, Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, 2Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, 3Department of Molecular Genetics, Erasmus MC, Rotterdam, NETHERLANDS, 4Oncode Institute, Erasmus MC, Rotterdam, NETHERLANDS.

OP-0048Modeling early radiation DNA damage occurring during [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapyG. Tamborino1,2, Y. Perrot3, M. De Saint-Hubert1, L. Struelens1, J. Nonnekens2,4, M. De Jong2, M. Konijnenberg2, C. Villagrasa3; 1Research in Dosimetric Application, Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, 2Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, 3IRSN, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay aux Roses, FRANCE, 4Department of Molecular Genetics, Erasmus MC, Rotterdam, NETHERLANDS.

OP-0049In silico study on the heterogeneity of the dose distribution and radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapyG. Birindelli1, M. Drobnjakovic1, V. Morath2, K. Steiger3, C. D’Alessandria2, E. Gourni1, A. Afshar-Oromieh1, W. Weber2, A. Rominger1, M. Eiber2, K. Shi1; 1Inselspital, University of Bern, Bern, SWITZERLAND, 2Klinikum rechts der Isar, Technical University of Munich, München, GERMANY, 3Technical University of Munich, München, GERMANY.

OP-0050Time and dose dependent DNA double strand damage induction and repair in peripheral blood mononuclear cells after internal ex vivo irradiation with [223Ra]RaCl2L. Göring1, H. Scherthan2, J. Müller2, S. Schumann1, A. K. Buck1, M. Port2, M. Lassmann1, U. Eberlein1; 1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, 2Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

OP-0051DSB repair in peripheral blood mononuclear cells after internal ex vivo irradiation of blood with [131I]NaI in patients before radioiodine therapyS. Schumann1, H. Scherthan2, K. Pfestroff3, S. Schoof2, A. Pfestroff3, P. Hartrampf1, N. Hasenauer1, A. K. Buck1, M. Luster3, M. Port2, M. Lassmann1, U. Eberlein1; 1Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, 2Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY, 3Department of Nuclear Medicine, Philips University Marburg, Marburg, GERMANY.



7372

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0073Negative Determinant Value of Myocardial Perfusion Scintigraphy on Solid State Gamma CamerasN. Talay, E. Sahin Kutuk, T. Bahceci, E. Ozdemir; Ankara City Hospital Nuclear Medicine Department, Ankara, TURKEY.

OP-0074Added value of Myocardial Flow Reserve measurement in cardiac SPECT for coronary artery disease screeningM. Bailly1, F. Thibault1, G. Metrard1, M. Courtehoux2, D. Angoulvant2, M. Ribeiro2; 1CHR Orléans, Orleans, FRANCE, 2CHRU Tours, Tours, FRANCE.

OP-0075Prone Myocardial Perfusion SPECT Imaging in attenuation artefacts may obviate the need for a Rest Study: Our ExperienceC. Fragkaki, A. T. Archontaki; Chania General Hospital ”St. George”, Chania, GREECE.

OP-0076Correlation between myocardial flow, coronary reserve and Framingham and ESC-SCORE cardiovascular risk scoresJ. Pinaquy, P. Ferenczi, F. Debordeaux, H. Douard, Y. Pucheu, T. Couffinhal, L. Bordenave; University Hospital of Bordeaux, Bordeaux, FRANCE.

301


CME 2: AI in Radiomics

OP-0079Challenges in Multi-Center Trials Using Radiomics Models - The Role of AI Based HarmonisationV. Jaouen; Institut Mines Telecom Atlantique, Plouzane, FRANCE.

OP-0080AI and Radiomics for Oncology ApplicationsM. Sollini; Humanitas University, Nuclear Medicine Division, Milan, ITALY.

OP-0081Potential Role of AI and Radiomics in Cardiac ImagingC. Rischpler; Hospital/Institute, Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY.

OP-0082What May AI and Radiomics Bring in Neuroimaging?R. Buchert; University Medical Center Hamburg-Eppendorf, Department of Nuclear Medicine, Hamburg, GERMANY.

302-1


Interview with the Expert 3 - Nuclear Endocrinology

OP-0084Interview - Nuclear EndocrinologyG. Treglia; Ente Ospedaliero Cantonale, Nuclear Medicine and PET/CT Center, Bellinzona, SWITZERLAND.

OP-0085Interview - Nuclear EndocrinologyL. Giovanella; Imaging Institute of Southern Switzerland, Clinic for Nuclear Medicine, Bellinzona, SWITZERLAND.

302-2

Wednesday, October 20, 2021, 12:45 –13:07Channel 2

Interview with the Expert 4 - Nuclear Medicine in Neurodegenerative Diseases

OP-0086Interview - Nuclear Medicine in Neurodegenerative Diseases F. Nobili; University of Genoa and Polyclinic San Martino Hospital, Department of Neuroscience (DINOGMI), Genoa, ITALY

OP-0087Interview - Nuclear Medicine in Neurodegenerative Diseases S. Morbelli; San Martino Hospital, University of Genoa, Nuclear Medicine, Genoa, ITALY.

OP-0062Preliminary evaluation of 64Cu-ATSM as a tracer of predictive assessment of neoadjuvant treatment response in locally advanced rectal cancerM. Colombié1, L. Ferrer1,2, M. Lacombe3, V. Fleury1, M. Le Thiec1, A. Morel1, B. Maucherat1, D. Rusu1, N. Varmenot1,4, P. Tremolieres3, N. Allam1, E. Rio1, V. Guimas1, I. Masson1, H. Senellart1, S. Hiret1, P. Salaun5,6, L. Campion1, A. Vidal4, F. Haddad4,7, A. Rauscher1, F. Kraeber-Bodéré8,2, M. Bourgeois8,2,4, C. Rousseau1,2; 1ICO René Gauducheau, Saint-Herblain, FRANCE, 2Université de Nantes, CNRS, Inserm, CRCINA, Nantes, FRANCE, 3ICO Paul Papin, Angers, FRANCE, 4Arronax, Saint-Herblain, FRANCE, 5University Hospital, Brest, FRANCE, 6EA GETBO 3878, University Western Brittany, Brest, FRANCE, 7SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes, FRANCE, 8University Hospital, Nantes, FRANCE.

OP-0063Predictive value of 18FDG-PET / CT tumor SUVmax value in terms of overall survival after neoadjuvant therapy in rectal cancerF. Demir, G. G. Avcı; Tokat Gaziosmanpasa University, Tokat, TURKEY.

OP-0064Postradiation pelvic fractures on FDG PET - types, incidence and lack of recognitionP. Bochev, G. Mateva, N. Novoselska; Acibadem Cityclinic UMBAL Mladost hospital, Sofia, BULGARIA.

211


Featured Session: Quantification in MPI - A Must!

OP-0066Quantification in MPI - Let’s do it? H. Verberne; Academic Medical Center, Department of Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0067Left Ventricular Hypertrophy in CZT SPECT Imaging: comparison with Cardiac Magnetic ResonanceE. Cerudelli1,2, M. Gazzilli1, L. Camoni1, F. Dondi1, A. Mazzoletti1, P. Bellini1, D. Albano1,2, R. Giubbini1,2; 1Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, ITALY, 2Università degli Studi di Brescia, Brescia, ITALY.

OP-0068Prognostic value of myocardial perfusion imaging using cardio-dedicated CZT-cameraT. Mannarino1, A. D’Antonio1, R. Bologna1, E. Criscuolo1, P. Buongiorno1, E. Caiazzo1, R. Assante1, E. Zampella1, V. Gaudieri1, R. Green1, V. Cantoni1, M. Petretta2, W. Acampa1, A. Cuocolo1; 1Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, 2IRCCS SDN, Diagnostic Imaging, Naples, ITALY.

OP-0069Dynamic SPECT myocardial perfusion imaging in coronary disease ; correlation with angiographic findingsJ. Pinaquy, E. Riahi, F. Debordeaux, H. Douard, T. Couffinhal, P. Coste, L. Bordenave; University Hospital of Bordeaux, Bordeaux, FRANCE.

OP-0070Coronary Vascular Function Assessed by Low Dose Dynamic CZT-SPECT MPI in Patients with Diabetes MellitusA. D’Antonio1, T. Mannarino1, E. Criscuolo1, R. Bologna1, P. Buongiorno1, R. Assante1, E. Zampella1, V. Gaudieri1, C. Nappi1, R. Green1, V. Cantoni1, M. Petretta2, W. Acampa1, A. Cuocolo1; 1Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Naples, ITALY, 2IRCCS SDN, Diagnostic Imaging, Naples, ITALY.

OP-0071Exercise Ischemia is an Efficient Predictor of Significant Coronary Artery Disease in Routine Reports of a Large-Scale Clinical Cohort using Very Low-Dose Myocardial Perfusion SPECTM. B. Chawki1, T. Gonçalves1, C. Boursier1, M. Bordonné1, A. Verger2, L. Imbert2, M. Perrin1, M. Claudin1, V. Roch1, K. Djaballah3, B. Popovic4, E. Camenzind4, P. Marie5; 1Université de Lorraine, CHRU-Nancy, Department of Nuclear Medicine and Nancyclotep Imaging Platform, Nancy, FRANCE, 2Université de Lorraine, CHRU-Nancy, Department of Nuclear Medicine and Nancyclotep Imaging Platform, INSERM U1254, IADI, Nancy, FRANCE, 3Université de Lorraine, CHRU-Nancy, Department of Cardiology, Nancy, FRANCE, 4Université de Lorraine, CHRU-Nancy, Department of Cardiology, INSERM, UMR-1116 DCAC, Nancy, FRANCE, 5Université de Lorraine, CHRU-Nancy, Department of Nuclear Medicine and Nancyclotep Imaging Platform, INSERM, UMR-1116 DCAC, Nancy, FRANCE.

OP-0072Prognostic value of heart rate reserve in patients with suspected coronary artery disease undergoing stress myocardial perfusion imagingF. Reina1, C. Nappi1, M. Petretta2, R. Assante1, E. Zampella1, V. Gaudieri1, V. Cantoni1, R. Green1, L. Piscopo1, F. Volpe1, C. Mainolfi1, E. Nicolai2, W. Acampa1, A. Cuocolo1; 1Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, 2IRCCS-SDN, Naples, ITALY.



7574

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

308


”M2M Track - TROP Session: It’s the Alpha, not the Beta”

OP-0106Preclinical study of Targeted Alpha Therapy using 211At-labeled phenylalaline derivative in a syngeneic Multiple Myeloma modelJ. Gaschet1, R. Echeynne1, N. Chouin2, S. Gazzola1, F. Guérard1, S. Gouard1, S. Marionnaud-Lambot3, A. Maubert1, C. Alliot1,4, P. O. Hofgaard5, B. Bogen5, E. Yan6, F. Haddad4,7, F. Kraeber-Bodéré8, M. Wheatcroft6, J. Gestin1, M. Chérel9,4; 1Université de Nantes, CNRS, INSERM, CRCINA, Nantes, FRANCE, 2Université de Nantes, CNRS, INSERM, CRCINA, Oniris, Nantes, FRANCE, 3Université de Nantes, CNRS, INSERM, CRCINA, CHU of Nantes, Nantes, FRANCE, 4GIP Arronax, Saint-Herblain, FRANCE, 5Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY, 6Telix Pharmaceuticals Ltd, Melbourne, AUSTRALIA, 7Université de Nantes, IMT Atlantique, CNRS, Subatech, Nantes, FRANCE, 8Université de Nantes, CNRS, INSERM, CRCINA, CHU of Nantes, ICO Gauducheau, Nantes, FRANCE, 9Université de Nantes, CNRS, INSERM, CRCINA, ICO Gauducheau, Nantes, FRANCE.

OP-0107FGFR3 Targeted Alpha Therapeutic [225Ac]-FPI-1966 induces regression in preclinical bladder xenograft modelY. Storozhuk, N. Grinshtein, N. Robinson, D. Rodriguez, I. Duffy, R. Simms, E. Burak, J. Valliant; Fusion Pharmaceuticals, Hamiton, ON, CANADA.

OP-0108Synergy of 224Ra-labeled microparticles and chemotherapy in a murine ovarian cancer modelR. Wouters1,2, S. Westrøm2, I. Vergote3,4, T. B. Bønsdorff2, A. Coosemans1; 1Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, BELGIUM, 2Oncoinvent AS, Oslo, NORWAY, 3Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, BELGIUM, 4Department of Oncology, Gynecological Oncology, KU Leuven, Leuven, BELGIUM.

OP-0109NTSR1 Targeted Alpha Therapeutic [225Ac]-FPI-2059 induces regression in preclinical colorectal xenograft modelS. Mahammad1, I. Duffy1, R. Simms1, J. Forbes1, C. Smerling2, N. Grinshtein1, E. Burak1; 1Fusion Pharmaceuticals Inc., Hamilton, ON, CANADA, 23B Pharmaceuticals GmbH, Berlin, GERMANY.

OP-0110Estimated absorbed dose in human after intravenous administration of [211At]NaAt for the FIH clinical trial of targeted alpha therapyT. Watabe1,2, T. Sato3, K. Kaneda2, K. Ooe1, Y. Liu1, K. Kurimoto1, A. Toyoshima2, A. Shinohara2, Y. Shirakami2; 1Osaka University Graduate School of Medicine, Suita, JAPAN, 2Institute for Radiation Sciences, Osaka University, Suita, JAPAN, 3Nuclear Science and Engineering Center, Japan Atomic Energy Agency, Tokai, JAPAN.

OP-0111Dose response of 212Pb-labeled calcium carbonate microparticles in mice with intraperitoneal ovarian cancerR. G. Li1,2,3, T. B. Bønsdorff3, K. Lindland3, M. M. Malenge3, R. H. Larsen3; 1University of Oslo, Oslo, NORWAY, 2Oslo university hospital, Oslo, NORWAY, 3Oncoinvent AS, Oslo, NORWAY.

OP-0112Large-scale production experiment for Ac-225 using an electron linear acceleratorM. Maeda1, T. Tadokoro1, Y. Ueno1, K. Nishida1, Y. Kani1, M. Itoh2, T. Sasaki2, T. Watanabe2, H. Kikunaga3, S. Kashiwagi3, K. Shirasaki4, S. Sekimoto5, T. Ohtsuki5, M. Inagaki5; 1Hitachi, Ltd., Research & Development Group, Hitachi, JAPAN, 2Hitachi, Ltd., Healthcare Buisiness Unit, Tokyo, JAPAN, 3Research Center for Electron Photon Science, Tohoku University, Sendai, JAPAN, 4Institute for Materials Research, Tohoku University, Sendai, JAPAN, 5Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-Cho, JAPAN.

OP-0113Comparison of PSMA-TO-1 and PSMA-617 labelled with

68Ga, 177Lu and 225Ac: a first in-human translational studyC. Meyer1, V. Prasad2, A. Stuparu1, G. Glatting2, P. Kletting2, J. Miksch2, C. Solbach2, K. Lueckerath1, L. Nyiranshuti1, S. Zhu1, J. Czernin1, M. Dahlbom1, J. Calais1, A. Beer2, R. Slavik1; 1UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, 2Department of Nuclear Medicine University Hospital Ulm, Ulm, GERMANY.

304


CTE 2: Managing the Paediatric Patient in Nuclear Medicine Departments

OP-0088Paediatric Patient Care - Technologist’s Practice ImprovementA. Santos; Hospital CUF Descobertas, Medicina Nuclear Department, Lisbon, PORTUGAL.

OP-0089Paediatric Patient Care - Clinician’s PerspectiveZ. Bar-Sever; Schneider Children’s Hospital, Department of Nuclear Medicine, Petach Tikva, ISRAEL.

OP-0090Paediatric Patient Care - Communication ImprovementA. Grilo; Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.

305


Joint Symposium 3 (EANM/EACVI): MPI after the ISCHEMIA Trial - Still Alive?

OP-0092The ISCHEMIA Trial - Design and ResultsR. Liga; Universita di Pisa, Cardiac-Thoracic-Vascular Department, Pisa, ITALY.

OP-0093Role of Anatomical Imaging after the ISCHEMIA TrialM. R. Dweck; University of Edinburgh, Department of Cardiology, Edinburgh, UNITED KINGDOM.

OP-0094Role of Functional Imaging after the ISCHEMIA TrialA. Saraste; Turku University Hospital, Heart Center, Turku, FINLAND.

OP-0095The ISCHEMIA Trial - Clear Answers, Open QuestionsE. Reyes-Torres; St Thomas’ Hospital, The PET Imaging Centre, London, UNITED KINGDOM. (Talk not uploaded)

306


Joint Symposium 4 (EANM/CIRSE): Biokinetics and Dosimetry in Intraarterial Therapy

OP-0097Radio-Embolization and HCC – Where Are We in the Guidelines and Why?A. Denys; CHUV centre hospitalier universitaire vaudois, Radiodiagnostic et radiologie interventionnelle, Lausanne, SWITZERLAND.

OP-0098Dosimetry and Radio-Embolization - Dose Specific Issues and New Solutions N. Schaefer; Centre Hospitalier Universitaire Vaudois (CHUV), Department of Nuclear Medicine and Molecular Imaging, Lausanne, SWITZERLAND.

OP-0099Dose-Effect Guided 90Y Microspheres Treatment PlanningL. Strigari; University of Bologna, Medical Physics department, Bologna, ITALY.

OP-0100TBA

307


Pitfalls & Artefacts 2: Pseudoprogression and Pseudoresponse in Brain Tumours

OP-0102Neurooncologist - The Neurooncologist’s PerspectiveM. Glas; University of Essen, Department of Clinical Neuro-oncology at the Essen University Hospital, Essen, GERMANY.

OP-0103Neuroradiologist - An MRI OverviewP. C. M. Sundgren; Lund University, Department of Diagnostic Radiology, Lund, SWEDEN.

OP-0104Nuclear Medicine Physician - ...And What About PET?I. Law; Copenhagen University Hospital, Dep. of Clinical Physiology, Copenhagen, DENMARK.



7776

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0125Correlation between tumoral infiltrating lymphocytes, 99mTc HYNIC-iFAP SPECT/CT and 18FDG PET/CT: a potential imaging biomarker of tumoral microenvironment aggressiveness in breast cancerO. Garcia-Perez1, P. Vallejo-Armenta1, L. Torres-Agredo2, P. Casanova1, F. Porras-Reyes1, J. Vargas-Ahumada1, I. Soldevilla-Gallardo1, Q. Pitalua-Cortes1, E. Bargallo1, G. Ferro-Flores3, C. Santos-Cuevas3, B. Ocampo-García1, E. Estrada-Lobato4, P. Cabrera-Galeana5; 1Instituto Nacional de Cancerologia, Mexico city, MEXICO, 2Universidad Autonoma de Bucaramanga, Bucaramanga, COLOMBIA, 3Instituto Nacional de Investigaciones Nucleares, Mexico city, MEXICO, 4International Atomic Energy Agency, Wien, AUSTRIA, 5Instituto Nacional de Cancerología, Mexico City, MEXICO.

OP-0126Comparison [68Ga]GaFAPİ-46 PET/CT and [18F]FDG PET/CT in Breast carcinoma staging: Preliminary results of randomised prospective clinical trial from AzerbaijanF. Novruzov1, E. Mehdi1, N. Orucova1, Q. Abdullayev1, N. Talibova2, M. Moore3, F. Valla3, S. Rahimzade4, J. Aliyev5; 1Azerbaijan National Centre Of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, 2Azerbaijan National Centre Of Oncology, Department of Medical Oncology, Baku, AZERBAIJAN, 3SOFIE, TOTOWA, NJ, UNITED STATES OF AMERICA, 4Azerbaijan National Centre Of Oncology, Department of Woman Health, Baku, AZERBAIJAN, 5Azerbaijan National Centre Of Oncology, Department of General Surgery, Baku, AZERBAIJAN.

OP-0128First-in-human study of 99mTc-labelled HER2-binding DARPin G3O. Bragina1,2, V. Chernov1,2, A. Schulga2,3, E. Konovalova3, A. Vorobyeva4,2, A. Orlova4,2, J. Sörensen5, R. Zelchan1,2, A. Medvedeva1, S. M. Deyev2,3, V. Tolmachev2,6; 1Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RUSSIAN FEDERATION, 2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 3Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, RUSSIAN FEDERATION, 4Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, 5Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 6Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN.

OP-0129Impact of hybrid whole-body 18F-FDG PET/MRI for breast cancer patients staging according to accepted guidelines: prognostic bioimaging markers associated with tumour aggressivenessE. Valls, A. Compte, J. Garcia, S. Ortiz, M. Cozar, P. Bassa, C. Galan, S. Mourelo, M. Soler, M. Buxeda, A. Blanch, E. Riera; CETIR-ASCIRES, Barcelona, SPAIN.

OP-0130Impact on the long-term prognosis of FDG PET/CT in luminal breast cancerM. Caracciolo1, L. Urso1, L. Evangelista2, S. Panareo1, N. Quartuccio3, N. Ortolan1, I. Zamberlan1, A. Schirone4, A. Frassoldati4, C. Cittanti1, G. Arnone3, M. Bartolomei1; 1Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Ferrara, ITALY, 2Nuclear Medicine Unit, Department of Nuclear Medicine DIMED, University of Padua, Padova, ITALY, 3Nuclear Medicine Unit, ARNAS Ospedali Civico, Di Cristina e Benfratelli, Palermo, ITALY, 4Clinical Oncology, Oncological Medical and Specialists Department, University Hospital of Ferrara, Ferrara, ITALY.

OP-0131The Relationship Between Tumor/ Lymph Node Suv Ratio And Immunohistochemical Features With Distant Metastases In Initial Staging F18-PET/CT In Breast CancerH. Tosun, B. B. Demirel, G. Uçmak; Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TURKEY.

OP-0132Ga-68 PSMA and F-18 FDG PET/CT Imaging in Patients with Triple Negative Breast Cancer and PSMA and Claudin 1, Claudin 4 and Claudin 7 Receptors in Primary Tumor TissuesE. Arslan1, N. Ergül1, E. Beyhan1, Ö. Erol1, M. Cin2, S. Battal Havare2, F. D. Can Trabulus3, Ö. Mermut4, S. Akbaş5, T. F. Çermik1; 1Istanbul Training and Research Hospital, Clinic of Nuclear Medicine, Istanbul, TURKEY, 2Istanbul Training and Research Hospital, Department of Pathology, Istanbul, TURKEY, 3Istanbul Training and Research Hospital, Clinic of Surgery, Istanbul, TURKEY, 4Istanbul Training and Research Hospital, Department of Radiation Oncology, Istanbul, TURKEY, 5Koç University Hospital, Department of Medical Oncology, Istanbul, TURKEY.

309


Cutting Edge Science Track - TROP Session: Dosimetry Methods

OP-0115An organ specific compartment TIAC fitting tool for IDAC-DoseM. Andersson1,2, S. Mattsson2; 1Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 2Medical Radiation Physics, Department of Translational Medicine Lund University, Malmö, SWEDEN.

OP-0116Evaluation of a new dual-energy quantitative computed tomography (DEQCT) method against 2-point Dixon MRI to quantify the yellow marrow and red marrow volume fraction for bone marrow dosimetry in molecular radiotherapyM. Salas Ramirez1, J. Tran-Gia1, P. Hartrampf1, A. Heidemeier2, M. Lassmann1; 1Department of Nuclear Medicine, University of Würzburg, GERMANY, 2Department of Diagnostic and Interventional Radiology, University of Würzburg, GERMANY.

OP-0117Physiologically-based pharmacokinetic modelling for radiopharmaceuticals using a multilevel object-oriented modelling methodologyR. Bouwman1, S. Herrero2, G. de With1; 1NRG, Arnhem, NETHERLANDS, 2Empresarios Agrupados Internacional, Madrid, SPAIN.

OP-0118Manual versus artificial intelligence-based segmentations as a pre-processing step in whole-body dosimetry calculationsJ. van Sluis, W. Noordzij, E. G. De Vries, I. C. Kok, D. A. De Groot, M. Jalving, M. N. Lub-de Hooge, A. H. Brouwers, R. Boellaard; University Medical Center Groningen, Groningen, NETHERLANDS.

OP-0119A thyroid iodide uptake and volume determination tool for the online version of IDAC-IodideM. Andersson1,2, S. Mattsson2; 1Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 2Medical Radiation Physics, Department of Translational Medicine Lund University, Malmö, SWEDEN.

OP-0120Investigation of the effect of small but frequently occurring patient movements onto 3D activity quantitation in Siemens xSPECT Quant reconstruction with integrated motion correctionA. Gosewisch1, M. Reymann2, H. Ilhan1, L. Beyer1, G. Platsch2, P. Bartenstein1, A. H. Vija3, G. Böning1; 1Department of Nuclear Medicine, University Hospital, LMU Munich, Muenchen, GERMANY, 2Siemens Healthcare GmbH, Molecular Imaging, Forchheim, GERMANY, 3Siemens Medical Solutions USA, Inc., Molecular Imaging, Hoffman Estates, IL, UNITED STATES OF AMERICA.

OP-0121Bone marrow dosimetry for terbium-161 reveals higher dependence on source distribution within the bone marrow cavities compared to lutetium-177J. Hemmingsson1, J. Svensson2, N. P. van der Meulen3,4, C. Müller3, P. Bernhardt1; 1Department of Medical Radiation Sciences, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 2Department of Oncology, Sahlgrenska University Hospital, Gothenburg, SWEDEN, 3Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, SWITZERLAND, 4Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, SWITZERLAND.

OP-0122The feasibility of dose estimation to thyroid remnants and salivary glands and avid following therapeutic131I administrationM. Abuqbeitah; Istanbul University, Istanbul, TURKEY.

310


Clinical Oncology Track - TROP Session: Breast

OP-0124First Results of Simultaneous FAPi-PET/MRI Targeting the Fibroblast Activation Protein in Primary Breast CancerP. Backhaus1,2, M. C. Burg3, W. Roll1, F. Büther1,2, H. Breyholz1, S. B. Weigel3, W. Heindel3, M. Pixberg1, P. J. Barth4, J. Tio5, M. Schäfers1,2; 1Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY, 2European Institute for Molecular Imaging, University of Münster, Münster, GERMANY, 3Clinic for Radiology, University Hospital Münster, Münster, GERMANY, 4Gerhard-Domagk Institute for Pathology, University Hospital Münster, Münster, GERMANY, 5Department of Gynecology & Obstetrics, University Hospital Münster, Münster, GERMANY.



7978

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0143Qualitative and quantitative cardiac 18F-FDG-PET findings in patients with suspected inflammatory cardiomyopathy: a pilot studyA. Franchini1, A. Scarale2, F. Baldassi1, G. Cabrini2, E. Gay2, M. Milella2, C. Rossetti2, S. Capitanio2; 1University of Milano-Bicocca, Milano, ITALY, 2ASST Grande Ospedale Metropolitano Niguarda, Milano, ITALY.

OP-0144Are stress-induced dyssynchrony parameters obtained from different nuclear modalities comparable in terms of identifying high-risk patients after surgical treatment of ischemic cardiomyopathy?V. Shipulin, A. Pryakhin, S. Andreev, V. M. Shipulin, K. Zavadovsky; Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

OP-0145Clinical differences between patients with Perugini’s grade 2 and grade 3 cardiac ATTR amyloidosis confirmed by 99mTc-DPD scanF. Sebastián Palacid, N. Álvarez Mena, B. Pérez López, C. Gamazo Laherrán, P. Turbay Eljach, M. Alonso Rodriguez, A. Sáinz Esteban, C. F. García García, M. Ruiz Gómez, M. J. González Soto, R. Ruano Pérez; Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

OP-0146Possibility of scintigraphic indexes of left ventricle mechanical dyssynchrony for predicting benefit from cardiac resynchronization therapy with comparing different response criteriaA. Mishkina, V. Saushkin, T. Atabekov, K. Zavadovsky; Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

OP-0147Impact of hybrid 18F-FDG PET/CMR on cardiac sarcoidosis diagnosis and disease stage differentiationJ. Garcia, R. Olivero, P. Bassa, M. Lopez, J. Monmeneu, E. Riera, L. Higueras, M. Garcia, A. Maceira; CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN.

313


EANM Awards Ceremony

OP-0150EANM Awards CeremonyW. Wadsak; EANM Secretary/Treasurer, Vienna, AUSTRIA.

314


Plenary Quiz (for Plenary 2)

OP-0151Plenary QuizV. Garibotto; University Hospital of Geneva, Nuclear Medicine and Molecular Imaging Division, Geneva, SWITZERLAND.

401


Plenary 2: Theranostics Applications and Challenges (incl. Marie Curie Lecture)

OP-0152We are TheranosticsB. Guillet; Radiopharmacy department, University Hospital Marseille, Marseille, FRANCE.

OP-0153PSMA Theranostics in 2021D. Oprea-Lager; Amsterdam University Medical Centers, Department of Radiology & Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0154Marie Curie Lecture: Other New TheranosticsR. Hicks; The Sir Peter MacCallum Cancer Center, Department of Oncology, Molecular Imaging and Therapeutic Nuclear Medicine, Melbourne, AUSTRALIA.

OP-0155Handling ChallengesL. Evangelista; University of Padova, Department of Medicine (DIMED), Padua, ITALY.

OP-0133FDG-PET/CT versus CE-CT for response monitoring in metastatic breast cancer - a prospective comparative studyM. Vogsen1,2,3, F. Harbo4, N. Jakobsen1, H. Nissen1, S. E. Dahlsgaard-Wallenius1, O. Gerke1,2, J. Jensen3, J. Asmussen4, A. Jylling5,2, P. Braad1, W. Vach6, M. Ewertz2, M. Hildebrandt1,2,7; 1Odense University Hospital, Department of Nuclear Medicine, Odense, DENMARK, 2University of Southern Denmark, Department of Clinical Research, Odense, DENMARK, 3Odense University Hospital, Department of Oncology, Odense, DENMARK, 4Odense University Hospital, Department of Radiology, Odense, DENMARK, 5Odense University Hospital, Department of Pathology, Odense, DENMARK, 6Basel Academy for Quality and Research in Medicine, Basel, SWITZERLAND, 7Centre for Innovative Medical Technology, Odense University Hospital, Odense, DENMARK.

OP-0134Evaluation of Cardiac Toxicity in Patients Undergoing Breast Cancer Treatment with HER2-inhibitorsA. Lazar1, M. Mutuleanu1, M. Gherghe1,2, I. Irimescu2; 1Carol Davila University of Medicine and Pharmacy, Bucharest, ROMANIA, 2Oncology Institute “Professor Doctor Alexandru Trestioreanu”, Bucharest, ROMANIA.

OP-0135The significance of the intramammarian sentinel lymph nodes in the lymphatic mappingZ. Koc, P. P. Özcan, F. Daloğlu, M. Berkeşoğlu, Z. S. Sağlam; Mersin University, Mersin, TURKEY.

311


Featured Session: Show me your Heart!

OP-0137Cardiac Sarcoid and Amyloid Imaging Are Here to Stay O. Lairez; University. hospital of Toulouse, Department of Nuclear Medicine and Cardiac Imaging Center, Toulouse, FRANCE.

OP-0138Volumetric Evaluation of 99mTc-pyrophosphate SPECT/CT in Patients with Transthyretin Cardiac Amyloidosis: Correlation with Cardiac Functional ParametersS. Watanabe, K. Nakajima, H. Wakabayashi, H. Yoneyama, S. Yoshida, J. Komatsu, A. Inaki, T. Konishi, S. Kinuya; Kanazawa University Hospital, Kanazawa, JAPAN.

OP-0139Diagnostic value of bone scintigraphy in cardiac amyloidosis after domino liver transplantationE. Piekarski1, L. Eliahou2,3, R. Chequer1, F. Scalbert1, D. Adams3,4, D. Le Guludec1, M. S. Slama3,5, D. Samuel3,6, I. Kounis6, F. Rouzet1, V. Algalarrondo2,3; 1Nuclear Medicine Department, Bichat-Claude Bernard Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), DHU APOLLO, Inserm UMR 1148, Université de Paris, Paris, FRANCE, 2Cardiology Department, Bichat-Claude Bernard Hospital, AP-HP, Inserm UMR-S 1180, Université de Paris, Paris, FRANCE, 3French Referent Center for Rare Diseases for FAP (Familial Amyloid Polyneuropathy) (CRMR-NNERF), Bicêtre, FRANCE, 4Neurology Department, AP-HP, Université Paris-Saclay, INSERM 1195, Bicêtre, FRANCE, 5Cardiology Department, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris, Paris, FRANCE, 6Centre Hépato Biliaire, AP-HP, Université Paris-Saclay, Hopital Paul Brousse, Villejuif, FRANCE.

OP-0140Bone scintigraphy in hereditary ATTR patients: characteristics and prognostic impact of the different clinical phenotypesF. Mattana1, M. Sguazzotti2, P. Massa2, A. Ponziani2, A. G. Caponetti2, G. Saturi2, R. Bonfiglioli1, S. Longhi2, C. Gagliardi2, E. Biagini2, P. Cortelli3, N. Galliè2, S. Fanti1; 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Metropolitan Nuclear Medicine, Bologna, ITALY, 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Cardiology Unit, Bologna, ITALY, 3IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, Bologna, ITALY.

OP-0141Does semiquantification using the H/CL ratio on 3h planar [99mTc]Tc-DPD imaging have additional prognostic value in cardiac amyloidosis?L. Lemos1, P. Soeiro1, R. Ferreira1,2, M. J. Cunha1, G. Costa1,3, J. Pedroso de Lima1,2,3; 1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 2Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL, 3Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL.

OP-0142Multiparametricassessment Of The Mechanical Function Of The Left Ventricleby CZT MPI: Comparison With Cardiac Magnetic ResonanceE. Cerudelli1,2, M. Gazzilli1, L. Camoni1, F. Dondi2, A. Mazzoletti2, P. Bellini2, D. Albano1,2, F. Bertagna1,2, R. Giubbini1,2; 1Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, ITALY, 2Università degli Studi di Brescia, Brescia, ITALY.



8180

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0169PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicentre studyW. Fendler1, J. Ferdinandus1, A. Farolfi1, W. Samuel2, M. Osama3, P. Scott4, M. Rodnick4, M. Pampaloni5, B. Viglianti4, M. Eiber6, K. Herrmann1, J. Czernin7, W. Armstrong8, J. Calais8, T. Hope5, M. Piert4; 1Department of Nuclear Medicine, Essen, GERMANY, 2Department of Urology, University of California San Francisco, CA, UNITED STATES OF AMERICA, 3Department of Radiation Oncology, University of California San Francisco, CA, UNITED STATES OF AMERICA, 4Department of Radiology, University of Michigan, Ann Arbor, Michigan, IL, UNITED STATES OF AMERICA, 5Department of Radiology and Biomedical Imaging, University of California San Francisco, CA, UNITED STATES OF AMERICA, 6Department of Nuclear Medicine, Klinikum rechts der Isar Munich, GERMANY, 7Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angele, CA, UNITED STATES OF AMERICA, 8Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-0170Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)B. Krause1, J. de Bono2, K. N. Chi3, K. Fizazi4, K. Herrmann5, K. Rahbar6, S. T. Tagawa7, L. T. Nordquist8, N. Vaishampayan9, G. El-Haddad10, C. H. Park11, T. M. Beer12, W. J. Pérez-Contreras13, M. DeSilvio13, E. Kpamegan13, G. Gericke14, R. A. Messmann13, M. J. Morris15, O. Sartor16; 1Rostock University Medical Centre, Rostock, GERMANY, 2The Institute of Cancer Research and Royal Marsden Hospital, London, UNITED KINGDOM, 3British Columbia Cancer Agency, Vancouver, BC, CANADA, 4Gustave Roussy Institute, Paris-Saclay University, Villejuif, FRANCE, 5University Hospital Essen, Essen, GERMANY, 6University Hospital Münster, Münster, GERMANY, 7Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, 8Urology Cancer Center, Omaha, NE, UNITED STATES OF AMERICA, 9School of Medicine, Wayne State University, Detroit, MI, UNITED STATES OF AMERICA, 10Moffitt Cancer Center and Research Institute, Tampa, FL, UNITED STATES OF AMERICA, 11Norton Cancer Institute, Louisville, KY, UNITED STATES OF AMERICA, 12Knight Cancer Institute, Oregon Health & Science University, Portland, OR, UNITED STATES OF AMERICA, 13Novartis Pharmaceuticals Corporation, East Hanover, NJ, UNITED STATES OF AMERICA, 14Novartis Pharma AG, Basel, SWITZERLAND, 15Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, 16Tulane University School of Medicine, New Orleans, LA, UNITED STATES OF AMERICA.

OP-0171Nomograms to predict outcome after LuPSMA radionuclide therapy in men with metastatic castration-resistant prostate cancer: an international multicenter retrospective studyA. Gafita1, J. Calais1, T. R. Grogan1, B. Hadaschik2, H. Wang3, M. Weber4, S. Sandhu5, C. Kratochwil6, R. Esfandiari7, R. Tauber3, A. Zeldin8, H. Rathke6, W. R. Armstrong1, A. Robertson3, P. Thin1, C. D’Alessandria3, M. B. Rettig1, E. S. Delpassand7, U. Haberkorn6, D. Elashoff1, K. Herrmann4, J. Czernin1, M. S. Hofman5, W. P. Fendler4, M. Eiber3; 1UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, 2University of Duisburg-Essen, Essen, CA, UNITED STATES OF AMERICA, 3Technical University Munich, Munich, GERMANY, 4University of Duisburg-Essen, Essen, GERMANY, 5Peter MacCallum Cancer Center, Melbourne, AUSTRALIA, 6University of Heidelberg, Heidelberg, GERMANY, 7Excel Diagnostics, Houston, TX, UNITED STATES OF AMERICA, 8Silicon Albion Ltd, London, UNITED KINGDOM.

504


CTE 3: PET/CT for RT Planning

OP-017320 years of Positron Emission Tomography in Radiation Therapy - Clinical PerspectiveR. Durmo; Arcispedale Santa Maria Nuova, Nuclear medicine, Reggio Emilia, ITALY.

OP-0174Recent Advances in RadiotherapyB. Bak; Greater Poland Cancer Centre, Radiotherapy Department II, Poznan, POLAND.

OP-0175Recent Updates of PET Imaging in Radiotherapy PlanningR. Allie; University College London Hospital, Institute of Nuclear Medicine, London, UNITED KINGDOM. & J. Heywood; University College London Hospital, Radiotherapy, London, UNITED KINGDOM.

OP-0156Risk Analysis in Radionuclide TherapyR. Dierckx; UMCG - University Medical Center Groningen, Department of Nuclear Medicine & Molecular Imaging, Groningen, NETHERLANDS.

OP-0157Tech ChallengesA. Santos; Hospital CUF Descobertas, Medicina Nuclear Department, Lisbon, PORTUGAL.

OP-0158Reimbursement ChallengesJ. Kunikowska; Medical University of Warsaw, Nuclear Medicine Department, Warsaw, POLAND.

501


CME 3: The Battle Continues - WBC Scan vs FDG PET/CT

OP-0161Radiolabelled WBC Scintigraphy for Musculoskeletal Infections - Pros and ConsE. Noriega-Álvarez; Hospital General Universitario de Ciudad Real, Department of Nuclear Medicine, Ciudad Real, SPAIN.

OP-0162FDG-PET for Musculoskeletal Infections - Pros and ConsZ. Keidar; Rambam Health Care Campus, Director, Department of Nuclear Medicine, Haifa, ISRAEL.

OP-0163Radiolabelled WBC Scintigraphy for Cardiovascular Infections - Pros and ConsF. Rouzet; GH Bichat-Claude Bernard, Department of Nuclear Medicine, Paris, FRANCE.

OP-0164FDG-PET for Cardiovascular Infections - Pros and ConsL. Leccisotti; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Nuclear Medicine Unit, Rome, ITALY.

502


The Top 3 Trials Sessions - 1- Prostate

OP-0166External Validation and Addition of PSMA-PET to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter StudyD. Meijer1, P. J. van Leeuwen2, M. J. Roberts3, A. R. Siriwardana3, A. Morton3, J. W. Yaxley3, H. Samaratunga4, L. Emmett5, P. M. van de Ven1, H. G. van der Poel2, M. L. Donswijk2, T. N. Boellaard2, I. G. Schoots2, D. E. Oprea-Lager1, G. D. Coughlin6, A. N. Vis1; 1Amsterdam UMC, Amsterdam, NETHERLANDS, 2Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 3Royal Brisbane and Women’s Hospital, Brisbane, AUSTRALIA, 4Aquesta Uropathology, Brisbane, AUSTRALIA, 5St. Vincent’s Hospital, Darlinghurst, AUSTRALIA, 6Wesley Hospital, Brisbane, AUSTRALIA.

OP-0167Quantitative 68Ga-PSMA-11 PET/CT Parameters of Intraprostatic Malignancy in Men with Prostate Adenocarcinoma in the proPSMA Study: Comparison to ISUP Grade GroupJ. P. Buteau1, F. de Galiza Barbosa2, R. Alipour1, S. Koschel1, E. Link1, O. Alghazo1,3, C. Mitchell1, S. F. Oon1, N. Lawrentschuk1,4, R. J. Francis5, S. Williams1, D. G. Murphy1, M. S. Hofman1; 1Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 2Hospital Sirio-Libanes, Sao Paulo, BRAZIL, 3Urology Division, Clinical Sciences Department, Yarmouk University, Irbid, JORDAN, 4Royal Melbourne Hospital, Melbourne, AUSTRALIA, 5Sir Charles Gairdner Hospital, Perth, AUSTRALIA.

OP-0168Comparing the clinical performance and cost efficacy of [ 68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov-chain decision analysisI. Alberts, C. Mingels, A. Rominger, A. Afshar-Oromieh; Institut für Nuklearmedizin, Bern, SWITZERLAND.



8382

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0192Therapeutic response of CCKBR-positive tumors to combinatory treatment with RAD001 and radiolabeled minigastrin analogue [177Lu]Lu-PP-F11NM. Grzmil1, S. Imobersteg1, A. Blanc1, R. Schibli1,2, M. Behe1; 1Paul Scherrer Institute, Villigen PSI, SWITZERLAND, 2Department of Chemistry and Applied Biosciences, ETH Zürich, SWITZERLAND.

OP-0193A new class of radiopharmaceuticals for CXCR4-expressing malignancies based on the endogenous antagonist EPI-X4R. Gaonkar1, Y. Schmidt1, R. Mansi1, M. Harms2, A. Seidel2, J. Münch2, M. Fani1; 1Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND, 2Institute of Molecular Virology, Ulm University Medical Center, Ulm, GERMANY.

OP-0194In Vitro Metabolic Activity and Internalisation Investigation of Copper-64 Radiopharmaceuticals As Theranostic Agents for Hypoxic TumoursT. Liu1,2, M. Dahle1, M. Karlsen2, K. Redalen1; 1Department of Physics, Norwegian University of Science and Technology, Trondheim, NORWAY, 2Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NORWAY.

OP-0195Alternating PSMA Expression Levels by Ionizing Radiation Exposure as an Additional Feature in PSMA-Targeting Prostate Cancer Treatment: First In Vitro EvaluationD. Arbuznikova1,2,3, M. Boll1,2,4, A. Grosu3,5, P. T. Meyer1,5, M. Eder1,2,4, C. Zamboglou3,5, A. Eder1,2,4; 1Department of Nuclear Medicine, University Medical Centre Freiburg, Freiburg, GERMANY, 2Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, GERMANY, 3Department of Radiation Oncology, University Medical Centre Freiburg, Freiburg, GERMANY, 4German Cancer Research Centre (DKFZ), Heidelberg, GERMANY, 5German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, GERMANY.

OP-0196Long-term radiotoxicity study with [177Lu]Lu-NeoBM. Verhoeven1, E. A. Ruigrok1, M. W. Konijnenberg1, E. de Blois1, C. M. de Ridder1, D. C. Stuurman1, M. J. Klomp1, L. W. de Kreij-de Bruin1, L. Bertarione2, K. Rolfo2, R. Manno3, M. de Jong1, S. U. Dalm1; 1Erasmus MC, Rotterdam, NETHERLANDS, 2Advanced Accelerator Applications, a Novartis Company, Colleretto Giacosa, ITALY, 3European Research Biology Center, Pomezia, ITALY.

OP-0197Imaging-guided co-targeting of HER2 and EpCAM using trastuzumab and DARPin-toxin fusion protein for theranostics of ovarian cancerT. Xu1, A. Schulga2,3, O. Vorontsova1, H. Ding4, T. Gräslund4, A. Orlova1,3, V. Tolmachev1,3, S. Deyev2,3,5, A. Vorobyeva1,3; 1Uppsala University, Uppsala, SWEDEN, 2Russian Academy of Sciences, Moscow, RUSSIAN FEDERATION, 3National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 4KTH Royal Institute of Technology, Stockholm, SWEDEN, 5National Research Nuclear University ‘MEPhI’, Moscow, RUSSIAN FEDERATION.

OP-0198Novel Radiolabelled CCK2R Antagonists Show Promise for In Vivo Theranostic UseD. Novak1,2, M. Anderluh2, R. Mansi3, M. Krošelj1, P. Kolenc1,2; 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Pharmacy, University of Ljubljana, Ljubljana, SLOVENIA, 3Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND.

OP-0199In vivo theranostic evaluation of a 64Cu-radiolabelled antibody in a murine model of multiple myelomaC. Métivier1, P. Remaud-Le-Saec1, S. Marionneau-Lambot1, F. Davodeau1, C. Chauvet1, C. Saï-Maurel1, P. Hofgaard2,3, B. Bogen2,3, R. Tripier4, F. Haddad5, J. Gaschet1, M. Chérel1, N. Chouin1, A. Faivre-Chauvet1, L. Rbah-Vidal1; 1Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000 Nantes, FRANCE, 2Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY, 3KG Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY, 4UMR CNRS 6521 CEMCA, University of Brest, Brest, FRANCE, 5GIP Arronax, Saint-Herblain, FRANCE.

OP-0200Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Radiotheragnostic ApplicationL. Deberle1, M. Benešová1,2, A. E. Becker1, P. Guzik1, R. Schibli1,2, C. Müller1,2; 1Paul Scherrer Institute, Villigen, SWITZERLAND, 2ETH Zurich, Zurich, SWITZERLAND.

OP-0201Production and in vitro evaluation of no-carrier-added radio-cisplatin emitting Auger electronsH. Obata1, A. B. Tsuji1, K. Nagatsu1, M. Ogawa2, M. R. Zhang1; 1National Institutes for Quantum and Radiological Science and Technology, Chiba, JAPAN, 2Hokkaido University, Hokkaido, JAPAN.

505


Joint Symposium 5 (EANM/SRS): Targeting Cancer with Peptides, Fragments or Antibodies

OP-0178In Peptides, We Trust!S. Dalm; Erasmus Medical Center, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-0179Antibody Fragments, Fast Kinetics are Essential!N. Devoogdt; Vrije Universiteit Brussel, Department of Medical Imaging, Brussels, BELGIUM.

OP-0180Antibodies as Radiopharmaceutical Vectors - Do the Benefits Outweigh the Costs?B. M. Zeglis; Hunter College, Department of Chemistry, New York, UNITED STATES OF AMERICA.

506


Joint Symposium 6 (EANM/SRS): Modifying Radiopharmaceuticals to Alter Pharmacokinetics

OP-0182How to “Fix” Tracer Pharmacokinetics - The Chemist’s ToolboxM. Schottelius; Centre Hospitalier Universitaire Vaudois (CHUV), Dept. of Nuclear Medicine, University of Lausanne (UNIL) and Ludwig Institute of Cancer Research (LICR), Dept. of Oncology, Lausanne, SWITZERLAND.

OP-0183Linker Modification Strategies to Alter the Pharmacokinetic Profile of Low Molecular Weight Radiopharmaceuticals A.-C. Eder; University Medical Center, Department of Nuclear Medicine, Division of Radiopharmaceutical Development, Freiburg, GERMANY.

OP-0184Incorporation of an Albumin Binder to Optimize Tumour Delivery of PSMA-Targeting Radiotherapeutic AgentsK.-S. Lin; University of British Columbia, Department of Radiology, Vancouver, CANADA.

OP-0185Blood-Brain Barrier Permeation of Brain-Targeted RadioligandsT. Billard; Université Claude Bernard - Lyon, ICBMS - Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, Lyon, FRANCE.

507


Pitfalls & Artefacts 3: Challenging Cases in Nuclear Neurology

OP-0187Challenging Cases in Neurodegenerative DementiaA. Chiaravalloti; University Tor Vergata, Department of Biomedicine and Prevention, Rome, ITALY.

OP-0188Challenging Cases in Movement DisordersM. Brendel; Department of Nuclear Medicine, University Hospital of Munich; Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

OP-0189Challenging Cases in NeuroncologyT. Traub-Weidinger; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

508


M2M Track - TROP Session: Theranostics - Various Targets

OP-0191Enhanced Therapeutic Effect of the Albumin-Binding [177Lu]Lu-Ibu-DAB-PSMA as Compared to [177Lu]Lu-PSMA-617 - A Preclinical Therapy StudyV. Tschan1, F. Borgna1, R. Schibli1,2, C. Müller1,2; 1Paul Scherrer Institute, 5232 Villigen-PSI, SWITZERLAND, 2ETH Zurich, 8093 Zurich, SWITZERLAND.



8584

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0212Comparison of Red Marrow Dosimetry Methodologies for Lu-177-PSMA Radionuclide TherapyW. Lehnert, I. Apostolova, R. Buchert, S. Klutmann; University Medical Center, Hamburg, GERMANY.

OP-0213Simplified dosimetry for peptide-receptor radionuclide therapy using physiologically-based pharmacokinetic and nonlinear mixed effect modellingD. Hardiansyah1, A. Riana1, P. Kletting2, A. J. Beer2, G. Glatting2; 1Universitas Indonesia, Depok, INDONESIA, 2Ulm University, Ulm, GERMANY.

OP-0214Optimization of three imaging time points for most reliable renal dosimetry in Peptide Receptor Radionuclide TherapyA. Konuparamban1,2, A. Nautiyal1,2, A. K. Jha1,2, S. Mithun1,2, V. Rangarajan1,2; 1Tata Memorial Hospital, Mumbai, INDIA, 2Homi Bhabha National Institute(HBNI), Deemed University, Mumbai, INDIA.

OP-0215Estimation of kidney absorbed doses from 177Lu-DOTATATE using single time point SPECT/CTS. Ballout1, D. Gillett1, E. Varzakis1, I. Harper1, D. Pitfield2, A. Powell1, R. T. Casey3,2, S. Heard1, L. Aloj4,1; 1Department of Nuclear Medicine, Cambridge University Hospitals NHSFT, Cambridge, UNITED KINGDOM, 2Department of Endocrinology, Cambridge University Hospitals NHSFT, Cambridge, UNITED KINGDOM, 3Department of Genetics, University of Cambridge, Cambridge, UNITED KINGDOM, Cambridge, UNITED KINGDOM, 4Department of Radiology, University of Cambridge, Cambridge, UNITED KINGDOM, Cambridge, UNITED KINGDOM.

510


Clinical Oncology Track - TROP Session: Lung

OP-0217Frequency and prognostic value of immune-related adverse effects assessed on18F-FDGPET/CT in NSCLC treated with immune checkpoint inhibitorsO. Humbert1, M. Bauckneht2, J. Gal1, D. Rener1, M. Paquet1, A. Schiazza1, D. Chardin1, C. Genova3, R. Schiappa1, G. Rossi4, L. Zullo3, J. Darcourt1, S. Morbelli3, J. Otto1; 1Antoine Lacassagne Cancer Center, Nice, FRANCE, 2Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genova, ITALY, 3IRCCS Ospedale Policlinico San Martino, Genova, ITALY, 4Ospedale Pare Antero Micone, Genova, ITALY.

OP-0218Using a semi-supervised clustering method to determine whether a radiomic phenotype can distinguish primary lung tumors from lung metastasesV. Cuplov, N. Captier, I. Buvat, F. Orlhac; Laboratory of Translational Imaging in Oncology, U1288 Inserm, Institut Curie, Univ. Paris Saclay, Orsay, FRANCE.

OP-0219The immune metabolic prognostic index discloses the presence of radiological progression in patients with non-small cell lung cancer (NSCLC) treated with NivolumabF. Lanfranchi1,2, M. Bauckneht1,2, C. Genova1,3, G. Rossi1,3, E. Rijavec4, M. G. Dal Bello1, G. Ferrarazzo1,2, M. Tagliamento1,3, C. Delucchi1,2, M. I. Donegani1,2, F. Biello5, S. Chiola6,7, L. Zullo1,3, S. Raffa1,2, G. Cittadini1, C. Marini1,8, G. Sambuceti1,2, F. Grossi4, S. Morbelli1,2; 1IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, ITALY, 2Department of Health Sciences (DISSAL), University of Genoa, Via Antonio Pastore 1, 16132, Genoa, ITALY, 3Department of Internal Medicine (DIMI), University of Genoa, Viale Benedetto XV 6, 16132, Genoa, ITALY, 4Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 28, 20122, Milan, ITALY, 5Department of Transitional Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100, Novara, ITALY, 6Humanitas Clinical and Research Center–IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, ITALY, 7Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, ITALY, 8Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Via Fratelli Cervi 93, 20090, Segrate, Milan, ITALY.of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, 3Department of Neurology, University of Leipzig, Leipzig, GERMANY, 4Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, GERMANY.

OP-0220Machine Learning Radiomics for Prediction of Survival in Non Small Cell Lung Cancer Patients Studied with PET/CT and FDGE. Giovannini1, L. Florimonte2, E. Bonatto3, C. Bareggi4, L. Dellavedova5, A. Milano6, G. Giovacchini1, V. Duce1, C. Aschele6, M. Castellani2, A. Ciarmiello1; 1Nuclear Medicine O.U. - Sant’Andrea Hospital, La Spezia, ITALY, 2Nuclear Medicine Department Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, ITALY, 3University of Milan, Milano, ITALY, 4Medical Oncology Unit Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, ITALY, 5Nuclear Medicine Department Ovest Milanese, Legnano, Milano, ITALY, 6Oncology Dip. S. Andrea Hospital, La Spezia, ITALY.

OP-0202Preparation and preclinical assessment of 188Re-Rituximab for RadioimmunotherapyB. Alirezapour1, H. Yousefnia1, A. Bahrami-Samani1, F. Shakeri2, M. Alizadeh2, M. Hashemizadeh3, M. Fathi2, B. Azizkalantari3; 1Nuclear Science and Technology Research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Zanjan University of Medical Sciences, Zanjan, IRAN, ISLAMIC REPUBLIC OF, 3Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

509


Cutting Edge Science Track - TROP Session: Lu-177 Dosimetry

OP-0204Impact of dead-time correction method on 177Lu quantitative SPECT and dosimetry in personalized PRRTA. Desy1,2, G. F. Bouvet1,2, J. M. Beauregard1,2; 1Department of Medical Imaging, and Research Center (Oncology Axis), CHU de Québec – Université Laval, Québec City, QC, CANADA, 2Department of Radiology and Nuclear Medicine, and Cancer Research Center, Université Laval, Québec City, QC, CANADA.

OP-0205Optimisation of the Radiation Dosimetry Protocol in 177Lu-PSMA TherapyM. Mink1,2, S. M. Peters1, B. M. Privé1, M. de Bakker1, C. H. Muselaers3, N. Mehra4, J. A. Witjes3, M. Gotthardt1, C. W. Timmermans2,5, J. Nagarajah1, M. W. Konijnenberg1,6; 1Department of Medical Imaging, Radboud university medical center, Nijmegen, NETHERLANDS, 2Radboud University, Nijmegen, NETHERLANDS, 3Department of Urology, Radboud university medical center, Nijmegen, NETHERLANDS, 4Department of Medical Oncology, Radboud university medical center, Nijmegen, NETHERLANDS, 5Nikhef, Amsterdam, NETHERLANDS, 6Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-0206Validation of a simplified single time point image-based dosimetry approach for 177Lu-PSMA therapyJ. Brosch-Lenz1,2, A. Gosewisch1, F. Völter1, L. Kaiser1, P. Bartenstein1, S. Ziegler1, A. Rahmim2,3,4, C. Uribe5,3, G. Böning1; 1Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, 2Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 3Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, 4Department of Physics, University of British Columbia, Vancouver, BC, UNITED STATES OF AMERICA, 5Functional Imaging, BC Cancer, Vancouver, BC, CANADA.

OP-0207A simplified method for kidney dosimetry in 177Lu therapies based on single SPECT-CT and multiple external probe measurementsD. Pistone1,2, T. Ligonnet3, L. Auditore4, A. Italiano2,1, E. Amato4,2, A. Campennì4,5, N. Schaefer6, S. Boughdad6, S. Baldari4,5, S. Gnesin3; 1MIFT Department, University of Messina, Messina, ITALY, 2INFN Section of Catania, Catania, ITALY, 3Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, 4BIOMORF Department, University of Messina, Messina, ITALY, 5Nuclear Medicine Unit, University Hospital “G. Martino”, Messina, ITALY, 6Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND.

OP-0208Evaluation of 2D/3D hybrid dosimetry in PSMA-targeted radioligand therapyF. Rosar, N. Schön, H. Bohnenberger, M. Bartholomä, T. Stemler, S. Maus, F. Khreish, S. Ezziddin, A. Schaefer-Schuler; Department of Nuclear Medicine, Saarland University - Medical Center, Homburg, GERMANY.

OP-0209Comparison of Voxel S-values and Monte Carlo Simulation in [177Lu]Lu-DOTA-TATE Quantification for Patient-Specific DosimetryC. Rodrigues1,2,3, P. Ferreira1, F. P. M. Oliveira1, Â. Silva1, L. Peralta2,3, D. C. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 2Faculdade de Ciências da Universidade de Lisboa, Lisbon, PORTUGAL, 3Laboratório de Instrumentação e Física Experimental de Partículas, Lisbon, PORTUGAL.

OP-0210Impact of SPECT Segmentation on Accuracy of Lu-177 Activity Quantification for Dosimetry in Radionuclide TherapyJ. Pfeil1, Z. Zsebe2, I. Apostolova2, R. Buchert2, S. Klutmann2, W. Lehnert2; 1Humboldt Universität zu Berlin, Berlin, GERMANY, 2University Medical Center, Hamburg, GERMANY.

OP-0211Ga-68-PSMA-11 PET Imaging as a Predictor for Absorbed Doses in Organs at Risk and Small Lesions in Lu-177-PSMA-617 TreatmentS. Peters1, R. Hofferber2, B. Privé1, M. De Bakker1, M. Gotthardt1, F. De Lange1, C. Muselaers1, N. Mehra1, A. Witjes1, P. Costa2, J. Nagarajah1, M. Konijnenberg1, W. Jentzen2; 1Radboudumc, Nijmegen, NETHERLANDS, 2Essen University Hospital, Essen, GERMANY.



8786

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-023218F-FDG in patients with embolic stroke of undetermined source (ESUS): A pilot study to identify and evaluate atherosclerotic plaquesL. Romero Robles, M. Garrastachu Zumaran, F. Julian Villaverde, X. Boulvard Chollet, M. Mangas Losada, I. Garcia Megias, A. Cabrera Villegas, R. Ramirez Lasanta, R. Delgado Bolton; Hospital San Pedro, Logroño (La Rioja), SPAIN.

OP-0233Detection of acute myocarditis with 68GA-DOTATOC digital-PET as compared with cardiac MRI : preliminary resultsC. Boursier, E. Chevalier, J. Varlot, L. Filippetti, O. Huttin, V. Roch, L. Imbert, E. Albuisson, M. Claudin, D. Mandry, P. Marie; CHRU Nancy, Vandoeuvre-les Nancy, FRANCE.

OP-0234Early detection of anthracycline cardiotoxicity by18F-FDG PET/MRI in oncology patientsT. Yuan, M. Wei, X. Chen, X. Wang; Department of Nuclear Medicine, Peking University Cancer Hospital & Institute,, Beijing, CHINA.

OP-0235Gated tomographic radionuclide angiography using 3D-ring CZT Starguide SPECT/CT : head-to-head comparison with a cardiac-dedicated CZT cameraT. Carsuzaa, F. Thibault, M. Bailly; CHR Orleans, Orleans, FRANCE.

OP-0236Incremental Value of 18F-FDG Cardiac PET Imaging Over Dobutamine Stress Echocardiography in Predicting Myocardial Ischemia in Patients with Suspected Coronary Artery DiseaseE. Zampella1, R. Assante1, A. D’Antonio1, T. Mannarino1, E. Criscuolo1, R. Bologna1, P. Buongiorno1, V. Gaudieri1, C. Nappi1, R. Green1, V. Cantoni1, M. Petretta2, W. Acampa1, A. Cuocolo1; 1Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, 2IRCCS SDN, Diagnostic Imaging, Naples, ITALY.

OP-0237Comparison of early imaging of 123I-BMIPP and myocardial washout rate for diagnosis of triglyceride deposit cardiomyovasculopathyR. Ono1, H. Miyauchi1, K. Hoshi2,3, T. Iimori4, M. Oyama5, K. Hirano6, Y. Kobayashi1; 1Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, JAPAN, 2Faculty of Medicine, Chiba University School of Medicine, Chiba, JAPAN, 3Internal Medicine, National Hospital Organization Disaster Medicine Center, Tachikawa City, JAPAN, 4Department of Radiology, Chiba University Hospital, Chiba, JAPAN, 5Division of Laboratory Medicine, Chiba University Hospital, Chiba, JAPAN, 6Laboratory of Cardiovascular Disease, Novel, Non-invasive, and Nutritional Therapeutics and Triglyceride Research Center, Graduate School of Medicine, Osaka University, Osaka, JAPAN.

OP-0238The impact of lung perfusion scintigraphy in the work-up of Acute Pulmonary Embolism diagnosis: healthcare and economic aspectsG. Rubini1, P. Mammucci1, C. Ferrari1, C. G. Leo2, P. Mincarone3; 1Section of Nuclear Medicine, DIM, University “Aldo Moro”, Bari, ITALY, 2National Research Council, Institute of Clinical Physiology, Branch of Lecce c/o Campus Ecotekne via Monteroni, Lecce, ITALY, 3National Research Council, Institute for Research on Population and Social Policies, Research Unit of Brindisi, Brindisi, ITALY.

OP-0239Left-ventricular volumes and ejection fraction from cardiac ECG-gated 15O-water positron emission tomography compared to cardiac magnetic resonance imaging using simultaneous hybrid PET/MRJ. Nordström, S. Kvernby, T. Kero, J. Sörensen, H. Harms, M. Lubberink; PET Center Uppsala Akademiska sjukhuset, Uppsala, SWEDEN.

OP-0240Incomplete Anatomical Revascularization in Multivessel Coronary Artery Disease: a Quantitative Myocardial Perfusion PET StudyA. Guarneri1, L. Leccisotti2,1, M. Grandinetti3, G. Locorotondo4, M. Iafrancesco3, P. Bruno3, F. Crea4, M. Massetti3, A. Giordano1,5; 1Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, ITALY, 2Unit of Nuclear Medicine, Department of Diagnostic Imaging, Radiation Oncology and Haematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, 3Unit of Cardiac Surgery, Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, 4Unit of Cardiology, Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, 5Unit of Nuclear Medicine, Department of Diagnostic Imaging, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

601


CME 4: Imaging Neuroinflammation – Everything You Always Wanted to Know, But Were Afraid to Ask

OP-0243Background of TSPO and Non-TSPO Targets and Their RadiotracersM. Brendel; Department of Nuclear Medicine, University Hospital of Munich; Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

OP-0221Therapeutic response assessment using [18F]-FDG-PET/CT in NSCLC patients treated with immune checkpoint inhibitorsI. Duran Derijckere1, N. Gohimont2, I. Karfis1, G. Critchi1, T. Berghmans3, P. Flamen1; 1Nuclear medicine department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 2Nuclear medicine department, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 3Thoracic oncology clinic, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BELGIUM.

OP-0222The role of 18F-FDG PET/CT for evaluating immunotherapy response in patients with NSCLC: a systematic review and meta-analysisM. Huang; The Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, CHINA.

OP-0223The role of 18F-FDG PET/CT in Predicting Response to PD-1 Blocking Immunotherapy and the prognostic significance of immune organs activationC. Ferrari1, G. Santo1, N. C. Merenda1, M. C. Bellomo1, G. Ranieri2, C. D. Gadaleta2, G. Rubini1; 1Section of Nuclear Medicine, DIM, University “Aldo Moro”, Bari, ITALY, 2Interventional Oncology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”, Bari, ITALY.

OP-0224Digital and respiratory-gated FDG PET/CT for characterization of lung lesionsT. Bartel, W. P. Fendler, K. Pabst, F. Barbato, C. Rischpler, K. Herrmann, H. Hautzel; Nuklearmedizin Universitätsklinikum Essen, Essen, GERMANY.

OP-0225Prognostic value of 18F-FDG PET/CT quantitative metrics in non-small cell lung cancerS. Fontão de Castro, I. Próspero, L. S. Violante, G. Ferreira, J. Teixeiro, H. Duarte; Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, PORTUGAL.

OP-0226Tc99m MAA tumor distribution as a predictive risk factor of occult nodal metastasis in clinically N0 non small cell lung cancer patientV. Murad, M. Suh, H. Choi, G. J. Cheon, K. J. Na, Y. T. Kim; Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

OP-0227Discriminative capacity of the 18F-FDG PET/CT quantitative parameters in the solitary pulmonary noduleM. Rashki1, E. Triviño-Ibáñez1, D. Rivas-Navas1, A. González-Jiménez2, A. Rodríguez-Fernández1; 1Nuclear Medicine department, University Virgen de las Nieves Hospital, Granada, SPAIN, 2Nuclear Medicine department, Jaén Hospital, Jaén, SPAIN.

OP-0228Clinical validation of a fully automated lung segmentation method in patients with pulmonary nodules: preliminary resultsZ. Mikó1,2, E. Szabó2, J. Csirik2, S. Urbán1, Z. Besenyi1, L. Pávics1; 1Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY, 2Institute of Informatics, University of Szeged, Szeged, HUNGARY.

511


Featured Session: New Kids on the Cardiovascular Block!

OP-0230Diamonds in the Rough - New Opportunities in Cardiovascular ImagingF. Hyafil; Assistance Publique - Hopitaux de Paris, European Hospital Georges Pompidou, Nuclear Medicine, Paris, FRANCE.

OP-0231Glycoprotein IIb/IIIa receptor targeted PET/CT imaging for detecting prosthetic valve thrombosis: a proof-of-concept studyV. Hugenberg1, R. Zabel1, R. Preuss1, K. Friedrichs2, T. Rudolph2, V. Rudolph2, S. Bleiziffer3, H. Milting4, A. Stephens5, N. Koglin5, J. Gummert3, W. Burchert1, M. Deutsch3; 1Institute of Radiology, Nuclear Medicine and Molecular Imaging, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY, 2Department of General und Interventional Cardiology/Angiology, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY, 3Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY, 4Erich and Hanna Klessmann Institute for Cardiovascular Research & Development (EHKI), Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY, 5Life Molecular Imaging GmbH, Berlin, GERMANY.



8988

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0408Covid Incidental infection finding in 18 FPSMA1007 PET CT in asymptomatic patientM. Agolti, L. Solari; Centro de Medicina Nuclear Clinica Modelo, Parana, ARGENTINA.

OP-040918F-FDG brain PET in a patient with neurological involvement after severe SARS-CoV-2 infection: a rather fast recovery of brain metabolic functionA. Martini1,2, G. Carli3, I. Laghai1, L. Kiferle4, P. Piersanti4, D. Perani3, S. Sestini1; 1Hospital Santo Stefano Nuclear Medicine Unit, Prato, ITALY, 2University of Florence, AUOC Careggi, Department of Nuclear Medicine, Florence, ITALY, 3University Vita Salute San Raffaele, Nuclear Medicine Unit Division of Neuroscieces, Milan, ITALY, 4Hospital Santo Stefano Neurology Unit, Prato, ITALY.

OP-0410The role of 18F-FDG PET/CT in diagnosis and evaluation of an unsuspected secondary cutaneous lesion in a patient with tumor of unknown origin (TUO) in times of COVID-19 pandemic - a case reportT. Stoeva, T. Yordanova, M. Dyankova, S. Chausheva, Z. Dancheva, B. Chaushev, A. Klisarova; UMHAT “Sveta Marina” EAD- Varna, Varna, BULGARIA.

OP-041118F-FDG PET/CT diagnostic challenges in differentiating between post-COVID-19 vaccination lymphadenopathy and acral lentiginous melanoma metastasis: A Case ReportI. Almasan, G. Rusu, L. Hitu, G. Kermoison, H. Haba, I. Alexiev, D. Piciu; Institute of Oncology „Prof Dr. Ion Chiricuta”, Cluj-Napoca, ROMANIA.

OP-0412Inguinal Bladder Hernia on FDG PET/CTN. Filizoglu, S. Kesim, C. O. Sahin, T. N. Kissa, K. Niftaliyeva, Z. C. Balaban Genc, K. Oksuzoglu, S. Ozguven, F. Sen, S. Inanır, T. Ones, H. T. Turoglu, T. Y. Erdil; Marmara University Pendik Training and Research Hospital, Istanbul, TURKEY.

OP-0413Demonstration of Peritoneal-Scrotal Communication by99mTc-MAA ScintigraphyA. Marques, F. Abreu, S. Pintão; Centro Hospitalar de Lisboa Ocidental, Lisbon, PORTUGAL.

OP-0414Pulmonary Embolism on Azygos Lobe Detected by Ventilation/Perfusion SPECT/CTS. Kesim, N. Filizoglu, C. O. Sahin, Z. C. Balaban Genc, K. Niftaliyeva, T. N. Kissa, K. Oksuzoglu, S. Ozguven, F. Sen, T. Ones, S. Inanir, H. T. Turoglu, T. Y. Erdil; Marmara University Istanbul Pendik Training and Research Hospital, Istanbul, TURKEY.

OP-0415Use of 2- [18F] FDG PET / CT in unusual pediatric tumorsM. Acuña Hernandez1, R. Palma Rosillo2, R. Mora Ramírez2; 1Universidad Autónoma de Bucaramanga, Bucaramanga, COLOMBIA, 2Instituto Nacional de Pediatría, Ciudad de México, MEXICO.

OP-0416Comparison [68Ga]FAPİ-46 PET/CT and [131I] SPECT/CT findings after ablation therapy with high-activity 131-I therapy of metastatic papillary thyroid cancer patients: Two case reportsF. Novruzov1, A. Aliyev2, S. Novruzova1, N. Orucova1, I. Aliyeva3, M. Moore4, F. Valla4, F. Giammarile5,1, E. Mehdi1; 1Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, 2Azerbaijan National Centre of Oncology, Department of Head and Neck Surgery, Baku, AZERBAIJAN, 3Azerbaijan Medical University, Department of Internal Medicine, Baku, AZERBAIJAN, 4SOFIE, Totowa, NJ, UNITED STATES OF AMERICA, 5International Atomic Energy Agency, Vienna, AUSTRIA.

OP-0417Peptide Receptor Radionuclide Therapy (PRRT) in Radioiodine-Refractory Thyroid Cancer. A Case Report of Significant Response to 177Lu-Dotatate TreatmentS. Ataei, K. Aryiana, S. Mostafavi, M. Esmati nia, H. Mohammad Zadeh Kosari, A. Aghaei; Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-0418Subacute Thyroiditis and Cardiovascular Events - a Report of Two Clinical CasesK. Bajuk Studen1,2, K. Zaletel1,2, E. Pirnat1,2, S. Gaberscek1,2; 1University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

OP-0244Imaging Neuroinflammation with TSPO Ligands - A Critical ReappraisalB. van Berckel; VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0245Imaging Neuroinflammation - Beyond TSPO ReceptorsD. van Weehaeghe; Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Leuven and KU Leuven, Leuven, BELGIUM.

602


Case Report Session: What’s the Case? Report it Now!

OP-0396PET/MRI Advantages in Primary Inferior Vena Cava LeiomyosarcomaB. Ronchi, G. Peña, C. Sacchi; FUESMEN, Mendoza, ARGENTINA.

OP-0397Giant Pelvic Plasmacytoma Detected by F-18 FDG PET/CT in a Patient with Multiple MyelomaS. Kesim, T. Ones, N. Filizoglu, C. O. Sahin, T. N. Kissa, Z. C. Balaban Genc, K. Niftaliyeva, K. Oksuzoglu, S. Ozguven, F. Sen, S. Inanir, H. T. Turoglu, T. Y. Erdil; Marmara University Istanbul Pendik Training and Research Hospital, Istanbul, TURKEY.

OP-0398Mosaic Pattern of Skin Granuloma Annulare on[18F]FDG PET/CTG. Abdullayev, E. Mehdi, F. Novruzov; Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN.

OP-0399A Case of Lumbar Osteomyelitis Imitating a Malignant TumorC. Sahin, K. Oksuzoglu, S. Kesim, N. Filizoglu, T. N. Kıssa, K. Niftaliyeva, Z. C. Balaban, S. Ozguven, F. Sen, T. Ones, H. T. Turoglu, S. Inanir, T. Y. Erdil; Marmara University Pendik Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TURKEY.

OP-0400Whole Body Lymphoscintigraphy and WB DWIBS-MRI in two cases of thoracic lymphangiomatosisC. Olianti1, A. Arena2, A. Perrone3, A. Tondo3; 1University Hospital of Florence, Florence, ITALY, 2Hospital of Prato, Prato, ITALY, 3University Hospital Meyer, Florence, ITALY.

OP-0401PET/CT as a key role imaging tool in infectious endocarditis (IE) complications: two cases of splenic abscesses, in patients with prosthetic valve endocarditis (PVE)Z. Dancheva, M. Dyankova, T. Stoeva, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova; St Marina University Hospital, Varna, BULGARIA.

OP-0402Extensive dermatomyositis mimicking insulin-induced skeletal muscle uptake in 18F-FDG PET/CTJ. Zhang-Yin1, N. Weynants2, G. Piret-Gerard3, P. Pierre2, B. Tang1; 1CSL hospital, Vivalia, Arlon, BELGIUM, 2Oncology, CSL hospital, Vivalia, Arlon, BELGIUM, 3Radiology, CSL hospital, Vivalia, Arlon, BELGIUM.

OP-0403The usefulness of 67Gallium-citrate scintigraphy in renal transplant infectionA. Marques, F. Abreu, S. Pintão; Centro Hospitalar de Lisboa Ocidental, Lisbon, PORTUGAL.

OP-0405Utility of 18Ffluorodeoxyglucose PET- CT in a Rare case of Granulomatosis with Polyangiitis (GPA) with Multi-organ involvement without raised serum Proteinase 3 antineutrophil cytoplasmic antibodies (c-ANCA)A. Dixit; MPCT cancer hospital, Navi Mumbai, INDIA.

OP-040618-FDG-PET/CT in thoracic sarcoidosis, mimicking a chondrosarcoma progression - a case reportZ. Dancheva1, A. Konsoulova2, M. Dyankova1, T. Yordanova1, B. Chaushev1, T. Stoeva1, S. Chausheva1, A. Klisarova1; 1St Marina University Hospital, Varna, BULGARIA, 2Department of Oncology, Complex Oncological Centre, Burgas, BULGARIA.

OP-0407Molecular Neuroimage and Parkinsonism after SARS-CoV2 InfectionA. Silva Mascarenhas, F. Menegatti Marino; Imagens Médicas de Brasília - IMEB, Brasília, BRAZIL.



9190

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0262The Role of Novel Radiotracers - FAPI Imaging in Systemic Sclerosis and IgG4-Related DiseaseC. Schmidkonz; University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY.

607


Pitfalls & Artefacts 4: Sentinel Lymph Node in Head & Neck, Penile and Gynaecological Cancers

OP-0264Sentinel Lymph Node in Malignant Skin MelanomaS. Balogová; Comenius University of Bratislava, St.Elisabeth Oncology Institute, Nuclear medicine, Bratislava, SLOVAKIA.

OP-0265Sentinel Lymph Node in Head and Neck CancersR. A. Valdés Olmos; Leiden University Medical Centre, Radiology, Section of Nuclear Medicine & Interventional Molecular Imaging Laboratory, Leiden, NETHERLANDS.

OP-0266Sentinel Lymph Node in Penile CarcinomaO. Brouwer; Netherlands Cancer Institute, Department of Surgical Oncology (Urology), Amsterdam, NETHERLANDS.

OP-0267Sentinel Lymph Node in Gynaecological CancersS. Vidal Sicart; Hospital Clínic Barcelona, Nuclear Medicine Dpt., Barcelona, SPAIN.

608


M2M Track - Featured Session: Mapping Brain Structures

OP-0269Evolution of Brain Mapping - From Bedside to Bench…F. Mottaghy; Universitätsklinikum Aachen, Klinik für Nuklearmedizin, Aachen, GERMANY.

OP-0270Preclinical Evaluation, Kinetic Modelling, And Assessment Of Test-Retest Reproducibility Of [18F]Synvest-1 For PET Imaging Of Synaptic Vesicle Glycoprotein 2AD. Bertoglio1, J. Verhaeghe1, F. Zajicek1, S. De Lombaerde1,2, A. Miranda1, S. Stroobants1,2, V. Khetarpal3, M. Skinbjerg3, C. Dominguez3, Y. Wang3, I. Munoz-Sanjuan3, J. Bard3, L. Liu3, S. Staelens1; 1University of Antwerp, Wilrijk, BELGIUM, 2Antwerp University Hospital, Edegem, BELGIUM, 3CHDI Management/CHDI Foundation, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-0271Head-to-Head Comparison of beta-Amyloid-PET Quantification in PET, PET/CT and PET/MRI: Towards Small Animal Multicenter StudiesM. Koehler1, K. Wind1, C. Klaus2, A. Zatcepin1,2, L. Sebastian Monasor2,3, J. Gnörich1,2, L. Beyer1, F. Eckenweber1, M. Scheifele1, F. Gildehaus1, B. von Ungern-Sternberg1, M. Patt4, C. Haass2,5,6, P. Bartenstein1,6, J. Herms2,6,7, S. Tahirovic2, S. Ziegler1, M. Brendel1,2,6; 1Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, GERMANY, 2German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, GERMANY, 3Graduate School of Systemic Neuroscience, Ludwig-Maximilians-University Munich, Munich, GERMANY, 4Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, 5Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, GERMANY, 6Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, 7Center of Neuropathology and Prion Research, University of Munich, Munich, GERMANY.

OP-0272Development and Translational Study of Novel Alpha-Synuclein PET TracersB. Uzuegbunam1, W. Paslawski2, H. Ågren3, C. Halldin2, D. Librizzi4, W. Weber1, M. Luster4, T. Arzberger5, B. H. Yousefi4; 1Technical University of Munich, Munich, GERMANY, 2Karolinska Institute, Stockholm, SWEDEN, 3University of Uppsala, Uppsala, SWEDEN, 4Philipps-University of Marburg, Marburg, GERMANY, 5Ludwig-Maximilians-University of Munich, Munich, GERMANY.

OP-0273[18F]MC225 PET for the dose-response assessment of tariquidar inhibition of blood-brain barrier P-glycoprotein function in vivoL. Garcia-Varela1,2, P. Mossel1, P. Aguiar2, D. A. Vazquez-Matias1, A. van Waarde1, A. T. Willemsen1, A. L. Bartels3, R. A. Dierckx1, P. H. Elsinga1, G. Luurtsema1; 1University Medical Center of Groningen, Groningen, NETHERLANDS, 2Department of Nuclear Medicine and Molecular Imaging Group, Clinical University Hospital, IDIS Health Research Institute, Santiago de Compostela, SPAIN, 3Department of Neurology, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-0419Imaging pituitary microadenoma by using 18F-FDOPA, 68Ga-DOTA-NOC and 18F-FDG PET/CTS. Li, T. Wollenweber, A. Göllner, T. Traub-Weidinger, J. Furtner-Sajer, G. Karanikas, A. Haug, M. Hacker; Medical University of Vienna, Vienna, AUSTRIA.

OP-0420A Benign Adrenal Mass with Changing Metabolism Mimicking Metastasis During Follow-up in a GIST PatientÜ. Yararbas, F. Tamer; Ege University Medical Faculty, Izmir, TURKEY.

OP-042199mTc-MIBI Retention in Graves’ DiseaseB. Seven1, M. Aslan1, M. Çapraz2; 1Department of Nuclear Medicine, Sabuncuoglu Serefeddin Training and Research Hospital, Amasya, TURKEY, 2Department of Internal Medicine, School of Medicine, University of Amasya, Amasya, TURKEY.

604


CTE 4: Cardiac PET/CT

OP-0251Introduction to Quantitative Cardiac PET/CTL. Camoni; University of Brescia, Nuclear Medicine and Molecular Imaging Department, Brescia, ITALY

OP-0252Clinical Examples of Rubidium PET/CTM. Mouden; Isala Hospital, Zwolle , NETHERLANDS.

OP-0253Research Tracers Used in Cardiac PET/CTA. Saraste; Turku University Hospital, Heart Center, Truku, FINLAND.

605


Joint Symposium 7 (EANM/EASD): My Foot is on Fire - Find the Hot Spot

OP-0255Diabetic Foot Infections - Clinical Challenges for DiabetologistsF. Game; University Hospitals of Derby and Burton NHS Foundation Trust, Department of Diabetes and Endocrinology, Derby, UNITED KINGDOM.

OP-0256Diabetic Foot Infections - Clinical Challenges for RadiologistsT. Kwee; University Medical Center Groeningen, Department of Radiology, Groningen, NETHERLANDS.

OP-0257Diabetic Foot Infections - Clinical Challenges for Nuclear Medicine PhysiciansC. Lauri; Sant’Andrea Hospital, Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine of “Sapienza” University, Rome, ITALY.

606


Joint Symposium 8 (EANM/EULAR): PET/CT and PET/MRI in Patients with Autoimmune Disorders

OP-0259Autoimmune Rheumatic Disorders - The Rheumatologist’s QuestionsR. Seror; Rheumatology Department, Université Paris Sud, Hôpitaux Universitaires Paris-Sud, Paris, FRANCE.

OP-0260Autoimmune Paraneoplastic Syndromes - The Clinician’s Point of ViewZ. Szekanecz; Department of Rheumatology, University of Debrecen, Debrecen, HUNGARY.

OP-0261The Current Role of FDG Imaging in Autoimmune DisordersL. Leccisotti; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Nuclear Medicine Unit, Rome, ITALY.



9392

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0285Dose volume histogram comparison between pre-treatment 99mTc-MAA SPECT/CT and post treatment 90Y PET/CT voxel-based dosimetry with rigid and deformable contour registration algorithms in radioembolization with resin 90Y microspheresG. Della Gala1, M. Santoro1, G. Paolani1, S. Strolin1, E. Lodi Rizzini2, A. Cappelli3, C. Mosconi3, L. Calderoni4, A. Morganti2, S. Fanti4, R. Golfieri3, L. Strigari1; 1Medical Physics Department IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, ITALY, 2Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine, IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, ITALY, 3Radiology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, ITALY, 4Department of Nuclear Medicine, IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, ITALY.

OP-0286Dosimetric comparison between planning SPECT and monitoring PET for 90Y-radioembolisationJ. Labour, T. Baudier, S. Parisse-Di Martino, F. Khayi, D. Sarrut, J. Badel; Centre Léon Bérard, Université de Lyon; CREATIS; CNRS UMR5220; Inserm U1044; INSA-Lyon; Université Lyon 1, Lyon, FRANCE.

OP-0287The Impact of an Optimised Methodology of Lung Shunt Fraction Estimation in Planar 99mTc-MAA Imaging on Prescribed Activity and Estimated Doses to Liver and Lungs for 90Y SIRT TreatmentsN. McArdle1, S. Cournane1,2, J. McCavana1, J. Lucey1, L. León Vintró2; 1St Vincent’s University Hospital, Dublin, IRELAND, 2University College Dublin, Dublin, IRELAND.

OP-0288Comparison of Two 90Y-charged Glass Microspheres Liver Radioembolisation Dosimetry Methods: Voxel S-values and Monte Carlo - GATEM. Ribeiro1,2, P. Ferreira1, F. P. Oliveira1, J. Cruz2, D. C. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisboa, PORTUGAL, 2NOVA School of Science and Technology, Almada, PORTUGAL.

OP-0289Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCCE. Veenstra, S. J. Ruiter, R. P. Bokkers, K. P. de Jong, W. Noordzij; University Medical Center Groningen, Groningen, NETHERLANDS.

610


Clinical Oncology Track - TROP Session: Gastro-Intestinal

OP-0291Head-to-head Comparison of [68Ga]Ga-Fapi-04 and [18F]-FDG PET/CT in Evaluating the Extent of Disease in Gastric AdenocarcinomaJ. Kuten1,2, C. Levine1,2, O. Shamni3, S. Pelles4,2, I. Wolf4,2, G. Lahat5,2, E. Mishani3, E. Even-Sapir1,2; 1Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAEL, 2Sackler School of Medicine, Tel Aviv University, Tel Aviv, ISRAEL, 3Cyclotron Radiochemistry Unit, Hadassah Medical Organization and Faculty of Medicine, Jerusalem, ISRAEL, 4Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAEL, 5Department of Surgery, Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAEL.

OP-0292Respiratory-gated FDG PET/MRI in Evaluation of Primary Gastric Lesions and Gastric Lymph Nodes in Patients with Gastric CancerS. Gulbahar Ates1, U. Aydos2, U. O. Akdemir2, O. Yuksel3, A. Uner4, A. Dursun5, L. O. Atay2; 1Department of Nuclear Medicine, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TURKEY, 2Department of Nuclear Medicine, Faculty of Medicine, Gazi University, Ankara, TURKEY, 3Department of General Surgery, Faculty of Medicine, Gazi University, Ankara, TURKEY, 4Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, TURKEY, 5Department of Pathology, Faculty of Medicine, Gazi University, Ankara, TURKEY.

OP-0293Static and dynamic FAPI-PET for the differentiation of low grade and high grade intraductal papillary mucinous neoplasmsA. Spektor1, M. Lang2, E. Gutjahr3, U. Heger2, C. Tjaden2, H. Rathke1, U. Haberkorn1, M. Röhrich1; 1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, 2Department of Surgery, University Hospital Heidelberg, Heidelberg, GERMANY, 3Department of Pathology, University Hospital Heidelberg, Heidelberg, GERMANY.

OP-0274Longitudinal follow-up of APJ receptor expression by microPET/CT in a rodent model of cerebral ischemia-reperfusionO. Nachar, N. Hugues, B. Louis, L. Balasse, V. Nail, A. Moyon, A. Bouhlel, G. Hache, F. Dignat-George, J. Laurin, P. Garrigue, B. Guillet; Aix-Marseille University, Marseille, FRANCE.

OP-0275Preclinical evaluation of [11C]HSP990 for in vivo visualization of heat shock protein 90 (Hsp90) in brain with positron emission tomography (PET)R. Cools1, K. Vermeulen2, C. Cawthorne3, G. Bormans1; 1Laboratory for Radiopharmaceutical Research, Department of Pharmacy and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, 2SCK CEN Belgian Nuclear Research Centre, Mol, BELGIUM, 3Nuclear Medicine & Molecular Imaging & MoSAIC, Department of Imaging & Pathology KU Leuven, Leuven, BELGIUM.

OP-0276Upregulation of Sigma-1 receptor expression depends on the severity of ischemia: Based on the imaging study with the sigma-1 receptor imaging agent, I-125-OI5VJ. Taki1, H. wakabayashi1, H. Mori1, T. Hiromasa1, N. Akatani1, K. Shiba2, K. Ogawa3, S. Kinuya1; 1Kanazawa University Hospital, Kanazawa, JAPAN, 2Kanazawa University, Advanced Science Research Center, Kanazawa, JAPAN, 3Kanazawa University, Institute for Frontier Science Initiative, Kanazawa, JAPAN.

OP-0277Pharmacological characterization of [18F]-FNM and evaluation of NMDA receptors activation in rat brain injury modelM. Beaurain1, F. Talmont2, D. Pierre3, S. Boucher1, P. Payoux1, A. Salabert1; 1Toulouse Neuroimaging Center (ToNIC, Inserm UMR1214), Toulouse, FRANCE, 2Institut de Pharmacologie et de Biologie Structurale (IPBS, CNRS), Toulouse, FRANCE, 3CHU de Toulouse, Toulouse, FRANCE.

OP-0279Early detection of Amyloid-β pathology via 89Zr-DFO*-Immuno-PET with a novel bispecific monoclonal antibodyN. Stergiou1, T. Wünsche1, M. Schreurs1, I. Mes1, M. Verlaan1, E. Kooijman1, A. Windhorst1, G. van Dongen1, L. Helboe2, S. Vergo2, S. Christensen2, A. Asuni2, A. Jensen2, B. Bang-Andersen2, D. Vugts1, W. Beaino1; 1Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology & Nuclear Medicine, Amsterdam, NETHERLANDS, 2H. Lundbeck A/S, Nykøbing Sjælland, DENMARK.

609


Cutting Edge Science Track - TROP Session: Clinical Dosimetry and Radioembolisation

OP-0281Preliminary results of INSPIRE clinical dosimetry studyC. Abreu1, L. Carnegie-Peake1, J. Taprogge1, P. Gape1, D. Rushforth1, C. Barker1, A. Divoli1, J. Gear1, L. McAreavey1, I. Murray1, B. Pratt1, B. Rojas1, L. Vavrova1, K. Wong2, K. Newbold2, G. Flux1; 1Joint Department of Physics, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UNITED KINGDOM, 2Head and Neck Oncology Unit, Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM.

OP-0282Therapy with 177Lu-DOTATATE: correlation between relative platelets reduction and image based bone marrow low absorbed doseS. Mazzaglia, G. Argiroffi, V. Fuoco, M. Maccauro, E. Seregni, A. Lorenzoni, G. Aliberti, M. Kirienko, C. Chiesa; IRCCS Istituto Nazionale Tumori, Milan, ITALY.

OP-0283Global Tumour Absorbed Dose Heterogeneity for Patients Treated with 177-Lilotomab SatetraxetanJ. Blakkisrud1,2, A. Løndalen1,3, J. Dahle4, A. Kolstad5, C. Stokke1,2; 1Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, 2Department of Physics, University of Oslo, Oslo, NORWAY, 3Faculty of Medicine, University of Oslo, Oslo, NORWAY, 4Nordic Nanovector ASA, Oslo, NORWAY, 5Department of Oncology, Oslo University Hospital, Oslo, NORWAY.

OP-0284Clinical dosimetry study of kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&TM. Uijen, B. Privé, C. van Herpen, M. Gotthardt, M. Konijnenberg, S. Peters, J. Nagarajah; Radboudumc, Nijmegen, NETHERLANDS.



9594

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0307Clinical Management in Patients with suspected Mycotic Aneurysms: Impact of FDG-PET/CTL. Husmann1, M. W. Huellner1, H. Gruenig1, N. Eberhard2, C. A. Mestres3, Z. Rancic4, B. Hasse5; 1Department of Nuclear Medicine, University Hospital of Zurich / University of Zurich, Zurich, SWITZERLAND, 2Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich / University of Zurich, Zurich, SWITZERLAND, 3Clinic for Cardiac Surgery, University Hospital of Zurich / University of Zurich, Zurich, SWITZERLAND, 4Clinic for Vascular Surgery, University Hospital of Zurich/ University of Zurich, Zurich, SWITZERLAND, 5Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Zurich, SWITZERLAND.

OP-0308[18F]FDG hypermetabolisms of the spleen and/or bone marrow: indirect signs of bacteremiaR. Zanca1, F. Bartoli1, E. Esposito1, E. Lazzeri1, M. Sollini2,3, R. Slart4,5, P. Erba1,4; 1Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa and AOUP, Pisa, ITALY, 2Nuclear Medicine, Humanitas Clinical and Research Center - IRCCS, Rozzano (Milan), ITALY, 3Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), ITALY, 4Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, 5Department of Biomedical Photonic Imaging, University of Twente, Enschede, NETHERLANDS.

OP-0309Blood Ketone Measurements Can Be Used to Predict Myocardial FDG UptakeP. Francis, C. Eland; Royal Children’s Hospital, Melbourne, AUSTRALIA.

OP-0310The diagnostic value of [18F]FDG-PET/CT in detecting septic thrombosis in patients with venous catheter-related Staphylococcus aureus bacteremiaR. Tuinte1, M. Gompelman1, E. Aarntzen1, I. Kouijzer1, E. van Leerdam1, M. Berrevoets2, J. ten Oever1, C. Bleeker-Rovers1, G. Wanten1; 1Radboud University Medical Center, Nijmegen, NETHERLANDS, 2Elisabeth-TweeSteden Ziekenhuis, Tilburg, NETHERLANDS.

OP-0311Inflammatory-Directed Whole-Body PET Can Alter Diagnosis in Treatment-Naïve Patients with Suspected Rheumatic DiseaseR. Werner1, K. V. Guggenberger2, S. Serfling1, T. Higuchi3, M. G. Pomper4, S. P. Rowe4, M. Schmalzing5, A. K. Buck1, T. Bley2, M. Fröhlich5; 1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, 2Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, GERMANY, 3Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Osaka, JAPAN, 4The Russell H Morgan Department of Radiology and Radiological Science, Division of Nuclear Medicine, Baltimore, MD, UNITED STATES OF AMERICA, 5Department of Internal Medicine II, Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, GERMANY.

OP-0312Evaluation of F-18-FDG-PET/MRI in patients with echinococcosisN. Eberhardt1, J. P. Steinacker1, L. Peters2, S. Kapp-Schwoerer2, P. Korf3, M. Beer4, C. Solbach1, T. Kull1, B. Grüner2, A. J. Beer1; 1Ulm University Medical Center, Department of Nuclear Medicine, Ulm, GERMANY, 2Ulm University Medical Center, Department of Internal Medicine III – Section for Infectious Diseases, Ulm, GERMANY, 3Siemens Healthcare GmbH, Erlangen, GERMANY, 4Ulm University Medical Center, Department of Diagnostic and Interventional Radiology, Ulm, GERMANY.

OP-0313Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imagingC. Schmidkonz1, S. Rauber2, A. Atzinger1, T. Götz1, A. Soare2, M. Cordes1, O. Prante1, P. Ritt1, T. Bäuerle1, M. Köhner1, U. Haberkorn3, T. Kuwert1, G. Schett1, A. Ramming2; 1University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY, 2University Hospital Erlangen, Department of Rheumatology, Erlangen, GERMANY, 3University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

OP-0314[68Ga]Ga-Deferoxamine for Imaging of Bacterial Infections- Preliminary Results of a Phase I/II StudyB. Nilica1, M. Petrik2, C. Rangger1, C. Uprimny1, J. Pfister1, M. Hajduch3, G. Weiss4, I. Virgolini1, C. Decristoforo1; 1Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA, 2Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Innsbruck, CZECH REPUBLIC, 3Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, CZECH REPUBLIC, 4Department of Internal Medicine II, Innsbruck Medical University, Innsbruck, AUSTRIA.

OP-0294The Role of 99mTc-HFAPi SPECT/CT for Patients with Malignancies of the Digestive TractX. Jia1, Y. Wang1, Y. Liu1, Y. Yang1, G. Qiu1, S. Chen2, F. Wang3, J. Zhang1, A. Yang1, R. Gao1; 1The first affiliated hospital of Xi’an jiaotong university, Xi’an, CHINA, 2Foshan Atomical Medical Equipment Ltd, Foshan, CHINA, 3Chinese Academy of Sciences;;Medical Isotopes Research Center, Peking, CHINA.

OP-0295Measure of future liver remnant function (FLR-F) in patients candidate to major liver resection with a new imaging tracer of hepatobiliary system: a pilot studyT. Graziani1, G. Baldari1, G. Serreli2, C. Cidda1, M. Scarlattei1, S. Migliari1, A. Sammartano1, L. Ruffini1; 1Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY, 2Medical Physic, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY.

OP-029618F-FDG PET/MRI in intraductal papillary mucinous neoplasms (IPMNs) of pancreas: a preliminary monocentric experienceM. Frigo, P. Bartoletti, V. Bodanza, R. Simeone, P. Zucchetta, D. Cecchin, L. Evangelista; University of Padua, Padova, ITALY.

OP-0297Accuracy of [18F]FDG PET-CT in the evaluation of the post-neoadjuvant local response in esophageal cancer by using cualitative and PERCIST criteriaS. Martin Aguilar1, C. Ponce Herrera1, C. Montiel Casado1, F. Moreno Ruiz1, M. Florez Rial1, M. Requena Santos1, A. Gutierrez Cardo1, V. Marín Parrilla1, M. Nicolás Aguado1, N. Álvarez Mena2, L. Lumbreras Vega1, D. Ramirez Ocaña1, M. Puentes Zarzuela1; 1Hospital Regional de Málaga, Málaga, SPAIN, 2Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

OP-0298Reliability and Prognostic value of qualitative and semiquantitative 18F-FDG PET/CT analysis in patients with gastrointestinal stromal tumours undergoing imatinib adjuvant treatment after surgeryC. Altini, C. D’Alò, N. C. Merenda, A. Di Palo, A. R. Pisani, G. Rubini; Section of Nuclear Medicine, DIM, University “Aldo Moro”, Bari, ITALY.

OP-0299Comparison of 18F-DOPA and 68Ga-DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapyE. Veenstra1, A. H. Brouwers1, D. A. de Groot1, J. Hofland2, A. M. Walenkamp1, T. Brabander2, Z. T. Wouter1, W. Noordzij1; 1University Medical Center Groningen, Groningen, NETHERLANDS, 2Erasmus University Medical Center, Rotterdam, NETHERLANDS.

OP-0301Accuracy of [18F] FDG PET-CT to identify the location and extent of local residual disease in esophageal cancerS. Martin Aguilar, C. Ponce Herrera, C. Montiel Casado, F. Moreno Ruiz, M. Requena Santos, M. Florez Rial, V. Marín Parrilla, E. López Rodriguez, M. Nicolás Aguado, L. Lumbreras Vega, D. Ramirez Ocaña, M. Puentes Zarzuela; Hospital Regional de Málaga, Málaga, SPAIN.

OP-0302Se-75-SehCAT in the diagnostic procedure of chronic diarrhoeC. Körber, N. Körber-Hafner; Nuclearmedicine, Fulda, GERMANY.

611


TROP Session: Top of Cardiovascular and Soft Tissue Infection/Inflammation Imaging

OP-0304Investigation of Pediatric Cardiac-Related Infections with 18F-FDG PET/CT: Optimization and PerformanceG. April, R. Lambert, S. Turpin; CHU Ste-Justine, Montreal, QC, CANADA.

OP-0305Diagnostic performance of digital PET with a dedicated head and neck protocol for the assessment of inflammation of cranial arteries in Giant Cell ArteritisB. Durand-Bailloud1, T. Thibault2, A. Bertaut3, C. Drouet1, R. popoff1, F. Godard1, G. Nodari1, B. Bonnotte2,4, M. Samson2,4, A. Cochet1,5,6, J. Alberini1,5,6; 1Department of Nuclear Medicine, Georges-François Leclerc Cancer Center, Dijon, FRANCE, 2Department of Internal Medicine and Clinical Immunology, François Mitterrand University Hospital, Dijon, FRANCE, 3Department of Methodology and Biostatistics, Georges-Francois Leclerc Research Cancer Center, Dijon, FRANCE, 4INSERM, UMR 1098, University of Bourgogne Franche-Comté, Dijon, FRANCE, 5Department of NMR spectroscopy and Nuclear Medicine, François Mitterrand University Hospital, Dijon, FRANCE, 6ImViA EA 7535, University of Burgundy, Dijon, FRANCE.

OP-0306New Possible Interpretation Criteria In 18F-FDG PET/CT SCAN For The Diagnosis Of Infective EndocarditisM. Gazzilli1, D. Albano1, S. Lucchini1, A. Peli1, E. Cerudelli1, F. Dondi2, A. Mazzoletti2, P. Bellini2, F. Bertagna2, R. Giubbini2; 1Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, ITALY, 2University of Brescia, Brescia, ITALY.



9796

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

805


Joint Symposium 9 (EANM/EAN): The New ATN Diagnostic Concept in Alzheimer’s Disease

OP-0331Introduction into the ATN ConceptB. Dubois; Salpétrière University Hospital, Behavioural Neurology Department and Dementia Research Center, Paris, FRANCE.

OP-0332PET Tracers to Establish the ATN ProfileV. Villemagne; University of Pittsburgh, Department of Psychiatry, Pittsburgh, UNITED STATES OF AMERICA.

OP-0333A Critical Clinician’s Perspective on the ATN ConceptG. Frisoni; Geneva University Hospital, Memory Clinic, Geneva, SWITZERLAND.

OP-0334PET Data Supporting/Opposing the ATN ConceptG. Chételat; Université de Caen Basse-Normandie, Multimodal Neuroimaging in Brain diseases Lab, Caen, FRANCE.

806


Joint Symposium 10 (EANM/ILAE): PET/MRI in Epilepsy

OP-0336IntroductionP. Federico; Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, CANADA.

OP-0337Epilepsy - The Role of MRI in Patients with Focal EpilepsyA. E. Vaudano; OCB Hospital, Neurological Unit, AOU Modena, Modena, ITALY.

OP-0338Epilepsy - The Role of FDG-PET and FDG-PET/MR in Patients with Focal EpilepsyE. Guedj; APHM, Service Central de Biophysique et Medecine Nucleaire, Marseille, FRANCE.

OP-0339Is FDG the Only PET Tracer Useful for Patients with Epilepsy?A. Hammers; PET Imaging Centre, King’s College London, London, UNITED KINGDOM.

807


Pitfalls & Artefacts 5: Pitfalls & Pearls in Paediatric Musculoskeletal

OP-0341Physiological, Variants & Benign TumoursD. de Palma; A.O. Ospedale di Circolo e Fondazione Macchi, Department of Nuclear Medicine, Varese, ITALY.

OP-0342Non-Tumoural and Paraneoplastics PitfallsI. Roca; University Hospital Vall d’Hebron, Department of Nuclear Medicine, Barcelona, SPAIN.

OP-0343Challenging CasesM. Terroir Cassou; Oncopole, Department of Nuclear Medicine, Toulouse, FRANCE.

808


M2M Track - Featured Session: Functional Brain Imaging

OP-0345Introduction TalkP. Payoux; CHU Purpan, Nuclear Medicine Department, Toulouse, FRANCE.

OP-0346Longitudinal Evaluation Of The First Mutant Huntingtin PET Radioligand As A Marker For mHTT Lowering Therapies For Huntington’s DiseaseD. Bertoglio1, J. Verhaeghe1, S. De Lombaerde1,2, F. Zajicek1, T. Vasilkovska1, A. Miranda3, A. Gaertner4, B. Huscher4, A. Kakoulidou4, I. Cardaun4, A. Cornelius4, T. Schwagarus4, A. Van der Linden1, S. Stroobants1,2, Y. Wang5, M. Skinbjerg5, C. Dominguez5, V. Khetarpal5, L. Liu5, I. Munoz-Sanjuan5, J. Bard5, S. Staelens1; 1University of Antwerp, Wilrijk, BELGIUM, 2Antwerp University Hospital, Edegem, BELGIUM, 3University of Antwerp, Antwerpen, BELGIUM, 4Evotec SE, Hamburg, GERMANY, 5CHDI Management/CHDI Foundation, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-0315PET-CT Imaging of Pulmonary Inflammation with [68Ga]Ga-DOTATATEE. Puuvuori1,2, F. Liggieri3, E. Chiodaroli3, I. Velikyan1, J. Sigfridsson3, H. Romelin3, S. Ingvast4, O. Korsgren4, O. Eriksson1, G. Perchiazzi3; 1Science for Life Laboratory, Uppsala University, Uppsala, SWEDEN, 2Department of Medicinal Chemistry, Uppsala, SWEDEN, 3Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 4Department of IGP, Uppsala University, Uppsala, SWEDEN.

801

Thursday, October 21, 2021, 09:00 - 10:30Channel 1

CME 5: Infiltration, Infection and Infiltrative Nuclear Cardiovascular Diseases - Think Nuclear!

OP-0318Cardiac SarcoidosisO. Gheysens; Cliniques Universitaires Saint-Luc, Leuven, BELGIUM.

OP-0319Cardiac AmyloidosisT. Kero; Uppsala University, Department of Surgical Sciences/Nuclear Medicine & PET, Uppsala, SWEDEN.

OP-0320EnodcarditisA. Scholtens; Meander Medical Center, Department of Nuclear Medicine, Amersfoort, NETHERLANDS.

OP-0321VasculitisL. Gormsen; Aarhus University Hospital, Department of Nuclear Medicine and PET Center, Aarhus, DENMARK.

802-1


Interview with the Expert 5 - Creating Tracers

OP-0323Interview - Creating TracersS. Fanti; University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

OP-0324Interview - Creating TracersU. Haberkorn; University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

802-2


Interview with the Expert 6 - Paediatric NM Today

OP-0325Interview - Paediatric NM TodayL. Biassoni; Great Ormond Street Hospital for Children, Radiology, London, UNITED KINGDOM.

OP-0326Interview - Paediatric NM TodayT. D. Barwick; Imperial College, London, UNITED KINGDOM.

804


CTE 5: Update in Inflammation Imaging

OP-0327Overview of Nuclear Medicine Techniques and Radiopharmaceuticals for Infectious and Inflammatory DiseasesC. Lund Denholt; Bispebjerg and Frederiksberg Hospital, Clinical department of physiology and nuclear medicine, PET & Cyclotron, Copenhagen, DENMARK.

OP-0328Radiolabeled WBC Scan for Infectious DiseasesE. Noriega-Álvarez; Hospital General Universitario de Ciudad Real, Department of Nuclear Medicine, Ciudad Real, SPAIN.

OP-0329PET/CT for Infectious and Inflammatory DiseasesA. W. J. M. Glaudemans; University Medical Center Groningen, Medical Imaging Center, Groningen, NETHERLANDS.



9998

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0353Evaluation of [18F]F-DPA PET for detecting microglial activation in the spinal cord of a rat model of neuropathic painS. Shimochi1,2, T. Keller1, J. Rajander3, E. Löyttyniemi4, O. Solin1, P. Nuutila1, S. Kanaya2, E. Yatkin5, T. J. Grönroos1, H. Iida1; 1Turku PET Centre, University of Turku, Turku, FINLAND, 2Nara Institute of Science and Technology, Ikoma City, JAPAN, 3Accelerator Laboratory, Turku PET Centre, Åbo Akademi University, Turku, FINLAND, 4Department of Biostatistics, University of Turku, Turku, FINLAND, 5Central Animal Laboratory, University of Turku, Turku, FINLAND.

OP-0354Validation of 2-Deoxy-2-[18F]fluorosorbitol (18F-FDS) repurposed as a PET imaging biomarker of Blood Brain Barrier integrity in vivoG. Hugon, S. Goutal, A. Dauba, A. Winkeler, A. Novell, N. Tournier; Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, Orsay, FRANCE.

OP-0355The (-)[18F]FBVM to in vivo vizualise the VAChT by PETJ. Vercouillie1, F. Buron2, P. Emond1, G. Chicheri1, S. Serrière1, J. Busson1, Z. Gulhan3, S. Bodard1, A. Oury1, L. Galineau1, H. Marzag2, D. Guilloteau1, S. Routier2, S. Chalon1; 1UMR 1253, iBrain, Université de Tours, Inserm, Tours, FRANCE, 2ICOA, UMR 7311, Univesrity of Orléans, Orleans, FRANCE, 3INSERM 1253, CERRP, Tours Hospital, Tours, FRANCE.

809


Cutting Edge Science Track - TROP Session: Diagnostic Dosimetry

OP-0357[123I]IMAZA: Biodistribution and Radiation Dosimetry in Patients with Adrenal TumorsS. Beykan1, H. Hänscheid1, S. Andreas1, S. Hahner2, A. K. Buck1, M. Lassmann1; 1Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, 2Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Würzburg, University of Würzburg, Würzburg, GERMANY.

OP-0358Pre-therapy 123I-NaI dosimetry for predicting salivary gland absorbed doses from 131I-NaI therapyL. Vávrová1, J. Gear1, J. Taprogge1, I. Murray1, S. Brown2, J. Swain2, J. Wadsley3, G. Flux1; 1The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UNITED KINGDOM, 2CTRU, University of Leeds, Leeds, UNITED KINGDOM, 3Weston Park Hospital, Sheffield, UNITED KINGDOM.Cardiology Beyond Perfusion Imaging

OP-0359First Evaluation of PET-Based Human Biodistribution and Radiation Dosimetry of 64Cu-iPSMAB. Góngora-Servín1, B. Rivera-Bravo1, A. R. Jalilian2, M. Avila-Rodriguez1; 1Universidad Nacional Autónoma de México, Ciudad de Mexico, MEXICO, 2International Atomic Energy Agency, Vienna, AUSTRIA.

OP-036064Cu-ATSM as a therapeutic agent in solid tumor? preliminary results of a whole body human dosimetry studyN. Varmenot1,2,3, M. Colombié1, C. Rousseau1,2,4, F. Haddad5,3,4, L. Ferrer1; 1ICO René Gauducheau, F-44800 Saint-Herblain, FRANCE, 2CRCINA UMR 1232 INSERM, F-44000 Nantes, FRANCE, 3GIP ARRONAX, F-44800 Saint-Herblain, FRANCE, 4Université de Nantes, F-44000 Nantes, FRANCE, 5SUBATECH, IMT Atlantique, CNRS/IN2P3, F-44000 Nantes, FRANCE.

OP-0361Biokinetics and radiation dosimetry of [18F]-PSMA-1007E. Hvittfeldt1, M. Bjöersdorff1, J. Oddstig2, S. Leide Svegborn3, G. Brolin2, D. Minarik3, E. Trägårdh1,4; 1Clinical Physiology and Nuclear Medicine, Skåne University Hospital and Lund University, Malmö, SWEDEN, 2Radiation Physics, Skåne University Hospital and Lund University, Lund, SWEDEN, 3Radiation Physics, Skåne University Hospital and Lund University, Malmö, SWEDEN, 4Wallenberg Centre for Molecular Medicine, Lund, SWEDEN.

OP-0362A revised compartmental model for biokinetics and dosimetry of 18F-FDGM. Andersson1,2, A. Kamp3, D. Noβke4, S. Mattsson2, A. Giussani3; 1Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 2Medical Radiation Physics, Department of Translational Medicine Lund University, Malmö, SWEDEN, 3Department of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection (BfS), Neuherberg, GERMANY, 4Department of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection (BfS), (retired), Neuherberg, GERMANY.

OP-0363Radiation dosimetry of 18F-CETO, a PET tracer for adrenocortical imagingM. Lubberink1, I. Silins1, A. Moreno1, F. Aigbirhio2, M. Gurnell2, M. Brown3, S. Roslin1, G. Antoni1, P. Hellman1, A. Sundin1; 1Uppsala University, Uppsala, SWEDEN, 2University of Cambridge, Cambridge, UNITED KINGDOM, 3Queen Mary University of London, London, UNITED KINGDOM.

OP-0347Microglia Phenotypes Impact Metabolic Connectivity in Mouse Models of Neurodegenerative DiseasesJ. Gnörich1,2, A. Reifschneider3, K. Wind1,2, A. Zatcepin1,2, T. Wiedemann3, M. Grosch4, X. Xiang3,5, M. Khojasteh-Fard3, F. Ruch-Rubinstein1, M. Koehler1, T. Blume2,6, Y. Shi2, G. Biechele1, L. Beyer1, F. Eckenweber1, M. Scheifele1, P. Bartenstein1,7, J. Herms2,6,7, S. Tahirovic2, A. Capell2,3, C. Haass2,3,7, S. Ziegler1,7, M. Brendel1,2,7; 1Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY, 2German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, 3Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, GERMANY, 4German Center for Vertigo and Balance Disorders, University Hospital of Munich, LMU Munich, Munich, GERMANY, 5CAS Key Laboratory of Brain Connectome and Manipulation, the Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research, Shenzhen, CHINA, 6Center for Neuropathology and Prion Research, Ludwig-Maximilians-University München, Munich, GERMANY, 7Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

OP-0348TREM2 Deficiency Desynchronises Microglial Activity in the Mouse BrainA. Zatcepin1,2, X. Xiang3,4, S. Parhizkar5, J. Gnörich1,2, M. Grosch6, K. Wind1,2, Y. Shi2, L. Beyer1, G. Biechele1, F. Eckenweber1, T. Wiedemann1, S. Lindner1, A. Rominger1,7, P. Bartenstein1,8, M. Willem3, S. Tahirovic2, J. Herms2,8,9, C. Haass2,3,8, S. I. Ziegler1,8, M. Brendel1,2,8; 1Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, GERMANY, 2German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, GERMANY, 3Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, Munich, GERMANY, 4CAS Key Laboratory of Brain Connectome and Manipulation, the Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science, Shenzhen, CHINA, 5Department of Neurology, Washington University in St. Louis, St. Louis, MO, UNITED STATES OF AMERICA, 6German Center for Vertigo and Balance Disorders, University Hospital of Munich, LMU Munich, Munich, GERMANY, 7Department of Nuclear Medicine, University of Bern, Inselspital, Bern, SWITZERLAND, 8Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, 9Center for Neuropathology and Prion Research, LMU Munich, Munich, GERMANY.

OP-0349Exploring The Neuroprotective Effects Of Montelukast Treatment In A Rat Model Of Quinolinic Acid-Induced NeurotoxicityM. Tassan Mazzocco1,2, V. Murtaj1,2, S. Belloli2,3, L. Presotto2, G. Mennuni2,3, T. Canu4, A. Coliva2, E. Toninelli2, R. M. Moresco2,3,5; 1PhD Program in Neuroscience, Medicine and Surgery Department, University of Milano-Bicocca, Milan, ITALY, 2Nuclear Medicine Department, San Raffaele Scientific Institute (IRCCS), Milan, ITALY, 3Institute of Molecular Bioimaging and Physiology (IBFM), CNR, Milan, ITALY, 4Department of Radiology, Experimental Imaging Center, San Raffaele Scientific Institute (IRCCS), Milan, ITALY, 5Medicine and Surgery Department, University of Milano-Bicocca, Milan, ITALY.

OP-0350New Brain Atlas tool for Parkinson’s Disease Images AnalysisS. Belloli1,2, L. Presotto3, D. Mercatelli4, G. Mennuni1,2, M. Tassan Mazzocco2,5, A. Coliva2, E. Toninelli2, T. Canu6, V. Bettinardi2, M. Morari4, R. M. Moresco1,2,7; 1IBFM-CNR, Segrate, ITALY, 2Nuclear Medicine Department, IRCCS San Raffaele, Milan, ITALY, 3Nuclear Medicine Department, IRCCS San Raffaele, Segrate, ITALY, 4Department of Neuroscience and Rehabilitation, University of the Study of Ferrara, Ferrara, ITALY, 5PhD Program in Neuroscience, Medicine and Surgery Department, University of Milano-Bicocca, Milan, ITALY, 6Department of Radiology, Experimental Imaging Center, IRCCS San Raffaele, Milan, ITALY, 7Medicine and Surgery Department, University of Milano - Bicocca, Milan, ITALY.

OP-0351Dynamic behavior of brain and muscle glucose uptake during insulin challengesC.-H. Malbert1, C. Marathe2, A. Chauvin3, M. Genissel3, J. Georges3, M. Horowitz4, K. Jones5; 1INRAE - Aniscan, Saint-Gilles, FRANCE, 2University of Adelaide, Endocrine and metabolic unit, Adelaide, AUSTRALIA, 3INRAE - UE3P, Saint-Gilles, FRANCE, 4University of Adelaide, Adelaide Medical school, Adelaide, AUSTRALIA, 5University of Adelaide, Endocrine and Metabolic unit, Adelaide, AUSTRALIA.

OP-0352Neuroinflammation PET imaging for in vivo evaluation of aging process in a Down syndrome animal modelL. Estessi de Souza, M. Penido da Silva, C. Cristiano Real, D. De Paula Faria; Universidade de São Paulo, São Paulo, BRAZIL.



101100

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0372Pancreatic uptake of radiolabeled exendin as a measure of beta cell mass in remission of type 2 diabetes in patients having metabolic surgeryL. Deden1, M. Boss2, H. de Boer3, E. Aarts1, M. Brom2, E. Hazebroek1, F. Berends1, M. Gotthardt2; 1Vitalys, Rijnstate Hospital, Arnhem, NETHERLANDS, 2Radboud University Medical Center, Nijmegen, NETHERLANDS, 3Rijnstate Hospital, Arnhem, NETHERLANDS.

OP-0373Ga-68 DOTATATE PET / Lu-177 DOTATATE SPECT Theranostics: Discordance in Neuroendocrine Tumor and Organ DistributionsK. Wong, K. A. Frey, J. Niedbala, R. K. Kaza, F. P. Worden, Y. K. Dewaraja; Michigan Medicine, Ann Arbor, MI, UNITED STATES OF AMERICA.

OP-0374[68Ga]Ga-DOTA-TOC PET/MRI validation compared to PET/CT, in patients with paraganglioma and pheochromocytoma. Initial resultsS. Prado Wohlwend, M. Ballesta Moratalla, P. Bello Arques, M. del Olmo García, I. Torres Espallardo, J. Merino Torres; Universitary and Polytechnic Hospital La Fe, Valencia, SPAIN.

OP-0375Prevalence and Significance of 68Ga-DOTA-conjugated Somatostatin Receptor-Targeting Peptide PET/CT Incidental Findings - A Systematic ReviewM. Bentestuen, F. Gossili, C. E. Almasi, H. D. Zacho; Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK.

OP-0376Higher diagnostic accuracy of FDG PET/CT than contrast enhance CT in initial staging of pancreatic cancers; Hybrid is better than SoloM. Zaman1, N. Fatima1, S. Zaman2, A. Zaman3, U. U. Zaman4; 1AKUH, Karachi, PAKISTAN, 2Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN, 3Dr Ruth Pfau (CHK), Karachi, PAKISTAN, 4Sunny Downstate Medical Center, NY, New York, NY, UNITED STATES OF AMERICA.AMERICA.

811


TROP Session: Top of Nuclear Medicine in COVID-19

OP-0378Long Covid hallmarks on [18F]FDG-PET/CT: a case-control studyF. Gelardi1, M. Sollini1, S. Morbelli2, M. Ciccarelli3, M. Cecconi1, A. Aghemo1, P. Morelli3, S. Chiola1, A. Chiti1; 1Humanitas University, Pieve Emanuele, ITALY, 2University of Genoa, Genoa, ITALY, 3Humanitas Research Hospital, Rozzano, ITALY.

OP-0379[68Ga]Ga-DOTA-(RGD)2 PET/CT imaging of endothelial activation in COVID-19 patientsE. Aarntzen, E. van Genugten, J. van Steenis, W. Hoefsloot, F. van de Veerdonk, M. Netea, M. Prokop; Radboud University Nijmegen Medical Centre, Nijmegen, NETHERLANDS.

OP-0380From early limbic inflammation to long COVID sequelae: targetting the transition from brain PET hypermetabolism to hypometabolismE. Guedj1, S. Morbelli2, E. Kaphan3, J. Y. Campion1, P. Dudouet1, M. Ceccaldi1, S. Cammilleri1, F. Nobili1, C. Eldin1; 1Aix Marseille Univ, Marseille, FRANCE, 2Genoa University, Genoa, ITALY, 3APHM, Marseille, FRANCE.

OP-0381Metabolic network underlying persistent hyposmia after mild or moderate Coronavirus disease 2019 (COVID-19)M. Donegani1, S. Chiola2,3, M. Pardini4, F. Lanfranchi1, F. D’Amico1, S. Raffa1, A. A. Miceli1, C. Mantarro5, C. Delucchi6, M. Bauckneht6, F. Massa4, D. Arnaldi6, L. Benedetti4, F. Nobili4, S. Morbelli1; 1Department of Health Sciences (DISSAL), University of Genoa, Genova, ITALY, 2Humanitas Clinical and Research Center–IRCCS, Rozzano (Mi), ITALY, 3Humanitas University, Department of Biomedical Sciences, Milan, ITALY, 4Department of Neuroscience (DINOGMI), University of Genoa, Genova, ITALY, 5Department of Biomedical and Dental Sciences and Morphological and Functional Images, University of Messina, Messina, ITALY, 6IRCCS Ospedale Policlinico San Martino, Genova, ITALY.

810


Clinical Oncology Track - TROP Session: Neuroendocrine

OP-0365[18F]AlF-NOTA-octreotide vs. [68Ga]Ga-DOTA-somatostatin analogue imaging in neuroendocrine tumour patients: results of planned interim analysis of a prospective registration trialE. Pauwels1, F. Cleeren2, T. Tshibangu2, M. Koole1, K. Serdons1, L. Boeckxstaens1, J. Dekervel3, E. Van Cutsem3, C. Verslype3, S. Stroobants4, T. Vandamme5,6, W. Lybaert6, K. Geboes7, G. Bormans2, C. M. Deroose1; 1Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, 2Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, 3Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM, 4Nuclear Medicine, Antwerp University Hospital; Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM, 5Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM, 6Oncology, NETwerk Antwerpen-Waasland CoE, Antwerp, BELGIUM, 7Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM.

OP-0366Prognostic value of whole-body PET volumetric parameters extracted from 68Ga-DOTATOC-PET/CT in well-differentiated neuroendocrine tumorsP. Thuillier1,2, V. Liberini1, S. Grimaldi1, O. Rampado3, E. Gallio3, B. De Santi4, E. Arvat5, A. Piovesan5, R. Filippi6, F. Molinari4, D. Deandreis1; 1Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, Turin, ITALY, 2Department of Endocrinology, University Hospital of Brest, Brest, FRANCE, 3Medical Physics Unit, AOU Città della Salute e della Scienza, Turin, ITALY, 4Biolab, Department of Electronics and Telecomunications, Politecnico di Torino, Turin, ITALY, 5Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Turin, ITALY, 6Department of Oncology Department of Medical Sciences, University of Turin, Turin, ITALY.

OP-0367Role of volumetric parameters on 68Ga-DOTATOC PET/CT in NET patients treated with PRRTL. Urso1, M. Caracciolo1, N. Ortolan1, I. Zamberlan1, A. Castello1, E. Tonini2, S. Panareo1, A. Nieri1, C. Cittanti1, L. Uccelli1, L. Lodi1, S. Bertelli1, S. Romani1, S. Zaccaria1, A. Turra2, M. Bartolomei1; 1Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Ferrara, ITALY, 2Sant’Anna Hospital, Medical Physics Unit, Ferrara, ITALY.

OP-0368Prediction of transient bone marrow suppression after [177Lu]Lu-DOTA-TATE treatment using [68Ga]Ga-DOTA-TOC PET/CT and clinical parameters in patients with gastroenteropancreatic neuroendocrine tumorsH. Ryoo, H. Choi, J. Paeng, K. Kang, G. Cheon; Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

OP-036918fluoro-Dopa positon emission tomography computed tomography and whole body magnetic resonance imaging are efficient and complementary imaging modalities for evaluation of extension in well-differentiated neuroendocrine tumor of small intestine patientsM. Terroir Cassou Mounat, C. Caramella, M. Attard, M. Faron, H. Tissot, L. Lamartina, J. Hadoux, T. Henry, M. Schlumberger, S. Leboulleux, E. Baudin; Institut Gustave Roussy, Villejuif, FRANCE.

OP-0370Two Birds with One Stone: Can [68Ga]Ga-DOTANOC PET/CT Image Quality Be Improved through BMI-Adjusted Injected Activity in Neuroendocrine Tumour Patients?E. Fortunati1, G. Argalia1, L. Zanoni2, D. Calabrò1, C. Malizia2, V. Allegri2, S. Civollani2, S. Fanti1,2, V. Ambrosini1,2; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-0371[68Ga]Ga-DOTANOC PET/CT Derived Radiomic Features Can Discriminate Pancreatic Neuroendocrine Tumours from Accessory Spleens: Preliminary ResultsG. Argalia1, S. Malavasi2,3, E. Fortunati1, D. Calabrò1, D. Campana4,5, R. Casadei6,5, C. Ricci6,5, A. Bevilacqua2,7, S. Fanti1,8, V. Ambrosini1,8; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Advanced Research Center for Electronic Systems (ARCES), University of Bologna, Bologna, ITALY, 3Research Institute on Global Challenges and Climate Change (Alma Climate), University of Bologna, Bologna, ITALY, 4Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 6Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 7Department of Computer Science and Engineering (DISI), University of Bologna, Bologna, ITALY, 8Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.



103102

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

904


CTE 6: Radionuclide Therapy Management

OP-0423Informed Consent in Radionuclide Therapy ManagementC. Deroose; University Hospitals Leuven, Nuclear Medicine, Leuven, BELGIUM.

OP-0424Patient Care during Radionuclide Therapy TreatmentL. Pereira; Maidstone and Tunbridge Wells NHS Trust, Nuclear Medicine, Royal Turnbridge Wells, UNITED KINGDOM.

OP-0425Radionuclide Therapy Waste ManagementP. Fragoso Costa; Clinic for Nuclear Medicine, University Hospital Essen, Essen, GERMANY.

905


Joint Symposium 11 (EANM/EANO): Advancements in Neuro-Oncology

OP-0427Artificial Intelligence in Glioma ImagingL. Papp; Medical University Vienna, Center for Medical Physics and Biomedical Engineering, Vienna, AUSTRIA.

OP-0428New PET Tracers for Brain Tumour ImagingN. Albert; LMU, Munich, GERMANY.

OP-0429The 2020 EANO Guidelines on Diagnosis and Management of Gliomas - Take-Home Messages for the ClinicianJ.-C. Tonn; University Hospital Munich (LMU), Department of Neurosurgery, Munich, GERMANY.

906


Joint Symposium 12 (EANM/EORTC): Nuclear Medicine in Precision Oncology

OP-0431Molecular Imaging of the Immune SystemA. Wu; Department of Immunology & Theranostics, Beckman Research Institute of the City of Hope, Duarte, UNITED STATES OF AMERICA.

OP-0432Targeted Alpha TherapyM. Koole; KU Leuven, Department of Nuclear Medicine and Molecular Imaging, Leuven, BELGIUM.

OP-0433Managing Radioiodine Refractory Thyroid CancerD. Vriens; Leiden University Medical Center, Department of Radiology, Leiden, NETHERLANDS.

907


Pitfalls & Artefacts 6: Pitfalls & Artefacts in Endocrine Imaging

OP-0435FDG-PET/CT - Endocrine Incidentalomas and BeyondD. Deandreis; Director of Nuclear Medicine Division, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienza, Turin, ITALY.

OP-0436Somatostatin Receptor Targeted PET - Often Obvious, But Not AlwaysA. Haug; AKH Vienna, Division of Nuclear Medicine, Vienna, AUSTRIA.

OP-0437Non-FDG Thyroid IncidentalomasL. Heijmen; Radboud University Medical Centre, Division of Nuclear Medicine, Nijmegen, NETHERLANDS.

OP-0382Lung scintigraphy for pulmonary embolism diagnosis in COVID-19 patients: a multicenter observational studyP. Le Roux1, P. Bonnefoy2, A. Bahloul3, B. Denizot4, B. Barres5, C. Moreau-Triby6, A. Girma7, A. Pallardy8, Q. Ceyrat9, L. Sarda-Mantel10, M. Razzouk-Cadet11, R. Zsigmond12, F. Cachin5, G. Karcher3, P. Salaun1; 1CHRU Brest, Brest, FRANCE, 2CHU Saint-Etienne, Saint-Etienne, FRANCE, 3CHU Nancy, Nancy, FRANCE, 4CH Alpes Léman, Contamine-sur-Arve, FRANCE, 5Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, FRANCE, 6Hospices Civils de Lyon, Lyon, FRANCE, 7Hôpital Foch, Suresnes, FRANCE, 8CHU Nantes, Nantes, FRANCE, 9Centre d’imagerie fonctionnelle, Bordeaux, FRANCE, 10Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, FRANCE, 11CHU Nice, Nice, FRANCE, 12Centre d’Imagerie Nucléaire d’Annecy, Annecy, FRANCE.

OP-0383Functional alterations due to COVID-19 lung lesions - Lessons from a multicenter V/Q scan-based registryP. Bonnefoy1, A. Bahloul2, B. Denizot3, B. Barres4, C. Moreau-Triby5, A. Girma6, A. Pallardy7, Q. Ceyrat8, L. Sarda-Mantel9, M. Razzouk-Cadet10, R. Zsigmond11, F. Cachin4, G. Karcher2, P. Salaun12, P. Le Roux12; 1CHU Saint-Etienne, Saint Etienne, FRANCE, 2CHU Nancy, Nancy, FRANCE, 3CH Alpes Léman, Contamine-sur-Arve, FRANCE, 4Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, FRANCE, 5Hospices Civils de Lyon, Lyon, FRANCE, 6Hôpital Foch, Suresnes, FRANCE, 7CHU Nantes, Nantes, FRANCE, 8Centre d’imagerie fonctionnelle, Bordeaux, FRANCE, 9Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, FRANCE, 10CHU Nice, Nice, FRANCE, 11Centre d’Imagerie Nucléaire d’Annecy, Annecy, FRANCE, 12CHRU Brest, Brest, FRANCE.

OP-0384Quantification of Loss of Hypoxic Pulmonary Vasoconstriction Using Lung Perfusion SPECT/CT and FDG-PET/CT in Patients with Covid-19C. Ramos, A. Fernandes, M. Takahashi, S. Souza, M. Fujiwara, N. Tobar, S. Dertkigil, J. Rodrigues, E. Gonçales, P. Trabasso, D. Zantut-Wittmann; University of Campinas, Campinas, BRAZIL.

OP-0385Myocardial Perfusion SPECT Findings In Postcovid PeriodM. Araz, G. Sutcu, B. Demir, E. Ozkan, C. Soydal; Ankara University, Ankara, TURKEY.

OP-0386Prior COVID-19 History Increases The Risk of Ischemia in Myocardial Perfusion CZT Detectors ScintigraphyE. Sahin Kutuk, N. B. Talay, T. Bahceci, E. Ozdemir; Ankara City Hospital, Ankara, TURKEY.

OP-0387Evaluation of the findings in [18F]-FDG PET/CT studies of patients with incidental diagnosis of lung tumors in radiological imaging, which are performed due to the clinical suspicion of SARS-CoV-2 pneumoniaG. Guzmán Prudencio, S. Alvarez Ruiz, L. Del Barco Diez Canseco, N. Canchumanya Huatuco, M. Calderón Calvente, L. De la Cueva Barrao, M. Falgás Lacueva, P. Navarro Beltrán, M. Sangrós Sahún, D. Abós Olivares; Hospital Universitario Miguel Servet, Zaragoza, SPAIN.

OP-0388Ipsilateral nodal uptake post COVID-19 vaccination and the impact on interpretation of 18F-FDG PET/CT scansM. Arora, A. Gomes Moura, M. Carmody, Z. Win, N. H. Patel, C. Bowen, S. R. Khan, T. Barwick; Imperial College Healthcare Trust, London, UNITED KINGDOM.

OP-0389Global Impact of COVID-19 on Nuclear Medicine Departments; an International Follow-up SurveyF. Giammarile, D. Paez, E. Estrada-Lobato, M. Mikhail, O. Pellet; Division of Human Health, Department of Nuclear Sciences and Applications International Atomic Energy Agency, Vienna, AUSTRIA.

901


CME 6: Quo vadis PET/MRI?

OP-0392Methodological DevelopmentsH. Quick; University Hospital Essen, Hybrid and High-Field MR Imaging, Essen, GERMANY.

OP-0393Oncological ApplicationsI. Burger; Kantonsspital Baden, Nuclear Medicine, Baden, SWITZERLAND.

OP-0394Beyond Oncological ApplicationsA. Hammers; King’s College London & Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, London, UNITED KINGDOM.



105104

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

908


M2M Track - TROP Session: Tumour Microenvironment and Immunotherapy

OP-0439Fluorescent FAPI, does it stain FAP or something else?T. Buckle, R. van Leeuwerden, D. van Willigen, F. van Leeuwen; LUMC, Leiden, NETHERLANDS.

OP-0440Optimization of immune cell labeling efficiency using [111In]In-PLGA-NH2 nanoparticles modified with TAT cell penetrating peptidesR. Raavé1, B. Manandhar1, M. Krekorian1,2, M. Srinivas2, J. de Vries2, S. Heskamp1, E. Aarntzen1; 1Department of Medical Imaging, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, NETHERLANDS, 2Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, NETHERLANDS.

OP-0441Evaluation of novel anti-CAIX antibodies by PET imaging and biodistribution studies in a colorectal adenocarcinoma modelH. Law1, J. Rousseau1, P. C. McDonald2, A. E. Lenferink3, N. Colpo1, J. Zeisler1, R. Tan1, S. Dedhar2, K. Lin1, F. Bénard1; 1Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 2Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 3National Research Council, Biotechnology Research Institute, Montreal, QC, CANADA.

OP-0442Development of 89Zr and 68Ga-anti-CD103 Fab fragment-based PET imaging for non-invasive assessment of cancer reactive T cell infiltrationM. Wazynska, X. Fan, A. Kol, M. de Bruyn, P. H. Elsinga, H. W. Nijman; University Medical Center Groningen, Groningen, NETHERLANDS.

OP-0443Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human lymphocytesL. Marotte1,2, M. Capitao1,2, C. Deleine1,2, T. Beauvais3,2, G. Cadiou1,2, J. Perrin1,2, M. Chérel4,5,6, Y. Guilloux1,2, E. Scotet1,2, F. Bruchertseifer7, A. Morgenstern7, A. Jarry1,2, N. Labarrière*1,2, J. Gaschet*1,2; 1University of Nantes, CNRS, INSERM, CRCINA, Nantes, FRANCE, 2LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, FRANCE, 3University of Nantes, CNRS, INSERM, CRCINA, CHU of Nantes, Nantes, FRANCE, 4University of Nantes, CNRS, INSERM, CRCINA, ICO Gauducheau, Nantes, FRANCE, 5LabEx IRON “Innovative Radiopharmaceuticals in Oncology and Neurology”, Nantes, FRANCE, 6GIP Arronax, Saint-Herblain, FRANCE, 7European Commission, Joint Research Centre, Karlsruhe, GERMANY.(*shared last authors)

OP-0444Development of 89Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltrationX. Fan, A. Kol, M. Wazynska, M. de Bruyn, P. H. Elsinga, H. W. Nijman; University Medical Center Groningen, Groningen, NETHERLANDS.

OP-0445Preclinical pharmacokinetic and dosimetry of a 89 Zr labelled anti-PDL1 in an orthotopic lung cancer modelA. Krache1,2, C. Fontan3, C. Pestouri4, M. Bardies5,6, P. Payoux7,8, E. Chatelut1, M. White-koning1, A. Salabert2,8; 1INSERM UMR1037 - CRCT (centre de recherche en cancérologie de toulouse), team 14 DIAD, Toulouse, FRANCE, 2INSERM UMR1214 - TONIC (Toulouse neuroimaging center), team DEVIN, Toulouse, FRANCE, 3Zionexa, Toulouse, FRANCE, 4US006/CREFRE - équipes de zootechnie expérimentale et d’exploration non invasive, Toulouse, FRANCE, 5INSERM UMR1194 - IRCM (Institut de recherche en cancérologie de Montpellier), Toulouse, FRANCE, 6INSERM UMR1194 - IRCM (Institut en cancérologie de Montpellier), Toulouse, FRANCE, 7INSERM UMR1214 - TONIC (Toulouse neuroimaging center), Toulouse, FRANCE, 8CHU Toulouse, Toulouse, FRANCE.

OP-044668Ga DOTA FAPI 46 and 18F FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancerP. U N, A. R. Bharathi, S. M. Desai, B. Srinath, H. Mohan; Sri Shankara cancer hospital and Research center, Bangalore, INDIA.

OP-0447Synthesis and preclinical evaluation of [18F]AlF-NODA-C6-CTHRSSVVC as a PET tracer for tumor-associated CD163+ macrophagesB. Fernandes1,2, I. F. Antunes1, D. A. Vazquez-Matias1, K. Prasad1, E. De Mattos3, W. Szymanski4, C. M. Jeckel2, E. F. de Vries1, P. H. Elsinga1; 1Dept. of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, 2Graduate Program in Biomedical Gerontology, School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, BRAZIL, 3Dept. of Biomedical Sciences of Cells & Systems, Section Molecular Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, 4Dept. of of Radiology, University Medical Center Groningen, Stratingh Institute for Chemistry, University of Groningen, Groningen, NETHERLANDS.

Radiopharmaceuticals & Radiochemicals

Radiopharmaceutical Development

Hot Cells & Radiation Protection Solutions

Radiosynthesis & QC Solutions

Radiation Therapy

Contract Manufacturing

Regulatory Support

Radioactive Logistics

www.medical.ezag.com

RADIOPHARMA ENGINEERING LAB DEVICES RADIATION THERAPY

Discover Eckert & Ziegler Medical



107106

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0448Expression of fibroblast activation protein by three prostate cancer cell linesO. Bélissant1, S. Geha2, M. I. Messihad3, A. Rioux-Chevalier3, J. V. Leyton1, E. Rousseau1; 1Département de médecine nucléaire et radiobiologie, Université de Sherbrooke, Sherbrooke, QC, CANADA, 2Département de Pathologie, Université de Sherbrooke, Sherbrooke, QC, CANADA, 3Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-0449Combined treatment of mice bearing HER2-expressing xenografts by trastuzumab and Affibody-mediated PNA-based pretargeting improves their survivalM. Oroujeni1, H. Tano2, A. Vorobyeva1,3, Y. Liu1, O. Vorontsova1, T. Xu1, K. Westerlund2, A. Orlova1,3, V. Tolmachev1,3, A. Eriksson Karlström2; 1Uppsala University, Uppsala, SWEDEN, 2KTH Royal Institute of Technology, Stockholm, SWEDEN, 3Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

OP-045068Ga-FAPI-04 PET/CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-related interstitial lung diseaseC. Schmidkonz1, J. Distler2, C. Treutlein3, A. Atzinger1, O. Prante1, P. Ritt1, T. Götz1, T. Bäuerle1, M. Cordes1, M. Köhner1, T. Kuwert1, A. Ramming2, G. Schett2, C. Bergmann2; 1University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY, 2University Hospital Erlangen, Department of Rheumatology, Erlangen, GERMANY, 3University Hospital Erlangen, Department of Radiology, Erlangen, GERMANY.

909


Cutting Edge Science Track - Featured Session: From Safety Culture to Fieldwork in Radiation Protection

OP-0452Radiation Protection in Nuclear Medicine - Opportunities and Challenges from Many Different PerspectivesS. L. Svegborn; Dept of radiation physics, Skåne university hospital, Malmö, SWEDEN.

OP-0453A novel method to determine radiation protection advice following radioisotope therapy by modelling public exposureB. Rojas, J. Gear, D. Rushforth, I. Murray, J. Robinson, J. Patel, G. Flux; Royal Marsden NHS Foundation Trust, Sutton, UNITED KINGDOM.

OP-0454Communicating Radiation Issues with Patients: Can We Do Better?L. Cunha1, A. R. Roda1,2, P. Ratão1,3, M. Capoulas1,4, H. C. Vasconcelos5,6, M. Sousa7, A. S. Moreira1, L. F. Metello1,8; 1IsoPor-Azores, Azores, PORTUGAL, 2Medical Physics Department, IPOFG, Coimbra, PORTUGAL, 3Nuclear Medicine Department, IPOFG, Lisboa, PORTUGAL, 4Pharmacy Department, HBA, Loures, PORTUGAL, 5Sc. Techn. Fac., Univ. Azores, Azores, PORTUGAL, 6CEFITEC, Physics Dept, Universidade Nova de Lisboa, Lisbon, PORTUGAL, 7Interdisciplinary Studies Research Center, ISEP.IPP, Porto, PORTUGAL, 8ESS-IPP, Porto, PORTUGAL.

OP-0455A Systematic National Review: Safety Assessment as a Tool for Development of Safety Culture in Nuclear Medicine Facilities in FinlandJ. Liukkonen, S. Kaijaluoto; Radiation and Nuclear Safety Authority (STUK), Helsinki, FINLAND.

OP-0457Adaptation of ICRP 128 Iodine Population Bio-kinetic Model to Thyroid Cancer Patients After ThyroidectomyL. Peake1,2, J. Taprogge1,2, I. Murray1,2, J. Gear1,2, G. Flux1,2; 1Joint Department of Physics, Royal Marsden Hospital NHSFT, London, UNITED KINGDOM, 2The Institute of Cancer Research, London, UNITED KINGDOM.

OP-0458Models of Internal Liver Vasculature within the Mesh-Type ICRP Adult Reference Phantom to Support Internal Dosimetry in Radiopharmaceutical TherapyC. Correa Alfonso1, S. Domal1, J. Withrow1, M. Abdulla1, C. Grassberger2,3, S. Xing2,3, J. Shin2,3, H. Paganetti2,3, W. Bolch1; 1University of Florida, Gainesville, FL, UNITED STATES OF AMERICA, 2Massachusetts General Hospital, Boston, MA, UNITED STATES OF AMERICA, 3Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA.

OP-0459Relevance of Internal Bremsstrahlung for estimating the exposure to pure beta emittersL. Auditore1, F. Juget2, A. Italiano3, D. Pistone4, Y. Nedjadi2, S. Gnesin2, E. Amato5; 1Section of Radiological Sciences, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, ITALY, 2Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, 3INFN, National Institute for Nuclear Physics, Section of Catania & MIFT Department, University of Messina, Messina, ITALY, 4MIFT Department, University of Messina & INFN, National Institute for Nuclear Physics, Section of Catania, Messina, ITALY, 5Section of Radiological Sciences, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina & INFN, National Institute for Nuclear Physics, Section of Catania, Messina, ITALY.

OP-0460How To Assess the Real Extremities Dosimetry Based On the Results of a Dosimeter Ring ?M. Armando1, A. Huet2, F. Vial1, M. Rannou1, R. Valette2, H. Hida3; 1Radiopharmacy unit, Pharmacy, Valence Hospital Center, Valence, FRANCE, 2Radiation Protection, Valence Hospital Center, Valence, FRANCE, 3Pharmacy, Valence Hospital Center, Valence, FRANCE.

OP-0461Calibration for 41Ar of radiation detectors for air exhaust systemsF. Zagni1, S. Vichi2, G. Pantalone3, V. Cabitza4, N. Sabba5, E. Moretti5, M. D’Arienzo6, S. Fanti7, L. Strigari1; 1Medical Physics Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 2Clinical engeneering department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 3Department of Industrial Engineering, University of Bologna, Bologna, ITALY, 4PET Radiopharmacy Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5Picomed srl, Mirnadola (MO), Italy, Mirandola (MO), ITALY, 6ENEA, National Institute of Ionizing Radiation Metrology, Rome, ITALY, 7Nuclear Medicine Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-0462Ambient Dose Measured at a Nuclear Medicine DepartmentV. de Sousa, G. Cardoso, A. I. Santos; Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL.

910


Clinical Oncology Track - Featured Session: Radioguided Surgery and Sentinel Lymph Nodes

OP-0464Radioguided Surgery in Prostate Cancer - Facilitating Cure?T. Maurer; University of Hamburg-Eppendorf (UKE), Hamburg, GERMANY.

OP-0465Hot needles can confirm accurate lesion sampling intraoperatively using [18F]PSMA-1007 PET guided biopsy in patients with suspected prostate cancerR. Laudicella1,2, D. A. Ferraro1,3, K. G. Zeimpekis1, I. Mebert1,4, J. Müller1, O. Donati5, M. T. Sapienza3, J. H. Rüschoff6, N. Rupp6, D. Eberli4, I. A. Burger1,7; 1Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 2Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY, 3Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, BRAZIL, 4Department of Urology, University Hospital Zürich, University of Zurich, Zurich, SWITZERLAND, 5Interventional and Diagnostic Radiology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 6Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 7Department of Nuclear Medicine, Kantonsspital Baden, Baden, SWITZERLAND.

OP-0466The value of SSTR2 receptor-targeted PET/CT in proton irradiation of grade I meningiomaM. Pelak, B. Flechl, R. Galalae, S. Tubin, M. Mumot, E. Hug, C. Lütgendorf-Caucig; MedAustron Ion Therapy Center, Wiener Neustadt, AUSTRIA.

OP-0467Preliminary evaluation of the hybrid tracer Indocyanine Green (ICG)-99mTc-nanocolloid for sentinel lymph node biopsy in bladder cancerD. Rietbergen1, E. van Gennep1, G. KleinJan1, M. Donswijk2, B. van Rijn2, R. Valdes Olmos1, H. van der Poel2, F. van Leeuwen1; 1Leids Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS, 2Netherlands Cancer Institute, Amsterdam, NETHERLANDS.



109108

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0468How signal intensity influences utility of a robotic DROP-IN gamma probe during surgery - a clinical comparison between sentinel lymph node and PSMA-receptor targeted tracersM. van Oosterom1, P. Dell’Oglio1, H. de Barros2, P. Meershoek1, T. Maurer3, E. M. Wit2, P. Stricker4, H. G. van der Poel2, P. J. van Leeuwen2, F. W. van Leeuwen1; 1Leiden University Medical Center, Leiden, NETHERLANDS, 2Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 3Martini-Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, 4St. Vincent’s Prostate Cancer Centre, Darlinghurst, AUSTRALIA.

OP-0469Promising results of I125 Radioguided seed localization (RSL) surgery of papillary thyroid cancer recurrenceO. Ajuria Illarramendi, P. Azpeitia Hernandez, A. Martinez-Lorca, M. Gutierrez Guerrero, P. Paredes Rodriguez, J. Bonilla Plaza, T. Navarro Martinez, M. Rioja Martin, M. Orduña Diez; Hospital universitario ramon y cajal, Madrid, SPAIN.

OP-0470Incidence and risk factoranalysis ofcomplications after sentinel node biopsy for penile cancer: a call for more precise identification of the true sentinel node only?L. Wever1, H. M. de Vries1,2, B. W. van Rhijn1, H. G. van der Poel1, N. M. Graafland1, M. L. Donswijk1, K. Sikorska1, S. Horenblas1, F. W. van Leeuwen1,2, O. R. Brouwer1,2; 1Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 2Leiden University Medical Center, Leiden, NETHERLANDS.

OP-0471Utility Of The 99MTC-Tilmanocept In Sentinel Lymph Node Biopsy Of Endometrial CancerA. Laverde Mächler, J. Suárez Fernández, C. Vigil Díaz, D. Lisei Coscia, J. Maraña González, L. Rodríguez Díaz, M. Domínguez Grande, N. Martín Fernández, F. González García; HUCA, Oviedo, SPAIN.

OP-0472The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs. intraprostatic tracer injection for sentinel node detectionE. Wit; NKI-AvL, Amsterdam, NETHERLANDS.

OP-0473Is the hottest sentinel lymph node (SLN) the true SLN in breast cancer or do we need to resect more to find it correctly?A. Bronte, A. Echaide, J. J. Rosales, J. F. Bastidas, V. Betech, F. Pareja, B. Olartecoechea, N. Rodríguez-Spiteri, F. Martínez-Regueira, M. J. García-Velloso, M. Rodríguez-Fraile; University Clinic of Navarra, Pamplona, SPAIN.

OP-0474Long Term Results of Sentinel Lymph Node Biopsy Using Combined Method: A Single Institution ExperienceB. Zengel1, U. Yararbas2, I. C. Tercan3, R. I. Durusoy4; 1University of Health Sciences Turkey, İzmir Bozyaka Health Practice and Research Center, Department of General Surgery, Izmir, TURKEY, 2Ege University Medical Faculty, Department of Nuclear Medicine, Izmir, TURKEY, 3University of Health Sciences Turkey, Izmir Bozyaka Health Practice and Research Center, Department of General Surgery, Izmir, TURKEY, 4Ege University, Faculty of Medicine, Department of Public Health, Izmir, TURKEY.

OP-0475Sentinel lymph node biopsy in muscle-invasive bladder cancer: single-center experienceR. Sadeghi, L. Zarifmahmoudi, H. Ghorbani, K. Sadri; Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-0476The impact of the COVID-19 outbreak on breast cancer with indication of surgical treatment and SLNBE. López Llobet, D. Monachello Araujo, C. Escabias Del Pozo, D. Travaglio Morales, Y. Abadi Sedraoui, J. Cordero García, L. Dominguez Gadea; Hospital Universitario La Paz, Madrid, SPAIN.

911


Featured Session: Molecular Imaging of Alzheimer’s Disease

OP-0478Brain Imaging for a Biological Definition of Alzheimer’s DiseaseA. Drzezga; Cologne University, Nuclear Medicine, Cologne, GERMANY.

OP-0479Visual assessment and Centiloid quantification across diagnostic groups: the AMYPAD projectL. Collij1, C. Buckley2, A. Palombit3, K. Gray3, M. Shekari4, G. Salvadó4, M. Battle2, D. Altomare5, R. Gismondi6, A. Stephens7, V. Garibotto8, B. N. van Berckel1, C. Ritchie9, P. Payoux10, B. Vellas10, O. Grau4, M. Boada11, A. Drzezga12, P. Scheltens1, Z. Walker13, J. Démonet14, A. Nordberg15, P. Visser1, G. Frisoni16, G. Farrar2, F. Barkhof1, J. Gispert4, On behalf of the AMYPAD consortium; 1Amsterdam UMC, location VUmc, Amsterdam, NETHERLANDS, 2GE Healthcare, Hammersham, UNITED KINGDOM, 3IXICO, London, UNITED KINGDOM, 4BarcelonaBeta Brain Research Center, Barcelona, SPAIN, 5University Hospital Geneva, Geneva, SWITZERLAND, 6Life Molecular Imaging, Geneva, SWITZERLAND, 7Life Molecular Imaging, Berlin, GERMANY, 8University Hospital Geneva, Geneva, SWITZERLAND, 9University of Edinburgh, Edinburgh, UNITED KINGDOM, 10University Hospital of Toulouse, Toulouse, FRANCE, 11Ace Alzheimer Center Barcelona, Barcelona, SPAIN, 12University College Cologne, Cologne, GERMANY, 13University College London, London, UNITED KINGDOM, 14Le Centre hospitalier universitaire vaudois, Laussane, FRANCE, 15Karolinska Institutet, Solna, SWEDEN, 16University Hospital of Geneva, Geneva, SWITZERLAND.

OP-0480Calibration and Evaluation of the Centiloid Scale for Amyloid Quantitation with Multiple Fluorine-18 RadiotracersW. Balhorn, K. Krawiec, N. Cole, A. S. Nelson; MIM Software, Beachwood, OH, UNITED STATES OF AMERICA.

OP-0481Concordance between molecular imaging, CSF and plasma biomarkers of Alzheimer’s disease: evidence from the memory clinicS. Stampacchia1, D. Altomare1, B. Melnic1, F. Ribaldi1, S. E. Tomczyk1, M. Martins1, M. Marizzoni1, N. Ashton2, H. Zetterberg2, K. Blennow2, I. Kern3, G. B. Frisoni4, V. Garibotto4; 1University of Geneva, Geneva, SWITZERLAND, 2University of Gothenburg, Gothenburg, SWEDEN, 3Geneva University Hospital, Geneva, SWITZERLAND, 4University of Geneva and Geneva University Hospital, Geneva, SWITZERLAND.

OP-0482A PET only 18F-flortaucipir quantification: comparison with an MRI-based methodR. Fahmi; Siemens Healthineers, Molecular Imaging, Knoxville, TN, UNITED STATES OF AMERICA.

OP-0483In vivo Braak staging of tau pathology in Alzheimer’s disease: A multicenter [18F]PI-2620 PET studyM. Rullmann1, M. Brendel2, M. L. Schroeter3, D. Saur4, J. Levin5, R. Perneczky6, S. Tiepolt1, M. Patt1, A. Mueller7, V. Villemagne8, J. Classen4, A. W. Stephens7, O. Sabri1, H. Barthel1;

1Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, 2Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, GERMANY, 3Clinic for Cognitive Neurology, University of Leipzig, Leipzig, GERMANY, 4Department of Neurology, University of Leipzig, Leipzig, GERMANY, 5Department of Neurology, University Hospital of Munich, LMU Munich, Munich, GERMANY, 6Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, GERMANY, 7Life Molecular Imaging GmbH, Berlin, GERMANY, 8Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, AUSTRALIA.

OP-0484Multi-parametric [18F]PI-2620 tau PET/MRI in Alzheimer’s disease variants: A proof-of-concept studyJ. Melasch1, M. Rullmann1, C. Scherlach2, D. Saur3, M. L. Schroeter4, S. Tiepolt1, A. Stephens5, N. Koglin5, S. Hesse1, M. Strauss6, M. Brendel7, G. Aghakhanyan8, A. Schildan1, O. Mishchenko1, M. Patt1, J. Claßen3, K. Hoffmann2, O. Sabri1, H. Barthel1; 1Department of Nuclear Medicine, University Hospital, Leipzig, GERMANY, 2Department of Neuroradiology, University Hospital, Leipzig, GERMANY, 3Department of Neurology, University Hospital, Leipzig, GERMANY, 4Clinic for Cognitive Neurology, University Hospital, Leipzig, GERMANY, 5Life Molecular Imaging, Berlin, GERMANY, 6Department of Psychiatry and Psychotherapy, University Hospital, Leipzig, GERMANY, 7Department of Nuclear Medicine, University Hospital, Munich, GERMANY, 8Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, Pisa, ITALY.

OP-0485Total P-Tau Brain Load (TTBL) quantification using F18-MK6240 PET: new approach and correlations with CSF phospho-tau and visual Braak stagingT. Gérard, V. Malotaux, V. Van Pesch, A. Ivanoiu, B. Hanseeuw, R. Lhommel; Université Catholique de Louvain, Bruxelles, BELGIUM.

OP-0486Association between tau and synaptic density in amnestic mild cognitive impairment: a longitudinal follow-up studyG. Vanderlinden1, T. Vande Casteele2,3, J. Ceccarini1, L. Michiels4,5, R. Lemmens4,5, E. Triau6, K. Serdons7, M. Koole1, M. Vandenbulcke2,3,8, K. Van Laere1,7; 1Nuclear Medicine and Molecular Imaging, Imaging Pathology, KU Leuven, Leuven, BELGIUM, 2Research Group Psychiatry, KU Leuven, Leuven, BELGIUM, 3Leuven Brain Institute, Leuven, BELGIUM, 4Department of Neurology, University Hospitals UZ Leuven, Leuven, BELGIUM, 5VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, BELGIUM, 6Private Practice Neurology, Leuven, BELGIUM, 7Department of Nuclear Medicine, University Hospitals UZ Leuven, Leuven, BELGIUM, 8Department of Old-Age Psychiatry, University Hospitals UZ Leuven, Leuven, BELGIUM.



111110

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0487In-vivo MRI imaging of locus coeruleus degeneration is coupled to brain glucose metabolism in Alzheimer’s disease pathologyG. Aghakhanyan1, A. Galgani2, F. Lombardo3, N. Martini4, H. Hlavata3, A. Leo1, F. Guidoccio1, G. Tognoni2, P. A. Erba1, N. Pavese5, F. S. Giorgi2, D. Volterrani1; 1Nuclear Medicine Unit, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, ITALY, 2Neurology Unit, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, ITALY, 3Cardiovascular and Neuroradiological Multimodal Imaging Unit, Fondazione “G. Monasterio”- National Research Council/Tuscany Region, Pisa, ITALY, 4Deep Health Unit, Fondazione “G. Monasterio”- National Research Council/Tuscany Region, Pisa, ITALY, 5Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne NE4 5PL, UNITED KINGDOM.

OP-0488Accuracy of FDG-PET at the individual level in MCI-LB versus MCI-AD: a stepwise approach from visual to semi-quantitative analysisS. Raffa1, F. Massa2, A. Chincarini3, M. Bauckneht1,4, E. Peira2,3, D. Arnaldi2,4, M. Pardini2,4, M. Pagani5,6, B. Orso2, M. Donegani1, A. Brugnolo2,4, E. Biassoni2, P. Mattioli2, N. Girtler2,4, U. Guerra7, S. Morbelli1,4, F. Nobili2,4; 1Department of Health Science (DISSAL), University of Genoa, Genoa, ITALY, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, ITALY, 3National Institute of Nuclear Physics (INFN), Genoa section, Genoa, ITALY, 4IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 5Institute of Cognitive Sciences and Technologies, Consiglio Nazionale delle Ricerche (CNR), Rome, ITALY, 6Department of Medical Radiation Physics and Nuclear Medicine, Karolinska Hospital, Stockholm, SWEDEN, 7formerly at Nuclear Medicine Unit, Fondazione Poliambulanza, Brescia, ITALY.

913



OP-0491Plenary QuizT. Van den Wyngaert; Antwerp University Hospital, Nuclear Medicine, Antwerp, BELGIUM.

1001


Plenary 3: Conventional Nuclear Medicine - Oldies but Goldies

OP-0492Why some Scans are Evergreen?O. Israel; Rappaport School of Medicine, Technion - Israel Institute of Technology, Haifa, ISRAEL.

OP-0493Bone ScanG. Gnanasegaran; Royal Free London NHS Foundation Trust, Department of Nuclear Medicine, London, UNITED KINGDOM.

OP-0494Thyroid ScanE. G. Karamanou; Aristotle University of Thessaloniki, University General Hospital AHEPA, Second Academic Nuclear Medicine Dpt., Thessaloniki, GREECE.

OP-0495Renal ScanM. Kalnina; Pauls Stradins Clinical University Hospital, Riga, LATVIA.

OP-0496V/Q ScanP. Pilkington; University Hospital 12 de Octubre, Servicio de Medicina Nuclear, Madrid, SPAIN.

OP-0497Parathyroid ImagingP. Petranović Ovčariček; University Hospital Center Sestre milosrdnice, Oncology and nuclear medicine, Zagreb, CROATIA.

OP-0498Lessons from the PastF. Verzijlbergen; Radboudumc, Erasmus MC Centreal Location, Nijmegen, NETHERLANDS.

1009


Cutting Edge Science Track - TROP Session: New Imaging Equipment and Techniques

OP-0501Performance Testing of a Novel, Fully 3D, Gamma CameraS. Cade, R. Leigh, M. Evans; Royal United Hospitals Bath NHS Foundation Trust, Bath, UNITED KINGDOM.

OP-0502First NEMA performance measurements of a new multi-detector CZT-Based SPECT/CT systemG. Le Rouzic1, R. Zananiri2, M. Bailly1; 1Centre Hospitalier Régional d’Orléans, Orléans, FRANCE, 2General Electric, Haïfa, ISRAEL.

OP-0503Dopamine transporter imaging using 3D-ring CZT StarGuide SPECT/CT: head-to-head comparison with a conventional systemM. Bailly, G. Le Rouzic, G. Metrard; CHR Orléans, Orleans, FRANCE.

OP-0504Digital SPECT: Improved Imaging using the Continuous Scan Mode on a General Purpose Whole-body Solid-State CZT CameraJ. Kennedy, Z. Keidar; Rambam - Health Care Campus, Haifa, ISRAEL.

OP-0505New multi-focal collimator designed for quantitative SPECT imaging in nuclear neurology applicationsF. Massanes1, A. H. Vija1, X. Ding1, D. Spence1, G. Platsch2, A. Yahil1, R. Malmin1; 1Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA, 2Siemens Healthcare Gmb, Erlangen, GERMANY.

OP-0506Evaluation Of New Features Of A Triple Head SPECT-PET-CT SystemL. Torres Aroche1, Y. Reyes González2, K. Batista García-Ramo2, C. Calderón Marín3, Y. Sánchez González2; 1CENTIS, Havana, CUBA, 2Centis, Havana, CUBA, 3Inor, Havana, CUBA.

OP-0507The First Clinical Trial of the Ultra-Compact Fully Integrated Brain PET System BPETE. Mikhaylova1, A. Buck1, V. Dao2, M. Hofbauer3, M. Hüllner3, P. Kaufmann3, K. Thielemans4, C. Tsoumpas2, V. Treyer3, M. Ahnen1, J. Fischer1; 1Positrigo AG, Zurich, SWITZERLAND, 2University of Leeds, West Yorkshire, UNITED KINGDOM, 3University Hospital Zurich, Zurich, SWITZERLAND, 4Algorithms and Software Consulting Ltd, London, UNITED KINGDOM.

OP-0508Dedicated PET/MRI insert for Breast CancerV. Schulz1,2,3, B. Weissler1,2, V. Nadig1, D. Schug1,2, F. Mueller1, H. Radermacher1, N. Gross-Weege1, T. Nolte1, m. Borgo4, M. d. Koning4, M. Mathlener5, J. Koelemann4, S. Aussenhofer6, T. Celik6, A. Salomon7, D. Schaart8, D. Kuznetsov8, P. Bakker8, K. Langen9, C. Kuhl10; 1Physics of Molecular Imaging Systems / University RWTH Aachen, Aachen, GERMANY, 2Hyperion Hybrid Imaging Systems GmbH, Aachen, GERMANY, 3Physics Institute III B, RWTH Aachen University, Aachen, GERMANY, 45Futura Composites b.v., Heerhugowaard, NETHERLANDS, 5Futura Composites b.v., Heerhugowaard, NETHERLANDS, 6NORAS MRI Products GmbH, Hoechberg, GERMANY, 7Philips Research, Eindhoven, NETHERLANDS, 8Delft University of Technology, Delft, NETHERLANDS, 9Forschungszentrum Juelich, Juelich, GERMANY, 10Department of Diagnostic and Interventional Radiology, University Hospital Aachen, Aachen, GERMANY.

OP-0509Monte Carlo simulation of a last generation PET scanner: preliminary results according to the NEMA NU2-2018 standardA. Merlet1, B. Presles1, A. Cochet1,2, J. M. Vrigneaud1,2; 1ImViA EA 7535, University of Burgundy, Dijon, FRANCE, 2Department of Nuclear Medicine, Georges-François Leclerc Cancer Center, Dijon, FRANCE.

OP-0510Snapshot of Global Nuclear Medicine Resources, Country by Country: the IAEA IMAGINE databaseM. Mikhail, D. Paez, Y. Pynda, T. Okolielova, F. Giammarile, E. Estrada-Lobato, O. Pellet; International Atomic Energy Agency, Vienna, AUSTRIA.

OP-0511Compton 3D Imaging with Sparse Number of Views: Progress on Image Quality @ 511 keVM. Hmissi1, G. Lebonvallet1, A. Iltis1, B. Mehadji2, C. Morel2; 1Damavan Imaging, 2 Rue Gustave Eiffel, 10430 Rosières-prés-Troyes, FRANCE, 2Aix-Marseille University, CNRS/IN2P3, CPPM, Marseille, FRANCE.



113112

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0512The addition of PET-CT in CT-guided bone biopsiesD. Rietbergen, M. Droste, I. Boekestijn, M. Oosterom, M. Burgmans, F. van Velden, F. van Leeuwen, D. Rietbergen; Leids Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS.

1101


CME 7: Developments and Challenges in Theranostics

OP-0515Where Are We with Theranostic Imaging Today?L.-F. de Geus-Oei; Department of Radiology, University Medical Center (LUMC), Leiden, NETHERLANDS.

OP-0516Terbium Radioisotopes for Theranostics, What to Expect?C. Müller; Paul Scherrer Institute, Center for Radiopharmaceutical Sciences, Villingen, SWITZERLAND.

OP-0517Quantitative Theranostic Imaging - Challenges and OpportunitiesM. Konijnenberg; Radiologie & Nucleaire Geneeskunde, Klinische Fysica, Erasmus Medical Center, Rotterdam, NETHERLANDS.

1102

Thursday, October 21, 2021, 15:05 – 16:35Channel 2

The Top 3 Trials Sessions - 2 - Rest of the Science

OP-0519A pilot study comparing 18F-FDG PET/CT and 68Ga-FAPI PET/CT for initial staging of early operable and locally advanced breast cancersP. Chandra, K. Senthil, M. Sridev, G. Chandran, J. Kumar, M. Merlin, P. Priya, J. Sangeetha, S. Nath; MIOT international, Chennai, INDIA.

OP-0520Safety analysis of a large European cohort on transarterial radioembolization using the adverse event burden scoreG. Maleux1, T. Albrecht2, D. Arnold3, I. Bargellini4, N. De Jong5, T. Helmberger6, N. Schaefer7; 1University Hospitals Leuven, Leuven, BELGIUM, 2Vivantes Klinikum Neukölln, Berlin, GERMANY, 3Asklepios Tumorzentrum Hamburg, Hamburg, GERMANY, 4University of Pisa, Pisa, ITALY, 5Cardiovascular and Interventional Radiological Society of Europe, Vienna, AUSTRIA, 6Klinikum Bogenhausen, München, GERMANY, 7Inselspital Hospital Lausanne, Lausanne, SWITZERLAND.

OP-0521Added Value of F18-FDG PET/MR Imaging for Detecting Liver Metastases in Patients with Colorectal CancerP. Gündüz1, E. Özkan1, D. Kuru Öz2, M. Araz1, Ç. Soydal1, Ö. Küçük1, G. Erden2, K. Kır1; 1Ankara University Faculty of Medicine Nuclear Medicine Department, Ankara, TURKEY, 2Ankara University Faculty of Medicine Radiology Department, Ankara, TURKEY.

OP-0522Efficacy of [18F]FDG-PET/CT in Evaluation of Cytologically Indeterminate Thyroid Nodules Prior to Surgery (EfFECTS): a Randomised-Controlled Multicentre TrialE. de Koster1, L. de Geus-Oei2,1,3, A. Brouwers4, E. van Dam5, L. Dijkhorst-Oei6, I. van Engen-van Grunsven1, T. Klooker7,8, R. Netea-Maier1, M. Snel2, W. Oyen1,9,10, D. Vriens2; 1Radboud University Medical Center, Nijmegen, NETHERLANDS, 2Leiden University Medical Center, Leiden, NETHERLANDS, 3University of Twente, Enschede, NETHERLANDS, 4University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, 5Amsterdam University Medical Center, VU University Medical Center, Amsterdam, NETHERLANDS, 6Meander Medical Centre, Amersfoort, NETHERLANDS, 7Amsterdam University Medical Center, University of Amsterdam, Amsterdam, NETHERLANDS, 8Flevo Hospital, Almere, NETHERLANDS, 9Rijnstate Hospital, Arnhem, NETHERLANDS, 10Humanitas University, Milan, ITALY.

OP-0523Lung Dose Assessment on PET/CTs Acquired After Yttrium-90 Radioembolization Showed Occurrence of Radiation Pneumonitis at Lung Dose Lower than 30 GyM. Stella, R. van Rooij, M. Lam, H. de Jong, A. Braat; University Medical Center, Utrecht, NETHERLANDS.

OP-0524The surgical benefits of using bimodal tracers for image-guided surgery; multicenter experience in >1900 patientsT. Buckle1, P. Dell’Oglio1, E. Mazzone1, D. Rietbergen1, H. de Vries1, S. Vidal-Sicart2, B. Karakullukcu3, M. Klop3, O. Brouwer3, E. Wit3, P. van Leeuwen4, H. van der Poel3, F. van Leeuwen1; 1LUMC, Leiden, NETHERLANDS, 2University Hospital Clinic Barcelona, Barcelona, SPAIN, 3Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 4Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Leiden, NETHERLANDS.

OP-0525In vivo imaging of tau pathology across PET-based stages of amyloid depositionA. Moscoso Rial1, M. J. Grothe2,1, M. Schöll1; 1Wallenberg Centre for Molecular and Translational Medicine and the Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, SWEDEN, 2Movement Disorders Group, Institute of Biomedicine of Seville-IBiS, Seville, SPAIN.

OP-0526Cognitive change in frail individuals with intermediate amyloid load: insight from the MAPT interventional studyL. Saint-Aubert1, I. Carrié2, A. Hitzel3, A. Salabert3, P. Payoux1; 1INSERM laboratory ToNIC, Toulouse, FRANCE, 2Gérontopôle - CHU de Toulouse, Toulouse, FRANCE, 3Service de médecine nucléaire, CHU de Toulouse, Toulouse, FRANCE.

OP-0527The Phase 3 NETTER-1 Study of [177Lu]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal SafetyP. Kunz1, M. E. Caplin2, P. B. Ruszniewski3, L. Bodei4, A. Hendifar5, E. Mittra6, E. M. Wolin7, J. C. Yao8, M. E. Pavel9, E. Grande10, E. Van Cutsem11, E. Seregni12, H. Duarte13, A. Demange14, S. Mutevelic14, J. R. Strosberg15, E. P. Krenning16; 1Yale School of Medicine, New Haven, CT, UNITED STATES OF AMERICA, 2Royal Free Hospital, London, UNITED KINGDOM, 3Université de Paris et Hôpital Beaujon, AP-HP, Clichy, FRANCE, 4Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, 5Cedars-Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, 6Oregon Health & Science University, Portland, OR, UNITED STATES OF AMERICA, 7Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA, 8University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA, 9Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, GERMANY, 10MD Anderson Cancer Center Madrid, Madrid, SPAIN, 11University of Leuven, University Hospital Gasthuisberg, Leuven, BELGIUM, 12Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY, 13Instituto Português de Oncologia, Porto, PORTUGAL, 14Novartis Pharma AG, Basel, SWITZERLAND, 15Moffitt Cancer Center, Tampa, FL, UNITED STATES OF AMERICA, 16Erasmus Medical Centre, Rotterdam, NETHERLANDS.

1104


CTE 7: Research - Technologist’s Involvement

OP-0529Conducting the ResearchS. Rep; University Medical Centre, Department of Nuclera Medicine, Ljubljana, SLOVENIA.

OP-0530Database Analysis - The Opportunity for TechnologistsI. Melo e Costa; Department of Biomedical Engineering & Imaging Sciences, King’s College London, London, UNITED KINGDOM.

OP-0531Team Science - Theory and PracticeD. Albano; University of Brescia and ASST Spedali Civili of Brescia, Department of Nuclear Medicine, Brescia, ITALY.

1105


Joint Symposium 13 (EANM/EHA): Biomarkers in Lymphoma

OP-0533Non-PET Biomarkers in LymphomaF. Broussais-Guillaumot; Hematology Department, LYSARC CHU Lyon Pierre Bénite, Caen, FRANCE.

OP-0534PET for Prognosis and Response PredictionS. Barrington; King’s College London and Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM.

OP-0535How to Combine PET and Non-PET BiomarkersA.-S. Cottereau; Cochin, Nuclear Medicine, Paris, FRANCE.



115114

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1106


Joint Symposium 14 (EANM/EHA): New Therapies in Lymphoma - Is Deauville Still Good Enough?

OP-0537From Checkpoint Inhibitors to Cell Therapy - New Standards in Malignant LymphomaP. Bröckelmann; Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, GERMANY.

OP-0538Evolution of Response Criteria in LymphomaJ. J. Eertink; Amsterdam UMC, VUmc, Hematology, Amsterdam, NETHERLANDS.

OP-0539Is Deauville Score Still the Solution?L. Dercle; University of Toulouse, Physics and signal processing, Toulouse, FRANCE.

1107


Teaching Session 1 (EANM/AGA): Imaging of Prosthetic Knee Joint Loosening - Spotlight on Quantitative and Multidisciplinary Algorithms

OP-0541Clinical Point of View for Selecting Imaging Modalities for the Assessment of Knee EndoprosthesisD. Mathis; Kantonsspital Baselland Bruderholz, Department of Orthopedics, Basel, SWITZERLAND.

OP-0542Anatomical Imaging in the Management of Prosthetic LooseningL. M. Sconfienza; I.R.C.C.S. Istituto Ortopedico Galeazzi, Unit of Diagnostic and Interventional Radiology, Milan, ITALY.

OP-0543Nuclear Medicine Modalities and Quantitative Approaches in the Management of Knee Prosthetic LooseningC. Lauri; Sant’Andrea Hospital, Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine of “Sapienza” University, Rome, ITALY.

OP-0544Summary Suggestion - A Consensus Document in the Diagnosis of Knee Prosthetic Joint LooseningF. Paycha; Assistance Publique-Hôpitaux de Paris, Université de Paris, Department of Nuclear Medicine, Paris, FRANCE.

1108


M2M Track - TROP Session: Peptides Only!

OP-0546[18F]AlF-NOTA-DV1-k-(DV3) for translational CXCR4-targeted molecular imagingK. Luyten1, T. Van Loy2, C. Cawthorne3, C. Deroose3, D. Schols2, G. Bormans1, F. Cleeren1; 1Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, 2Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BELGIUM, 3Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM.

OP-0547Functionalising a PET nanoradiotracer towards integrins enables better tumour targeting in a mouse orthotopic glioblastoma modelL. Sakiroff, B. Louis, J. Ou, L. Balasse, V. Nail, O. Nachar, A. Moyon, A. Bouhlel, T. Roussel, F. Dignat-George, L. Peng, P. Garrigue, B. Guillet; Aix-Marseille University, Marseille, FRANCE.

OP-0548Synthesis and biological evaluation of the first 68Ga/111In-radiolabelled peptide targeting the neuropeptide-Y receptor 5 (Y5) in cancersS. Bodin1,2, D. J. Worm3, E. Jestin4, D. Vimont1, I. Ait-Arsa4, E. Hindié1,2, A. G. Beck-Sickinger3, C. Morgat1,2; 1Univ. Bordeaux, CNRS, INCIA, UMR5287, F-33000 Bordeaux, FRANCE, 2University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 3Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, GERMANY, 4CYclotron Réunion Océan Indien CYROI, 2 rue Maxime Rivière, F-97490 Sainte-Clotilde, FRANCE.

OP-0549Double targeting of NTS1 and GRPR receptors using 68Ga-labelled heterodimersS. Bodin1,2, S. Previti3, E. Jestin4, D. Vimont1, F. Lamare1,2, I. Ait-Arsa4, E. Hindié1,2, F. Cavelier3, C. Morgat1,2; 1Univ. Bordeaux, CNRS, INCIA, UMR5287, F-33000 Bordeaux, FRANCE, 2University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 3Univ. Montpellier, CNRS, Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, F-34000 Montpellier, FRANCE, 4CYclotron Réunion Océan Indien CYROI, 2 rue Maxime Rivière, F-97490 Sainte-Clotilde, FRANCE.

OP-0550Pyridyl-Ala substitution in the third position of somatostatin receptor antagonists: regioisomerisation modulates their biodistributionR. Mansi, N. Bertarelli, L. Del Pozzo, S. Zanger, H. Maecke, M. Fani; Div. Radiopharmaceutical Chemistry. University Hospital Basel, Basel, SWITZERLAND.

OP-0551Biodistribution and pharmacokinetics of Zr89-antiVEGF mAbs using PET in glioblastoma rat modelsD. Rey Bretal1, L. García Varela1, X. García Otero2,3, N. Gómez Lado1, A. Moscoso2, M. Piñeiro Fiel1,2, C. Mondelo García3,4, A. Costoya Sánchez1, A. Fernández Ferreiro3,4, J. Silva Rodríguez2, Á. Ruibal1,2, P. Aguiar1,2; 1Molecular Imaging Group, Department of Radiology, Faculty of Medicine, University of Santiago de Compostela (USC), IDIS, Campus Vida, 15782, Santiago de Compostela, SPAIN, 2Nuclear Medicine Department and Molecular Imaging Group, IDIS and University Hospital Santiago de Compostela (CHUS), Travesía da Choupana s/n, 15706, Santiago de Compostela, SPAIN, 3Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706, Santiago de Compostela, SPAIN, 4Pharmacology Group, Health Research Institute of Santiago de Compostela (FIDIS), 15706, Santiago de Compostela, SPAIN.

OP-0552Proof-of-concept of a pretargeting strategy mediated by sstr2 antagonist for the therapy of neuroendocrine tumoursS. Koustoulidou, M. Handula, J. Nonnekens, M. Hendriks-de Jong, Y. Seimbille; Erasmus MC, Rotterdam, NETHERLANDS.

OP-0553Physiologically Based Pharmacokinetic Models to Predict Organ and Tumor Distribution and Assess the Tumor Sink Effect of 68Ga-DOTATATE and 68Ga-HA-DOTATATE in Patients with Gastroenteropancreatic Neuroendocrine TumorsH. Siebinga1,2, B. de Wit-van der Veen2, T. P. Dorlo1, A. D. Huitema1,3,4, J. J. Hendrikx1,2; 1Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 2Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 3Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, NETHERLANDS, 4Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.

OP-0554Automated preparation and preclinical evaluation of 68Ga-labelled DOTA-MGS5 for PET/CT imaging of CCK2R expressing tumoursA. Hörmann, M. Klingler, C. Rangger, C. Mair, C. Decristoforo, C. Uprimny, I. Virgolini, E. von Guggenberg; Medical University of Innsbruck, Innsbruck, AUSTRIA.

OP-0555Development and Pre-clinical evaluation of a novel hybrid peptide analog based on Mucin168Ga-NODAGA-MUC1 and 68Ga-NODAGA-MUC1-FA hybrid peptide conjugates and Folic acid: Potential breast/ovarian cancers PET imaging agentI. Aljammaz1, S. Alhabardi2, B. Alotaibi1, S. Okarvi1; 1King Faisal Specialist Hospital and Research centre, Riyadh, SAUDI ARABIA, 2King Saud University, Riyadh, SAUDI ARABIA.

OP-0556Al18F-3p-C-NETA-TATE: Combining a versatile and highly effective chelator with an established somatostatin analogueS. Ahenkorah1, E. Murce2, Y. Seimbille2, T. Cardinaels3, C. M. Deroose4, G. Bormans1, M. Ooms3, F. Cleeren1; 1KU Leuven, Leuven, BELGIUM, 2Erasmus MC, Rotherdam, NETHERLANDS, 3SCK CEN, Mol, BELGIUM, 4UZ Leuven, Leuven, BELGIUM.

OP-055799mTc-HYNIC-LHRH analog as novel breast cancer imaging agentL. Alfaya1, X. Camacho1, F. García1, M. Cabrera1, M. Tassano1, M. Fernández1, T. Freire2, E. Osinaga3, J. Gambini4, P. Cabral1; 1Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, URUGUAY, 2Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY, 3Instituto Pasteur de Montevideo; Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY, 4Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY.



117116

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1109


Cutting Edge Science Track - Featured Session: Software Developments in Total Body PET

OP-0559Software Developments in Total Body PETK. Shi; Inselspital, University of Bern, Bern, SWITZERLAND.

OP-0560176Lu detection for daily PET quality control: initial clinical experiencesS. McQuaid, J. C. Dickson; Institute of Nuclear Medicine, UCLH, London, UNITED KINGDOM.

OP-0561Development and evaluation of a CT-less reconstruction framework for long-axial FOV PET scanners using LSO background radiationH. Sari1,2, M. Teimoorisichani3, C. Mingels2, I. Alberts2, V. Panin3, D. Bharkhada3, K. Shi2, A. Rominger2, M. Conti3; 1Siemens Healthineers A.G., Lausanne, SWITZERLAND, 2Department of Nuclear Medicine, Inselspital, Bern, SWITZERLAND, 3Siemens Medical Solutions USA Inc., Knoxville, TN, UNITED STATES OF AMERICA.

OP-0562Development of a deep learning method for CT-free correction for an ultra-long axial field of view PET scannerS. Xue1, K. Bohn1, R. Guo2, H. Sari3, M. Viscione1, A. Rominger1, B. Li2, K. Shi1; 1University of Bern, Bern, SWITZERLAND, 2Shanghai Jiaotong University, Shanghai, CHINA, 3Siemens Healthcare AG, Lausanne, SWITZERLAND.

OP-0563Dynamic total-body 18F-FDG parametric imaging on a long-axial FOV PET/CT scannerH. Sari1,2, J. Hu3, C. Mingels2, I. Alberts2, J. Hong2, V. Panin3, L. Eriksson3, M. Conti3, K. Shi2, P. Cumming2,4, A. Rominger2; 1Siemens Healthineers AG, Bern, SWITZERLAND, 2Department of Nuclear Medicine, Inselspital, Bern, SWITZERLAND, 3Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA, 4School of Psychology and Counselling, Queensland University of Technology, Brisbane, AUSTRALIA.

OP-0564Clinical validation of a population-based input function for dynamic whole-body 18F-FDG multiparametric PET imaging using a standard injectorA. H. Dias1, D. Pigg2, A. M. Smith2, V. Shah2, L. C. Gormsen1, O. L. Munk1; 1Aarhus University Hospital, Aarhus, DENMARK, 2Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

OP-0565Normative tissue FDG uptake values from 112 patients undergoing whole-body dynamic 18F-FDG PET/CT - Validation of automated software tools and a normal value databaseA. H. Dias, O. L. Munk, L. C. Gormsen; Aarhus University Hospital, Aarhus, DENMARK.

OP-0566Non-invasive method for quantitative measurement of the cerebral glucose metabolic rateA. Cuculiza Henriksen1, M. Lonsdale1, V. Nersesjan2, D. Kondziella2, L. Marner1; 1Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, DENMARK, 2Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DENMARK.

OP-0567Population-based input function and image-derived input function for whole-body dynamic 68Ga-DOTATOC-PET/CT acquisition: methodology and clinical validationP. Thuillier1,2, D. Bourhis3,2, J. Metges4, R. Le Pennec3,2, U. Schick5, F. Blanc-Beguin3,2, S. Hennebicq3,2, P. Salaun3,2, V. Kerlan1,2, N. Karakatsanis6, R. Abgral3,2; 1Department of Endocrinology, University Hospital of Brest, Brest, FRANCE, 2EA GETBO 3878, University Hospital of Brest, Brest, FRANCE, 3Department of Nuclear Medicine, University Hospital of Brest, Brest, FRANCE, 4Department of Oncology, University Hospital of Brest, Brest, FRANCE, 5Department of Radiotherapy, University Hospital of Brest, Brest, FRANCE, 6Department of Radiology, Weil Cornell Medical College of Cornell University, New York, NY, UNITED STATES OF AMERICA.

OP-0568Motion correction using multi-resolution scheme (MOTIONLESS) for 18F-FDG Total-body PET/CT systemsL. Shiyam Sundar1, Y. Wang2, B. A. Spencer2, G. Wang2, E. Li2, S. R. Cherry2, T. Beyer1, R. D. Badawi2; 1Medical university of Vienna, Vienna, AUSTRIA, 2University of California, Davis, CA, UNITED STATES OF AMERICA.

OP-0569ENHANCE-PET: Exploring the Human Functional Connectome Using Total-Body [18F]FDG-PETL. Shiyam Sundar1, R. D. Badawi2, B. A. Spencer2, E. Li2, S. R. Cherry2, Y. G. Abdelhafez2, M. Hacker1, T. Jones2, T. Beyer1; 1Medical university of Vienna, Vienna, AUSTRIA, 2University of California, Davis, CA, UNITED STATES OF AMERICA.

1110


Clinical Oncology Track - TROP Session: Prostate Staging

OP-0571Predicting Early Biochemical Progression in Prostate Cancer Patients staged with PSMA PET and multiparametric Magnetic Resonance ImagingD. Meijer1, P. J. van Leeuwen2, M. L. Donswijk2, T. N. Boellaard2, I. G. Schoots2, H. G. van der Poel2, N. H. Hendrikse1, D. E. Oprea-Lager1, A. N. Vis1; 1Amsterdam UMC, Amsterdam, NETHERLANDS, 2Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-0572Multiparametric MRI and [18F]PSMA-1007 PET to detect local prostate cancer; a prospective comparative study with correlation to histopathologyB. Privé, B. Israel, M. J. Janssen, M. M. van der Leest, C. H. Muselaers, M. G. Schilham, P. Zamecnik, J. G. Bomers, G. De Lauw, A. J. Smits-van de Camp, J. Sedelaar, W. A. van Gemert, M. Gotthardt, J. O. Barentsz, I. M. van Oort, J. Nagarajah; Radboudumc, Nijmegen, NETHERLANDS.

OP-0573The Prognostic Value of Histopathological Nodal Features and PSMA-PET findings in Patients with Pelvic Lymph Node Metastases of Prostate Cancer after Extended Pelvic Lymph Node DissectionD. Meijer1, R. H. Ettema1, P. J. van Leeuwen2, H. G. van der Poel2, N. H. Hendrikse1, D. E. Oprea-Lager1, E. M. Bekers2, A. N. Vis1; 1Amsterdam UMC, Amsterdam, NETHERLANDS, 2Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-0574Standardized Uptake Values as Determined on Prostate-specific Membrane Antigen Positron Emission Tomography/Computer Tomography are associated with Gleason Grade and Biochemical Recurrence of Disease in Patients with Prostate CancerY. Bodar1, H. Veerman2, K. De Bie1, D. Meijer1, H. N. Hendrikse1, P. J. van Leeuwen2, B. A. Windhorst1, M. Donswijk2, R. Boellaard1, A. N. Vis1, D. E. Oprea-Lager1; 1Amsterdam UMC, location VUmc, Amsterdam, NETHERLANDS, 2Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-0575A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate CancerH. Duan, V. Ferri, P. Ghanouni, B. Daniel, N. Hatami, G. A. Davidzon, C. Mari Aparici, A. Thong, G. A. Sonn, A. Iagaru; Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

OP-0576Prospective Pilot Trial On 68Ga-PSMA And 68Ga-DOTA-RM2 PET/MRI In High-Risk Prostate Cancer StagingS. Ghezzo1, P. Mapelli1,2, E. Preza2, G. Brembilla1, V. Cucchiara1, A. Samanes Gajate2, C. Bezzi1, L. Presotto2, V. Bettinardi2, A. Savi2, P. Magnani2, R. Menichini2, A. Coliva2, I. Neri2, E. Di Gaeta3, L. Gianolli2, A. Briganti1,4, F. De Cobelli1,3, P. Scifo2, M. Picchio1,2; 1Vita-Salute San Raffaele University, Milan, ITALY, 2Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 4Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP-0577Prospective analysis of Prostate Cancer Local Staging with 18F-DCFPyL PET/MRI combined with multiparametric MRI - a comparison to histopathology in the radical prostatectomy specimenY. Bodar, G. J. Zwezerijnen, J. P. van der Voorn, B. Jansen, R. Smit, S. Kol, D. Meijer, K. De Bie, A. Windhorst, N. Hendrikse, A. Vis, D. Oprea-Lager; Amsterdam UMC, location VUmc, Amsterdam, NETHERLANDS.

OP-0578A Pilot Study of68Ga-PSMA11 and68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) TherapyH. Duan, P. Ghanouni, N. Hatami, G. A. Davidzon, C. Mari Aparici, A. Thong, G. A. Sonn, A. Iagaru; Stanford University, Stanford, CA, UNITED STATES OF AMERICA.



119118

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0579Quantitative imaging parameters to predict local staging of prostate cancer in intermediate- to high-risk patientsR. Laudicella1,2, S. Skawran1, D. A. Ferraro1,3, U. Mühlematter1, A. Maurer1, H. Grünig1, O. Donati4, D. Eberli5, I. A. Burger1,6; 1Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 2Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, ITALY, 3Department of Radiology and Oncology, Faculdade de Medicina, FMUSP, Universidade de Sao Paulo, Sao Paulo, BRAZIL, 4Interventional and Diagnostic Radiology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 5Department of Urology, University Hospital Zürich, University of Zurich, Zurich, SWITZERLAND, 6Department of Nuclear Medicine, Kantonsspital Baden, Baden, SWITZERLAND.

OP-0580Heterogeneous PSMA expression in prostate cancer: reason for negative 68Ga-PSMA PET/CT scan? Immunohistochemical validation of 40 surgical specimensW. Cytawa1, S. Kircher2, A. K. Seitz2, S. Weber2, P. Hartrampf2, T. Bandurski1, P. Lass1, W. Polom1, C. Lapa3, A. K. Buck2; 1Medical University of Gdansk, Gdansk, POLAND, 2University Hospital Würzburg, Würzburg, GERMANY, 3University of Augsburg, Augsburg, GERMANY.

OP-0581Pre-Therapeutic n.c.a. 177Lu-PSMA I&T (“LuteScan”) as a SPECT compatible radioligand for Imaging of Metastatic Prostate Cancer PatientsG. Limouris1, M. B. Dolgushin2, V. Krylov3, A. G. Zafeirakis4; 1Nuclear Medicine, Medical School, National and Kapodistrian University of Athens, Athens, GREECE, 2N.N. Blokhin Russian Oncological Research Center, Moscow, RUSSIAN FEDERATION, 3Nucl Med Dept, Anatoly Tsyb Research Center, Obninsk, RUSSIAN FEDERATION, 4Nucl Med Dept, Army Share Fund Hospital of Athens, Athens, GREECE.

OP-0582Infiltrative growth-pattern on histopathology is associated with lower diffusion restriction: a potential reason for false-negative mpMRI in prostate cancerR. Laudicella1,2, J. H. Rüschoff3, D. A. Ferraro1,4, D. Hausmann5,6, I. Mebert1, A. Maurer1, T. Hermanns7, D. Eberli7, N. Rupp3, I. A. Burger1,8; 1Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 2Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, ITALY, 3Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 4Department of Radiology and Oncology,

Faculdade de Medicina, FMUSP, Universidade de Sao Paulo, Sao Paulo, BRAZIL, 5Department of Radiology, Kantonsspital Baden, Baden, SWITZERLAND, 6Department of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY, 7Department of Urology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 8Department of Nuclear Medicine, Kantonsspital Baden, Baden, SWITZERLAND.

1111


Featured Session: Molecular Imaging of Movement Disorders

OP-0584What Lies Behind Cognitive Deficits in Parkinsonisms?F. Nobili; University of Genoa and Polyclinic San Martino Hospital, Department of Neuroscience (DINOGMI), Genoa, ITALY.

OP-0585Prospective paired comparison of 123I-FP-CIT SPECT images obtained with a 360°-CZT and a conventional camerasY. Piatkova1, P. Payoux2,3, C. Boursier1, M. Bordonne1, V. Roch1, P. Y. Marie1,4, L. Imbert1,5, A. Verger1,5; 1Université de Lorraine, Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Nancy, FRANCE, 2Department of Nuclear Medicine, Toulouse CHU, Purpan University Hospital, Toulouse, FRANCE, 3Toulouse NeuroImaging Center, University of Toulouse, INSERM, UPS, Toulouse, FRANCE, 4Université de Lorraine, INSERM, DCAC, Nancy, FRANCE, 5Université de Lorraine, IADI, INSERM U1254, Nancy, FRANCE.

OP-0586Imaging With [18F]FE-PE2I Suggests a Non-Linear Relationship Between Dopamine Transporter Availability and Motor Symptom Severity in Patients With Non-Advanced Parkinson´s DiseaseV. Kerstens, P. Fazio, M. Sundgren, C. Halldin, P. Svenningsson, A. Varrone; Karolinska Institute, Stockholm, SWEDEN.

OP-058718F-FDOPA PET for the diagnosis of cortico-basal syndromesJ. Darcourt1, A. Schiazza1, D. Chardin1, A. El Ouartassi2, N. Sapin1, P. Koulibaly1, O. Humbert1, C. Giordana2; 1Centre Antoine Lacassagne - UCA, Nice, FRANCE, 2CHU - UCA, Nice, FRANCE.

OP-0588Dopaminergic Activity and Functional Connectivity After Intranasal Insulin. A 11C-raclopride PET/MRI StudyD. Blum1, S. Kullmann2, B. A. Jaghutriz2, C. Gassenmaier3, B. Bender4, H. Häring2, G. Reischl5, H. Preissl2, C. la Fougère1, A. Fritsche2, M. Reimold1, M. Heni2; 1Nuclear Medicine and Molecular Imaging, Tübingen, GERMANY, 2Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, Tübingen, GERMANY, 3Department of Internal Medicine, Division of Hematology, Oncology, Clinical Immunology and Rheumatology, Tübingen, GERMANY, 4Department of Diagnostic and Interventional Neuroradiology, Tübingen, GERMANY, 5Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Tübingen, GERMANY.

OP-058918F-PI-2620 binding in dopaminergic pathways is associated with decreased dopamine transporter availability in four-repeat tauopathiesC. Ferschmann1, M. Scheifele1, H. Barthel2, K. Marek3,4, C. Palleis5,6, S. Katzdobler5, U. Fietzek5, A. Finze1, G. Biechele1, L. Beyer1, F. Eckenweber1, S. Wall1, D. Saur7, M. Schroeter7,8,9, J. Rumpf7, M. Rullmann2, A. Schildan2, M. Patt2, A. Stephens10, J. Classen7, P. Bartenstein1,11, J. Seibyl3,4, J. Levin5,6,11, G. Höglinger6,11,12, O. Sabri2, M. Brendel1; 1Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, GERMANY, 2Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, GERMANY, 3InviCRO, LLC, Boston, MA, UNITED STATES OF AMERICA, 4Molecular Neuroimaging, A Division of inviCRO, New Haven, CT, UNITED STATES OF AMERICA, 5Department of Neurology, University Hospital of Munich, LMU Munich, Munich, GERMANY, 6German Center for Neurodegenerative Diseases (DZNE), Bonn, GERMANY, 7Department of Neurology, University Hospital Leipzig, Leipzig, GERMANY, 8Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, GERMANY, 9LIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, GERMANY, 10Life Molecular Imaging GmbH, Berlin, GERMANY, 11Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, 12Department of Neurology, Medizinische Hochschule Hannover, Hannover, GERMANY.

OP-0590Interplay of tau and functional network connectivity in progressive supranuclear palsy: A [18F]PI-2620 PET/MRI studyG. Aghakhanyan1,2, M. Rullmann1, J. Rumpf3, M. L. Schroeter4, C. Scherlach5, M. Patt1, M. Brendel6, J. Classen3, K. T. Hoffmann7, O. Sabri1, H. Barthel1; 1Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, 2Regional Center of Nuclear Medicine, University Hospital of Pisa and Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, ITALY, 3Department of Neurology, University of

Leipzig, Leipzig, GERMANY, 4Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, GERMANY, 5Department of Neuroradiology, University of Leipzig, Leipzig, GERMANY, 6Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, GERMANY, 7Department of Neuroradiolgy, University of Leipzig, Leipzig, GERMANY.

OP-0591[18F]FDG PET/CT assessed by supervised machine learning classify Parkinson’s and Atypical Parkinsonian DisordersG. Aghakhanyan1, G. Puccini2, D. Frosini3, M. Allocca4, E. Esposito1, A. Leo1, D. Genovesi5, P. A. Erba1, A. Giorgetti5, R. Ceravolo3, V. Berti4, D. Volterrani1, AIMN Neurology Study Group; 1Nuclear Medicine Unit, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, ITALY, 2Department of Nuclear Medicine, Hospital of Prato, Prato, ITALY, 3Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ITALY, 4Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, ITALY, 5Division of Nuclear Medicine, Fondazione CNR/Regione Toscana, Pisa, ITALY.

OP-0592Different metabolism characteristics of 18F-FDG PET/CT imaging associated with non-motor symptoms in Parkinson’s diseaseM. Xin, X. Yu, C. Zhang, C. Wang, J. Liu; Renji hospital, School of medicine, Shanghai Jiao Tong university, Shanghai, CHINA.

OP-0593Cerebral[18F]FDG PET in the diagnosis of Atypical Parkinson Disease - a retrospective studyN. Houssein1,2, L. Marner1, A. Hejl3; 1Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, DENMARK, 2Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK, 3Department of Neurology, Copenhagen University Hospital Bispebjerg, Copenhagen, DENMARK.

OP-0594Widespread loss of presynaptic terminal marker SV2A in early Huntington’s diseaseA. Delva1,2, L. Michiels1,2, M. Koole2, K. Van Laere1,2, W. Vandenberghe1,2; 1UZ Leuven, Leuven, BELGIUM, 2KU Leuven, Leuven, BELGIUM.



121120

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1201


CME 8: Pregnancy and Breastfeeding in the Context of Nuclear Medicine

OP-0597Status of Guidelines on BreastfeedingS. Leide-Svegborn; Radiation Physics, Skåne University Hospital Malmö and Medical Radiation Physics Malmö, Lund University, Malmö, SWEDEN.

OP-0598The Pregnant Patient - Risks for the FoetusF. Jamar; Cliniques universitaires St-Luc, Nuclear Medicine, Brussels, BELGIUM.

OP-0599How to Estimate the Radiation Doses?M. Cremonesi; European Institute of Oncology, Radiation Research Unit, Milan, ITALY.

1202-1


Interview with the Expert 7 - The Theranostic Unit

OP-0601Interview - The Theranostic UnitA. Iagaru; Stanford University, Stanford Hospital and Clinics, Radiology / Nuclear Medicine and Molecular Imaging, Stanford, UNITED STATES OF AMERICA.

OP-0602Interview - The Theranostic UnitC. Mari Aparici; Stanford University, Nuclear Medicine and Molecular Imaging, Stanford, UNITED STATES OF AMERICA.

1204


Technologists - TROP Session: Sharing Technologist’s Experience 1

OP-0603Feasibility of dose reduction in [18F]-FE-PE2I PET in DAT imagingT. Lehnskov, D. Riisberg, L. Marner, M. Lonsdale; Bispebjerg/Frederiksberg Hospitall, Copenhagen, DENMARK.

OP-0604Development of a brain perfusion SPECT attenuation correction method using synthetic CT images generated by MR images with a deep convolutional neural networkY. Morisawa1, Y. Uchiyama2, A. Takaki3, S. Ito2; 1Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, 2Faculty of Life Sciences, Kumamoto University, Kumamoto, JAPAN, 3Department of Radiological Technology, Faculty of Fukuoka Medical Technology, Teikyo University, Fukuoka, JAPAN.

OP-0605Comparative study of Dopamine transporter Imaging between a conventional camera and an innovative 3D-ring hybrid gamma-camera: technologist’s point of viewJ. Dessoubrais, P. Oudot, F. Clouse, M. Bailly; Regional Hospital Center of Orleans, Orléans, FRANCE.

OP-0606Bayesian penalized-likelihood reconstruction algorithm in the advanced digital PET/CT system for 18F DOPA PET/CT in patients with Parkinson’s disease and Glioblastoma MultiformeR. Alhemaidani, M. AL-Daas, A. Esmail, F. Marafi; Jaber Alahmad Center for Molecular Imaging, Kuwait, KUWAIT.

OP-0607Development of the ascending aorta region of interest setting program using deep neural networks for 99mTc-ECD regional cerebral blood flow quantificationT. Sakata1, Y. Uchiyama2, A. Takaki3, S. Ito2; 1Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, 2Faculty of Life Science, Kumamoto University, Kumamoto, JAPAN, 3Department of Radiological Technology, Faculty of Fukuoka Medical Technology, Teikyou University, Fukuoka, JAPAN.

OP-0608Eating should be avoided during the administration and early biodistribution of PSMA-directed radioligand therapyN. Bruin, V. Mohan, J. van de Kamer, J. Sonke, W. Vogel; The Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-0609Validation process of a new radiolabeled tracers preparation : 177Lu-PSMA-1P. Orhon1, M. Piquemal1, P. Bedouch2, J. Vuillez3, L. Djaileb3, M. Desruet1, J. Leenhardt1; 1Radiopharmacy, Grenoble Alpes University Hospital, Grenoble, FRANCE, 2Pharmacy department, Grenoble Alpes University Hospital, Grenoble, FRANCE, 3Nuclear Medicine, Grenoble Alpes University Hospital, Grenoble, FRANCE.

OP-0610Image quality assessment in two different SPECT scanners: study with a phantomL. Vieira1,2, E. Pereira3, A. Geão4, L. Freire5; 1Health & Technology Research Center, ESTeSL - Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, PORTUGAL, 2Centro de Investigação em Modelação e Optimização de Sistemas Multifuncionais, Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, 3NuclearMed, Hospital Particular de Almada, Almada, PORTUGAL, 4Serviço de Medicina Nuclear, Hospital CUF Descobertas, Lisbon, PORTUGAL, 5Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.

OP-0611Basic study on imaging acquisition conditions for somatostatin receptor scintigraphy with phantomM. Nishio1, N. Fujita2, H. Ikeda1, Y. Ochi1, S. Abe2, K. Kato1; 1Nagoya University, Nagoya, JAPAN, 2Nagoya University Hospital, Nagoya, JAPAN.

OP-0612Gallium-68 cyclotron production from liquid target: Experiences and challenges in the integration into routine production of 68Ga-labelled radiotracersA. Uhlending, J. Wegener, T. Ortgies, G. Höger, H. März, W. Burchert, V. Hugenberg; Institut für Nuklearmedizin, Radiologie und Molekulare Bildgebung, Bad Oeynhausen, GERMANY.

1205


Joint Symposium 15 (EANM/EHA): Imaging Challenges in Multiple Myeloma - Quo Vadis 2021?

OP-0614Therapy Assessment with FDGF. Kraeber-Bodéré; University Hospital of Nantes, Nuclear Medicine Department, Nantes, FRANCE.

OP-0615WB-MRI - My Favourite!F. Lecouvet; Clinique Universitaires Saint-Luc UCL Brussels, Department of Radiology, Louvain, BELGIUM.

OP-0616Update in Non FDG C. Lapa; University Hospital Augsburg Department of Nuclear Medicine, Augsburg, GERMANY.

1206


Joint Symposium 16 (EANM/ESMO): Combination Treatments - What can Radioligand Therapy be Combined with?

OP-0618Combination Treatment in Prostate CancerU. Vogl; Oncology Institute of Southern Switzerland, Ospedale Regionale die Bellinzona e Valli, Bellinzona, SWITZERLAND.

OP-0619Combination Treatment in NETsM. Pavel; Universitätsklinikum Erlangen, Department of Internal Medicine 1, Erlangen, GERMANY.

OP-0620Preclinical Considerations for Combination TreatmentJ. Czernin; University of California Los Angeles, Molecular and Medical Pharmacology, Los Angeles, UNITED STATES OF AMERICA.



123122

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1207


Teaching Session 2: All About Cardiac SPECT

OP-0622SPECT-MPIF. Caobelli; Universitätsspital Basel, Klinik für Nuklearmedizin, Basel, SWITZERLAND.

OP-0623Cardiac Bone ScansO. Lairez; University. hospital of Toulouse, Department of Nuclear Medicine and Cardiac Imaging Center, Toulouse, FRANCE.

OP-0624WBC-SPECTK. Benali; APHP, Department of Nuclear Medicine, Paris, FRANCE.

OP-0625ERNAS. Massalha; Rambam HealthCare Campus, Haifa, ISRAEL.

1208


M2M Track - TROP Session: Radiochemistry - Cook it or Leave it

OP-0627Toward a reproductive radiolabeling with {Al18F}2+ complex?S. Schmitt, E. Moreau; UMR INSER/UCA 1240 IMOST, Clermont-Ferrand, FRANCE.

OP-0628Fully Automated Radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for Clinical PET Imaging of PD-L1C. Wichmann1,2,3, S. Poniger3, N. Guo1, P. Roselt4, S. Rudd5, P. S. Donnelly5, F. Hegi-Johnson4, M. MacManus4, A. M. Scott1,2,3; 1Olivia Newton-John Cancer Research Institute, Heidelberg, AUSTRALIA, 2La Trobe University, Bundoora, AUSTRALIA, 3Austin Health, Heidelberg, AUSTRALIA, 4Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 5The University of Melbourne, Parkville, AUSTRALIA.

OP-0629Optimization and automation of radiolabeling FAPI-74 using [18F]AlF chemistryM. Laube, J. Pietzsch, T. Kniess, K. Kopka, O. Neels; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY.

OP-0630An efficient route to obtain (radio)fluorinated or (radio)iodinated 1,2,3,4-tetrahydro-7-hydroxyisoquinoline-3-carboxylic acid (TIC(OH)) analogues as potential radiotracers for imaging of solid tumoursA. Maisonial Besset1, M. Chao1, A. Serre1, E. Debiton1, D. Canitrot1, T. Witkowski1, F. Degoul1, S. Tarrit1, B. Wenzel2, E. Miot-Noirault1, J. M. Chezal1; 1UMR1240 IMoST INSERM Clermont Auvergne University, Clermont-Ferrand, FRANCE, 2Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Leipzig, GERMANY.

OP-0631Synthesis and characterisation of the corresponding Cu, In and Lu complexes of a cyclen based chelator with four methylimidazole armsI. Hierlmeier, P. Pfeiffer, T. Stemler, S. Maus, S. Ezziddin, M. Bartholomä; Saarland University Medical Centre, Homburg, GERMANY.

OP-0632Preclinical proof of concept study towards modifiable

225Ac-chelators for mild condition labeling and PSMA-targetingF. Reissig1, D. Bauer1, K. Zarschler1, Z. Novy2, K. Bendova2, M. Ludik1, K. Kopka1, H. Pietzsch1, M. Petrik2, C. Mamat1; 1Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY, 2Palacky University Olomouc, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Olomouc, CZECH REPUBLIC.

OP-0633Radiosynthesis of [11C]Flumazenil and [11C]Deprenyl using a fully automated iMiDEV microfluidic radiosynthesizerH. Mallapura Chandrashekara1, L. Tanguy2, B. Långström3, L. Le Meunier2, C. Halldin1, S. Nag1; 1Karolinska Institutet, Stockholm, SWEDEN, 2PMB Alcen, Peynier, FRANCE, 3Uppsala University, Uppsala, SWEDEN.

OP-0634Development of in-House Synthesis and Quality Control of [99mTc]Tc-PSMA-I&SE. Plhak1,2, C. Pichler2, E. Gößnitzer2, R. M. Aigner1, H. Kvaternik1; 1Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA, 2University of Graz, Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, Graz, AUSTRIA.

OP-0635Patient Dose Formulation of 90Y-CHX-A”-DTPA-Rituximab Using Indigenously sourced 90Y-Acetate sourced from Nuclear Reprocessing WasteA. Mitra1, A. Chakraborty2,3, S. Sahu2, M. Tawate2, S. Lad2, S. Gaikwad2,3, T. Upadhye2, S. Menon3,4, M. Ray2, A. Damle2, S. Kulkarni2,3, S. Banerjee3,5; 1MCF, RMC, BRIT, Parel, Mumbai, INDIA, 2RMC, BARC, Parel, Mumbai, INDIA, 3HBNI, Mumbai, INDIA, 4HPD, BARC, Trombay, Mumbai, INDIA, 5ACTREC, TMC, Navi Mumbai, INDIA.

OP-0636Crown, a macrocyclic chelator for Lu-177, Bi-213, and Ac-225H. Yang1, L. Wharton2, C. Zhang3, F. Bénard3, V. Radchenko1, P. Schaffer1; 1TRIUMF, Vancouver, BC, CANADA, 2University of British Columbia, Vancouver, BC, CANADA, 3BC Cancer Research Centre, Vancouver, BC, CANADA.

OP-0637Impact of DOTA position on biodistribution of 177Lu-labelled ABD-fused affibody moleculesY. Liu1, A. Vorobyeva1,2, T. Xu1, A. Orlova1,2, A. Loftenius3, J. Feldwisch3, P. Jonasson3, F. Frejd3,1, V. Tolmachev1,2; 1Uppsala University, Uppsala, SWEDEN, 2National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 3Affibody AB, Solna, SWEDEN.

1209


Cutting Edge Science Track - TROP Session: Imaging of Non-Standard Radionuclides

OP-0640The Impact of Different 99mTc Activities on Dual Isotope Imaging for 166Holmium Scout Radioembolization ProcedureM. Stella, A. Braat, M. Lam, H. de Jong, R. van Rooij; University Medical Center, Utrecht, NETHERLANDS.

OP-0641Dicentric trial with iodine-124 PET dosimetry to optimize therapy of metastatic thyroid cancer: PET scanner’s SUV verification used to check accuracy of activimetersC. Chiesa1, F. Severi2, W. Jentzen3, S. Mazzaglia1, S. Ferretti2, G. Gorgoni4, E. Cazzola4, A. Alessi1, M. Salgarello5, E. Seregni1, M. Maccauro1; 1Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY, 2Medical Physics, Hospital IRCCS Sacro Cuore Don Calabria, Negrar, ITALY, 3Nuclear Medicine, University Hospital, Essen, GERMANY, 4Radiopharmacy & Cyclotron, Hospital IRCCS Sacro Cuore Don Calabria, Negrar, ITALY, 5Nuclear Medine, Hospital IRCCS Sacro Cuore Don Calabria, Negrar, ITALY.

OP-0642Imaging Properties and Quantification Accuracy of 68Ga and 124I in a New Generation Preclinical PET/CT System: A Phantom StudyA. Moraitis1, W. Jentzen1, P. Mollet2, S. L. Kazek1, J. M. Klose1, W. P. Fendler1, P. Fragoso Costa1; 1Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY, 2MOLECUBES NV, Ghent, BELGIUM.

OP-064390Y quantification using PMT- and SiPM-based PET systems: A phantom studyP. Fragoso Costa1, W. Jentzen1, D. Jeromin1, W. P. Fendler1, C. Rischpler1, K. Herrmann1, M. Conti2, M. Manuel1, D. Kersting1; 1Clinic for Nuclear Medicine, Essen, GERMANY, 22Siemens Medical Solutions, Knoxville, TN, UNITED STATES OF AMERICA.

OP-0644Phantom study of the effect of varying acquisition duration on optimisation of Bayesian penalized likelihood reconstruction for Zirconium-89 PET/CTL. Bonney1, M. D. Walker1, D. R. McGowan1,2; 1Oxford University Hospitals NHS Foundation Trust, Oxford, UNITED KINGDOM, 2Oxford University, Oxford, UNITED KINGDOM.



125124

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0645Use of [89Zr]Zr-Df-IAB22M2C CD8 PET for Directing Solid Tumor Biopsies to Assess the Immune Status Within the Tumor Microenviroment (TME)D. Hays1, E. St. Amour1, C. Randall1, I. Wilson2, W. Le2, R. Korn3; 1CARTI Cancer Center, Little Rock, AR, UNITED STATES OF AMERICA, 2ImaginAb, Inc., Inglewood, CA, UNITED STATES OF AMERICA, 3Imaging Endpoints, Scottsdale, AZ, UNITED STATES OF AMERICA.

OP-0646Modelling Aspects for Quantitative Monte Carlo-based SPECT Reconstruction of Radium-223J. Gustafsson1, P. Mínguez2,3; 1Department of Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, SWEDEN, 2Department of Medical Physics and Radiation Protection, Gurutzeta/Cruces University Hospital/Biocruces Health Research Institute, Barakaldo, SPAIN, 3Faculty of Engineering, Department of Applied Physics, UPV/EHU, Bilbao, SPAIN.

OP-0647I-131 Quantitative SUV-SPECT/CT Standardisation and ValidationT. Alkahtani1,2,3, V. Lewington1,2, L. Livieratos1,2; 1King’s College London, London, UNITED KINGDOM, 2Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London, UNITED KINGDOM, 3Princess Nourah bint Abdulrahman University, Riyadh, SAUDI ARABIA.

OP-0648Sequential vs simultaneous acquisition of 81mKr-99mTc V/Q SPECT - Influence in pulmonary embolism quantificationH. Fernando1,2, C. Sibley- Allen2, L. Livieratos1,2, C. Fowler1,2; 1King’s College London, London, UNITED KINGDOM, 2Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London, UNITED KINGDOM.

OP-0649Influence of V/Q SPECT reconstruction parameters on pulmonary embolism quantificationH. Fernando1,2, S. Allen1,2, C. Fowler1,2, L. Livieratos1,2; 1King’s College London, London, UNITED KINGDOM, 2Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London, UNITED KINGDOM.

OP-0650Ex vivo tissue analysis for translation of targeted image-guided surgery solutionsT. Buckle1, H. de Vries2, M. van Oosterom1, D. van Willigen1, M. van Alphen2, P. van Leeuwen2, O. Brouwer2, B. Karakullukcu2, H. van der Poel2, F. van Leeuwen1; 1LUMC, Leiden, NETHERLANDS, 2Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

1210


Clinical Oncology Track - TROP Session: Prostate Varia and Others

OP-0652Combining Diffusion Weighted MRI and 68Ga-PSMA PET/CT and using SUVmax/ADC ratio as a biomarker for diagnosis of biopsy naïve prostate cancerP. Chandra1, S. Chinnappan2, A. Sharma1, G. Chandran1, J. Kumar1, S. Nath1; 1MIOT international, Chennai, INDIA, 2Dept. of Radiodiagnosis, SRIHER, Chennai, INDIA.

OP-065368Ga-PSMA-11 PET/CT volumetric parameters as prognostic biomarkers in metastatic castration-resistant prostate cancer patients treated with cabazitaxelQ. A. Shagera, C. Artigas, T. Gil, P. Flamen; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BELGIUM.

OP-0654Japanese multicenter cohort study in patients with prostate cancer with bone metastasis using bone scan index: hormonal therapy and chemotherapyK. Nakajima1, A. Mizokami1, H. Matsuyama2, T. Ichikawa3, G. Kaneko4, S. Takahashi5, H. Shiina6, H. Horikoshi7, K. Hashine8, Y. Sugiyama9, T. Miyao10, M. Kamiyama11, K. Harada12, A. Ito13, PROSTAT-BSI Investigators; 1Kanazawa University, Kanazawa, JAPAN, 2Yamaguchi University, Ube, JAPAN, 3Chiba University, Chiba, JAPAN, 4Saitama Medical University International Medical Center, Saitama, JAPAN, 5Nihon University School of Medicine, Tokyo, JAPAN, 6Shimane University Faculty of Medicine, Shimane, JAPAN, 7Gunma Prefectural Cancer Center, Ota, JAPAN, 8National Hospital Organization Shikoku Cancer Center, Matsuyama, JAPAN, 9Kumamoto University, Kumamoto, JAPAN, 10Gunma University Graduate School of Medicine, Maebashi, JAPAN, 11University of Yamanashi, Yamanashi, JAPAN, 12Kobe University Graduate School of Medicine, Kobe, JAPAN, 13Iwate Medical University, Yahaba, JAPAN.

OP-0655PSMA PET and radiomics for the evaluation of liver metastases in castration-resistant prostate cancer patients: a multicenter retrospective studyS. Mattoni1, F. Formaggio1, G. Bruno2, P. Caroli3, J. Cerci4, M. Eiber5, W. Fendler6, R. Golfieri7, K. Herrmann6, F. Matteucci3, C. Mosconi7, G. Paolani8, M. Santoro8, L. Strigari8, C. Nanni1, P. Castellucci1, S. Fanti1, A. Farolfi1; 1Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 2Fundación Centro Diagnóstico Nuclear (FCDN), Buenos Aires, ARGENTINA, 3Department of Nuclear Medicine, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori “Dino Amadori” (IRST), Meldola, ITALY, 4Department of Nuclear Medicine, Quanta Diagnóstico e Terapia, Curitiba, BRAZIL, 5Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich (TUM), Munich, GERMANY, 6Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY, 7Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Bologna, ITALY, 8Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-0656Sarcopenia represents an independent adverse event in metastatic castration-resistant prostate cancer (mCRPC) patients candidates to Radium-223 therapyF. D’Amico1,2, R. Lai3, M. Donegani1,2, A. Miceli1,2, S. Raffa1,2, C. Campi3, C. Delucchi1,2, D. Schenone3, S. Rebuzzi4,5, G. Fornarini4, M. Piana3, C. Marini1,6, S. Morbelli1,2, G. Sambuceti1,2, M. Bauckneht1,2; 1IRCCS Ospedale Policlinico San Martino, Genova, ITALY, 2Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genova, ITALY, 3Department of Mathematics (DIMA), University of Genoa, Genova, ITALY, 4Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, ITALY, 5Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genova, Genova, ITALY, 6CNR Institute of Molecular Bioimaging and Physiology (IBFM), Segrate, ITALY.

OP-0657Clinical Utility of Molecular Imaging in Neuroendocrine Prostate Cancer: Comparison of 18F-FDG, DOTATOC and PSMA PET/CTJ. Vargas Ahumada, O. Garcia Pérez, S. Medina Ornelas, Q. Pitalúa Cortés, E. Gomez Argumosa, E. Ignacio Álvarez, I. Soldevilla Gallardo, A. Scabuzzo, M. Jimenez Rios, L. Vargas Ahumada; Instituto Nacional de Cancerologia, Mexico city, MEXICO.

OP-0658The Impact of PSMA Peptide Amount and Tumor Volume on Tumor Uptake on 68Ga-PSMA PET/CT in Primary Prostate Cancer PatientsH. Siebinga1,2, J. olde Heuvel1, E. J. Rijkhorst3, J. J. Hendrikx1,2, B. J. de Wit-van der Veen1; 1Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 2Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 3Department of Medical Physics and Technology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-0659Contribution of Ga-68 DOTA-FAPI-4 PET / CT to Tumor Imaging; First Results in 20 Different Types of CancerN. Ergul1, B. Yılmaz1, G. Olguner Mercanoğlu2, T. F. Çermik1; 1Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TURKEY, 2University of Health Sciences, Faculty of Pharmacy, Istanbul, TURKEY.

OP-0660Utility Of 18F-FDG PET / CT In The Staging And Restaging Of Thymic Epithelial TumorsA. Laverde Mächler, M. Domínguez Grande, H. Torres, D. Lisei, B. Fernández Llana, C. Vigil Díaz, J. Suárez Fernández, J. Maraña González, A. Álvarez, L. Rodríguez Díaz, N. Martín Fernández, F. González García; HUCA, Oviedo, SPAIN.

OP-0661Usefulness of 18F-FDG PET/CT in patients affected by locally advanced cutaneous squamous-cell carcinoma submitted to anti PD-1 immunotherapy with cemiplimabL. Filippi1, I. Proietti2, R. Pirisino1, C. Potenza2, O. Bagni1; 1Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, ITALY, 2Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit “Daniele Innocenzi”, Sapienza University of Rome, Rome, ITALY.

OP-0662Prognostic Value of Volumetric-Metabolic Parameters Obtained in F18-FDG PET/CT Imaging for the Short-term Follow-up of Patients with Advanced Bladder CancerT. Bahceci, E. Şahin Kütük, N. Talay, E. Özdemir; Ankara City Hospital, Ankara, TURKEY.

OP-0663Comparison 2- [18F] FDG and [68Ga] Ga-DOTA-NOC PET / CT in re-staging of patients with EsthesioneuroblastomaL. Torres1, F. O. García Perez2, E. Ignacio Álvarez2, F. A. Sinisterra Solís2, D. A. Arguelles Pérez2; 1Autonomous University of Bucaramanga, Bucaramanga, Santander, COLOMBIA, 2The National Cancer Institute (INCan), Mexico City, MEXICO.



127126

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1211


Featured Session: Amino Acid Imaging of Gliomas

INVILAA Imaging of Gliomas - Moving the FrontiersI. Law; Copenhagen University Hospital, Dep. of Clinical Physiology, Copenhagen, DENMARK

OP-0665Impact of Point-Spread Function Reconstruction on Dynamic and Static FDOPA PET/CT Quantitative Parameters in GliomaA. Girard1, F. Madani2, N. Chaboub2, P. Le Reste3, A. Devillers1, H. Saint-Jalmes4, F. Le Jeune1, X. Palard-Novello1; 1Centre Eugène Marquis, Rennes, FRANCE, 2Université Rennes 1, Rennes, FRANCE, 3University Hospital of Rennes, Rennes, FRANCE, 4LTSI - Rennes 1 University, Rennes, FRANCE.

OP-0666Dynamic 18F-FDopa PET imaging for gliomas: is a semi-quantitative model sufficient?T. Zaragori1,2, M. Doyen1,2, F. Rech3,4, M. Blonski5,4, L. Taillandier5,4, L. Imbert1,2, A. Verger1,2; 1Université de Lorraine, IADI, INSERM, UMR 1254, Vandoeuvre-lès-Nancy, FRANCE, 2CHRU-Nancy, Université de Lorraine, Department of Nuclear Medicine & Nancyclotep Imaging platform, Nancy, FRANCE, 3CHRU-Nancy, Université de Lorraine, Department of Neurosurgery, Vandoeuvre-lès-Nancy, FRANCE, 4Université de Lorraine, Centre de Recherche en Automatique de Nancy CRAN, CNRS UMR 7039, Nancy, FRANCE, 5CHRU-Nancy, Université de Lorraine, Department of Neuro-oncology, Nancy, FRANCE.

OP-066711C-methionine PET for the preoperative assessment of molecular subtype and prognosis in patients with grade II/III gliomas: a retrospective studyG. Ninatti1, M. Sollini1, B. Bono1, N. Gozzi2, D. Fedorov1, L. Antunovic2, F. Gelardi1, F. Pessina1, A. Chiti1; 1Humanitas University, Pieve Emanuele (MI), ITALY, 2Humanitas Research Hospital, Rozzano (MI), ITALY.

OP-066818F-FET PET diagnostic and prognostic value in pre-treated glioma patients presenting with equivocal MRI findings for glioma recurrenceM. Celli, P. Caroli, L. Fantini, V. Rossetti, I. Marini, G. Paganelli, F. Matteucci; Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST IRCCS, Meldola, ITALY.

OP-0669Voxel-wise Correlation of Amino Acid and TSPO PET with Relative Contrast Enhancement in T1-Weighted MRI in GliomasL. Kaiser1, A. Holzgreve1, M. Unterrainer1,2, F. Vettermann1, J. Brosch-Lenz1, A. Gosewisch1, G. Böning1, R. Rupprecht3, J. C. Tonn4, P. Bartenstein1, S. Ziegler1, N. L. Albert1; 1Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, 2Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY, 3Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, GERMANY, 4Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY.

OP-0670Prognostic parameters of post-therapeutic positron emission tomography using amino acids (AA PET) in malignant brain tumoursM. Schürer1, S. Striepe1,2, K. Jähne3, S. Klagges4, C. Scherlach5, P. Kuzman6, M. Patt1, C. Seidel2, O. Sabri1, S. Hesse1; 1Department of Nuclear Medicine, University of Leipzig Medical Centre, Leipzig, GERMANY, 2Department of Radiotherapy and Radiooncology, University of Leipzig Medical Centre, Leipzig, GERMANY, 3Department of Neurosurgery, University of Leipzig Medical Centre, Leipzig, GERMANY, 4Clinical Cancer Registry, University of Leipzig Medical Centre, Leipzig, GERMANY, 5Department of Neuroradiology, University of Leipzig Medical Centre, Leipzig, GERMANY, 6Department of Neuropathology, University of Leipzig Medical Centre, Leipzig, GERMANY.

OP-0671Sensitivity of 18F-fluoroethyltyrosine PET in the diagnosis of recurrent high grade gliomaT. Schlürmann, S. Kleiner, W. Weber, I. Yakushev; Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY.

OP-0672The Utility of Dual Time-Point FET-PET/CT in Recurrence Assessment of Glioma PatientsA. Spataro1, R. Laudicella1, A. Vento1, D. Romeo1, S. Russo1, D. Cardile1, G. Giacoppo1, F. La Torre1, B. Pagano1, S. Bisdas2,3, F. Minutoli1, S. Baldari1; 1Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY, 2Department of Neuroradiology, University College London Hospitals NHS Trust, London, UNITED KINGDOM, 3Department of Brain Repair and Rehabilitation, University College London, London, UNITED KINGDOM.

OP-0673Diagnostic utility of amino acid PET in the differential diagnosis of recurrent brain metastases and pseudoprogression: a meta-analysisT. Schlürmann1, B. Waschulzik2, W. Weber1, I. Yakushev1; 1Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY, 2Technical University of Munich, School of Medicine, Institute of Medical Informatics, Statistics and Epidemiology, Munich, GERMANY.

OP-0674A prospective, multi-centre trial of FET PET inGlioblastoma patients - the TROG 18.06 FIG StudyA. Scott1,2,3, R. Francis4,5, M. Ebert4,5, H. Gan1,2,3, S. Lee1,3, E. Lau2,3, A. Moore6, A. Grose6, E. Barnes7, B. Moffat3, F. Scott1, L. Adda1, F. Foroudi2,1, R. De Abreu Lourenco8, A. Nowak5,4, D. Bailey9, E. Koh10,11,12; 1Olivia Newton-John Cancer Research Institute and La Trobe University, Melbourne, AUSTRALIA, 2Austin Health, Melbourne, AUSTRALIA, 3University of Melbourne, Melbourne, AUSTRALIA, 4Sir Charles Gairdner Hospital, Perth, AUSTRALIA, 5University of Western Australia, Perth, AUSTRALIA, 6Trans Tasman Radiation Oncology Group (TROG), Newcastle, AUSTRALIA, 7NHMRC Clinical Trials Centre, University of Sydney, Sydney, AUSTRALIA, 8Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, AUSTRALIA, 9Royal North Shore Hospital and University of Sydney, Sydney, AUSTRALIA, 10Liverpool and Macarthur Cancer Therapy Centres, Liverpool, Sydney, AUSTRALIA, 11University of New South Wales, Sydney, AUSTRALIA, 12Collaboration for Cancer Outcomes, Research and Evaluation, Ingham Institute for Applied Medical Research, Liverpool,Sydney, AUSTRALIA.

1301

Friday, October 22, 2021, 09:00 - 10:30Channel 1

CME 9: Back to the Future - New Kit-Based Approaches for Labelling Radiopharmaceuticals (68Ga, Al[18F]F,...)

OP-0677Labelling Cold Kit With 68Ga - The Future is BrightC. Morgat; Centre Hospitalier Universitaire de Bordeaux, Service de Médecine Nucléaire, Groupe Hospitalier Pellegrin, Bordeaux, FRANCE.

OP-0678Al[18F]F - From Modules Toward a Kit-Based Radiofluorination?C. Da Pieve; Institute of Cancer Research, Division of Radiotherapy and Imaging, London, UNITED KINGDOM.

OP-0679Regulatory Aspects of Cold Kit-Based Radiopharmaceuticals in the EUO. Neels; Institute of Radiopharmaceutical Cancer Research Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, GERMANY.

1302-1


Interview with the Expert 8 - Vision Trial

OP-0681Interview - Vision TrialS. Fanti; University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

OP-0682Interview - Vision TrialB. Krause; University Medical Center Rostock, Rostock, GERMANY.

1302-2


Interview with the Expert 9 - The Best Young NM

OP-0683Interview - The Best Young NMS. Fanti; University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

OP-0684Interview - The Best Young NMK. Herrmann; Universitätsklinikum Essen, Nuclear Medicine, Essen, GERMANY.



129128

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1304



OP-0685Reduction of effective dose using single-CT for attenuation correction in myocardial perfusion imagingC. Bruneby1, C. Hasselbring1, M. Simonsson1, M. Toth Cervin1, R. Madru2; 1Centralsjukhuset Kristianstad, Kristianstad, SWEDEN, 2Skane University Hospital, Lund, SWEDEN.

OP-0686Cardiac scintigraphy examination for high BMI patients using 3D-ring CZT SPECT/CTP. Oudot, J. Dessoubrais, F. Clouse, M. Bailly; Centre Hospitalier Regional d’Orléans, Orleans, FRANCE.

OP-0687Intra- and interobserver variability in LVEF measurements by Multi-Gated Nuclear Ventriculography using semi-automatic and manual postprocessingL. Plet1, T. Q. Christensen2, S. Hess1,3, M. W. Kusk1; 1Department of Radiology and Nuclear Medicine. Hospital South West Jutland, Esbjerg, DENMARK, 2Department of Clinical Engineering, Region of Southern Denmark, Esbjerg, DENMARK, 3Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, DENMARK.

OP-0688Could the quality and the quantitative amount of 99mTc-albumin colloidal particles injected could affect the lymph node detection failure in breast cancer patients?M. Marazzini, C. Cidda, T. Graziani, S. Migliari, A. Sammartano, C. Lazzara, L. Ruffini; Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY.

OP-0689Glomerular filtration rate in terms of Tc-99m-DTPA clearance: Injection and blood sampling by portC. Holm Led1, L. J. Jeppesen1, J. A. Simonsen1, T. L. Andersen1,2, L. B. Petersen1, S. Hvidsten1; 1Department of Nuclear Medicine, Odense, DENMARK, 2Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen, DENMARK.

OP-0690Comparison of low pulmonary perfusion index using 99mTc-MAA SPECT images and hemodynamic indices in chronic thromboembolic pulmonary hypertensionY. Ochi, Y. Tsutsumi, N. Fujita, H. Ikeda, M. Nishio, Y. Asano, S. Abe, K. Kato; Aichi, Nagoya, JAPAN.

OP-0691Comparison Between Different Acquisition Times And Different Reference Tissues In The Interpretation Of The Scintigraphy With 99MTC-HMPAO-Leucocytes In Muscle-Skeleton InfectionsR. Rinaldi, D. Albano, F. Dondi; Nuclear Medicine dpt - ASST Spedali Civili, Brescia, ITALY.

OP-0692A Phantom Study on Compton Scatter Correction Methods in 99mTc ImagingM. Can1, Ö. Karadeniz2,1, T. Ertay3,1, G. Çapa Kaya3,1; 1Department of Medical Physics, Institute of Health Sciences, Dokuz Eylül University, Izmir, TURKEY, 2Department of Physics, Faculty of Sciences, Dokuz Eylül University, Izmir, TURKEY, 3Department of Nuclear Medicine, Faculty of Medicine, Dokuz Eylül University, Izmir, TURKEY.

OP-0693First clinical experiences with a new long axial field-of-view PET/CT: the technologist’s point-of-viewR. Schepers, I. Alberts, A. Afshar-Oromieh, M. Viscione, A. Rominger; Inselspital, Bern, SWITZERLAND.

OP-0694Learning from our mistakes: a teaching tool to improve the quality of Nuclear Medicine Technologist’s practicesE. Lemos Pereira, A. Garcia, A. Malaia, M. Fateixa; NuclearMed - Hospital Particular Almada, Almada, PORTUGAL.

1305


Joint Symposium 17 (EANM/EAU): What to Do and Not Do in Prostate Imaging

OP-0696What does Urology want to know from NM? T. Maurer ; University of Hamburg-Eppendorf (UKE), Hamburg, GERMANY.

OP-06979 years of PSMA - Where do we have Evidence for Being Helpful?H. Zacho; University Hospital, Department of Nuclear Medicine, Aalborg, DENMARK.

OP-06989 years of PSMA - Where do we have Evidence for not Being Helpful (yet)?A. Afshar-Oromieh; University Hospital Insel-Spital, Department of Nuclear Medicine, Bern, SWITZERLAND.

OP-0699Prostate Cancer Imaging - Others than PSMA LigandsL. Evangelista; University of Padova, Department of Medicine (DIMED), Padua, ITALY.

1306


Joint Symposium 18 (EANM/EAU): Urological Challenges for Imaging Beyond Prostate

OP-0701The Needs of Urologists and Oncologists in Urological Disease Beyond Prostate CancerJ. Walz; Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, FRANCE.

OP-0702The Role of PET Imaging in Bladder CancerA. Capozza; ASST Santi Paolo e Carlo, Department of Nuclear Medicine, Milan, ITALY.

OP-0703PET Imaging with Diverse Radiopharmaceuticals in Renal CancerL. Evangelista; University of Padova, Department of Medicine (DIMED), Padua, ITALY.

OP-0704The Role of PET Imaging in the Management of Testicular CancerY. Loriot; Gustave Roussy Institute, Oncology Department, Villejuif, FRANCE.

1307


Teaching Session 3: Radiobiology as a Missing Link in Improving and Understanding Nuclear Medicine

OP-0706Radiobiology in Nuclear MedicineS. Terry; King’s College London, School of Biomedical Engineering & Imaging Sciences, London, UNITED KINGDOM.

OP-0707Why We Cannot Rely on EBRT RadiobiologyM. Konijnenberg; Radiologie & Nucleaire Geneeskunde, Klinische Fysica, Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-0708Need for Radiobiology in Preclinical ResearchK. Lückerath; University Hospital Essen, Clinic for Nuclear Medicine, Essen, GERMANY.

OP-0709Need for Radiobiology in the ClinicR. Hustinx; Centre hospitalier Universitaire de Liège, Liege, BELGIUM.

1308


M2M Track - TROP Session: Out of the Box Innovations

OP-0711The Imageable GenomeP. Jané1, V. Taelman2, E. Jané3, O. Bejuy2, M. Gómez Martínez4, R. A. Dumont5, M. A. Walter1; 1Hôpitaux Universitaires de Genève, Geneva, SWITZERLAND, 2Centre d’imagerie biomédicale (CIBM), Geneva, SWITZERLAND, 3Universidad Politécnica de Madrid, Madrid, SPAIN, 4Hospital Universitario Ramón y Cajal, Madrid, SPAIN, 5Université de Genève, Geneva, SWITZERLAND.

OP-0712Optimizing a PET nanoradiotracer to overcome tumor heterogeneityB. Louis, L. Balasse, L. Sakiroff, J. Ou, V. Nail, O. Nachar, A. Moyon, A. Bouhlel, T. Roussel, F. Dignat-George, L. Peng, P. Garrigue, B. Guillet; Aix-Marseille Université, Marseille, FRANCE.



131130

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0713Pharmacokinetic studies and modeling to efficiently predict nanoradiotracer PET biodistributionJ. Ou, B. Louis, L. Sakiroff, V. Nail, L. Balasse, A. Bouhlel, O. Nachar, A. Moyon, T. Roussel, F. Dignat-George, L. Peng, B. Guillet, P. Garrigue, F. Gattacceca; Aix-Marseille University, Marseille, FRANCE.

OP-0714The evaluation of [18F]FDG and [18F]FLT radiotracers as potential biomarkers of early treatment outcome in triple negative breast cancer (TNBC)P. Rainone1,2, S. Valtorta1,3,2, S. Todde1,3, D. Salvatore1,2, R. Moresco1,3,2; 1Department of Medicine and Surgery and Tecnomed Foundation, University of Milano – Bicocca, Monza, ITALY, 2Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Segrate, ITALY.

OP-0715Copper-64 as a translational tool for evaluating pharmacodynamics and efficacy of a new gene therapy treatment in a preclinical mouse model of Wilson’s diseaseM. Collantes1,2, M. Ecay3, G. Quincoces4,2, D. Moreno5, O. Murillo5, V. Ferrer6, B. Bénichou6, G. González-Aseguinolaza7, I. Peñuelas1,3,4; 1Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN, 2Navarra Institute for Health Research (IdisNA), Pamplona, SPAIN, 3Translational Molecular Imaging Unit (UNIMTRA), University of Navarra, Pamplona, SPAIN, 4Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN, 5Gene Therapy and Regulation of Gene Expression, CIMA, Pamplona, SPAIN, 6Vivet Therapeutics SAS, Paris, FRANCE, 7Vivet Therapeutics SL, Pamplona, SPAIN.

OP-0716Defining a clinical imaging protocol for platinum-195m SPECT/CTJ. R. Hendriksen, D. M. Huizing, B. J. de Wit-van der Veen, W. V. Vogel, E. A. Aalbersberg; Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-0717Solid Targets Made Simple: Making >25 GBq of [68Ga]Ga-PSMA-11 in 60 Minutes Including Beam TimeK. Gagnon, J. Svedjehed, M. Pärnaste; GEMS PET Systems, Uppsala, SWEDEN.

OP-0718[68Ga]Ga-THP-Pam: A PET Radiotracer for Imaging Vascular CalcificationG. Keeling1, F. Baark1, O. L. Katsamenis2, A. J. Reader1, G. E. Smith3, S. Y. Terry1, P. J. Blower1, R. T. M. de Rosales1; 1King’s College London, London, UNITED KINGDOM, 2University of Southampton, Southampton, UNITED KINGDOM, 3Theragnostics Ltd, Bracknell, UNITED KINGDOM.

OP-0719Preclinical evaluation of 68Ga-labelled artificial siderophores of the Ferrioxamine typeI. Hubmann1, A. Mular2, E. Gumienna-Kontecka3, M. Misslinger4, J. Pfister1, H. Haas5, M. Petrik6, C. Decristoforo1; 1Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA, 2Faculty of Chemistry, University of Wroclaw, Wroclaw, POLAND, 3Faculty of Chemistry, University of Wroclaw, Wrozlaw, POLAND, 4Division of Molecular Biology, Medical University Innsbruck, Innsbruck, AUSTRIA, 5Division of Molecular Biology, Medizinische Universität Innsbruck, Innsbruck, AUSTRIA, 6IMTM, Faculty of Medicine and Dentistry, Palacky University, Innsbruck, AUSTRIA.

OP-0720New opportunity for imaging in oncology: targeting the neurotensin receptor-2 with JMV7488, a new peptide analogue radiolabelled with gallium-68S. Bodin1,2, S. Previti3, E. Jestin4, D. Vimont1, F. Lamare1,2, I. Ait-Arsa4, S. S. Bertrand1, E. Hindié1,2, F. Cavelier3, C. Morgat1,2; 1Univ. Bordeaux, CNRS, INCIA, UMR5287, F-33000 Bordeaux, FRANCE, 2University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 3Univ. Montpellier, CNRS, Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, F-34000 Montpellier, FRANCE, 4CYclotron Réunion Océan Indien CYROI, 2 rue Maxime Rivière, F-97490 Sainte-Clotilde, FRANCE.

1309


Cutting Edge Science Track - Featured Session: Harmonisation and Standardisation

OP-0722The Importance of Harmonisation and StandardisationÁ. Krizsán; ScanoMed Nuclear Medicine Centers, Translational Imaging Laboratory, Budapest, HUNGARY.

OP-0723The Canadian PET Phantom for Prostate Oncology (C3PO) - A Multimodality Imaging Phantom for 18F-PSMA HarmonizationR. Fedrigo1,2, R. Coope3, A. Rahmim1,2,4, F. Bénard1,2,4, C. Uribe2,4; 1BC Cancer Research Institute, Vancouver, BC, CANADA, 2University of British Columbia, Vancouver, BC, CANADA, 3Genome Science Institute, Vancouver, BC, CANADA, 4BC Cancer, Vancouver, BC, CANADA.

OP-0724Acquisition and reconstruction protocols revisited for F18 PSMA imagingT. Hekimsoy, H. Porger, C. Lohrmann, A. Reinhardt, F. Lahner, C. Meisinger, M. Eiber, W. A. Weber, S. G. Nekolla; TU München, München, GERMANY.

OP-0725Comparison of quantitative measures between EARL1 and EARL2 specifications in PET/CT studies using Gallium-68R. Oliveira1,2,3, F. Oliveira1, C. Constantino1, L. Vieira4, M. Costa1,3, D. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 2Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, 3Mercurius Health, Oeiras, PORTUGAL, 4Health and Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.

OP-0726The Effect of Residual Counts from Medical Materials Used for 18F-FDG Injection on Quantitative Parameters of PET/CT Imaging in Pediatric Oncology PatientsN. Gülaldi, B. Cagdas; Department of Nuclear Medicine, Ministry of Health, Ankara City Hospital, Ankara, TURKEY.

OP-0727Negative-Cast Modelling for Oncology (NCMO) - Development of a Novel Technique for Casting Radioactive Tumour ModelsR. Fedrigo1,2, R. Coope3, I. Bloise1, C. Gowdy4, A. Rahmim1,2,5, C. Uribe2,5; 1BC Cancer Research Institute, Vancouver, BC, CANADA, 2University of British Columbia, Vancouver, BC, CANADA, 3Genome Science Institute, Vancouver, BC, CANADA, 4BC Children’s Hospital, Vancouver, BC, CANADA, 5BC Cancer, Vancouver, BC, CANADA.

OP-0728Development of a patient-specific kidney phantom with inhomogeneous activity distribution using only a single fillable compartmentA. Theisen, M. Lassmann, A. K. Buck, J. Tran-Gia; Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY.

OP-0729Accuracy of thyroid uptake calibration method: a multi-centric study with realistic phantomsT. Beaumont1, F. Bouchet2, D. Broggio1, G. Brouquieres3, B. Farman4, A. Forbes5,6, C. Jaudet7, G. Le Rouzic8, J. Maisonobe9, F. Maurel10, C. Murat11, Y. Petegnief12, B. Piron13, L. Santoro14, B. Serrano15, P. Tylski16, N. Varmenot17, M. Demonchy18; 1IRSN/SDOS/LEDI, Fontenay-Aux-Roses, FRANCE, 2CHU Angers, Angers, FRANCE, 3CHITS-Hôpital Sainte Musse, Toulon, FRANCE, 4CHU La Timone, Marseille, FRANCE, 5AP-HP Hôpital Bicêtre, Le Kremlin-Bicêtre, FRANCE, 6AP-HP Hôpital Antoine Béclère, Clamart, FRANCE, 7Centre François Baclesse, Caen, FRANCE, 8Centre Hospitalier Régional d’Orléans, Orléans, FRANCE, 9Groupe Hospitalier Pité-Salpêtrière, Paris, FRANCE, 10CHU de Nice, Nice, FRANCE, 11Centre Hospitalier d’Avignon, Avignon, FRANCE, 12CHRU Jean MINJOZ, Besancon, FRANCE, 13CHU Nîmes, Nîmes, FRANCE, 14ICM Val d’Aurelle, Montpellier, FRANCE, 15Centre Hospitalier Princesse Grace, Monaco, FRANCE, 16Hospices Civils de Lyon, Bron, FRANCE, 17Institut de cancérologie de l’Ouest R. Gauducheau, Saint-Herblain, FRANCE, 18CHI Fréjus Saint-Raphael, Fréjus, FRANCE.

OP-0730Radioiodine uptake measurement on planar scintigraphic images: an automatic process reducing thyroid volume effectT. Beaumont1, A. Forbes2,3, E. Durand2, A. Castilla-Lièvre3, D. Broggio1; 1IRSN/SDOS/LEDI, Fontenay-Aux-Roses, FRANCE, 2AP-HP Bicêtre Hospital, Le Kremlin-Bicêtre, FRANCE, 3AP-HP Antoine Béclère Hospital, Clamart, FRANCE.

OP-0731Myocardial Perfusion Imaging and Extra-Myocardial Uptake: The Effect of Post-Processing Decisions on Left Ventricular Contraction Quantitative Parameters for a Dedicated Cardiac SPECT CameraJ. Kennedy1, T. Hasdai2, Z. Keidar1; 1Rambam - Health Care Campus, Haifa, ISRAEL, 2B. and R. Rappaport School of Medicine, Technion – Israel Institute of Technology, Haifa, ISRAEL.

OP-0732Towards a comprehensive validation for Monte Carlo SPECT simulationsS. Pells1,2, D. M. Cullen1, A. P. Robinson2,1,3, B. Pietras1, D. Deidda2, A. Fenwick2,4, K. Ferreira2, A. Fish1, D. Hamilton3, W. Heetun2, P. Julyan3, G. Needham1, E. Page3, E. Price1, J. Tipping3; 1The University of Manchester, Manchester, UNITED KINGDOM, 2The National Physical Laboratory, Teddington, UNITED KINGDOM, 3The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, 4Cardiff University, Cardiff, UNITED KINGDOM.



133132

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1310


Clinical Oncology Track - TROP Session: Prostate BC Recurrence

OP-0734Diagnostic Performance and Prognostic Value of Combined 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate CancerP. Mapelli1,2, S. Ghezzo1, E. Preza2, A. Samanes Gajate2, V. Cucchiara1, G. Brembilla1, C. Bezzi1, R. Rigamonti2, P. Magnani2, E. Toninelli2, V. Bettinardi2, A. Savi2, A. Palmisano3, N. Suardi4, L. Gianolli2, P. Scifo2, A. Briganti1,4, A. Esposito1,3, M. Picchio1,2; 1Vita-Salute San Raffaele University, Milan, ITALY, 2Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 4Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP-073568[Ga]PSMA-11 PET/TC in prostate cancer: accurate localization for an accurate treatment managementR. Viglialoro1, L. Marzorati1, A. Marciano1, G. Aghakhanyan1, E. Esposito1, F. Bartoli1, R. Zanca1, M. Sollini2,3, P. A. Erba1,4; 1Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medi, Pisa, ITALY, 2Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medi, Pieve Emanuele, ITALY, 3IRCCS humanitas Research Hospital, Rozzano (Milan), ITALY, 4Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, Groningen, NETHERLANDS.

OP-0736Oncological Outcomes after 68Ga-PSMA-11 PET/CT performed in Hormone-Sensitive Prostate Cancer (HSPC) patients for Biochemical Recurrence and eligible for Salvage TherapyF. Ceci1, G. Rovera1,2, G. C. Iorio3, A. Guarneri3, V. Chiofalo3, R. Passera1, M. Oderda4, S. Dall’Armellina1, A. Giordano2, P. Gontero4, U. Ricardi3, D. Deandreis1; 1Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, ITALY, 2Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, ITALY, 3Radiation Oncology, Department of Oncology, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, 4Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Turin, ITALY.

OP-0737Pattern of failure in patients with biochemical recurrence after PSMA-radioguided surgeryL. Schweiger1, T. Maurer2, R. Simon3, T. Horn3, M. Eiber1, W. Weber1, I. Rauscher1; 1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY, 2Martini-Clinic Prostate Cancer Center at University of Hamburg-Eppendorf (UKE), Hamburg, GERMANY, 3Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY.

OP-0738Head-To-Head Comparison Between wb-MRI And 68Ga-PSMA PET/CT In Restaging Biochemical Recurrent Prostate CancerR. Mei1, M. Moscarino1, A. Farolfi1, P. Castellucci1, L. Calderoni1, F. Mattana1, S. Telo1, F. Serani1, F. Ceci2, S. Fanti1; 1Nuclear Medicine Policlinico S.Orsola-Malpighi IRCCS, Bologna, ITALY, 2IEO European Institute of Oncology IRCCS, Milano, ITALY.

OP-0739Safety of [68Ga]Ga-PSMA-11 prepared with the Sterile Cold Kit used in a pivotal clinical trialL. Ravasi1, S. Chowdhury2, C. Hayward3, D. Kryza4, A. Giraudet4; 1Telix pharmaceuticals, Herstal, BELGIUM, 2Medical Oncology Guy’s Hospital, London, UNITED KINGDOM, 3Telix Pharmaceuticals, Indianapolis, IN, UNITED STATES OF AMERICA, 4Centre Léon Bérard, Lyon, FRANCE.

OP-0740First experiences with late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancerI. Alberts1, G. Prenosil1, C. Mingels1, K. Bohn1, M. Viscione1, H. Sari2, A. Rominger1, A. Afhsar-Oromieh1; 1Institut für Nuklearmedizin, Bern, SWITZERLAND, 2Advanced Clinical Imaging Technology, Lausanne, SWITZERLAND.

OP-0741How to deal with a negative Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA PET/CT) during biochemical recurrence?H. Lanzafame1, F. Serani2, A. Farolfi2, C. Malizia2, S. Fanti2,3, R. Mei4, G. Aluisio5, F. Medici6,7; 1Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY, 2Nuclear Medicine, IRCSS, Azienda Ospedaliero- Universitaria di Bologna, Bologna, ITALY, 3Nucleare Medicine- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 4Nuclear Medicine, IRCSS, Azienda Ospedaliero- Universitaria di Bologna, Bologna, ITALY, 5Radiation Oncology, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, ITALY, 6Department of Experimental, Diagnostic and Specialty Medicine - DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, 7Radiation Oncology IRCSS Azienda Ospedaliero- Universitaria di Bologna, Bologna, ITALY.

OP-0742Potential value of 68Ga-PSMA-11 PET to predict biochemical recurrence in primary prostate cancer after radical prostatectomyH. Wang1, T. Amiel2, T. Langbein1, I. Rauscher1, T. Horn2, M. Heck2, T. Maurer3,4, W. Weber1, M. Eiber1; 1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, GERMANY, 2Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, GERMANY, 3Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY, 4Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY.

OP-0743Therapy impact of 18F-PSMA PET/CT in biochemical recurrence of prostate cancer patients with PSA< 1 ng/ml postprostatectomy and 18F-Choline PET/CT negativeM. Cózar Santiago1, J. García Garzón1, J. Pastor Peiro2, P. Bassa Massanas1, A. Canoves Llombart1, J. Aguilar Barrios1, R. Sanz Llorens1, V. Faus Rodrigo1, M. Soler Lopez1, J. Ferrer Rebolleda1; 1ASCIRES-Nuclear Medicine Department. General Hospital Universitary, Valencia, SPAIN, 2ASCIRES-Radiotherapy Department. General Hospital Universitary, Valencia, SPAIN.

OP-0744Detection rate of 18F-Choline positron emission tomography/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancerP. Artioli1, F. Zattoni2, M. Burei3, A. Chiaravalloti4, D. Donner5, S. Panareo6, L. Evangelista1; 1University of Padova, Padova, ITALY, 2University of Udine, Udine, ITALY, 3IOV, Padova, ITALY, 4University of Rome, Rome, ITALY, 5Hospital of Trento, Trento, ITALY, 6University of Ferrara, Ferrara, ITALY.

OP-0745The detection rate of PSMA-PET is still preserved in a low probability setting of a positive scan in patients with biochemical recurrence: a dual phase protocol with diuretic enhancementA. Miceli1, V. Feudo2, C. Baiocco3, S. Genovese3, P. Scalzi3, A. Trevisan3, G. Sambuceti1, C. Poti3; 1DISSAL, Genoa, ITALY, 2Section of Nuclear Medicine, University Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, Rome, ITALY, 3Unit of Nuclear Medicine, Aosta Regional Hospital, Aosta, ITALY.

1311


Featured Session: Brain Tumor Imaging - More than Amino Acids in Gliomas

OP-0747CXCR4 and SSTR Imaging of Brain TumoursT. Traub-Weidinger; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

OP-0748Quantitative Parameters from 18F-FDG PET/MRI Reveal Intratumoral Heterogeneity in Primer Brain Tumors Confirmed by PathologyK. Seker1, E. Çeltikçi2, U. Aydos1, S. Gülbahar Ateş3, M. A. İnan4, Ü. Ö. Akdemir1, L. Ö. Atay1; 1Gazi University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TURKEY, 2Gazi University Faculty of Medicine, Department of Neurosurgery, Ankara, TURKEY, 3Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Nuclear Medicine, Ankara, TURKEY, 4Gazi University Faculty of Medicine, Department of Medical Pathology, Ankara, TURKEY.

OP-0749Brain metabolic changes in patients with disseminated malignant melanoma receiving immunotherapyM. Sizova1, F. Sampedro2, V. Camacho1, S. Abouzian1, F. Fuentes-Ocampo1, A. Teixido1, A. Fernandez1, D. López-Mora1, J. Duch1, A. Flotats1, M. Estorch1, I. Carrio1; 1Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, SPAIN, 2Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

OP-0751Differential alterations in tumoral and extra-tumoral cerebral blood flow in grades III and IV glioma patients using quantitative [15O]H2O PETA. J. Gonçalves1, M. Alotaibi1, A. R. Carlin1, Y. Chen1, C. Y. Wong1, I. K. Djoukhadar2, G. Krokos3,1, A. Jackson1, D. Coope2, M. C. Asselin1; 1The University of Manchester, Manchester, UNITED KINGDOM, 2Salford Royal NHS Foundation Trust, Manchester, UNITED KINGDOM, 3King’s College London, London, UNITED KINGDOM.



135134

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0752The rise of metabolism: Expression of pentose phosphate pathway enzymes in treatment-naïve gliomasE. Klebermass1,2, A. Woehrer3, G. Ricken3, N. Poetsch1, S. Bucconi1, A. Miller4,5, A. Haschemi4, T. Balber6, M. Hacker1, H. Viernstein2, M. Mitterhauser6, T. Traub-Weidinger1; 1Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, 2Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Vienna, AUSTRIA, 3Institute of Neurology, Medical University of Vienna, Vienna, AUSTRIA, 4Department of Laboratory Medicine, Medical University of Vienna, Vienna, AUSTRIA, 5Department of Neurobiology, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA, 6Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA.

OP-0753Role of 64CuCl2 in the diagnosis and in the dosimetry assessment in paediatric high-grade gliomasF. Fiz1, M. Ugolini2, G. Ferrarazzo3, A. Cistaro2, G. Bottoni2, S. Righi2, M. Massollo2, A. Cirone2, A. Piccardo2; 1Humanitas Clinical and Researhc Center - IRCCS, Milan, ITALY, 2E.O. “Ospedali Galliera”, Genoa, ITALY, 3A.S.L. 3, Genoa, ITALY.

OP-0754Meningiomas as Incidentalomas Visualized on 68Ga-DOTATOC-PET/CTE. Alevroudis1, T. Liotsou2, M. Metaxas2, M. Tsoli3, E. Anagnostou3, G. Kaltsas3, S. N. Chatziioannou1,2; 12nd Department of Radiology, Nuclear Medicine Unit, National and Kapodistrian University of Athens, General University Hospital “Attikon”, Athens, GREECE, 2Nuclear Medicine Division, Biomedical Research Foundation Academy of Athens, Athens, GREECE, 31st Department of Propaedeutic Internal Medicine, Endocrine Unit, National and Kapodistrian University of Athens, Athens, GREECE.

OP-0755Imaging of primary glial tumor using [68Ga]Ga-PSMA-11 PET/CT - preliminary experienceK. Pelka1,2, K. Koczyk3, L. Królicki1, J. Kunikowska1; 1Nuclear Medicine Department, Medical University of Warsaw, Warsaw, POLAND, 2Department of Methodology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, POLAND, 3Department of Neurosurgery, Medical University of Warsaw, Warsaw, POLAND.

OP-0756Role of Gallium 68 PSMA PET CT in evaluating recurrence in previously treated patients with glioma of the brainP. U N, A. R. Bharathi, S. M. Desai, K. Rishi, G. GV, B. Srinath, H. Mohan; Sri Shankara Cancer Hospital and Research Center, Bangalore, INDIA.

OP-0757The Role of 68Ga-PSMA PET/CT Imaging in Intracranial MetastasesE. Arslan1, N. Ergül1, R. Şahin1, Y. Karagöz2, Y. Bozkaya3, T. F. Çermik1; 1Istanbul Training and Research Hospital,Clinic of Nuclear Medicine, Istanbul, TURKEY, 2Istanbul Training and Research Hospital,Department of Radiology, Istanbul, TURKEY, 3Istanbul Training and Research Hospital,Department of Medical Oncology, Istanbul, TURKEY.

1401


CME 10: Radionuclide Therapies - Management of Side Effects and Complications

OP-0760Radioiodine Therapy in Thyroid CancerM. Luster; University Hospital Marburg, Department of Nuclear Medicine, Marburg, GERMANY.

OP-0761Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumoursradiation therapyG. Gnanasegaran; Royal Free London NHS Foundation Trust, Department of Nuclear Medicine, London, UNITED KINGDOM.

OP-0762177Lu and 225Ac PSMA Therapy for Prostate CancerS. Schwarzenböck; Rostock University Medical Center, Department of Nuclear Medicine, Rostock, GERMANY.

1402-1


Interview with the Expert 10 - Running a Preclinical Lab in New York City

OP-0924Interview - Running a Preclinical Lab in New York CityJ. Lewis; Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.

OP-0925Interview - Running a Preclinical Lab in New York CityS. Lyashchenko; Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.

1402-2


Interview with the Expert 11 - New PET Tracers in Oncology

OP-0247Interview - New PET Tracers in Oncology W. Cai; University of Wisconsin-Madison, Department of Radiology and Medical Physics, Madison, UNITED STATES OF AMERICA.

OP-0248Interview - New PET Tracers in Oncology M. Younis; University of Wisconsin-Madison, Department of Radiology and Medical Physics, Madison, UNITED STATES OF AMERICA.

1404



OP-0767Multiple-Time-Point 2-[18F]FDG PET/CT: Adrenal Glands Normal Metabolic Pattern CharacterizationI. Rodrigues1, A. Martins1, S. Carmona2, M. J. Vieira2, L. Oliveira1; 1Grupo Joaquim Chaves Saúde - Lisbon, Portugal/ Portuguese Red Cross Health School - Lisbon, Portugal, Lisbon, PORTUGAL, 2Grupo Joaquim Chaves Saúde - Lisbon, Portugal, Lisbon, PORTUGAL.

OP-0768Feasibility of 3D TOF PET/CT scanning with reduced [18F]-FDG activity obtaining equivalent clinical and semi-quantitative parametersJ. Pilz, L. Hehenwarter, G. Schweighofer-Zwink, G. Rendl, M. Beheshti, C. Pirich; Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA.

OP-0769The effect of patient’s body mass indices on PET/CT images with 68Ga PSMAY. Parlak, D. Goksoy, G. Gumuser, E. Sayit; Celal Bayar University, Manisa, TURKEY.

OP-0770Image quality of 18F-FDG for patients with different body mass indexB. Olsson1, E. Trägårdh1,2, J. Oddstig2,3, S. Leide-Svegborn4; 1Clinical Physiology and Nuclear Medicine, Lund, SWEDEN, 2Wallenberg Center for Molecular Medicine, Lund, SWEDEN, 3Radiation Physics, Lund, SWEDEN, 4Radiation Physics, Malmö, SWEDEN.

OP-0771The influence of metal artifacts on PET dataM. Jensen; Bispebjerg/Frederiksberg Hospital, Copenhagen, DENMARK.

OP-0772Mouse Handling for 18F-FDG PET Imaging: Preparing the Way for a Future GuidelineF. Ribeiro1, A. Santos2, J. Veloso1; 1Institute for Nanostructures, Nanomodelling and Nanofabrication (i3N), Department of Physics, University of Aveiro (DFis-UA), Aveiro, PORTUGAL, 2Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine of the University of Coimbra (FMUC), Area of Environment Genetics and Oncobiology (CIMAGO), Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, PORTUGAL.

OP-0773Improving patient experience during [18F]FDG PET-CT scan using an audiovisual scenarios interventionS. Abouzian, A. Flotats, A. Domènech, M. Sizova, A. Teixidó, F. Fuentes, A. Bagües, R. Berlanga, M. Izquierdo, I. Liarte, R. Ramil, R. Vila, A. Fernández, J. Duch, V. Camacho, D. López-Mora, M. Estorch, I. Carrió; Nuclear Medicine Department. Hospital Santa Creu i Sant Pau, Barcelona, SPAIN.

OP-0775The effect of TOF on image quality and its correlation with patient BMI using 18F NAF PET/CTY. Aldowaisan1, L. Ali2, F. Marafi1; 1Jaber Alahmad Center for Molecular Imaging, Kuwait, KUWAIT, 2Allied health sciences-Kuwait University, Kuwait, KUWAIT.



137136

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1405


Joint Symposium 19 (EANM/EFOMP): Harmonisation and Standardisation

OP-0778The Need for Harmonisation and Standardisation in Nuclear MedicineS. Barrington; King’s College London and Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM.

OP-0779PET Harmonisation Beyond EARLR. Boellaard; VU University Medical Centre, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0780Towards Harmonisation of SPECT/CTS. Peters; Radboud University Medical Centre, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

OP-0781Reproducible Radiomics Through Image Biomarker StandardisationA. Zwanenburg; National Center for Tumor Diseases, Partner site Dresden, Dresden, GERMANY.

1406


Joint Symposium 20 (EANM/AAPM): Artificial Intelligence for Image Processing and Quantification

OP-0783IntroductionM. Hatt; LaTIM, INSERM, UMR 1101, Univ Brest, Brest, FRANCE.

OP-0784Modern A.I. Methods for Image ReconstructionI. Häggström; MSKCC, Physics department, New York, UNITED STATES OF AMERICA.

OP-0785A.I. Algorithms in Detection and Segmentation TasksP.-H. Conze; IMT-Atlantique, Brest, FRANCE.

OP-0786A.I. Applied to Image Triaging and Predictive ModellingA. Gafita; UCLA, Department of molecular and medical pharmacology, Los Angeles, UNITED STATES OF AMERICA.

1407


Teaching Session 4: Immunotherapy - Assessing Organs and Events on [18F]FDG PET/CT

OP-0788Immune Activation on PET - Beneficial or Detrimental?C. Lasnon; François Baclesse Cancer Centre, Nuclear Medicine, Caen, FRANCE.

OP-0789Hunting Down Immune Activation and irAEsN. Aide; CHU de Caen, Service de Médecine Nucléaire, Caen, FRANCE.

OP-0790Tricky Cases from Daily Routine ActivityR. J. Hicks; The Sir Peter MacCallum Cancer Center, Department of Oncology, Molecular Imaging and Therapeutic Nuclear Medicine, Melbourne, AUSTRALIA.

1409


Cutting Edge Science Track - TROP Session: Data Analysis

OP-0792Visual reading and centiloid scaling for the evaluation of brain amyloid PET imagingE. Prieto, V. Puente, J. F. Bastidas, J. J. Rosales, L. Irazola, B. Echeveste, M. Riverol, J. Arbizu; Clínica Universidad de Navarra, Pamplona, SPAIN.

AnyScan® &nanoScan® FamiliesImaging solutions for clinical and preclinical applications



139138

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0793Interpretation of discordances among amyloid biomarkers: the role of semiquantitative methods in cerebral amyloid load determinationM. Nerattini1, F. Rubino1, A. Arnone1, C. Polito2, S. Mazzeo2, G. Lombardi3, B. Nacmias2, G. Puccini4, S. Sorbi2, M. De Cristofaro1, R. Sciagrà1, V. Bessi2, V. Berti1; 1Nuclear Medicine Unit - Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, 2Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA) - Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, 3IRCCS Fondazione Don Carlo Gnocchi - IRCCS Fondazione Don Carlo Gnocchi, Florence, ITALY, 4Nuclear Medicine Unit - S. Stefano Hospital of Prato, Prato, ITALY.

OP-0794Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PETJ. Hong1, K. Shi1, A. Rominger1, H. Choi2; 1University of Bern/Inselspital, Bern, SWITZERLAND, 2Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

OP-0795Impact of meningeal uptake and partial volume correction techniques on differences in [18F]MK-6240 binding between healthy controls and aMCI patientsN. Mertens1, L. Michiels2,3, G. Vanderlinden1, R. Lemmens2,3, M. Vandenbulcke4, K. Van Laere1, M. Koole1; 1Nuclear Medicine and Molecular Imaging, University Hospital and KU Leuven, Leuven, BELGIUM, 2UZ Leuven/KU Leuven, Neurology, Neurosciences, Experimental Neurology, Leuven, BELGIUM, 3VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, BELGIUM, 4Old-Age Psychiatry, University Hospital and KU Leuven, Leuven, BELGIUM.

OP-0796Image-Derived Input Functions From Dynamic 15O-Water Positron Emission Tomography Scans Using Penalised ReconstructionP. Young1,2, L. Appel3, A. Tolf4, S. Kosmidis3, J. Burman4, A. Rieckmann5,6, M. Schöll1,2,7, M. Lubberink3; 1Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, SWEDEN, 2Wallenberg Centre for Molecular and Translational Medicine, Gothenburg, SWEDEN, 3Radiology & Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 4Neurology, Department of Neurosciences, Uppsala University, Uppsala, SWEDEN, 5Department of Radiation Sciences, Umeå University, Umeå, SWEDEN, 6Munich Center for the Economic of Aging, Max Planck Institute for Social Law and Social Policy, Munich, GERMANY, 7Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UNITED KINGDOM.

OP-0797Evaluation of partial volume correction and comparison of PET normalization methods in PET/MR myocardial viability assessment for recovery prediction of left ventricular contractility after percutaneous revascularisation of coronary chronic total occlusionsA. Villagran Asiares1, T. Vitadello2, E. L. Solari1, T. Ibrahim2, S. G. Nekolla1; 1Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, München, GERMANY, 2Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar der Technischen Universität München, München, GERMANY.

OP-0798Textural Analysis of 18F-FDG PET Images to Evaluate Treatment ResponseX. Hu1, S. Han1, L. Wang2, Q. Chu2, N. D’Ascenzo1,3, Q. Xie1,3; 1Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, CHINA, 2Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, 3Department of Medical Physics and Engineering at the Istituto Neurologico Mediterraneo NEUROMED I.R.C.C.S, Pozzilli, ITALY.

OP-0799Image quality assessment of low dose 68Ga DOTA-TOC PET using traditional semi-quantitative metrics, clinical assessment and radiomic feature extractionA. McCann1, S. Cournane2, E. Loughnane1, A. Stone1, R. Killeen1, L. León Vintró2, J. Lucey1; 1St Vincents University Hospital, Dublin, IRELAND, 2University College Dublin, Dublin, IRELAND.

OP-0800A 3-minute semi-automated PSMA PET organ segmentation method to use in the clinic and train neural networksG. Chaussé1, I. Bloise1, N. Colpo1, I. Klyuzhin1, F. Yousefi1, J. Brosch-Lenz1, S. Probst2, A. Rahmim1, C. Uribe1, F. Bénard1; 1BC Cancer / Research Institute, Vancouver, BC, CANADA, 2Jewish General Hospital, Montreal, QC, CANADA.

OP-0801Fuzzy c-means clustering in input function and wash-in parameter derivation for dynamic SPECT cardiac studyA. Studen1,2, M. Bunc3, M. Mrak3, S. Rep4,5, L. Ležaić4,6; 1Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA, 2Jožef Stefan Institute, Ljubljana, SLOVENIA, 3Department of Cardiology, UMC Ljubljana, Ljubljana, SLOVENIA, 4Department of Nuclear Medicine, UMC Ljubljana, Ljubljana, SLOVENIA, 5Medical Imaging and Radiotherapy Department, Faculty of Health Sciences, University of Ljubljana, Ljubljana, SLOVENIA, 6Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

OP-0802A simulation study to compare cross-validation versus holdout or external testing to assess the performance of machine learning based clinical prediction rulesR. Boellaard1, J. J. Eertink1, P. J. Lugtenburg2, G. J. Zwezerijnen1, S. E. Wiegers1, H. C. de Vet1, J. M. Zijlstra1; 1Amsterdam University Medical Centers, Amsterdam, NETHERLANDS, 2Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS.

OP-0803A novel methodology for assessing reproducibility of heterogeneity metrics in PET radiomics using noise-equivalent count rate, Monte Carlo simulation and 3D-printed patient-specific tumour phantomsG. Needham1,2, P. Julyan2, D. M. Cullen1, J. Tipping2, D. Hamilton2, S. Pells1,2,3, A. Fish1,2; 1University of Manchester, Manchester, UNITED KINGDOM, 2The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, 3National Physical Laboratory, Teddington, UNITED KINGDOM.

1410


Clinical Oncology Track - TROP Session: Local Radionuclide Therapy and Other Oncological Treatments

OP-0805Holmium-166 radioembolization as adjuvant treatment after radiofrequency ablation of early-stage hepatocellular carcinoma up to 5 cm: a dose escalation study (HORA EST HCC trial)P. Hendriks1, D. D. Rietbergen1, A. R. van Erkel1, M. J. Coenraad1, M. Arntz2, R. Bennink3, A. E. Braat1, A. L. Crobach1, O. M. van Delden3, T. van der Hulle1, H. Klumpen3, R. W. van der Meer1, F. Nijsen2, C. S. van Rijswijk1, J. Roosen2, B. N. Ruijter1, F. Smit1, M. K. Stam1, B. Takkenberg3, M. E. Tushuizen1, F. H. van Velden1, L. de Geus-Oei1, M. C. Burgmans1; 1Leiden University Medical Center, Leiden, NETHERLANDS, 2Radboud UMC, Nijmegen, NETHERLANDS, 3Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-0806The first steps to fully personalized selective internal radiation therapy: intraprocedural MRI-based dosimetry of holmium-166 microspheresJ. Roosen1, M. A. Arntz1, M. Janssen1, C. G. Overduin1, M. W. Konijnenberg1,2, J. J. Fütterer1, J. F. Nijsen1; 1Radboud University Medical Centre, Nijmegen, NETHERLANDS, 2Erasmus Medical Centre, Rotterdam, NETHERLANDS.

OP-0807Dose-response for yttrium-90 resin microesphere radioembolization in Hepatocellular carcinomaM. Rodríguez-Fraile1, A. Cabrera1, J. Rosales1, J. Bastidas1, F. Grisanti1, M. Sanchez2, A. Martínez de la Cuesta1, M. Iñarrairaegui1, J. Bilbao1, B. Sangro1; 1Clínica Universidad de Navarra, Pamplona, SPAIN, 2Universitat de València, Valencia, SPAIN.

OP-0808Suggested protocol for Y-90 PET/CT dosimetry in liver therapy with Y-90 microspheresK. Knesaurek; Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

OP-0809Feasibility and Therapeutic Potential of 177Lu- Fibroblast Activation Protein Inhibitor (FAPI) for Patients With Relapsed or Refractory of Various Cancers: A preliminary studyM. Assadi1, S. Rekabpour1, G. Divband2, B. Nikkholgh2, H. Ahmadzadehfar3, E. Jafari1, N. Shakibazad1, N. Jokar1, I. Nabipour1; 1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF, 2Khatam PET-CT center, Khatam Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Department of Nuclear Medicine, Klinikum Westfalen, Dortmund, GERMANY.

OP-0810Radioimmunotherapy for relapsed or refractory B cell non-Hodgkin lymphoma: 3-year follow-up of 66 patientsK. Maruyama, K. Utsunomiya, Y. Kono, Y. Ueno, N. Tanigawa; Kansai Medical University, Osaka, JAPAN.

OP-0811Cosmetic Outcome after Brachytherapy with Not-sealed 188Rhenium-resin in Patients with Non-Melanoma Skin CancersL. Vetrone1, P. Castellucci2, F. Savoia3, A. Farina1, S. Vichi4, F. Zagni5, A. Patrizi3, L. Strigari5, A. G. Morganti6,7, S. Fanti1,2; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 3Dermatology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 4Clinical Engineering Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5Medical Physics Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 6Radiation Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 7Radiation Oncology Department, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY.



141140

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0812High Dose Brachytherapy with 188Re-(Rhenium) Resin in Patients with Non-Melanoma Skin CancersL. Vetrone1, F. Savoia2, A. Farina1, S. Vichi3, F. Zagni4, L. Strigari4, A. G. Morganti5,6, A. Patrizi2, S. Fanti1,7, P. Castellucci7; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Dermatology, IRCCS Policlinico di Sant’Orsola, Department of Experimental, Diagnostic and Speciality Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, ITALY, 3Clinical Engineering Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 4Medical Physics Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5Radiation Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 6Radiation Oncology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 7Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-0813Initial clinical experience with [90Y]Y-FAPI-46 radioligand therapy for advanced stage solid tumorsJ. Ferdinandus1, P. Fragoso Costa1, L. Kessler1, M. M. Weber1, N. Hirmas1, K. Kostbade1, S. Bauer1, M. Schuler1, M. Ahrens2, H. U. Schildhaus1, C. Rischpler1, J. T. Siveke1, K. Herrmann1, W. P. Fendler1, R. Hamacher1; 1University Hospital Essen, Essen, GERMANY, 2University Hospital Frankfurt, Frankfurt, GERMANY.

OP-0814Efficacy and safety of 124-I-MIBG guided high activity 131-I-MIBG therapy of metastatic pheochromocytoma and neuroblastomaI. Maric1, M. M. Weber1, W. Jentzen1, J. Schmitz1, N. Unger2, T. D. Poeppel1, A. Prochnow1, K. Herrmann1, W. P. Fendler1; 1Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, GERMANY, 2Department of Endocrinology, Diabetes and Metabolism, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, GERMANY.

OP-0815Potential theranostic approach of 177Lu-trastuzumab and 177Lu-FAPI in metastatic breast cancer: An ongoing studyM. Assadi1, S. Rekabpour1, N. Jokar1, H. Ahmadzadehfar2, E. Jafari1; 1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF, 2Department of Nuclear Medicine, Klinikum Westfalen, Dortmund, GERMANY.

OP-0816Targeted Radionuclide Therapy with Lu 177-Dotatate, Iodine 131-Mibg and RAI in Children: Applicability and EfficacyU. Korkmaz, S. Soyluoglu; Trakya University Medical Faculty, Department of Nuclear Medicine, Edirne, TURKEY.

1411


Featured Session: Novel Molecular Brain Imaging Applications

OP-0818No Novel Applications Without QuantificationJ. C. Price; Harvard Medical School, Department of Radiology, Cambridge, UNITED STATES OF AMERICA.

OP-0819Simultaneous [18F]FDG PET/MR in visual snow syndrome: multimodal findings and diagnostic accuracy of [18F]FDG PETJ. Gebruers*1, J. Ceccarini*2, K. Goffin1,2, E. Boon3, K. Van Laere1,2; 1Nuclear Medicine, UZ Leuven, Leuven, BELGIUM, 2Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, 3Division of Neurology and Psychiatry, UPC Kortenberg and UZ Leuven, Leuven, BELGIUM.(*shared first authors)

OP-0820Association of neuroinflammation and myelin content with functional disability in multiple sclerosis: a multi-tracer PET/MR studyM. Pitombeira1, M. Koole2, A. M. de Souza3, F. L. Duran4, K. R. Campanholo1, D. J. Fontoura Solla5, C. M. Rimkus6, M. F. Mendes1, S. L. Apóstolos-Pereira1, G. Busatto Filho7, D. Callegaro1, C. A. Buchpiguel3, D. de Paula Faria3; 1Department of Neurology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, BRAZIL, 2Division of Nuclear Medicine, Department of Imaging and Pathology, University Hospitals Leuven and KU Leuven, Leuven, BELGIUM, 3Laboratory of Nuclear Medicine (LIM43), Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, BRAZIL, 4Laboratory of Psychiatric Neuroimaging (LIM-21), Department and Institute of Psychiatry, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, BRAZIL, 5Division of Neurosurgery, Department of Neurology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, BRAZIL, 6Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, BRAZIL, 7Department of Psychiatry, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, BRAZIL.

OP-0821Pharmacodynamic effects of padsevonil using simultaneous [11C]-UCB-J PET-MR Arterial Spin Labeling perfusion measurementsM. Koole1, B. Lacroix2, M. Devrome1, H. Chanteux2, R. P. Maguire2, K. Van Laere1,3; 1KU Leuven, Leuven, BELGIUM, 2UCB Pharma, Braine l’Alleud, BELGIUM, 3UZ Leuven, Leuven, BELGIUM.

OP-0822Learning results in metabolically driven adaptations of brain connectivityS. Klug1, L. Rischka1, G. M. Godbersen1, W. Wadsak2,3, V. Pichler2,4, M. Hacker2, R. Lanzenberger1, A. Hahn1; 1Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, AUSTRIA, 2Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, 3Center for Biomarker Research in Medicine (CBmed), Graz, AUSTRIA, 4Department of Pharmaceutical Chemistry, University of Vienna, Vienna, AUSTRIA.

OP-0823Relationships between different measures of brain connectivityI. Yakushev, A. Lizarraga, I. Ripp, A. Sala, W. Weber; Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY.

OP-0824Longitudinal metabolic brain connectivity analysis after acute unilateral vestibulopathyM. Grosch1, S. Becker-Bense1, P. Bartenstein2, M. Dieterich3, S. Ziegler2, A. Zwergal1; 1German Center for Vertigo and Balance Disorders, LMU Hospital, München, GERMANY, 2Department for Nuclear Medicine, LMU Hospital, München, GERMANY, 3Department of Neurology, LMU Hospital, München, GERMANY.

OP-0825Quantification of P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PETP. Mossel1, A. T. Willemsen1, L. Garcia Varela1, W. Arif1,2, R. Boellaard1,3, P. H. Elsinga1, P. de Deyn4,5,6, R. A. Dierckx1, A. A. Lammertsma1,3, A. L. Bartels4, G. Luurtsema1; 1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS, 2Department of Radiological Sciences, King Saud University, Riyadh, SAUDI ARABIA, 3Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NETHERLANDS, 4Department of Neurology, University Medical Center Groningen, Groningen, NETHERLANDS, 5Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, BELGIUM, 6Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Born-Bunge (IBB), University of Antwerp, Antwerp, BELGIUM.

OP-0826First-in-human mapping of the GluN2B subunits of the N-methyl-D-aspartate receptor using (R)-[11C]Me-NB1 and PETL. Rischka1, C. Vraka2, V. Pichler2,3, S. Rasul2, L. Nics2, G. Gryglewski1, P. Handschuh1, M. Murgaš1, G. M. Godbersen1, L. R. Silberbauer1, J. Unterholzner1, C. Wotawa1, A. Haider4, H. Ahmed4, R. Schibli4, T. Mindt2,5,6, M. Mitterhauser2,5, W. Wadsak2,7, A. Hahn1, R. Lanzenberger1, M. Hacker2, S. M. Ametamey4; 1Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, AUSTRIA, 2Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, 3Department of Pharmaceutical Chemistry, University of Vienna, Vienna, AUSTRIA, 4Centre for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Zurich, SWITZERLAND, 5Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA, 6Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, AUSTRIA, 7Center for Biomarker Research in Medicine (CBmed), Graz, AUSTRIA.

OP-0828Role of [18F]FDG and [18F]Florbetapir PET/CT to predict Alzheimer’s disease development in patients with Down syndromeS. Abouzian1, R. Valverde2, J. Pegueroles3,4, M. Sizova1, F. Fuentes1, A. Fernández1, J. Duch1, D. López-Mora1, M. Estorch1, I. Barroeta3,4, M. Carmona-Iragui3,4, A. Lleó3,4, I. Carrió1, A. Flotats1, J. Fortea3,4, V. Camacho1; 1Nuclear Medicine Department. Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, SPAIN, 2Nuclear Medicine Department. Hospital de Cruces, Bilbao, SPAIN, 3Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, SPAIN, 4CIBERNED, Madrid, SPAIN.

1413



OP-0831Plenary QuizM. Benesova; DKFZ Heidelberg, Molecular Biology of Systemic Radiotherapy, Heidelberg, GERMANY. & G. Bakos; German Cancer Research Center (DKFZ), Molecular Biology of Systemic Radiotherapy (E270), Heidelberg, GERMANY.



143142

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1501


Plenary 4: Isotopes’ Past and Future

OP-0833The Importance of the IsotopeJ. Sosabowski; Queen Mary University of London, Barts Cancer Institute, Centre for Molecular Oncology, London, UNITED KINGDOM.

OP-0834Clinical Applications of Alpha vs BetaM. Eiber; Technical University Munich, Department of Nuclear Medicine, Munich, GERMANY.

OP-0835New Isotopes on the BlocksU. Köster; Institut Laue-Langevin (ILL), Grenoble, FRANCE.

OP-0836Isotopes’ AvailabilityV. Pichler; Department of Pharmaceutical Sciences, Vienna, AUSTRIA.

OP-0837Zr and FriendsD. Vugts; VUmc Imaging Center Amsterdam Radiology & Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0838Beta Emitters for Surface TherapyP. Castellucci; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine Unit, Bologna, ITALY.

OP-0839The Best has yet to ComeP. Laverman; Radboud University Nijmegen Medical Center, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

1601


CME 11: New Concepts for Imaging and Therapy of Bone Metastases

OP-0849Nuclear Imaging of Bone MetastasesH. Zacho; University Hospital, Department of Nuclear Medicine, Aalborg, DENMARK.

OP-0850Radionuclide Therapy of Bone MetastasesA. Afshar-Oromieh; University Hospital Insel-Spital, Department of Nuclear Medicine, Bern, SWITZERLAND.

OP-0851Radiation Therapy of Bone MetastasesP. Dirix; University of Antwerp, Radiation Oncology, iridium network, Antwerp, BELGIUM.

1602


The Top 3 Trials Sessions - 3 - New Tracers

OP-085318F-Fluoroglutamine PET as a Promising Prognostic Tool in IDH Mutant GliomaS. Krebs, M. S. Graham, M. Grkovski, A. Mauguen, R. Goel, S. B. Thakur, L. R. Schaff, I. K. Mellinghoff, R. J. Young, T. Kaley, M. P. Dunphy; Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-0854Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastomaA. Scott1,2,3, L. Cher1,2, P. Inglis4, Z. Lwin4, E. Lau2, C. Wichmann1, U. Ackermann1,2, A. Gunjur2, A. McDonald1, N. Coombs2, K. Remen2, N. Guo1, S. Lee1,2,3, S. Gong2, J. Palmer1,3, K. Pathmaraj2, G. O’Keefe2, F. Scott1,3, B. Day5, A. Boyd1,4, O. Ahmed6, D. Chappell6, P. Thomas4, C. Durrant6, H. Gan1,2,3; 1Olivia Newton-John Cancer Research Institute, Melbourne, AUSTRALIA, 2Austin Health, Melbourne, AUSTRALIA, 3La Trobe University, Melbourne, AUSTRALIA, 4Royal Brisbane and Women’s Hospital, Brisbane, AUSTRALIA, 5QIMR Berghofer Medical Research Institute, Brisbane, AUSTRALIA, 6Humanigen Inc, Burlingame, CA, UNITED STATES OF AMERICA.

OP-0855Use of SPECT with “99mTc-1-thio-D-glucose” for the Diagnosis of Brain TumorsR. Zelchan1, A. Medvedeva1, O. Bragina1, A. Ribina1, E. Stasyuk2, V. Chernov1, E. Mishina3; 1Cancer Research Institute is a subdivision of the Federal State Budgetary Scientific Institution “To, Tomsk, RUSSIAN FEDERATION, 2National Research Tomsk Polytechnic University, Tomsk Polytechnic University, TPU., Tomsk, RUSSIAN FEDERATION, 3Siberian State Medical University , SSMU, Tomsk, RUSSIAN FEDERATION.

OP-085668Ga-ABY-025 PET Predicts the Metabolic Response in Breast Cancer Patients: Preliminary Results From a Phase II StudyA. Alhuseinalkhudhur1,2, H. Lindman2, M. Lubberink1, V. Iyer3, P. Liss3, T. Sundin4, F. Y. Frejd2,5, J. Hartman6, I. Velikyan1, J. Sörensen1; 1Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 2Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, 3Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, SWEDEN, 4Clinical Research and Development Unit, Uppsala University Hospital, Uppsala, SWEDEN, 5Affibody AB, Solna, SWEDEN, 6Department of Oncology and Pathology, Karolinska Institute, Stockholm, SWEDEN.

OP-0857Preliminary results of a pilot study with [18F]-DPA-714 PET-CT to explore Tumor-Associated-Macrophages in triple negative breast cancerC. Rousseau1, N. Arlicot2, O. Kerdraon3, J. Vercouillie4, L. Ferrer5, I. Doutriaux-Dumoulin3, R. Movassaghi3, L. Ouldamer6, F. Boiffard3, C. Renaudeau3, M. Colombié3, V. Fleury3, M. Le Thiec3, B. Maucherat3, A. Morel-Thierry3, D. Rusu3, N. Allam3, M. Santiago-Ribeiro7, F. Kraeber-Bodéré8; 1ICO René Gauducheau, F-44800 Saint-Herblain, France; Université de Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, FRANCE, 2UMR 1253, iBrain, Université de Tours, Inserm CIC 1415, University Hospital, F-37000, Tours, FRANCE, 3ICO René Gauducheau, F-44800, Saint Herblain, FRANCE, 4UMR 1253, iBrain, Université de Tours, Inserm, F-37000, Tours, FRANCE, 5ICO René Gauducheau, F-44800 Saint-Herblain, France; CNRS, Inserm, CRCINA, F-44000, Nantes, FRANCE, 6CHRU de Tours, Hôpital Bretonneau, F-37000 Tours, France ; Laboratoire “Nutrition, Growth and Cancer”, Université de Tours, INSERM UMR1069, F-37000, Tours, FRANCE, 7UMR 1253, iBrain, Université de Tours, Inserm, CHRU de Tours, Hôpital Bretonneau, F-37000, Tours, FRANCE, 8Université de Nantes, CHU de Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, FRANCE.

OP-0858Tumor uptake of the anti-LAG-3 tracer [89Zr]Zr-BI 754111 in HNSCC and NSCLC patients progressing on previous anti-PD-1 treatmentI. H. C. Miedema1, M. C. Huisman1, G. J. Zwezerijnen1, A. Thiele2, R. Grempler2, A. P. Pitarch2, D. J. Vugts1, T. D. de Gruijl1, C. W. Menke-van der Houven van Oordt1; 1Amsterdam UMC, location VUmc, Amsterdam, NETHERLANDS, 2Boehringer Ingelheim, Ingelheim am Rein, GERMANY.

OP-0859Pilot phase study of 18F-FP-R01-MG-F2 PET in pancreatic cancer patientsR. Nakamoto, V. Ferri, H. Duan, N. Hatami, M. Goel, J. Rosenberg, R. Kimura, M. Wardak, T. Haywood, R. Kellow, B. Shen, W. Park, A. Iagaru; Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

OP-0860PSMA-PET/CT and additional PET/MRI using [F-18]siPSMA-14: Improvement in local tumour detection in prostate cancer patients with biochemical recurrence after radical prostatectomy and prior to salvage therapyJ. Miksch1, Y. Funk1, W. P. Thaiss1, J. P. Steinacker1, M. Grunert2, D. Di Carlo3, F. Zengerling4, C. Solbach1, M. Beer5, T. Wiegel6, V. Prasad1, H. J. Wester3, A. J. Beer1; 1Department of Nuclear Medicine University Hospital Ulm, Ulm, GERMANY, 2Department of Nuclear Medicine, German Armed Forces Hospital, Ulm, GERMANY, 3Pharmaceutical Radiochemistry, Technical University Munich, Garching, GERMANY, 4Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, GERMANY, 5Department of Radiology, University Hospital Ulm, Ulm, GERMANY, 6Department of Radiation Oncology and Therapy, University Hospital Ulm, Ulm, GERMANY.

OP-0861First results of biodistribution and tumour targeting of 68Ga-DOTA-MGS5 PET/CT in advanced medullary thyroid cancer patientsC. Uprimny, S. Bayerschmidt, G. di Santo, M. Klingler, A. Hörmann, B. Warwitz, C. Rangger, E. von Guggenberg, I. Virgolini; Medical University of Innsbruck, Innsbruck, AUSTRIA.



145144

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0862First in human biodistribution and first imaging results of 68Ga- EMP-100 PET - a novel ligand for imaging c-MET-expression in metastatic renal cell carcinomaL. Mittlmeier1, A. Todica1, F. Gildehaus1, M. Unterrainer2, L. Beyer1, M. Brendel1, H. Ilhan1, S. T. Ledderose3, M. Schott4, S. Rodler4, L. Rath4, J. Marcon4, C. C. Cyran2, C. G. Stief4, M. Staehler4, P. Bartenstein1; 1LMU Munich, Department of Nuclear Medicine, Munich, GERMANY, 2LMU Munich, Department of Radiology, Munich, GERMANY, 3LMU Munich, Department of Pathology, Munich, GERMANY, 4LMU Munich, Department of Urology, Munich, GERMANY.

OP-0863First clinical experience with Zr-89-Df-IAB22M2C PET/MRI in patients with metastatic cancerJ. Schwenck1,2,3, D. Sonanini2,4, D. Seyfried2, W. Ehrlichmann2, G. Kienzle2, G. Reischl2,3, I. Wilson5, W. Le5, G. Smith5, R. Korn5, F. Seith6, A. Forschner7, T. Eigentler7, M. Röcken7,3,8, L. Zender4,3,8, B. Pichler2,3,8, L. Flatz7, M. Kneilling2,3,7, C. la Fougere1,3,8; 1Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University, Tübingen, GERMANY, 2Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, GERMANY, 3Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, Eberhard Karls University, Tübingen, GERMANY, 4Department of Medical Oncology and Pneumology (Internal Medicine VIII), Eberhard Karls University, Tübingen, GERMANY, 5ImaginAb, Inc, Inglewood, CA, UNITED STATES OF AMERICA, 6Department of Diagnostic and Interventional Radiology, Eberhard Karls University, Tübingen, GERMANY, 7Department of Dermatology, Eberhard Karls University, Tübingen, GERMANY, 8German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Tübingen, GERMANY.

1604


Mini Course 1: Safety in PET/MRI

OP-0842Safety in Magnetic ResonanceV. Silva; Centro Hospitalar Universitário São João, Magnetic Resonance Department, Porto, PORTUGAL.

OP-0843Safety in the Hybrid PET/MR SystemM. Federspiel; Copenhagen University Hospital, Rigshospitalet, Dept. of Nuclear Medicine & PET, Copenhagen, DENMARK.

1605


Joint Symposium 21 (EANM/AAPM): Numerical and Computer Phantoms

OP-0868Digital Human Phantoms for Dosimetry in Nuclear Medicine Imaging and Therapy - Historical Development and Recent AdvancesW. Bolch; University of Florida, Advanced Laboratory for Radiation Dosimetry Studies, Gainesville, UNITED STATES OF AMERICA.

OP-0869The Use of Computer Phantoms in Nuclear Medicine ImagingK. Sjögreen Gleisner; Lund University, Department of Medical Radiation Physics, Lund, SWEDEN.

OP-0870Computing Models for Dosimetry, and BeyondM. Bardiès; U1194 INSERM/ICM/Montpellier University, Cancer Research Institute of Montpellier, Montpellier, FRANCE.

1606


Joint Symposium 22 (EANM/EURAMED): The MEDIRAD Project - Impact on Nuclear Medicine Practice

OP-0873Introduction - The MEDIRAD ProjectG. Flux; Royal Marsden Hospital and Institute of Cancer Research, Radioisotope Physics, Sutton, UNITED KINGDOM.

OP-0874Multi-Centre Clinical Trials Involving Dosimetry of Radioiodine Treatment for Thyroid CancerJ. Taprogge; Royal Marsden Hospital and Institute of Cancer Research, Radioisotope Physics, Sutton, UNITED KINGDOM.

OP-0875DNA Damage and Repair during Radioiodine Therapy within the MEDIRAD ProjectU. Eberlein; University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

OP-0876Hybrid Imaging in Nuclear Medicine - Results from the MEDIRAD ProjectK. Bacher; Ghent University, Division of Medical Physics, Ghent, BELGIUM.

1607


Teaching Session 5: Radiation Detection and Measurement

OP-0845Radiation Detectors - Which is the Right One for the Task?A. Mackenzie; University College London Hospitals, Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-0846The Importance of Quality Control and Instrumentation PerformanceR. Freudenberg; Universitätsklinikum Dresden, Klinik und Poliklinik für Nukleamedizin, Dresden, GERMANY.

OP-0847What and When to Measure? Establishing Standard Operating Procedures T. Kracmerova; University Hospital Motol, Nuclear medicine, Prague, CZECH REPUBLIC.

1609


Cutting Edge Science Track - Featured Session: PET Reconstructions and Corrections

OP-0882Developments in PET Reconstructions and CorrectionsB. Hutton; University College London (UCL), Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-0883Optimization of reconstruction parameters of a block sequential regularized expectation maximization algorithm for 68Ga-DOTOTAC PET/CT studiesT. Christensen1, A. L. Nielsen2, M. H. Vilstrup2, P. Braad2; 1Department of Clinical Engineering, Region of Southern Denmark, Esbjerg, DENMARK, 2Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

OP-0884Optimization of Q.Clear β Penalization Factor for Dynamic PET ImagingE. Lysvik1, L. G. Mikalsen1,2, T. Hjørnevik1; 1Oslo University Hospital, Oslo, NORWAY, 2Oslo Metropolitan University, Oslo, NORWAY.

OP-0885BSREM for Brain Metastases Detection with [18F]FDG PET/CT in Lung Cancer PatientsV. Liberini1,2, D. A. Pizzuto3,2, M. Messerli2, E. Orita4,2, H. Grünig2, A. Maurer2, C. Mader2, L. Husmann2, D. Deandreis1, F. Kotasidis5,2, J. Trinckauf2, A. Curioni6, I. Opitz7, S. Winklhofer8, M. W. Huellner2; 1UNITO - University of Turin, Turin, ITALY, 2Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Zürich, SWITZERLAND, 3Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, 4Department of Radiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, JAPAN, 5GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA, 6Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Zürich, SWITZERLAND, 7Department of Thoracic Surgery, University Hospital Zurich, Zürich, SWITZERLAND, 8Department of Neuroradiology, Clinical Neuroscience Center, University Hospital Zurich, Zürich, SWITZERLAND.

OP-0886Clinical feasibility and assessment of impact of data-driven respiratory motion-correction studied in 659 whole-body 18F-FDG PET/CT scansA. H. Dias1, P. Schleyer2, M. H. Vendelbo1, K. Hjorthaug1, L. C. Gormsen1, O. L. Munk1; 1Aarhus University Hospital, Aarhus, DENMARK, 2Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

OP-0887Improvement of myocardial perfusion images with data-driven corrections of motion and respiration: Comparison between retrospective and prospective gating methodsK. Nakajima1, T. Shibutani1, F. Massanes2, H. A. Vija2, T. Shimizu2, S. Yoshida1, H. Yoneyama1, M. Onoguchi1, S. Kinuya1; 1Kanazawa University, Kanazawa, JAPAN, 2Siemens Medical Solutions USA, Hoffman Estate, IL, UNITED STATES OF AMERICA.



147146

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0888Regularized Reconstruction in Combination with Quiescent Phase Respiratory Gating on a Time-of-Flight PET/MR Scanner for 18F-FDG Examinations in Patients with Esophageal CancerN. Korsavidou Hult, S. Kvernby, J. Hedberg, G. Linder, H. Ahlström, T. Bjerner, M. Lubberink; Uppsala University, Uppsala, SWEDEN.

OP-0889Prostate cancer imaging with PSMA PET/MRI: The effects of data-driven bulk patient motion and its compensationB. Bogdanovic, E. Solari, A. Villagran Asiares, S. Schachoff, M. Eiber, W. Weber, S. Nekolla; Klinikum rechts der Isar der Technischen Universität München, Munich, GERMANY.

OP-0890Zero-TE vs 2-point Dixon MRI-based Attenuation Correction for Chest FDG PET/MRI with Deep Learning: Comparison of Quantitative Values on Pseudo CT and Reconstructed PET dataM. Nogami1, H. Matsuo1, M. Nishio1, M. Tachibana1, J. Inukai1, F. Zeng1, T. Kurimoto2, K. Kubo1, T. Murakami1; 1Kobe University Hospital, Kobe, Hyogo, JAPAN, 2GE Healthcare, Hino, Tokyo, JAPAN.

OP-0891Influence of Spatial Resolution and SNR of Attenuation Correction Maps on Breast PET images in a Fully-Hybrid PET/MR systemI. Neri1, M. Emendi1, C. Canevari1, A. Savi1, V. Bettinardi1, C. Losio2, R. Menichini1, N. Ferjani1, L. Presotto1, R. Di Micco3, O. Gentilini3, M. Picchio1,4, L. Gianolli1, P. Scifo1; 1Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 2Radiology Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Breast Surgery Unit Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 4Vita-Salute San Raffaele University, Milan, ITALY.

OP-0892A concept for quality assurance of PET/MRI attenuation correction with B0-mapsE. Wallstén, J. A. Lundman, M. Bylund, M. Adjeiwaah, A. Larsson, T. Nyholm; Umeå University, Umeå, SWEDEN.

1610


Clinical Oncology Track - Featured Session: Prostate Cancer Therapy

OP-0894The Visions Beyond VISIONB. Hadaschik; Universitätsklinikum Essen, Urology, Essen, GERMANY.

OP-0895Minimally Invasive Robot-Assisted PSMA-Guided Salvage Surgery in Recurrent Prostate Cancer Using DROP-IN Radioguidance - A Prospective Feasibility StudyH. de Barros1, M. N. van Oosterom1,2, M. L. Donswijk3, J. J. Hendrikx3,4, F. W. van Leeuwen1,2, T. Maurer5, H. G. van der Poel1, P. J. van Leeuwen1; 1Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 2Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, 3Department of Nuclear Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 4Department of Pharmacy & Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 5Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Hamburg, GERMANY.

OP-0896Development of a novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP): an international multicenter studyA. Gafita1, I. Rauscher2, M. Weber3, B. Hadaschik3, H. Wang2, W. R. Armstrong1, R. Tauber2, T. R. Grogan1, J. Czernin1, M. B. Rettig1, K. Herrmann3, J. Calais1, W. A. Weber2, M. R. Benz1, W. P. Fendler3, M. Eiber2; 1UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, 2Technical University Munich, Munich, GERMANY, 3University of Duisburg-Essen, Essen, GERMANY.

OP-0897The prognostic role of inflammatory indices from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Radium-223 (BIO-Ra-223 study)M. Donegani1, S. E. Rebuzzi2,3, M. Ponzano1, M. Bauckneht4, V. Frantellizzi5, E. Lodi Rizzini6, M. Mascia7, V. Lavelli8, A. Gaudiano8, M. L. Stazza9, M. Licari10, V. Murianni2,3, A. Signori1, L. Cavallini6,11, V. Laghi6,11, L. Cindolo12, R. P. Costa10, A. Spanu9, G. Rubini8, F. Monari6, G. De Vincentis5, G. Fornarini2; 1Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY, 2Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 3Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, ITALY, 4Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 5Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, ITALY, 6Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 7Unit of Nuclear Medicine, Spirito Santo Hospital, Pescara, ITALY, 8Nuclear Medicine Department, University of Bari “Aldo Moro”, Bari, ITALY, 9Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, ITALY, 10Unit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, ITALY, 11Department of Experimental Diagnostic and Specialty Medicine-Alma Mater Studiorum Bologna University, Bologna, ITALY, 12Department of Urology, Villa Stuart Private Hospital, Rome, ITALY.

OP-0898Oncological and postoperative outcome of salvage PSMA-radioguided surgery in recurrent prostate cancerT. Maurer1, S. Knipper1, M. Irai1, D. Köhler2, I. Rauscher3, F. W. van Leeuwen4, P. van Leeuwen5, H. de Barros5, L. Budäus1, T. Steuber1, M. Graefen1, M. M. Heck6, R. Simon6, T. Horn6, M. Eiber3; 1Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY, 2Department of Radiology and Nuclear Medicine, Hamburg-Eppendorf, GERMANY, 3Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY, 4Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden, NETHERLANDS, 5Department of Urology, Antoni van Leeuwenhoek Hospital – the Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 6Department of Urology, Technical University of Munich, Munich, GERMANY.

OP-0899Pain response and clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): Final results from a prospective, noninterventional study (PARABO)H. Palmedo1, H. Ahmadzadehfar2, S. Eschmann3, I. Selkinski4, A. Niesen5, J. Schönberger6, V. Barsegian7, K. Liepe8, F. M. Mottaghy9, R. Guan10, J. Pinkert11, S. Buetikofer11, K. Herrmann12; 1Institute of Radiology and Nuclear Medicine Kaiser-Passage and PET/CT Centre Johanniter Hospital, Bonn, GERMANY, 2Klinikum Westfalen, Dortmund, GERMANY, 3Marienhospital Stuttgart, Stuttgart, GERMANY, 4Radiomedicum, Frankfurt, GERMANY, 5Diakovere Henriettenstift, Hannover, GERMANY, 6Klinikum Weiden, Weiden, GERMANY, 7Helios Kliniken Schwerin, Schwerin, GERMANY, 8Klinikum Frankfurt (Oder) GmbH Nuklearmedizin, Frankfurt, GERMANY, 9University Hospital RWTH Aachen University, Aachen, GERMANY, 10Bayer HealthCare Pharmaceuticals, Whippany, NJ, UNITED STATES OF AMERICA, 11Bayer AG, Berlin, GERMANY, 12Universitätsklinikum Essen, Essen, GERMANY.

OP-0900Tumor-to-liver ratio (TLR) by 68Ga-PSMA-11 PET/CT for response assessment and prediction of progression-free survival in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapyF. Khreish1, M. Wiessner1, F. Rosar1, Z. Ghazal1, A. Sabet2, S. Maus1, J. Linxweiler3, M. Bartholomä1, S. Ezziddin1; 1Department of Nuclear Medicine , Saarland University, Homburg, GERMANY, 22)Dept. of Nuclear Medicine, Frankfurt University, Frankfurt am Main, GERMANY, 3Department of Urology , Saarland University, Homburg, GERMANY.

OP-0901[225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT in challenging advanced mCRPC patientsF. Rosar1, J. Krause1, M. Bartholomä1, S. Maus1, T. Stemler1, I. Hierlmeier1, J. Linxweiler2, S. Ezziddin1, F. Khreish1; 1Department of Nuclear Medicine, Saarland University - Medical Center, Homburg, GERMANY, 2Department of Urology, Saarland University - Medical Center, Homburg, GERMANY.

OP-0902PSMA-targeted photodynamic therapy in surgical prostate tumor samplesY. Derks1, M. Schilham1, S. van Lith1, M. Sedelaar1, D. Somford2, M. Gotthardt1, D. Löwik3, S. Lütje4, S. Heskamp1, M. Rijpkema1; 1Radboud university medical center, Nijmegen, NETHERLANDS, 2Canisius Wilhelmina Hospital, Nijmegen, NETHERLANDS, 3Radboud University, Nijmegen, NETHERLANDS, 4University Hospital Bonn, Bonn, GERMANY.



149148

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0903Factors that could predict tumour sink effect: Experience with Lu177 Prostatespecific membrane antigen therapyM. Tuncel1, T. Telli1, M. Tuncalı1, E. Karabulut2; 1Hacettepe University, Department of Nuclear Medicine, Ankara, TURKEY, 2Hacettepe University, Department of Biostatistics, Ankara, TURKEY.

OP-0904Tumor regression and response of local tumor in mCRPC patients after two cycles of [177Lu]Lu-PSMA-617F. Khreish, P. Flach, M. Bartholomä, S. Maus, S. Ezziddin, F. Rosar; Department of Nuclear Medicine , Saarland University, Homburg, GERMANY.

OP-090568Ga-PSMA-11-PET/MRI radiomics in patients receiving 177Lu-617-PSMA-therapyW. Roll, P. Schindler, M. Masthoff, R. Seifert, M. Bögemann, M. Weckesser, K. Rahbar; University Hospital Münster, Münster, GERMANY.

OP-0906Efficacy and Safety of Lu-177 PSMA in Heavily Pretreated Population with mCRPC; Experience from King Hussein Cancer Center (KHCC) in JordanA. Al-Ibraheem, D. Sweedat, F. Anwer, N. Al-Hajaj, Y. Saleh, A. Mohamedkhair, M. Shahait, R. Abu-Hijlih, A. Abufara, S. Salah; King Hussein Cancer center, Amman, JORDAN.

1611


TROP Session: Paediatric Nuclear Medicine

OP-0908Metabolic [18F]FDG-PET parameters at diagnosis are prognostic for overall survival in pediatric sarcoma patientsM. Fosbøl, L. L. Hjalgrim, A. K. Berthelsen, L. Borgwardt; Rigshospitalet, Copenhagen, DENMARK.

OP-090918F-DOPA PET imaging in pediatric brain tumors: clinical applications and radiation safety profileM. Pizzoferro1, C. Polito2, G. Megaro3, S. Sollaku4, C. Altini1, M. F. Villani1, E. Casciani4, A. Napolitano2, D. Ciucci2, F. Martire2, S. Donatiello2, S. Colafati5, V. Cannatà2, A. Cacchione3, M. A. De Ioris3, A. Mastronuzzi3, M. C. Garganese1; 1IRCCS Bambino Gesù Children’s Hospital, Nuclear Medicine

Unit/Imaging Department, Rome, ITALY, 2IRCCS Bambino Gesù Children’s Hospital, Physics Unit, Rome, ITALY, 3IRCCS Bambino Gesù Children’s Hospital, Department of Oncohematology, Rome, ITALY, 4Private Hospital Pio XI, Nuclear Medicine Unit/Imaging Department, Rome, ITALY, 5IRCCS Bambino Gesù Children’s Hospital, Neuroradiology Unit/Imaging Department, Rome, ITALY.

OP-0910Preliminary investigation into use of 18F-fluorethyltyrosine PET (18F-FET-PET) within the paediatric population for stratification and prognostication of brain gliomasP. Francis, Y. Shvarts; Royal Children’s Hospital, Melbourne, AUSTRALIA.

OP-0911Role of 18F FDG PET/CT In Pediatric Malign MelanomaE. Isik1, S. Kuyumcu1, D. Has Şimşek1, S. Büyükkapu Bay2, R. Kebudi2, S. N. Ünal1; 1Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TURKEY, 2Istanbul University Oncology Institute, Department of Pediatric Hematology-Oncology, Istanbul, TURKEY.

OP-0912[18F]metafluorobenzylguanidine (MFBG) PET-CT vs. [123I]metaiodobenzylguanidine (MIBG) imaging in neuroblastoma patientsA. Samim1,2, G. A. Tytgat1, T. Blom1, A. J. Poot1,2, N. Tolboom1,2, A. J. Braat1,2, M. M. van Noesel1, M. G. Lam2, B. de Keizer1,2; 1Princess Máxima Centre for Paediatric Oncology, Utrecht, NETHERLANDS, 2University Medical Centre Utrecht, Utrecht, NETHERLANDS.

OP-0913Evaluating the Diagnostic Utility of 68Ga-DOTA-TOC PET/CT and 18F-FDG-PET PET/CT in High-Risk Neuroblastoma Pediatric Patients Compared to the standard Modalities (123I-MIBG, Bone Scans and CT)A. Al-Ibraheem1, U. Al-Rasheed1, N. Hirmas2, H. Halalsheh1, F. Ajlouni1, A. Mohamedkhair1, N. Mashahdani,1, I. Sultan1; 1King Hussein Cancer center, Amman, JORDAN, 2Universitätsklinikum Essen, Essen, GERMANY.

OP-0914Evaluation of Physiological Thymic, Splenic and Hepatic Activity with 18F-FDG PET/CT: Exploration of Normal Range among Pediatric PatientsG. April, R. Lambert, S. Turpin; CHU Ste-Justine, Montreal, QC, CANADA.

OP-0915Weight based optimization of administered activity for [18F]FDG PET/CT in paediatric patientsC. P. Cox, D. M. van Assema, F. A. Verburg, T. Brabander, M. Konijnenberg, M. Segbers; Erasmus MC, Rotterdam, NETHERLANDS.

OP-0916Evaluation of semi-quantitative scoring systems for metaiodobenzylguanidine (mIBG) scans in patients with stage 4 neuroblastoma: A single-center experienceM. Tuncel, M. E. Mavi, P. Ö. Kıratlı; Hacettepe University, Department of Nuclear Medicine, Ankara, TURKEY.

OP-0917[99mTc]Tc-MAG3 Renal Scintigraphy and Relative Renal Function: C-shaped or inferior background ROI?S. Fontão de Castro1, I. Próspero1, I. Lopo2, L. Violante1, R. Silva2,3, T. Saraiva2,3, H. Duarte1, G. Costa2; 1Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, PORTUGAL, 2Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 3Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL.

1701


CME 12: Nuclear Medicine in the Evaluation of Child Abuse

OP-0920Child Abuse Clinical Features, Diagnosis and ManagementH. Yechiam; Meir Medical Center, Emergency Medicine department and Beit Lyn Child Advocacy Center, Kfar Saba, ISRAEL.

OP-0921Nuclear Medicine in the Diagnosis of Child AbuseL. Drubach; Boston Children’s Hospital, Division of Nuclear Medicine, Boston, UNITED STATES OF AMERICA.

OP-0922Radiological Aspects of Child AbuseC. Giraudo; University Hospital of Padova, Institute of Radiology Department of Medicine DIMED, Padua, ITALY.

1702-1


Interview with the Expert 12 - Radiopharmacy Running

OP-0926Interview - Radiopharmacy RunningS. Fanti; University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

OP-0927Interview - Radiopharmacy RunningC. Decristoforo; Medical University Innsbruck, Department of Nuclear Medicine, Innsbruck, AUSTRIA.

1704


Mini Course 2: Case Studies (PET/CT & PET/MRI)

OP-0865Clinical Cases in PET Radiopharmaceutical ProductionG. Kodahl; Aarhus University Hospital, Nuclear Medicine & PET, Aarhus, DENMARK.

OP-0866Clinical Cases in PET/CT & PET/MRA. Dias; Aarhus University Hospital, Nuclear Medicine & PET, Aarhus, DENMARK.

1705


Joint Symposium 23 (EANM/EURADOS): Extremity Dosimetry - It’s in Your Hands!

OP-0931European Survey on Extremity DosimetryL. Cunha; IsoPor-Azores, Nuclear Medicine and Molecular Imaging, Azores, PORTUGAL.

OP-0932Pilot Studies on New RadionuclidesA. McCann; St. Vincent’s University Hospital, Department of Medical Physics and Clinical Engineering, Dublin, IRELAND.



151150

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0933Skin Contamination Dose on the FingersP. Covens; Vrije Universiteit Brussel, Department of Radiation Protection, Brussels, BELGIUM.

OP-0934Technologist’s ExperienceA. Geão; Hospital CUF Descobertas, Nuclear Medicine Department, Lisbon, PORTUGAL.

1706


Joint Symposium 24 (EANM/ESMO): Theranostics in Thyroid Cancer Beyond Radioactive Iodine

OP-0936Molecular Basis of Differentiated Thyroid CancerS. Leboulleux ; Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, FRANCE.

OP-0937New Targets for Thyroid Cancer in Pre-Clinical ResearchC. D’Alessandria; Head of Radiopharmacy, Nuclear Medicine Department, Klinikum rechts der Isar of Technical University of Munich, Munich, GERMANY.

OP-0938PSMA in Thyroid CancerM. Sollini; Humanitas University, Nuclear Medicine Division, Milan, ITALY.

OP-0939PRRT and Alpha Emitters in Thyroid CancerD. Deandreis; Director of Nuclear Medicine Division, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienza, Turin, ITALY.

1707


Teaching Session 6: Animal Models - Technical Considerations and Recommendations

OP-0878Animal models: general aspectsC. Baun; Department of Nuclear Medicine, The Preclinical Imaging Facility, Odense University Hospital , Odense, DENMARK.

OP-0879Animal models for the evaluation of radiopharmaceuticalsM. Toussaint; Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research in the Helmholtz-Zentrum Dresden-Rossendorf, Leipzig, GERMANY.

OP-0880How to avoid errors in translation?T. Balber; Ludwig Boltzmann Institute Applied Diagnostics, Applied Translational Research, Vienna, AUSTRIA.

1709


Cutting Edge Science Track - TROP Session: Data/Image Processing Based on Deep Learning

OP-0941Deep Learning for Predicting Gamma-Ray Interaction Positions in LYSO DetectorC. Clement1, G. Birindelli1, M. Pizzichemi2, F. Pagano2, A. Rominger1, E. Auffray2, K. Shi1; 1Inselspital, Bern, SWITZERLAND, 2CERN, Geneva, SWITZERLAND.

OP-0942Monte Carlo-based assessment of a deep learning-based method for acceleration of SPECT imaging by generating synthetic projectionsJ. Leube1, M. Salas-Ramirez1, M. Lassmann1, J. Gustafsson2, J. Tran-Gia1; 1Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, 2Department of Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, SWEDEN.

OP-0943Deep learning-based time-of-flight (TOF) PET image enhancement of non-TOF PET/CT scansA. Mehranian1, S. D. Wollenweber2, M. D. Walker3, K. M. Bradley4, P. Fielding5, M. W. Huellner6, F. Kotasidis7, K. Su2, R. Johnsen2, F. Jansen2, D. R. McGowan8,3; 1GE Healthcare, Oxford, UNITED KINGDOM, 2GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA, 3Oxford University Hospitals NHS FT, Oxford, UNITED KINGDOM, 4Wales Research and Diagnostic PET Imaging Centre, University Hospital of Wales, Cardiff, UNITED KINGDOM, 5Department of Radiology, University Hospital of Wales, Cardiff, UNITED KINGDOM, 6Zurich University Hospital, Zurich, SWITZERLAND, 7GE Healthcare, Zurich, SWITZERLAND, 8Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.

OP-0944Whole body non-rigid PET/CT alignment using synthetic CT generation from non-attenuation corrected 18F-FDG PET images with a 3D CycleGANS. Khushu1, C. CA von Gall2, M. Reymann3, L. Sibille2, B. Spottiswoode2, P. Ritt4, T. Kuwert4, V. Shah2; 1FAU Erlangen, Erlangen, GERMANY, 2Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA, 3Siemens Healthcare GmbH, Erlangen, Germany, Erlangen, GERMANY, 4Clinic of Nuclear Medicine University Hospital Erlangen, Erlangen, GERMANY.

OP-0945The clinical performance of artificial intelligence based PET denoising on a digital PET/CTK. Weyts, C. Lasnon, R. Ciappuccini, J. Lequesne, E. Quak, A. Corroyer Dulmont, B. Clarisse, L. Roussel, S. Bardet, C. Jaudet; Centre François Baclesse, Caen, FRANCE.

OP-0946Sparse deep-learning: Multi-organ objective segmentation (MOOSE) for 18F-FDG PET/CT total body datasetsL. Shiyam Sundar, O. Kulturer, B. Fueger, T. Nakuz, D. Kifjak, M. Hacker, T. Beyer; Medical University of Vienna, Vienna, AUSTRIA.

OP-0947Evaluation of a Deep Learning Skeleton Segmentation Method to Aid in the Identification of PSMA-positive Bone LesionsV. Gopalakrishnan, P. Soroush, K. Dong, C. Halley, M. Bending, A. Kruzer, A. S. Nelson; MIM Software, Beachwood, OH, UNITED STATES OF AMERICA.

OP-0948Automated analysis of total tumour burden on Ga-68 PSMA PET/CT using convolutional neural network and novel watershed filteringL. McIntosh1,2, J.P. Buteau3, P. Jackson1,4, J. Ferdinandus5, N. Hardcastle1,6,7, R. Franich2,1, M. Hofman3,6; 1Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 2School of Science, RMIT University, Melbourne, AUSTRALIA, 3Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 4Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 5Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY, 6Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, AUSTRALIA, 7Centre for Medical Radiation Physics, University of Wollongong, Wollongong, AUSTRALIA.

OP-0949Comparison of Deep Learning-Based Glioma Segmentation Using [18F]FET PET Data With Clinically Established Threshold MethodsB. Kotulski, A. Holzgreve, J. Brosch-Lenz, A. Gosewisch, G. Böning, P. Bartenstein, N. L. Albert, S. Ziegler, L. Kaiser; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY.

OP-0950Automatic lesion detection and segmentation in PSMA PET/CT images using deep neural networksY. Xu1, I. Klyuzhin1,2,3, S. Harsini2, A. Ortiz1, A. Rahmim2,3, J. Lavista Ferres1; 1Microsoft AI for Good Research Lab, Redmond, WA, UNITED STATES OF AMERICA, 2BC Cancer Research Institute, Vancouver, BC, CANADA, 3University of British Columbia, Vancouver, BC, CANADA.

OP-0951Development of a Deep Learning Natural Language Processing Model for Classification of Lung Cancer Radiology ReportsS. Mithun1,2,3, A. K. Jha1,2,3, U. B. Sherkhane1,2, V. Jaiswar2, A. Nautiyal2,3, N. C. Purandare2,3, V. Rangarajan2,3, A. Dekker1, L. Wee1; 1Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, NETHERLANDS, 2Tata Memorial Hospital, Mumbai, INDIA, 3Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.

OP-095218F-FDG dynamic brain PET study estimating the arterial plasma radioactivity curve using a convolutional neural network (CNN)K. Kawauchi, C. Katoh; Hokkaido University, Sapporo, JAPAN.

1710


Clinical Oncology Track - Featured Session: Neuroendocrine Therapy

OP-0954What is coming after NETTER-1?V. Prasad; Department of Nuclear Medicine, Uniklinik Ulm, Ulm, GERMANY.



153152

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0955Comparison Between Standard and Intensive Radionuclide Therapy with 177LU-DOTATATE in Advanced Neuroendocrine Tumors: Preliminary Results from a Randomized Phase II StudyI. Grassi1, M. Monti2, S. Nicolini1, M. Sansovini1, F. Foca2, M. Caracciolo3, A. Corrado1, L. Fabbri4, V. Fausti5, S. Severi1, G. Paganelli1; 1Nuclear medicine department IRST “Dino Amadori” IRCCS Meldola, Meldola Fc, ITALY, 2Unit of Biostatistics and Clinical Trials IRST “Dino Amadori” IRCCS Meldola, Meldola Fc, ITALY, 3Nuclear Medicine Unit, University of Ferrara, Ferrara, ITALY, 4Unit of Biostatistics and Clinical Trials IRST “Dino Amadori” IRCCS, Meldola Fc, ITALY, 5Osteoncology and Rare Tumors Center IRST “Dino Amadori” (IRST), IRCCS, Meldola Fc, ITALY.

OP-0956A Phase I/II Clinical Trial for High-dose 131I-meta-iodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Single Myeloablative Chemotherapy and Hematopoietic Stem Cell TransplantationH. Wakabayashi1, R. Kuroda2, R. Araki2, A. Inaki1, R. Nishimura2, Y. Ikawa2, K. Yoshimura3, T. Murayma4, Y. Imai5, T. Funasaka5, T. Wada2, S. Kinuya1; 1Dept of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN, 2Dept of Pediatrics, Kanazawa University Hospital, Kanazawa, JAPAN, 3Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, JAPAN, 4Dept of Clinical Development, Kanazawa University Hospital, Kanazawa, JAPAN, 5Innovative Clinical Research Center, Kanazawa University, Kanazawa, JAPAN.

OP-0957Health-related quality of life during and the years after peptide receptor radionuclide therapy in patients with neuroendocrine tumorsC. Andersson1, P. Hellman1, D. Granberg2, P. Lagergren2, E. Thiis-Evensen3, A. Sundin1, K. Edfeldt1; 1Dept. of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 2Dept. of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SWEDEN, 3Dept. of Gastroenterology, Oslo University Hospital, Oslo, NORWAY.

OP-0958Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN): PRRT in the Treatment of Neuroendocrine Tumor (NET) PatientsS. Dureja1, T. Kolarova2, M. McDonnell3, D. Van Genechten4, C. Bouvier5, E. Gellerman6, D. O’Toole7, H. Singh8, J. Chen9, J. Howe10, S. Singh11, M. Pavel12, C. Rodien-Louw13, S. Leyden14, R. Hicks15; 1SMH Cancer Centre, New Delhi, INDIA, 2International Neuroendocrine Cancer Alliance (INCA), Boston, MA, UNITED

STATES OF AMERICA, 3NET Patient Network, Dublin, IRELAND, 4vzw NET & MEN Kanker Belgium, Kortrijk, BELGIUM, 5Neuroendocrine Cancer UK, Leamington Spa, UNITED KINGDOM, 6NET Research Foundation (NETRF), Boston, MA, UNITED STATES OF AMERICA, 7National Centre for Neuroendocrine Tumours, St. Vincent’s University and Department of Clinical Medicine, St. James Hospital and Trinity College, Dublin, IRELAND, 8Prince Court Medical Centre, Kuala Lumpur, MALAYSIA, 9Department of Gastroenterology, the First Affiliated Hospital Sun Yat-Sen University, Guangzhou, CHINA, 10University of Iowa Carver College of Medicine, Iowa City, IA, UNITED STATES OF AMERICA, 11Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, CANADA, 12Department of Endocrinology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, GERMANY, 13APTED France, Lyon, FRANCE, 14NeuroEndocrine Cancer Australia, Blairgowrie, AUSTRALIA, 15Peter MacCallum Cancer Center, Melbourne, AUSTRALIA.

OP-0959Lutetium177 in patients with stage IV neuroendocrine tumours of any origin. Data from 321 patients of the multicenter national registryM. Mitjavila Casanovas1, P. Belló2, V. Pubul3, A. García4, J. Arbizu5, T. Navarro6, D. Marin7, M. Castellón8, C. Duran9, C. Field10, B. Llana11, B. Miguel12, M. Estorch13, J. Hernando14, A. Custodio15, A. Repetto16, J. Vercher-Conejero17, A. Muros18, J. Cano19, E. Caballero20, P. García21, C. Blanco22, J. Aller1, A. Carmona23, P. Jimenez-Fonseca11; 1Hospital Universitario Puerta de Hierro Majadahonda, Madrid, SPAIN, 2Hospital Universitario La Fe, Valencia, SPAIN, 3Hospital Universitario Santiago Compostela. , Santiago de Compostela, SPAIN, 4Hospital Universitario Vall d´Hebron, Barcelona, SPAIN, 5Clínica Universitaria Navarra., Pamplona, SPAIN, 6Hospital Universitario Ramón y Cajal, Madrid, SPAIN, 7Hospital Universitario 12 de Octubre, Madrid, SPAIN, 8Hospital Virgen de la Arrixaca, Murcia, SPAIN, 9Hospital General Universitario Gregorio Marañón, Madrid, SPAIN, 10Hospital Madrid Sanchinarro, Madrid, SPAIN, 11Hospital Universitario Central de Asturias, Oviedo, SPAIN, 12Hospital Universitario de Burgos, Burgos, SPAIN, 13Hospital Sant Pau, Barcelona, SPAIN, 14Hospital Universitario Vall d´hebron, Barcelona, SPAIN, 15Hospital Universitario La Paz, Madrid, SPAIN, 16Hospital Universitario Son Espases, Palma de Mallorca, SPAIN, 17ICO - Hospital Universitario Bellvitge, Barcelona, SPAIN, 18Hospital Universitario Virgen de las Nieves, Granada, SPAIN, 19Hospital General Universitario Ciudad Real, Ciudad Real, SPAIN, 20Hospital Universitario Doctor Peset, Valencia, SPAIN, 21Hospital Universitario Getafe, Madrid, SPAIN, 22Hospital Universitario Príncipe de Asturias, Madrid, SPAIN, 23Hospital General Universitario Morales Meseguer, Murcia, SPAIN.

OP-0960Peptide Receptor Radionuclide Therapy (PRRT) as neoadjuvant therapy in neuroendocrine tumors - one center experienceM. Opalinska1, A. Sowa-Staszczak2, A. Grochowska3, H. Zwinczewska2, A. Hubalewska-Dydejczyk1; 1Nuclear Medicine Unit, Endocrinology Department, University Hospital in Krakow, Krakow, POLAND, 2Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND, 3Department of Radiology, University Hospital, Krakow, POLAND.

OP-0961Effects of simplifications of absorbed dose calculation to the kidneys in later therapy sessions in patients with neuroendocrine tumours receiving 177Lu-Octreotate therapyM. Sandstrom1,2, M. Lubberink1,2, K. Fröss-Baron1, U. Garske-Román1, A. Sundin1; 1Nuclear medicine & PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 2Medical Physics, Uppsala, SWEDEN.

OP-0962Treatment of metastatic paragangliomas with 177Lu-DOTATATE: outcomes from a single centre experienceI. Próspero, S. F. Castro, C. Costa, J. Oliveira, H. Duarte, I. L. Sampaio, G. Ferreira; Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

OP-0963Prospective evaluation of glucose metabolism variations assessed with FDG PET/CT in a cohort of NET patients treated with PRRTL. Urso1, S. Panareo1, A. Castello1, M. Caracciolo1, I. Zamberlan1, N. Ortolan1, A. Nieri1, E. Tonini1, C. Morotti2, G. Valpiani2, L. Uccelli1, C. Cittanti1, M. Bartolomei1; 1Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Ferrara, ITALY, 2Research Innovation Quality and Accreditation Unit, University Hospital of Ferrara, Ferrara, ITALY.

OP-0964Predictive factors of adverse events onset in GEPNET patients treated with PRRTF. Scalorbi1, G. Argiroffi1, A. Lorenzoni1, M. Baccini2, L. Gherardini2, V. Fuoco1, N. Prinzi1, S. Pusceddu1, G. Calareso1, E. M. Garanzini1, S. Mazzaglia1, M. Milione1, C. Chiesa1, E. Seregni1, M. Maccauro1; 1Istituto Nazionale Tumori Milano, Milan, ITALY, 2Department of Statistics, University of Florence, Florence, ITALY.

OP-0965Diagnostic 68Ga-DOTATOC imaging parameters and correlations with absorbed dose from 177Lu-DOTATATE treatment in GEP-NET-patientsR. Bruvoll1,2, J. Blakkisrud1,2, L. Mikaelsen2,3, J. Connelly2, C. Stokke1,2; 1Department of Physics, University of Oslo, Oslo, NORWAY, 2Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, 3Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, NORWAY.

OP-0966Investigation of miRNAs as outcome predictors in midgut NET treated with PPRTF. Scalorbi, L. Roz, G. Pollaci, G. Centonze, V. Lagano, F. Facchinetti, G. Calareso, E. M. Garanzini, L. Cattaneo, M. Maccauro, M. Gariboldi, E. Seregni, M. Milione; Istituto Nazionale Tumori Milano, Milan, ITALY.

1711


TROP Session: General Nuclear Medicine

OP-0968Diagnostic value of early and late postvoid static imaging after diuretic renogram with [99mTc] Tc-MAG-3L. Del Barco Diez Canseco, S. Álvarez Ruíz, L. de la Cueva Barrao, P. Navarro Beltran, G. Guzman Prudencio, M. Calderon Calvente, N. Canchumanya Huatuco, M. Falgas Lacueva, M. Sangrós Sahún, D. Abós Olivares; Hospital Universitario Miguel Servet, Zaragoza, SPAIN.

OP-0969The Impact of Background ROI on Relative Renal Function in Different Patients SubsetsS. Fontão de Castro1, I. Póspero1, I. Lopo2, L. Sobral Violante1, R. Silva2, T. Saraiva2, H. Duarte1, G. Costa2; 1Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, PORTUGAL, 2Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL.

OP-0970Is diuretic renography useful in patients with Bricker procedure?D. Vega Perez, M. D. Marin Ferrer, A. Galiana Moron, P. Zaragoza Ballester, S. Ruiz Solis, A. Saviatto, E. Martinez Albero, V. M. Godigna Guilloteau, P. Pilkington Woll, P. Sarandeses Fernandez, A. Gomez Grande, M. J. Tabuenca Mateo; Hospital 12 de Octubre, Madrid, SPAIN.



155154

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-0971Dose Reduced [18F]PSMA-1007 PET is Feasible for Functional Imaging of the Renal CortexK. Valind1,2, G. Brolin1,3, J. Jögi1,2, D. Minarik1,3, E. Trägårdh1,2; 1Wallenberg Centre for Molecular Medicine, Lund University, Lund, SWEDEN, 2Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund and Malmö, SWEDEN, 3Radiation Physics, Skåne University Hospital, Lund and Malmö, SWEDEN.

OP-0972Evaluation of Dynamic Renal 68Ga-DOTA PET/CT to Monitor the Urinary Efflux and to Estimate the Glomerular Filtration Rate Using a Compartmental Kinetic Modelling ApproachD. Kersting1, M. Sraieb1, R. Seifert1, P. Fragoso Costa1, S. Kazek1, L. Umutlu2, M. Nader1, W. Fendler1, W. Jentzen1, K. Herrmann1, C. Rischpler1; 1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, 2Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY.

OP-0973Pulmonary embolism - a diagnostic dilemma with perfusion only SPECT/CT during the COVID 19 pandemicO. Evbuomwan, G. Engelbrecht; University of The Free State, Bloemfontein, SOUTH AFRICA.

OP-0974Contribution of Ventilation/Perfusion SPECT/CT in alternative diagnosis for pulmonary embolism suspicionL. Besson1, V. Habouzit1, M. Castan2, A. Viallon2, L. Bertoletti3, N. Prévôt-Bitot1, P. Bonnefoy1; 1Nuclear medicine department, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, FRANCE, 2Emergency department, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, FRANCE, 3Department of vascular and therapeutic medicine, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, FRANCE.

OP-0975Diagnosis of pulmonary embolism during COVID-19 pandemic: comparison of perfusion SPECT/CT to CTPAJ. C. Ferro, S. Carmona, R. T. Ferreira, A. I. Santos; Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL.

OP-0976Pre-surgical Prognostic Assessment by Mebrofenin 99mTc Scintigraphy in Patients Undergoing Resective Liver SurgeryJ. Uña, J. Valderrey Pulido, A. Allende Riera, C. Cárdenas Negro; Servicio Canario Salud, Santa Cruz de Tenerife, SPAIN.

OP-0977Quantitative approaches to selective spleen detection in Technetium-99m-labelled denatured red blood cells scintigraphy - a quantitative single centre analysisA. Holzgreve1, F. Völter1, A. Gosewisch1, M. P. Fabritius2, M. Brendel1, N. L. Albert1, P. Bartenstein1, M. Unterrainer2, L. M. Mittlmeier1; 1Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, 2Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY.

OP-0978Colorectal scintigraphy and abdominal ultrasound to assess bowel peristalsis during transanal irrigation in spinal cord injury patients: preliminary resultsG. Rubini1, A. Branca1, G. Frasca2, R. Sinisi2, D. F. Altomare3, A. Gaudiano1; 1Section of Nuclear Medicine, DIM, University “Aldo Moro”, Bari, ITALY, 2Physical and Medicine Rehabilitation Departement of Basci Science, Neuroscience and Sense Organs, University “Aldo Moro”, Bari, ITALY, 3Department of Emergency and Organ Transplantation, University of Bari., Bari, ITALY.

OP-0979Clinical usefulness of 99mTc-labelled heat-denatured red blood cell SPECT/CT in the investigation of suspected ectopic splenic tissueS. Georga, A. Kalaitzoglou, D. Katsampoukas, G. Arsos; 3rd Dept. of Nuclear Medicine, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, GREECE.

1801

Saturday, October 23, 2021, 09:00 - 10:30Channel 1

CME 13: Immunotheranostics

OP-0982Immunotherapy and Nuclear Medicine diagnostics - Where do we Stand?E. G. E. de Vries; University Medical Center Groningen (UMCG), Department of Medical Oncology, Groningen, NETHERLANDS.

OP-0983Combining Immunotherapy and Radiation - Is the Whole more than the Sum of its Parts?F. Herrera; Centre Hospitalier Universitaire Vaudois (CHUV), Department of Oncology, Division of Radiation Oncology, Lausanne, SWITZERLAND.

OP-0984Nuclear Medicine Immunotheranostics - Synergisms and AntagonismsN. Schaefer; Centre Hospitalier Universitaire Vaudois (CHUV), Department of Nuclear Medicine and Molecular Imaging, Lausanne, SWITZERLAND.

1802-1


Interview with the Expert 13 - The Patient interviews the Doctor – A Roman Conversation

OP-0986Interview - The Patient interviews the Doctor – A Roman ConversationI. Carrio; Research Institute, Hospital Sant Pau, Barcelona, SPAIN.

OP-0987Interview - The Patient interviews the Doctor – A Roman ConversationPatient, Rome, ITALY.

1802-2


Interview with the Expert 14 - Prostate Cancer Imaging – Girls Just Want to Have Fun(ctional) E-PSMA Guidelines

OP-0988Interview - Prostate Cancer Imaging – Girls Just Want to Have Fun(ctional) E-PSMA GuidelinesD. Oprea-Lager; Amsterdam University Medical Centers, Department of Radiology & Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0989Interview - Prostate Cancer Imaging – Girls Just Want to Have Fun(ctional) E-PSMA GuidelinesJ. Adam; Amsterdam University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

1804


Mini Course 3: Case Studies (Conventional Nuclear Medicine)

OP-0928Interesting Cases in Conventional Nuclear MedicineC. Pestean; Ion Chricuta Oncology Institute, Nuclear Medicine Department, Cluj Napoca, ROMANIA.

OP-0929How Clinic Affects the Image and its InterpretationM. Gazzilli; Spedali Civili, Nuclear medicine unit, Brescia, ITALY.

1805


Joint Symposium 25 (EANM/ESES/ESSO): Global Cost-Effectiveness of Different DTC Management Strategies

OP-0990Costs of OVER - Diagnosis, Treatment and Follow-up of DTC Patients. How to Get Out of “a Vicious Circle”?T. Geliashvili; N.N. Blokhin National Medical Research Center of Oncology (N.N. Blokhin NMRCO), Department of radionuclide therapy department, Moscow, RUSSIA.

OP-0991 Is Active Surveillance of Micro-Differentiated Thyroid Carcinoma Really Cheaper than Surgical Approach?M. Raffaelli; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Division of Endocrine and Metabolic Surgery, Department of Medical and Surgical Sciences, Rome, ITALY.

OP-0992Сost-Effectiveness of Different Surgical Approaches in Differentiated Thyroid Cancer PatientsJ. Gómez-Ramírez; Hospital Ramón y Cajal, Madrid, SPAIN.

OP-0993Cost-Effectiveness of Postsurgical Pretreatment Radioiodine ImagingJ. Mihailovic; Oncology institute of Vojvodina, Department of Nuclear Medicine, Sremska Kamenica, SERBIA.



157156

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1806


Joint Symposium 26 (EANM/ESMI/WMIS): Imaging Mitochondria and Mitochondrial Dysfunction

OP-0995Imaging Mitochondrial Dysfunction in the Context of NeuroinflammationC. Barca; Westfälische Wilhelms-Universität Münster, European Institute for Molecular Imaging (EIMI), Münster, GERMANY. (Talk not uploaded)

OP-0996Value of TSPO Imaging in Cardiac DiseaseJ. Thackeray; Hannover Medical School, Department of Nuclear Medicine, Translational Cardiovascular Molecular Imaging, Hannover, GERMANY.

OP-0997Imaging Oxidative Stress in Neurodegenerative DiseasesH. Okazawa; University of Fukui, Biomedical Imaging Research Center, Fukui, JAPAN.

OP-0998In Vivo Imaging of Mitochondrial Membrane Potential in CancerM. Han; UCLA, David Geffen School of Medicine, Division of Pulmonary and Critical Care Medicine, Los Angeles, UNITED STATES OF AMERICA.

1809


Cutting Edge Science Track - TROP Session: Artificial Intelligence - Clinical Applications

OP-1000PBPK Model Based Voxel-wise Prediction of Post-therapy Dosimetry for 177Lu-PSMA I&T TherapyS. Xue1, A. Gafita2, M. Drobnjakovic1, Y. Zhao2, G. Birindelli1, A. Afshar-Oromieh1, M. Eiber2, A. Rominger1, K. Shi1; 1University of Bern, Bern, SWITZERLAND, 2Technical University of Munich, Munich, GERMANY.

OP-1001A Neural Network Add-on to Classify I123-Ioflupane ImagesJ. McCormick, R. Staff; NHS Grampian, Aberdeen, UNITED KINGDOM.

OP-1002Prediction of Major Adverse Cardiac Events after Myocardial Perfusion Imaging using multi-task deep neural network and time-to-event dataK. Pieszko1, A. Singh1, A. Killekar1, Y. Otaki1, T. Sharir2, A. J. Einstein3, M. B. Fish4, T. D. Ruddy5, P. Kaufmann6, A. J. Sinusas7, E. J. Miller7, T. M. Bateman8, S. Dorbala9, M. Di Carli9, D. Dey1, J. Liang1, D. S. Berman1, P. J. Slomka1; 1Department of Imaging (Division of Nuclear Medicine), Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, 2Department of Nuclear Cardiology, Assuta Medical Centers, Tel Aviv, ISRAEL, 3Division of Cardiology, Department of Medicine, and Department of Radiology, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, UNITED STATES OF AMERICA, 4Oregon Heart and Vascular Institute, Sacred Heart Medical Center, Springfield, OR, UNITED STATES OF AMERICA, 5Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, CANADA, 6Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Zurich, SWITZERLAND, 7Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Heaven, CT, UNITED STATES OF AMERICA, 8Cardiovascular Imaging Technologies LLC, Kansas City, MT, UNITED STATES OF AMERICA, 9Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Brigham and Women’s Hospital, Boston, ME, UNITED STATES OF AMERICA.

OP-1003A convolutional neural network-based program to predict nodal metastasis of non-small cell lung cancer in18F-FDG PETE. Kidera, S. Koyasu, T. Ishimori, Y. Nakamoto; Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, JAPAN.

OP-1004Artificial Intelligence based outcome classification from baseline 18F-FDG PET/CT in de novo diffuse Large B-cell lymphoma patientsR. Boellaard1, D. Wesseling1, C. Eertink1, B. de Vries1, E. Lugtenburg2, B. Zwezerijnen1, S. Wiegers1, R. Vet1, S. Golla1, J. Zijlstra1; 1Amsterdam University Medical Centers, Amsterdam, NETHERLANDS, 2Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS.

OP-1005Bone scintigraphy classification: a comparison between machine learning and deep learning classifiers using imaging data onlyM. Silva1,2,3, F. Oliveira1, J. Castanheira1, Â. Silva1, L. Vieira4, D. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 2Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, 3Mercurius Health, Oeiras, PORTUGAL, 4Health and Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, PORTUGAL.

OP-1006Estimation of FAZA-uptake regions in high-grade glioma from MR images: a preliminary transfer learning artificial intelligence studyL. Presotto1, C. Bezzi2, V. Bettinardi1, S. Ghezzo2, P. Mapelli2,1, F. Fallanca1, B. Catalfamo3, A. Castellano4,2, G. Conte5, I. Neri1, C. Monterisi1, A. Panzacchi1, P. Scifo1, L. Gianolli1, N. Anzalone4,2, P. Maria1,2; 1Nuclear Medicine Unit, IRCCS Ospedale San Raffaele, Milan, ITALY, 2Vita-Salute San Raffaele University, Milan, ITALY, 3University of Messina, Messina, ITALY, 4Department of neuroradiology, IRCCS Ospedale San Raffaele, Milan, ITALY, 5Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA.

OP-1007An exploratory study of the application of convolutional neural networks to 99mTc-DPD scans for amyloidosis classificationE. Sousa1,2, A. Tweddel2, G. Avery2, A. Turner3, S. J. Archibald1,2; 1Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, Hull, UNITED KINGDOM, 2Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust, Castle Road, Cottingham, East Yorkshire, HU16 5JQ, Hull, UNITED KINGDOM, 3School of Computer Science, University of Nottingham, Computer Science Building, Wollaton Rd, Lenton, Nottingham NG8 1BB, Nottingham, UNITED KINGDOM.

OP-1008Fully Automated Detection and Segmentation of Hypermetabolic Lesions in Pretherapeutic [18F]FDG PET / CT Images of Lymphoma and Sarcoidosis PatientsA. Iantsen1, P. Lovinfosse2, M. Ferreira3, A. Jadoul2, N. Withofs2, C. Derwael2, A. Frix4, J. Guiot4, D. Visvikis1, M. Hatt1, R. Hustinx2,3; 1LaTIM, INSERM, UMR 1101, Univ Brest, Brest, FRANCE, 2Division of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, BELGIUM, 3GIGA-CRC in vivo Imaging, University of Liège, Liège, BELGIUM, 4Pneumology Department, University Hospital of Liège, Liège, BELGIUM.

OP-1009A Fully Automated Method For Bladder Segmentation In PSMA PET/CT ScansY. Farag1, R. de Schaetzen1, G. Chaussé2, F. Yousefirizi1, I. Klyuzhin2, A. Rahmim2,3, C. Uribe2,3; 1BC Cancer Research Institute, Vancouver, BC, CANADA, 2BC Cancer, Vancouver, BC, CANADA, 3Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

OP-1010Classification of the image embeddings extracted from pretrained CNNs using tree-based models: a proof-of-concept study in medical imagingN. Gozzi1, E. Giacomello2, M. Sollini3,1, M. Kirienko4, C. Jones5, P. Lanzi2, D. Loiacono2, A. Chiti3,1; 1IRCCS Humanitas Research Hospital, Rozzano - Milan, ITALY, 2Dipartimento di Elettronica, Informazione e Bioingengeria, Politecnico di Milano, Milan, ITALY, 3Department of Biomedical Sciences, Humanitas University, Pieve Emanuele - Milan, ITALY, 4Fondazione IRCCS Istituto Nazionale Tumori, Milan, ITALY, 5Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, ITALY.

OP-1011Automatic PET image quality control using Convolutional Neural NetworksE. Pfaehler; University of Augsburg, Augsburg, GERMANY.



159158

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1810


Clinical Oncology Track - TROP Session: Lymphoma and Other Hematological Tumours

OP-1013Reliability of Deauville Scale for Lymphoma PET assessment in FIL and IELSG multi-center clinical trialsF. Bergesio1, L. Guerra2, F. Fallanca3, M. Gregianin4, S. Morbelli5, U. Ficola6, S. Peano7, G. Storto8, A. Franceschetto9, L. Melis10, E. Borsasti11, G. Treglia12, L. Ceriani12, A. Versari13, S. Chauvie1; 1Medical Physics Division, S. Croce e Carle Hospital, Cuneo, ITALY, 2Nuclear Medicine Division, S. Gerardo Hospital, Monza, ITALY, 3Nuclear Medicine Division, S. Raffaele Hospital, Milan, ITALY, 4Nuclear Medicine Division, Istituto Oncologico Veneto IRCCS, Padua, ITALY, 5Nuclear Medicine Division, S.Martino Hospital, Genova, ITALY, 6Nuclear Medicine Division, La Maddalena Hospital, Palermo, ITALY, 7Nuclear Medicine Division, S. Croce e Carle Hospital, Cuneo, ITALY, 8Nuclear Medicine Division, IRCCS CROB, Rionero in Vulture, ITALY, 9Nuclear Medicine Division, AO Universitaria, Modena, ITALY, 10Nuclear Medicine Division, A. Businco Hospital, Cagliari, ITALY, 11Nuclear Medicine Division, CRO Hospital, Aviano, ITALY, 12Nuclear Medicine Division, IOSI Hospital, Bellinzona, SWITZERLAND, 13Nuclear Medicine Division, S. Maria Nuova Hospital, Reggio Emilia, ITALY.

OP-1014The superiority of [18F]-FDG over 68Ga-FAPI-04 PET/CT in diagnosis of various types of lymphomaX. Chen, T. Yuan, M. Wei, X. Wang; Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-10152-[18F]FDG-PET/CT imaging and radiomics as predictors of early response in patients with lymphoma undergoing chimeric antigen receptor T-cell therapy (CAR-T)A. Paccagnella, A. Farolfi, G. Paolani, G. Della Gala, M. Santoro, C. Malizia, B. Casadei, S. Mattoni, L. Strigari, P. Zinzani, S. Fanti; IRCCS Azienda Ospedaliero-Universitaria, Bologna, ITALY.

OP-1016Lesion dissemination feature (Dmax) calculated at baseline PET/CT improves risk stratification of ABVD treated Hodgkin Lymphoma patientsR. Durmo1,2, A. Cottereau3, L. Rebaud4, C. Nioche4, A. Ruffini5, F. Fioroni1, S. Luminari1, F. Merli1, M. Meignan6, I. Buvat4, A. Versari1; 1AUSL-IRCCS of Reggio Emilia, Reggio Emilia, ITALY, 2PhD program in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, ITALY, 3Department of Nuclear Medicine, Cochin Hospital, AP-HP, University of Paris, Paris, FRANCE, 4LITO laboratory, UMR 1288 Université Paris Saclay/Inserm/Institut Curie, Orsay, FRANCE, 5GRADE Onlus, Reggio Emilia, ITALY, 6Lysa Imaging, Henri Mondor University Hospital, AP-HP, University Paris East, Creteil, FRANCE.

OP-1018Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in primary gastric DLBCLD. Albano, F. Dondi, A. Mazzoletti, P. Bellini, M. Gregorelli, A. Calabrò, L. Camoni, F. Bertagna, R. Giubbini; University of Brescia and Spedali Civili of Brescia, Brescia, ITALY.

OP-1019Interim FDG PET/CT Predicts Response to Treatment and Outcome in Hodgkin’s Lymphoma Patients; Experience from KHCC Tertiary Cancer Center in JordanA. Al-Ibraheem1, F. M. Anwer1, Q. Shagera2, M. Juweid3, A. N. Khalaf1, M. Ma’koseh1; 1King Hussein Cancer center, Amman, JORDAN, 2Institute Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 3Jordan University, Amman, JORDAN.

OP-1020Automatic lymph lesion quantification by artificial intelligence in lymphoma patients examined with [18F]FDG PET/CTM. Sadik1, J. López-Urdaneta1, J. Ulén2, O. Enqvist3, P. Andersson4, E. Trägårdh5, L. Edenbrandt1; 1Nuclear Medicine, Gothenburg, SWEDEN, 2Eigenvision AB, Malmö, SWEDEN, 3Eigenvision AB and Electrical Engineering, Malmö and Gothenburg, SWEDEN, 4Haematology and Medicine, Borås and Gothenburg, SWEDEN, 5Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN.

OP-1021The prognostic significance of 18F-FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)C. Sachpekidis1, M. Merz2, V. Weru3, A. Kopp-Schneider3, A. Jauch4, H. Goldschmidt2, A. Dimitrakopoulou-Strauss1; 1Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, 2Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, GERMANY, 3Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, 4Institute for Human Genetics, University of Heidelberg, Heidelberg, GERMANY.

OP-1022The Relationship Between Bone Marrow Involvement on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and Bone Marrow Biopsy in Patients with Multiple MyelomaK. Gebreslassie1, F. Bassa2, J. Warwick1, Z. Chapanduka3; 1Stellenbosch University, Tygerberg Hospital, Nuclear Medicine Division, Cape Town, SOUTH AFRICA, 2Stellenbosch University, Tygerberg Hospital, Haematology Division, Cape Town, SOUTH AFRICA, 3Stellenbosch University, Tygerberg Hospital, Hematopathology Division, Cape Town, SOUTH AFRICA.

OP-1023Semi-automated extraction and histogram analysis of physiological uptake in bone marrow with 18F-FDG PET/CTY. Satoh1,2, S. Funayama2, M. Imai1, H. Onishi2; 1Yamanashi PET Imaging Clinic, Chuo, JAPAN, 2University of Yamanashi, Department of Radiology, Chuo, JAPAN.

OP-1024Correlation between Baseline PET/CT Findings and Clinical Parameters in Multiple Myeloma PatientsA. Arçay1, F. Aydın1, C. N. Dündar Çağlayan1, E. Vural2, U. Iltar2, M. N. Engin1, Z. G. Kıprak1, A. Boz1; 1Akdeniz University Hospital, Department of Nuclear Medicine, Antalya, TURKEY, 2Akdeniz University Hospital, Department of Internal Medicine, Antalya, TURKEY.

1811


TROP Session: Nuclear Thyroidologist and Thyroid Cancer Management - Current Update and Future Perspectives

OP-102668Ga-FAPI PET/CT Accuracy In Patients With Recurrent Papillary Thyroid CarcinomaU. Elboga, Z. Sayıner, E. Sahin, S. Ozturk, Y. Cayirli, Y. Celen, E. Akarsu; Gaziantep University, Gaziantep, TURKEY.

OP-1027Diagnostic Radioiodine Scintigraphy After the First Radioiodine Treatment in High-risk Thyroid Cancer: Is it Necessary?A. Bay1, K. Vase Jepsen1, N. Møldrup Jakobsen1, O. Gerke1, L. Bastholt2, M. Grubbe Hildebrandt1, P. Grupe1; 1Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, 2Department of Oncology, Odense University Hospital, Odense, DENMARK.

OP-1028Targeting the Amyloid with [18F]AV-45 for Medullary Thyroid Carcinoma PET/CT ImagingC. Li1, P. Zhang2, R. Nie1, X. Gong1, J. Xie1, Z. Yu3, R. Yan*3, Z. Lu*1; 1Department of Nuclear Medicine, First Affiliated Hospital of Dalian Medical University, Da Lian, CHINA, 2Department of Pathology, First Affiliated Hospital of Dalian Medical University, Da Lian, CHINA, 3King’s College London, School of Biomedical Engineering and Imaging Sciences, St. Thomas’ Hospital, SE1 7EH, London, UNITED KINGDOM.

OP-102999mTc-Hynic-TOC Scan in Differentiated Thyroid Cancer Patients with Negative 131I Whole-Body Scan: low cost but relatively effective methodA. Aghaei, K. Aryana, E. Askari, P. Jahan Panah, N. Ayati, S. Shafiei, S. Zakavi; Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-1030Multivariate analysis of initial prognostic factors in pediatric differentiated thyroid carcinoma after RAI: a multicentric Italian experienceD. Albano1, N. Quartuccio2, F. Dondi1, A. Campennì3,4, M. Siracusa3, S. Panareo5, L. Urso5, M. Bartolomei5, S. Scotti6, D. De Palma6, A. Piccardo7, M. Massollo7, M. Garganese8, M. Villani8, M. Pizzoferro8, C. Altini8, A. Grossi9, S. Baldari3, F. Bertagna1, R. Giubbini1, A. Cistaro10,11;



161160

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

1University of Brescia and Spedali Civili of Brescia, Brescia, ITALY, 2A.R.N.A.S. Ospedale Civico Di Cristina Benfratelli, Palermo, ITALY, 3Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY, 4Thyroid Committee, European Association of Nuclear Medicine, Vienna, AUSTRIA, 5Nuclear Medicine Department, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, ITALY, 6Nuclear Medicine Unit, ASST-Settelaghi, Varese, ITALY, 7Nuclear Medicine Unit, Ente Ospedaliero Ospedali Galliera, Genova, ITALY, 8Diagnostic Imaging Department - Nuclear Medicine Unit, IRCCS Bambino Gesù Pediatric Hospital, Rome, ITALY, 9DPUO, Endocrine Unit, IRCCS Bambino Gesù Pediatric Hospital, Rome, ITALY, 10Nuclear Medicine Division, Salus Alliance Medical, Genova, ITALY, 11Pediatric Study Group Committee, Italian Association of Nuclear Medicine and Molecular Imaging, Milan, ITALY.

OP-1031Clinical Analysis of Differentiated Thyroid Cancer in Pediatric Age Group: A Single Medical Institution Experience of 33 YearsH. Nalbant, S. Gülbahar Ateş, B. B. Demirel, G. Uçmak; Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TURKEY.

OP-1032Mapping of Iodine Avidity in Papillary Thyroid Cancer Reveal Associations with Thyroglobulin Expression and Tissue ProliferationJ. Nilsson, J. Siikanen, C. Hedman, C. Juhlin, C. Ihre Lundgren; Karolinska Institutet, Stockholm, SWEDEN.

OP-1033Ablative treatment with131I in low-risk papillary thyroid cancer: is low-dose as effective as high-dose?A. Roteta Unceta Barrenechea1,2, A. Andrés Gracia1,2, L. Tardin Cardoso1, Y. Saker Diffalah1, P. Razola Alba1, T. Escalera Temprado1, M. Delgado Castro1, E. Prats Rivera1, M. Abós Olivares1; 1UCMHMNA - Clinic Hospital “Lozano Blesa”, Zaragoza, SPAIN, 2IIS-Aragón, Zaragoza, SPAIN.

OP-1034Prospective, observational study on radioiodine treatment in DTC patients with intermediate risk or micro lymph node metastasesA. Ledwon, A. Blewaska, E. Paliczka-Cieslik, T. Olczyk, A. Sygula, A. Kropinska, E. Lewandowska-Jablonska, D. Handkiewicz-Junak; Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Department of Nuclear Medicine and Endocrine Oncology, Gliwice, POLAND.

OP-1035Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysisL. Piscopo1, M. Klain1, C. Nappi1, E. Zampella1, V. Gaudieri1, V. Cantoni1, R. Green1, F. Volpe1, M. Manganelli1, E. Caiazzo1, M. De Risi1, M. Petretta2, M. Schlumberger1, A. Cuocolo1; 1Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, 2IRCCS SDN, Naples, ITALY.

OP-1036Recurrence-free survival and prognostic factors after adjuvant therapy with radioactive iodine-131 in patients with differentiated thyroid carcinomaY. Iizuka1,2, T. Katagiri2, K. Ogura2, M. Inoue2, K. Nakamura2, T. Mizowaki2; 1Shizuoka City Shizuoka Hospital, Shizuoka, JAPAN, 2Kyoto University, Kyoto, JAPAN.

OP-1037Anxiety And Depression In Patients With Differentiated Thyroid Carcinoma (DTC) Treated With Radioiodine In The Pandemic YearB. Pérez López1, Á. Sánchez-Anguita Muñoz2, E. Martín Gómez3, F. Pulido López3, J. De la Torre Laso2, A. Álvarez Delgado3, R. Ruano Pérez1; 1Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN, 2University of Salamanca, Salamanca, SPAIN, 3Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN.

1901


CME 14: Probing Tumour Metabolism - An Update

OP-1040Imaging Nucleoside Transport for Monitoring Targeted Therapy in CancerF. Iommelli; National Research Council, Institute of Biostructures and Bioimages, Naples, ITALY.

OP-1041Illuminating Metabolic Heterogeneity and Vulnerabilities in Lung CancerD. Lewis; Cancer Research UK Beatson Institute, Glasgow, UNITED KINGDOM.

OP-1042Imaging Tumour Metabolism and its Heterogeneity with MRIF. Gallagher; Department of Radiology, University of Cambridge, Cambridge, UNITED KINGDOM.

1902-1


Special Talk by Declan Murphy

OP-1045Prostate Cancer along the Yellow Brick RoadD. Murphy; Consultant Urologist & Director of Genitourinary Oncology, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

1902-2


Interview with the Expert 15 - Reflections on the Development of PET and Theranostics Downunder - A 25-Year Journey into the Light

OP-1046Interview - Reflections on the Development of PET and Theranostics Downunder - A 25-Year Journey into the LightR. Hicks; The Sir Peter MacCallum Cancer Center, Department of Oncology, Molecular Imaging and Therapeutic Nuclear Medicine, Melbourne, AUSTRALIA.

OP-1047Interview - Reflections on the Development of PET and Theranostics Downunder - A 25-Year Journey into the LightJ. J. Morigi; Royal Darwin Hospital, PET/CT centre, Darwin, AUSTRALIA.

1905


Joint Symposium 27 (EANM/JSNM): Advances in Molecular Imaging of Neurodegenerative Disorders

OP-1049Advances in Tau ImagingL. Beyer; Ludwig Maximillian University Munich, Department of Nuclear Medicine, Munich, GERMANY.

OP-1050Advances in MAO-B ImagingR. Harada; Tohoku University Graduate School of Medicine, Department of Pharmacology, Sendai, JAPAN.

OP-1051Advances in Synaptic Density ImagingK. Van Laere; Catholic University Leuven, Department of Nuclear Medicine, Leuven, BELGIUM.

OP-1052Advances in Alpha-Synuclein ImagingM. Ono; National Institutes for Quantum and Radiological Science and Technology, Department of Functional Brain Imaging Research, Chiba, JAPAN.

1906


Joint Symposium 28 (EANM/IAEA): Lancet Oncology Commission on Medical Imaging and Nuclear Medicine

OP-1095The Lancet Oncology CommissionsD. Collingridge; The Lancet Oncology, London, UNITED KINGDOM.

OP-1096Goals and Scope of the Lancet Oncology Commission on Medical Imaging and Nuclear MedicineD. Paez; Division of Human Health, International Atomic Energy Agency, Vienna, AUSTRIA.



163162

FI

NA

L P

RO

GR

AM

ME

| O

RA

L P

RE

SE

NT

AT

ION

S OR

AL

PR

ES

EN

TA

TIO

NS

| FI

NA

L P

RO

GR

AM

ME

OP-1097Global Utilization of Imaging and Nuclear Medicine in OncologyA. Scott; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, AUSTRALIA.

OP-1098Health Economic Analysis of Cancer ImagingR. Atun; Centre for Health Decision SCience, Harvard TH Chan School of Public Health, Boston, UNITED STATES OF AMERICA.

OP-1099Overview and RecommendationsH. Hricak; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.

1909


Cutting Edge Science Track - TROP Session: Radiomics - Methodology and Clinical Applications

OP-1054How to improve the transportability of radiomic models?F. Orlhac1, C. Nioche1, M. Soussan1,2, I. Buvat1; 1LITO, U1288 Inserm/Institut Curie, Orsay, FRANCE, 2AP-HP, Université Paris 13, Hôpital Avicenne, Department of Nuclear Medicine, Bobigny, FRANCE.

OP-1055Comparison of multicentre harmonization strategies: ComBat harmonization vs. pre-selection based on robustnessR. Da-ano1, F. Lucia1,2, I. Masson1,3, R. Abgral4, J. Alfieri5, C. Rousseau6, A. Mervoyer3, C. Reinhold7,8, O. Pradier1,2, U. Schick1,2, D. Visvikis1, M. Hatt1; 1INSERM - DR GRAND OUEST/ LaTIM U1101, Brest, FRANCE, 2Radiation Oncology Department, University Hospital, Brest, FRANCE, 3Department of Radiation Oncology, Institut de cancérologie de l’Ouest René-Gauducheau, Saint-Herblain, FRANCE, 4Department of Nuclear Medicine, University of Brest, Brest, FRANCE, 5Department of Radiation Oncology, McGill University Health Centre, Montreal, QC, CANADA, 6Department of Nuclear Medicine, Institut de cancérologie de l’Ouest René-Gauducheau, Saint-Herblain, FRANCE, 7Department of Radiology, McGill University Health Centre, Montreal, QC, CANADA, 8Augmented Intelligence & Precision Health Laboratory of the Research Institute of McGill University Health Centre, Montreal, QC, CANADA.

OP-1057A radiomic signature based on features extracted from baseline 18F-FDG PET/CT predicts 2-year PFS in Hodgkin Lymphoma patientsR. Durmo1,2, V. Trojani1, M. Casali1, F. Fioroni1, A. Ruffini3, S. Luminari1, F. Merli1, M. Iori1, A. Versari1, M. Bertolini1; 1AUSL-IRCCS of Reggio Emilia, Reggio Emilia, ITALY, 2PhD program in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, ITALY, 3GRADE Onlus, Reggio Emilia, ITALY.

OP-1058From multidimensional (PET radiomics, clinical and semantic) to patient-based “short-format” fingerprint for Hodgkin Lymphoma outcome predictionF. Gelardi1, N. Gozzi2, L. Cavinato3, M. Sollini1,2, M. Kirienko4, M. Biroli1, F. Ricci2, F. Ieva3,5, A. Santoro1,2, C. Carlo-Stella1,2, A. Chiti1,2; 1Humanitas University, Pieve Emanuele, ITALY, 2IRCCS Humanitas Research Hospital, Rozzano, ITALY, 3MOX–Modelling and Scientific Computing lab, Department of Mathematics, Politecnico di Milano, Milan, ITALY, 4Fondazione IRCCS Istituto Nazionale Tumori, Milan, ITALY, 5CADS–Center for Analysis, Decision, and Society, Human Technopole, Milan, ITALY.

OP-1059[18F]FDG PET radiomics for the prediction of genetic clusters in pheochromocytomas and paragangliomasW. A. Noortman1,2, D. Vriens1, E. H. Aarntzen3, A. van Berkel3, H. J. Timmers3, L. F. de Geus-Oei1,2, F. H. van Velden1; 1Leiden University Medical Center, Leiden, NETHERLANDS, 2University of Twente, Enschede, NETHERLANDS, 3Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-1060Context-aware saliency guided PET/CT radiomics: joint prediction of phenotype and outcome in multi-center head and neck cancerW. Lv, J. Ma, L. Lu; Southern Medical University, Guangzhou, CHINA.

OP-1061Predicting the presence of targetable molecular alterations with clinico-metabolic 18F-FDG PET radiomics in non-Asian lung adenocarcinoma patientsC. Lasnon1, K. Weyts1, R. Gervais1, N. Aide2; 1François Baclesse Cancer Centre, Caen, FRANCE, 2CHU de Caen, Caen, FRANCE.

OP-1062Prognostic value of radiomics features extracted from 18F-FDG PET/CT image in Diffuse Large B-Cell Lymphoma (DLBCL) patientsL. Travaini, G. Lo Presti, F. Botta, S. Raimondi, S. Mazzara, M. Ferrari, E. Derenzini, S. Pileri, M. Cremonesi, F. Ceci; IEO, European Institute of Oncology, Milan, ITALY.

OP-1063MIRAS: an end-to-end solution with a graphical user interface for radiomicsF. Tixier1,2, B. Laurent1, V. Jaouen1, O. Tankyevych3,1, C. Cheze-Le-Rest3,1, M. Hatt1, D. Visvikis1; 1INSERM, LaTIM, Brest, FRANCE, 2Brest University Hospital, Radiation Therapy Department, Brest, FRANCE, 3University Hospital of Poitiers, Nuclear medicine department, Poitiers, FRANCE.

OP-1064Postsurgical Gleason score prediction enhanced by PSMA PET/MRI radiomicsE. Solari1, A. Gafita2, S. Schachoff1, B. Bogdanović1, A. Villagrán Asiares1, I. Rauscher1, D. Visvikis3, W. Weber1, N. Navab4, M. Eiber1, M. Hatt3, S. G. Nekolla1; 1Technical University of Munich, Department of Nuclear Medicine, Klinikum rechts der Isar, München, GERMANY, 2Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, UNITED STATES OF AMERICA, 3LaTIM, INSERM, UMR 1101, Univ Brest, Brest, FRANCE, 4Technical University of Munich, Computer Aided Medical Procedures & Augmented Reality, School of Informatics, München, GERMANY.

OP-1065The performance of 18F-PSMA-1007 PET/CT Radiomics on risk stratification discrimination and distant metastases prediction in newly diagnosed prostate cancerZ. Wang1, A. Zheng1, W. Dong1, Y. Li1, J. Gao1, Q. Nie2, C. Ding2, X. Duan1; 1The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, CHINA, 2Philips Healthcare, Shanghai, CHINA.

1910


Clinical Oncology Track - TROP Session: Gynaecological and Melanoma

OP-106718F-FDG PET/MRI for Preoperative Assessment of Endometrial Cancer: Diagnostic Performance and Predictive ValueP. Mapelli1,2, G. Ironi3, F. Fallanca2, A. Bergamini4, C. Bezzi1, L. Monaco5, G. Mathoux5, F. Baldassi5, S. Ghezzo1, A. Samanes Gajate2, N. Ferjani2, G. Candotti4, V. Bettinardi2, G. Taccagni6, P. Rancoita7, G. Mangili4, L. Bocciolone4, L. Gianolli2, P. Scifo2, M. Picchio1,2, F. De Cobelli1,3; 1Vita-Salute San Raffaele University, Milan, ITALY, 2Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Radiology Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 4Unit of Obstetrics and Gynaecology, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 5University of Milano-Bicocca, Milan, ITALY, 6Unit of Pathology, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 7University Centre of Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, ITALY.

OP-1068Relation Between SUVmax And ADC Values Of Primary Cervical Tumor And Their Correlation With Lymph Node Metastasis Detected By PET/MRIF. Aghazada, R. L. Uslu Besli, M. S. Sager, K. Sonmezoglu; Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine Department of Nuclear Medicine, Istanbul, TURKEY.

OP-1069Prognostic value of pretreatment18F-FDG PET/CT metabolic parameters in advanced high grade serous ovarian cancerD. Travaglio Morales, M. Coronado Poggio, C. Huerga Cabrerizo, D. Monachello Araujo, E. López Llobet, Y. Abadi Sedraoui, J. Cordero García, S. Rodado Marina, C. Lancha Hernandez, C. Escabias del Pozo, S. Rizkallal Monzón, L. Dominguez Gadea; Hospital Universitario La Paz, Madrid, SPAIN.

OP-1070Can 2-[18F]FDG PET/CT predict cervical cancer response to chemoradiotherapy?M. Monteiro1, P. Lapa1,2, T. Saraiva1, G. Costa1,2, J. Pedroso de Lima1,3; 1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 2Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL, 3Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL.



165164

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

OP-1071Predictive Role of 18F-FDG PET/CT in Gestational Trophoblastic NeoplasiaC. Bezzi1, P. Mapelli1,2, L. Monaco3, G. Mathoux3, A. Bergamini1,4, E. Zambella1, F. Fallanca2, S. Ghezzo1, A. M. Samanes Gajate2, L. Presotto2, G. Sabetta4, G. Mangili4, R. Cioffi4, V. Bettinardi2, L. Gianolli2, P. Scifo2, M. Picchio1,2; 1Vita-Salute San Raffaele University, Milan, ITALY, 2Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3University of Milano-Bicocca, Milan, ITALY, 4Unit of Obstetrics and Gynaecology, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP-1072Comparison of FDG-PET/CT findings and quantitative parameters and tumor markers in Ovarian Ca patients with peritoneal metastasisC. Dündar Çaglayan1, F. Aydin1, M. Engin1, A. Arçay Öztürk1, Z. G. Kiprak1, S. Sezgin Göksu2, A. Boz1; 1Akdeniz University Hospital Nuclear Medicine Department, Antalya, TURKEY, 2Akdeniz University Hospital Medical Oncology Department, Antalya, TURKEY.

OP-1073Prognostic significance of follow-up18F-FDG PET/CT in uterine sarcomaA. K Majeed, R. Kumar, A. Sharma, S. T. Arunraj, C. Bal; All India Institute of Medical sciences, Delhi, INDIA.

OP-1074 Sentinel Node Mapping in Patients with Ovarian Tumors: A Study Using Intraoperative 99mTc-Phytate Gamma Probing and Post-Operative SPECT/CT LymphoscintigraphyS. Ataei, M. Farazestanian, S. Mostafavi, K. Sadri, A. Azad, N. Jahani, M. Esmaeil Poor, Z. Yousefi, M. Hassanzadeh, R. Sadeghi; Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-1075Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaJ. Ferdinandus, A. Zaremba, L. Zimmer, L. Umutlu, R. Seifert, F. Barbato, S. Ugurel, E. Chorti, V. Grünwald, K. Herrmann, D. Schadendorf, W. P. Fendler, E. Livingstone; University Hospital Essen, Essen, GERMANY.

OP-1076An externally validated nomogram to predict 1-year PFS of patients with metastatic melanoma before anti-PD-1 therapy, based on clinical, biological and [18]F-FDG PET-derived featuresA. Girard1, C. Pontoizeau - Guery1, M. Paquet2, X. Palard-Novello1, A. Devillers1, O. Humbert2,3; 1Centre Eugène Marquis, Rennes, FRANCE, 2Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d’Azur (UCA), Nice, FRANCE, 3TIRO-UMR E 4320, UCA/CEA, Nice, FRANCE.

OP-1077Predictive value of baseline [18F]FDG PET/CT for response to systemic therapy in patients with advanced melanomaV. Liberini1, R. Mimmo2, R. Passera1, E. Califaretti1, F. Ceci1, P. Fava3, M. Rubatto3, L. Tonella3, G. Polverari1,4, S. Ribero1, M. Bellò1, V. Arena4, P. Quaglino3, D. Deandreis1; 1Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, Turin, ITALY, 2UNITO - University of Turin, Turin, ITALY, 3Dermatology Clinic, University of Turin, Turin, ITALY, 4PET Center, Affidea IRMET, Turin, ITALY.

OP-107818F-FDG-PET/CT in the Staging, Follow-up and Treatment Tailoring of Malignant Melanoma - First “Full-Digital” Experience in a Single InstituitionL. Chavdarova1, I. Gavrilova2, E. Piperkova1; 1University Specialized Hospital for Active Treatment in Oncology, Clinic of Nuclear Medicine, Sofia, BULGARIA, 2University Specialized Hospital for Active Treatment in Oncology, Clinic of Dermatooncology, Sofia, BULGARIA.

1911


TROP Session: Nuclear Medicine Imaging and Therapy in Thyroid and Parathyroid Disorders

OP-1080Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodulesM. Mostert1,2, E. J. de Koster3, W. A. Noortman1,4, L. de Geus-Oei1,3,4, F. H. van Velden1, W. J. Oyen5,6,3, D. Vriens1; 1Leiden University Medical Center, Leiden, NETHERLANDS, 2Delft University of Technology, Delft, NETHERLANDS, 3Radboud University Medical Center, Nijmegen, NETHERLANDS, 4University of Twente, Enschede, NETHERLANDS, 5Rijnstate Hospital, Arnhem, NETHERLANDS, 6Humanitas University, Milan, ITALY.

OP-1081Do ultrasound elastography and thyroid imaging reporting and data systems correctly classify hyperfunctioning nodules on thyroid scintigraphy?M. Tuncel, B. S. Turan, Z. Işık; Hacettepe University, Department of Nuclear Medicine, Ankara, TURKEY.

OP-1082Evaluation of treatment efficiency in 301 patients with hyperthyroidism treated with a single dose of I-131 as outpatientB. Ince, A. Namazova, S. Bilgic, A. Nazari, A. Kibar, F. Aghazada, S. Asa, R. Uslu Besli, M. Sager, K. Sonmezoglu; Istanbul University-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TURKEY.

OP-1083Does functional heterogeneity play a role in Graves’ Disease response to RAI treatment? A retrospective decade-long radiomic analysisM. Monteiro1, A. P. Moreira1,2, G. Costa1,3, J. Isidoro1, P. Gil1, J. Pedroso de Lima1,2,3; 1Centro Hospitalar Universitário de Coimbra, Coimbra, PORTUGAL, 2Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL, 3Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

OP-1084The Incidence of Radioiodine-Induced Graves’ Disease Following Treatment of Thyroid Autonomous TissueŽ. Rot1, T. Zaletel2, D. Krković3, S. Gaberšček1,4, K. Zaletel1,4; 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2School of Clinical Medicine, University of Cambridge, Cambridge, UNITED KINGDOM, 3Department of Nuclear Medicine, University Medical Centre Maribor, Maribor, SLOVENIA, 4Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

OP-1085Effectiveness of Radioactive Iodine Therapy of Immune Reconstitution Inflammatory syndrome Associated-Associated Graves Disease in People Living with HIV infectionI. Lawal1, K. Mokoala1, G. Popoola2, A. Orunmuyi3, T. Lengana1, N. Mokgoro1, M. Sathekge1; 1University of Pretoria, Pretoria, SOUTH AFRICA, 2University of Ilorin, Ilorin, NIGERIA, 3University of Ibadan, Ibadan, NIGERIA.

OP-1086Parathyroid scintigraphy in hyperparathyroidism: the added value for radioguided parathyroidectomyR. T. Ferreira, J. C. Ferro, C. R. Santos, S. Carmona, I. Nascimento, A. F. Gomes, R. R. Marques, P. M. Costa, A. I. Santos; Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL.

OP-1087Parathyroid Histopathology and [18F]F-Choline Uptake in PET/MR in Primary HyperparathyroidismV. Liberini1,2, G. B. Morand3, N. J. Rupp4, E. Orita5, D. Deandreis1, M. Broglie Däppen3, M. Hofbauer2, A. Maurer2, L. Husmann2, C. E. Mader2, H. Grünig2, A. A. Alharbi2, M. Messerli2, M. W. Huellner2; 1UNITO - University of Turin, Turin, ITALY, 2Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Zürich, SWITZERLAND, 3Department of Head & Neck Surgery, University Hospital Zurich, University of Zurich, Zürich, SWITZERLAND, 4Department of Pathology and Molecular Pathology, University Hospital Zurich, Zürich, SWITZERLAND, 5Department of Radiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, JAPAN.

OP-1088Role of ¹⁸F-Fluoromethylcholine PET/CT in addition to conventional imaging techniques in patients with primary hyperparathyroidism candidate to radioguided surgeryS. Casanueva Eliceiry, N. Sánchez Izquierdo, M. Manyalich Blasi, P. Domínguez Garijo, A. Fritsch Medina, M. Mora Porta, F. Hanzu, M. Rodrigo-Calvo, S. Vidal-Sicart, O. Vidal-Pérez, D. Fuster Pelfort; Hospital Clínic Barcelona, Barcelona, SPAIN.

OP-1089Interobserver agreement and utility of [18F]fluorocholinePET/CT for the assessment of parathyroid adenomas (preliminary results)I. Sánchez Rodríguez1, M. Suárez-Piñera1, A. Sabaté-Llobera1, I. Gil-Viciano1, J. Vercher-Conejero1, P. Moreno-Llorente2, A. Palomar-Muñoz1, A. Benítez-Segura1, M. Cortés-Romera1; 1PET-Unit. Department of Nuclear Medicine, L’Hospitalet De Llobregat., Barcelona, SPAIN, 2Endocrine Surgery Unit, Department of Surgery, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN.



167166

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

OP-1090Evaluation of C-11-methionine-PET/MRI in primary hyperparathyroidismN. Eberhardt1, J. P. Steinacker1, A. Hillenbrand2, A. Müller-Reinartz3, C. Michalski3, P. Korf4, M. Beer5, C. Solbach1, T. Kull1, A. J. Beer1; 1Ulm University Medical Center, Department of Nuclear Medicine, Ulm, GERMANY, 2Surgical and Orthopedic Practice Clinic SI, Riedlingen, GERMANY, 3Ulm University Medical Center, Department of General and Visceral Surgery, Ulm, GERMANY, 4Siemens Healthcare GmbH, Erlangen, GERMANY, 5Ulm University Medical Center, Department of Diagnostic and Interventional Radiology, Ulm, GERMANY.

OP-1091C11-Choline PET/CT usefulness in patients with primary hyperparathyroidism and negative or inconclusive 99mTc-MIBI scanÁ. Gutiérrez-González, O. Cuenca-Vera, I. Martínez-Rodriguez, F. Gómez-de la Fuente, M. De Arcocha-Torres, A. Sánchez-Salmón, N. Martínez-Amador, S. Ruiz-Llama, J. Jiménez-Bonilla, J. Andrés-Pacheco, R. Quirce; Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN.

2001


Closing Session

OP-1094Closing SessionS. Fanti; EANM Congress Chair, Bologna, ITALY.

212


e-Poster Presentation Session 1: The Nuclear Cardiovascular World at its Best

EPS-001Myocardial blood flows and reserves on solid state camera; correlations with coronary history and cardiovascular risk factorsJ. Pinaquy, P. Ferenczi, F. Debordeaux, H. Douard, Y. Pucheu, T. Couffhinal, Q. Ceyrat, L. Bordenave; University Hospital of Bordeaux, Bordeaux, FRANCE.

EPS-002Influence of Music During Cardiac Stimulation for Myocardial Perfusion Imaging StudiesJ. Prieto Prieto1,2, M. Guiote Moreno1,2, B. Luque Espejo1, F. Maza Muret1,2, R. Zurera Pareja2, J. Vallejo Casas1,2; 1University Hospital Reina Sofia, Córdoba, SPAIN, 2IMIBIC. Maimonides Biomedical Research Institute of Córdoba, Córdoba, SPAIN.

EPS-00399mTc-HMDP Quantification in Cardiac Amyloidosis: the Heart to Whole-Body RatioA. Marques, B. M. Rocha, M. Cruz, M. Paiva, S. Maltês, P. Lopes, J. Carvalho, F. Abreu, C. Aguiar, M. Mendes, S. Pintão; Centro Hospitalar de Lisboa Ocidental, Lisboa, PORTUGAL.

EPS-004Utility of Hybrid Imaging SPECT/CT VS Planar Imaging in ATTR Cardiac AmyloidosisO. Bourogianni1, N. Kapsoritakis1, I. Zaganas2, A. Patrianakos1, M. Stahaki1, A. Tsaroucha1, S. Koukouraki2; 1University Hospital of Crete, Heraklion, GREECE, 2School of Medicine, University of Crete, Heraklion, GREECE.

EPS-005Transthyretin Cardiac Amyloidosis: The Utility of Cardiac Scintigraphy with 99mTc-HDPM. Tagliatori Nogueira, C. Paniagua Correa, M. de la Rubia Marcos, B. Manzarbeitia Arroba, M. Álvarez Moreno, C. Sandoval Moreno, A. Herrero Muñoz, L. Castillejos Rodriguez, M. Balsa Bretón; Hospital Universitario de Getafe, Madrid, SPAIN.

EPS-006Global and Regional Coronary Flow Reserve assessed by routine perfusion SPECT improves the interpretation of the final reportL. Philippe, C. Prunier-Aesch, Y. El. Yaagoubi; Medecine Nucleaire Tourangelle, Chambray-les-Tours, FRANCE.

EPS-007Performance Of Different Myocardial Suppression Protocols For Assessing InflammationB. Rodriguez-Alfonso, F. Dominguez-Rodriguez, A. Prieto-Soriano, D. de Castro-Campos, S. Guzman-Ortiz, M. Mitjavila-Casanovas; Hospital Universitario Puerta De Hierro, Majadahonda, SPAIN.

EPS-008Reliability of [123I]I-metaiodobenzylguanidine cardiac SPECT assessment in postinfarction heart failure patientsA. Teresinska, J. Wnuk, O. Wozniak, A. Maciag, E. K. Biernacka; National Institute of Cardiology, Warsaw, POLAND.

EPS-009Insulin loading for optimal cardiac Fluorine-18 fluorodeoxyglucose positron emission tomography: an easier and more efficient preparationY. Chen; Quanzhou 1st hospital, Quanzhou, CHINA.

EPS-010Radiomic assessment of epicardial adipose tissue and cardiac innervation imaging in prognosis of catheter ablation of atrial fibrillationY. Varlamova1, E. Popov1, S. Sazonova1, N. Nikitin2, S. Minin3, A. Romanov3, I. Kisteneva1, R. Batalov1, S. Popov1; 1Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION, 2Medical Center “Avicenna”, Novosibirsk, RUSSIAN FEDERATION, 3E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Novosibirsk, RUSSIAN FEDERATION.

EPS-011Coronary flow reserve in patients with preserved left ventricle ejection fraction and non-obstructive coronary artery diseaseA. Mochula, K. Kopeva, A. Maltseva, K. Zavadovsky, E. Grakova; Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION.

EPS-012Quantification of Cardiac 99mTc-bisphosphonates (DPD) uptake using SPECT-CT images in Amyloidosis Transthyretin patientsM. Solá, G. Moragas, M. Salcedo Pujantell, J. Deportos, M. N. Torres, M. H. Olivares, S. Lafuente, V. Vallejos, M. Domingo; Hospital Universitari Germans Trias i Pujol, Badalona, SPAIN.

EPS-013The value of CZT SPECT myocardial blood flow and reserve assessment in terms of identifying high-risk patients after surgical treatment of ischemic cardiomyopathyV. Shipulin, A. Pryakhin, S. Andreev, A. Mochula, M. Gulya, K. Zavadovsky, V. M. Shipulin; Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EPS-014The Clinical-Diagnostic Relevance of Visual Score 1 at [99mTc]Tc-2,3-dicarboxypropane-1,1-diphosphonate Scintigraphy ([99mTc]Tc-DPD) for Cardiac AmyloidosisL. Vetrone1, N. Fraccascia1, G. Argalia1, E. Fortunati1, A. Giovannetti2, R. Bonfiglioli3, E. Tabacchi3, S. Longhi4, C. Gagliardi4, E. Biagini4, N. Galiè4,5, S. Fanti1,3; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 3Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 4Cardiology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EPS-015[99mTc]Tc-2,3-dicarboxypropane-1,1-diphosphonate (99mTc-DPD)-SPECT/CT in patients with low mediastinal uptake in the assessment of Transthyretin Cardiac Amylodosis: an Italian single center experienceN. Fraccascia1, R. Bonfiglioli2, E. Tabacchi2, G. Argalia1, L. Vetrone1, C. Malizia2, S. Fanti2,3; 1Nuclear Medicine, DIMES, Alma Mater Studiorum, University of Bologna, Bologna, ITALY, 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, via Massarenti 9, Bologna, ITALY, 3Nuclear Medicine, DIMES, Alma Mater Studiorium, University of Bologna, via Massarenti 9, Bologna, ITALY.

EPS-017Molecular imaging in diagnosis of cardiovascular and lung damage in patients with COVID-19A. Kudryavtsev, M. M. Beregov, A. K. Kondakov, D. S. Kharina, D. Y. Mosin, I. A. Znamenskiy, A. E. Nikitin; CCH of RAS, Moscow, RUSSIAN FEDERATION.



169168

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

100

90

80

70

60

50

40

30

20

10

0

24

Prog

ress

ion-

Free

Sur

viva

l (%

)

30 36 42 480 6 12 18

Time (in months)N at Risk

PROGRESSION FREE SURVIVALAccording to RECIST 1.1 by Blinded Independent Central Review

213 76 9 1 0 0 0 0 0215 111 29 13 2 1 1 1 0

TheraSphereControl

Log-Rank p-value(one-sided superiority)

= 0.0013

TheraSphereControl

31%

41%

Progression Free Survival According to recist 1.1 by Blinded independent Central Review

TheraSphere arm: 8.0 months (95% CI, 7.2, 9.2) Control arm: 7.2 months (95% CI, 5.7, 7.6)

Hepatic Progression Free Survival According to recist 1.1 by Blinded independent Central Review

TheraSphere arm: 9.1 months (95% CI, 7.8, 9.7) Control arm: 7.2 months (95% CI, 5.7, 7.6)

Patients receiving TheraSphere with second-line chemotherapy had a 31% risk reduction of overall progression or death compared to chemotherapy alone.

100

90

80

70

60

50

40

30

20

10

0

24

Hep

atic

Pro

gres

sion

-Fre

e Su

rviv

al (%

)

30 36 42 48 540 6 12 18

Time (in months)N at Risk

HEPATIC PROGRESSION FREE SURVIVALAccording to RECIST 1.1 by Blinded Independent Central Review

213215

76118

932

114

04

01

01

01

01

00

Log-Rank p-value(one-sided superiority)

< 0.0001

TheraSphereControl

TheraSphereControl

JOIN BOSTON SCIENTIFIC SYMPOSIUM

22ND OCTOBER - 15:05 CETTO LEARN MORE ABOUT THE RESULTS

All trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material is not intended for use in France. 2021 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. PI-1144802-AA.

TheraSphere™

Y-90 Glass MicrospheresThe Proven Choice

EPOCH is the only positive level 1 evidence, phase III RCT using SIRT to treat CLM that demonstrated statistically significant improvements in PFS and hepatic PFS in patients that had progressive disease after first-line chemotherapy.

Patients receiving TheraSphere with second-line chemotherapy had a 41% risk reduction of hepatic progression or death compared to chemotherapy alone.

312


e-Poster Presentation Session 2: Dosimetry

EPS-018Potential Limitations of Established Blood-Dosimetry Models for Lu-177 TherapyP. Ritt1, C. Jobic1, A. Grings1, M. Beck1, C. Schmidkonz1, T. Kuwert1, M. Uder2, M. Brand2; 1Clinic for Nuclear Medicine, Erlangen, GERMANY, 2Department of Radiology, Erlangen, GERMANY.

EPS-019Patient-specific dosimetric workflow with a reduced number of time-points for 177Lu treatmentsL. Vergnaud1, A. L. Giraudet2, A. Moreau2, T. Baudier1, D. Kryza2, J. N. Badel2, D. Sarrut1; 1Centre Léon Bérard / CREATIS, Lyon, FRANCE, 2Centre Léon Bérard, Lyon, FRANCE.

EPS-020Assessing neuroendocrine tumour response to peptide receptor radionuclide therapy with 177Lu-DOTATATE using voxel-based dosimetryL. Ram, S. Bissell, S. Hughes, E. Ross, I. Geh; Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM.

EPS-021Experimental Validation of Monte Carlo Beta and Gamma Depth Dose and Bone Equivalent Attenuation for Lu-177B. Van, Y. Dewaraja, J. Niedbala, M. Kazmierski, D. Hubers, S. Wilderman, J. Mikell; University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

EPS-022Optimization of the voxel-based 90Y-PET SIRT dosimetry: definition of clinical and technical margins around the anatomical target to establish the therapeutic reference isodose and DVHs of toleranceC. Ouardek1,2, N. Ghazzar2, M. Bernardini2; 1Université Grenoble Alpes, Grenoble, FRANCE, 2Hôpital Européen Georges Pompidou, Paris, FRANCE.

EPS-023Automatic evaluation of patient biokinetics based on hybrid planar/SPECT imaging using OEDIPE software for 3D dosimetry in radionuclide therapyM. Bensiali1, N. Anizan2, S. Lamart1, E. Davesne1,3, D. Broggio1, A. Desbrée1, D. Franck1; 1Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Fontenay-aux-Roses, FRANCE, 2Institut de Cancérologie Gustave Roussy, Villejuif, FRANCE, 3INSTN, Gif-sur-Yvette, FRANCE.

EPS-024Voxel-wise Dosimetry of [68Ga]Ga-PSMA-11 and Comparison With the LiteratureJ. Morgado1, P. Ferreira2, S. Di Maria3, F. P. Oliveira2, R. Vigário4, D. C. Costa2; 1Institute for Systems and Computer Engineering, Technology and Science, Porto, PORTUGAL, 2Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 3Centre for Nuclear Sciences and Technologies, Lisbon, PORTUGAL, 4NOVA School of Science and Technology, Almada, PORTUGAL.

EPS-025Accuracy and reproducibility assessment of commercially available Dosimetry Toolkit software: A phantom studyA. Nautiyal1,2, A. K. Jha1,2, A. Konuparamban1,2, S. Mithun1,2, V. Rangarajan1,2; 1Tata Memorial Hospital, Mumbai, INDIA, 2Homi Bhabha National Institute(HBNI), Deemed University, Mumbai, INDIA.

EPS-026PET-CT-based dosimetry for Y-90 Selective Internal Radiation Therapy (SIRT)M. Kuc1, A. Budzyńska2,3, A. Kubik2, M. Maciak1, M. Konior4, P. Piasecki5, M. Dziuk2,3, E. Iller4; 1Radiological Metrology and Biomedical Physics Division (H2), National Centre for Nuclear Research, Otwock, POLAND, 2Department of Nuclear Medicine, Military Institute of Medicine, Warsaw, POLAND, 3Affidea Mazovian PET/CT Medical Centre, Warsaw, POLAND, 4National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, POLAND, 5Department of Interventional Radiology, Military Institute of Medicine, Warsaw, POLAND.

EPS-027Independent Validation of Monte Carlo Simulations within In-House Dosimetry Software Using ICRP 110 PhantomsP. Gape, D. Rushforth, J. Gear, G. Flux; The Royal Marsden Hospital NHS Foundation Trust, Sutton, UNITED KINGDOM.



171170

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-028Dosimetry of iodine-125 eye plaque in brachytherapy of retinoblastoma tumor in animal model of rabbitS. Moradi1, S. Sheibani1, M. Mokhtari Dizaji2, F. Ghassemi3, M. Arjmand3; 1Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-029Retrospective Single Time Point Spinal cord and Lesional Dosimetry for Radioiodine Treatment of Thyroid Cancer with High-Uptake in Vertebral LesionsR. Gregory1, H. McMeekin1,2, R. Lewis1, K. Beaton3, M. Burniston1; 1Barts Health NHS Trust, London, UNITED KINGDOM, 2Hermes Medical Solutions Ltd., London, UNITED KINGDOM, 3Barking, Havering and Redbridge University Hospitals NHS Trust, Barking, Havering and Redbridge, UNITED KINGDOM.

512


e-Poster Presentation Session 3: More on Infection & Inflammation Imaging and NM in COVID-19

EPS-030Reliability of 18F-FDG PET/CT qualitative and semi-quantitative analysis in patients with suspicion of cardiac implantable electronic device infectionV. Lavelli, R. Ruta, F. Iuele, A. G. Nappi, A. Gaudiano, A. R. Pisani, G. Rubini; Section of Nuclear Medicine, DIM, University “Aldo Moro”, Bari, ITALY.

EPS-031Role Of [18F] FDG PET/CT In Infective Endocarditis On Prosthetic Valve And Intracardiac DevicesN. Alvarez Mena1, C. Ponce Herrera2, A. Gutiérrez Cardo2, S. Martín Aguilar2, M. Nicolás Aguado2, E. Espinosa Muñoz2, V. Marín Parrilla2, D. Ramírez Ocaña2, M. Puentes Zarzuela2; 1Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN, 2Hospital Regional Universitario de Málaga, Málaga, SPAIN.

EPS-032Semiquantitative [18F] FDG PET/CT Analysis In infective Endocarditis On Prosthetic Valve And Intracardiac DevicesN. Alvarez Mena1, C. Ponce Herrera2, A. Gutiérrez Cardo2, S. Martín Aguilar2, M. Nicolás Aguado2, E. Espinosa Muñoz2, V. Marín Parrilla2, D. Ramírez Ocaña2, M. Puentes Zarzuela2; 1Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN, 2Hospital Regional Universitario de Málaga, Málaga, SPAIN.

EPS-033The effectiveness of the combination of extended fasting with dietary manipulation for suppressing physiologic myocardial 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for sarcoidosisA. Georgakopoulos1, E. Manali2, A. Papaioannou2, H. Gialafos3, M. Metaxas4, L. Kolilekas5, S. Papiris2, S. Chatziioannou1,4; 12nd Department of Radiology, General University Hospital “Attikon”, Medical School, National and Kapodistrian University, Athens, GREECE, 22nd Pulmonary Medicine Department, General University Hospital “Attikon”, Medical School, National and Kapodistrian University, Athens, GREECE, 3Aiginitio Hospital, Medical School, National and Kapodistrian University, Athens, GREECE, 4Foundation for Biomedical Research of the Academy of Athens, Nuclear Medicine Division, Athens, GREECE, 57th Pulmonary Department, Athens Chest Hospital “Sotiria”, Athens, GREECE.

EPS-034Lung Segmentation and Measurements of Pulmonary Metabolic Activity with FDG-PET/CT is Reproducible in Patients with COPDA. Dogan1,2, T. Christensen3, T. Jensen1, O. Hilberg4, C. Juhl1,5,2, S. Hess6,2; 1Department of Medicine, Hospital South West Jutland, Esbjerg, DENMARK, 2Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, DENMARK, 3Department of Clinical Engineering, Region of Southern Denmark, Esbjerg, DENMARK, 4Department of Medicine, Lillebaelt Hospiltal, Vejle, DENMARK, 5Steno Diabetes Center, Odense, DENMARK, 6Department of Radiology and Nuclear Medicine, Hospital South West Jutland, Esbjerg, DENMARK.

EPS-035Staging of Alveolar Echinococcosis with PET/CT: Prediction of the Length of Benzimidazole Therapy in Inoperable PatientsL. Husmann1, H. Gruenig1, C. S. Rainer2, A. Deibel3, B. Ledergerber4, U. J. Muehlematter1, F. Grimm5, M. Messerli1, B. Hasse4, B. Muellhaupt3, M. W. Huellner1; 1Department of Nuclear Medicine, University Hospital of Zurich / University of Zurich, Zurich, SWITZERLAND, 2Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 3Division of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 4Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 5Institute of Parasitology, University of Zurich, Zurich, SWITZERLAND.

EPS-037Added Diagnostic Value of Lung Perfusion Scintigraphy In Admitted COVID-19 PatientsM. Algarni; KFMMC, Dhahran, SAUDI ARABIA.

EPS-038Role of Perfusion Lung Scan in discharged patients post SARS-CoV2 pneumoniaM. L. De Rimini1, D. D’Arienzo1, G. Fiorentino2, A. Annunziata2, M. Flora2, T. Valente3, G. Borrelli1, M. Bifulco1, G. Mazzarella1, M. Scarpato1; 1Nuclear Medicine Unit AO Ospedali dei Colli - Monaldi, Naples, ITALY, 2Respiratory Pathophysiology and Rehabilitation AO Ospedali dei Colli - Monaldi, Naples, ITALY, 3Radiology Unit AO Ospedalidei Colli - Monaldi, Naples, ITALY.

EPS-039Pulmonary Perfusion SPECT/CT Results in Thromboembolism Diagnosis in Patients at Post-COVID-19 Infection PeriodH. Nalbant, S. Demirtaş Şenlik, B. B. Demirel, G. Uçmak; Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TURKEY.

EPS-040Diagnostic Contribution Of Lung Perfusion SPECT/CT Imaging During The COVID-19 PandemicN. Alvarez Mena, F. Sebastián Palacid, P. Turbay Eljach, C. García García, B. Pérez López, C. Gamazo Laherrán, M. Alonso Rodríguez, A. Sainz Esteban, M. González Soto, M. Ruiz Gómez, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EPS-041Pulmonary embolism in non-hospitalized COVID-19 infected patients without severe diseaseO. Evbuomwan, G. Engelbrecht; University of The Free State, Bloemfontein, SOUTH AFRICA

EPS-042Incremental values for Perfusion SPECT/CT in detection of PE in COVID-19 patients with deteriorating respiratory functions. Pilot StudyH. Elzeftawy, D. Omran, W. Waggas, A. El-Zeftawy; King Faisal Specialist Hospital and Research Center, Jeddah, SAUDI ARABIA.

EPS-043FDG PET-CT Imaging Of Immune Activation Post COVID Vaccination In Oncology PatientsS. Ali, A. Hussien, M. Kula, W. Ibrahim; King Hamad University Hospital, AlSayh, BAHRAIN.

EPS-044Our experience in the assessment of pulmonary embolism with lung perfusion SPECT/ CT in COVID-19 patientsM. Salcedo Pujantell, J. Deportós, M. Solà, V. Vallejos, S. Lafuente Carrasco, M. Olivares, M. Torres, G. Moragas; Hospital Universitari Germans Trias i Pujol, Badalona, SPAIN.

EPS-045Ventilation/Perfusion Scintigraphy in the Assessment of Pulmonary Sequelae in COVID-19 Patients with Pneumonia and Pulmonary EmbolismC. Soldevila Lozano1, J. Mora-Salvadó1, M. Bajén-Lázaro1, A. Benítez-Segura1, G. Reyes-Junca1, P. Notta1, S. Bondia-Bescós1, L. Fernández-Romero1, A. Riera-Mestre2, A. Iriarte-Fuster2, J. Mora-Lujan2, M. Cortés-Romera1; 1Nuclear Medicine-PET (IDI). Hospital Universitari de Bellvitge, L’Hospitalet De Llobregat, SPAIN, 2Internal Medicine Department. Hospital Universitari de Bellvitge, L’Hospitalet De Llobregat, SPAIN.

EPS-046Preliminary study of quantitative evaluation for lung glucose metabolism using 18F-FDG PET imaging in patients with pulmonary arterial hypertension related to congenital heart diseaseX. Wang1, L. Wang2, W. Fang2, C. Yan1; 1Center of Structural Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, 2Department of nuclear medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.



173172

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

612


e-Poster Presentation Session 4: Radiochemistry

EPS-047The importance of precursor concentration for PET diagnostics with Ga-68-PSMA-11N. Nithack, Y. Zhao, A. Helm, U. Lützen, M. Zuhayra; Universitätsklinikum Schleswig-Holstein, Klinik für Nuklearmedizin, Molekulare Bilddiagnostik und Therapie, Kiel, GERMANY.

EPS-04868Ga-radiolabeling and pharmacological characterization of a kit-based formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) antagonist RM2 for convenient preparation of [68Ga]Ga-RM2C. Morgat1,2, A. Chastel1,2, D. Vimont2, S. Claverol3, M. Berndt4, M. Zerna4, S. Chaignepain3, E. Hindié1,2; 1Nuclear Medicine Department - University Hospital of Bordeaux, Bordeaux, FRANCE, 2University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux, FRANCE, 3Proteome Platform, Univ Bordeaux, Bordeaux, FRANCE, 4Life Molecular Imaging, Berlin, GERMANY.

EPS-049Securing Gallium-68 availability with liquid target production on mid-energy cyclotrons: Users’ experience and scaling upC. Gameiro1, V. H. Alves2, A. Abrunhosa2, F. Alves2, D. Goblet1, B. Nactergal1, A. Uhlending3, V. Hugenberg3, T. Ortgies3, G. Hoeger3, J. Manrique-Arias4, R. Freifelder5, K. Hye-Yeong5, M. Bhuiyan,5, A. Kucharski5; 1IBA, Louvain-La-Neuve, BELGIUM, 2Institute for Nuclear Sciences Applied to Health (ICNAS), Coimbra, PORTUGAL, 3Department of Radiology, Nuclear medicine and Molecular Imaging, Bad Oeynhausen, GERMANY, 4Cyclotron Department, Doctors Hospital, Monterrey, MEXICO, 5Department of Radiology, University of Chicago, Chicago, IL, UNITED STATES OF AMERICA.

EPS-050Production of Sm-153 with high specific activity for targeted radionuclide therapyM. Van de Voorde1, C. Duchemin2,3, R. Heinke2,3, L. Lambert2, E. Chevallay2, T. E. Cocolios3, T. Cardinaels1,3, B. Ponsard1, M. Ooms1, T. Stora2, A. Burgoyne1; 1SCK CEN, Mol, BELGIUM, 2CERN, Geneva, SWITZERLAND, 3KU Leuven, Leuven, BELGIUM.

EPS-051Optimization of the Radiolabeling of Silk Fibroin Nanoparticles with Tc-99m by a direct methodM. Asensio Ruiz1,2, Á. Alonso García1, J. Cenis Anadón3, A. Lozano Pérez2,3, M. Martínez Martínez1,2; 1Unidad de Radiofarmacia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN, 2Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia, SPAIN, 3Departamento de Biotecnología, Genómica y Mejora Vegetal, Instituto Murciano de Investigación y Desarrollo Agrario y Alimentario, 30150-La Alberca, Murcia, SPAIN.

EPS-05218F-PSMA-1007 Synthesis: a production upgrade that enabled a federal experience in ArgentinaM. Agolti1, G. Messina2, G. Casale2, L. Solari1, J. Sandobal2, S. Fila2; 1Centro de Medicina Nuclear Clinica Modelo, Parana, ARGENTINA, 2Laboratorios Bacon, Buenos Aires, ARGENTINA.

EPS-053Targeted alpha therapy with Actinium-225 radiopharmaceuticals: In-house preparation and quality controlR. Vatsa, S. Pandey, A. Chhabra, B. R. Mittal, J. Shukla; Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA.

EPS-054Production of one or three patient doses (in one batch) of [177Lu]Lu-PSMA-I&T on a fully-automated synthesis moduleA. Cankaya, M. Balzer, H. Amthauer, W. Brenner, S. Spreckelmeyer; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Nuclear Medicine, Berlin, GERMANY.

EPS-055Validation of an analytical method on HPLC for 177Lu-PSMA-1C. Brentot, A. Revy, L. Batret, S. Levesque, F. Cachin, M. Tempier; Centre de lutte contre le cancer Jean Perrin, Clermont-Ferrand, FRANCE.

EPS-056EU vs US radiopharmaceutical manufacturing and dispensing modalitiesC. Ignace1, O. Koper2, L. Augustine3; 1Cardinal Health, Mesa, AZ, UNITED STATES OF AMERICA, 2Cardinal Health Nuclear and Precision Health Solutions, Dublin, OH, UNITED STATES OF AMERICA, 3Cardinal Health Nuclear and Precision Health Solutions, Omaha, NE, UNITED STATES OF AMERICA.

EPS-057Time-dependent sterility testing to determine the viability of microorganisms and autosterilisation in radiopharmaceutical therapeuticsA. Gummesson1, G. Schwenk2, S. Knolle2, S. Protze2, S. Weißflog2, M. Joksch1, B. J. Krause1, C. Bergner1; 1Department of Nuclear Medicine, Rostock University Medical Center, Rostock, GERMANY, 2CUP Laboratorien Dr. Freitag GmbH, Radeberg, GERMANY.

EPS-058New radiopharmaceutical synthesis : Stability study of 177Lu-PSMA-1L. Batret, C. Brentot, A. Revy, S. Levesque, M. Tempier; Centre Jean Perrin, Clermont Ferrand, FRANCE.

EPS-059Optimization of Radiolabelling of [68Ga]Ga-Macroaggregated AlbuminP. Bhardwaj1,2, S. Mithun1,2, A. K. Jha1,2, P. Kamble1,2, K. Chitnis1,2, A. Nautiyal1,2, V. Rangarajan1,2; 1Tata Memorial Hospital, Mumbai, INDIA, 2Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.

EPS-060Production of W-188/Re-188 generator based on Al2O3M. Karamivand, F. Johari, M. Davarpanah; Pars Isotope, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-061Comparison of the performance of four purification cartridges in the synthesis of 68Ga-PSMA-11J. Stein1, Q. Citerne1, N. Veran1, B. Demoré1,2; 1Nancy University Hospital, Pharmacy Department, Vandoeuvre-lès-Nancy, FRANCE, 2Lorraine University, EA 4360 APEMAC, Nancy, FRANCE.

EPS-062Quality Control of [68Ga]Ga-PSMA-11 injectable solutions: preparation of a long-term stable PSMA-11 reference solution (3 μg/mL) for Chemical Purity determinationA. Iudicello1, F. Genovese2, S. Boschi3; 1Pharmaceutical Department, Azienda USL of Modena and Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria of Modena, Modena, ITALY, 2Centro Interdipartimentale Grandi Strumenti, University of Modena and Reggio Emilia, Modena, ITALY, 3Department for Life Quality Studies, University of Bologna, Bologna, ITALY.

EPS-063Development of 211At and 125I Radiopharmaceuticals for Pretargeted Radioimmunotherapy of Disseminated CancerC. Timperanza1, H. Jensen2, E. Aneheim1,3, S. Lindegren1; 1Department of Medical Radiation Science, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 2Cyclotron and PET Unit, KF-3982, Rigshospitalet, Copenhagen, DENMARK, 3Region Västra Götaland, Sahlgrenska University Hospital, Department of Oncology, Gothenburg, SWEDEN.

812


e-Poster Presentation Session 5: Theranostics

EPS-064Synergy when treating ovarian cancer cell lines with Radium-224 and PARP inhibitorsM. Malenge, T. B. Bønsdorff; Oncoinvent AS, Oslo, NORWAY.

EPS-065Theranostic Approach of CD38 and IL-1RAP Positive Haematological Malignancies Based on Radiolabelled AntibodiesJ. Frenay1, P. Bellaye1, M. Moreau2, C. Rossi3, O. Casasnovas3, L. Ringenbach4, C. Ferrand5,6, B. Collin1,2; 1Centre Georges François Leclerc, Dijon, FRANCE, 2Institut de Chimie Moléculaire de l’Université de Bourgogne, ICMUB, Dijon, FRANCE, 3CHU Dijon Bourgogne - Hôpital François Mitterrand, Dijon, FRANCE, 4Diaclone, Besançon, FRANCE, 5CanCell Therapeutics, Besançon, FRANCE, 6Etablissement Français du Sang de Bourgogne Franche-Comté, Besançon, FRANCE.



175174

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-067In Vitro and nanoSPECT/CT Imaging of Long-acting Radiolabeled PSMA Peptide in Animal Model of Prostate Cancer Bone MetastasisY. Huang, M. Chen, S. Chen, S. Lo, S. Lo, S. Li, L. Chen, M. Li, C. Chang, S. Farn; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EPS-068Assessing potential damage to the healthy vascular endothelium from targeted radiopharmaceutical therapeuticsR. Ramadan1, L. Geenen1, N. Daems1, A. Aerts1, S. Baatout1,2; 1Radiobiology Unit, Blegian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, 2Department of Molecular Biotechnology, Ghent University, Ghent, BELGIUM.

EPS-069A local (para)sympathetic blockage to overcome PSMA ligand uptalke in salivary glandsV. Nail1,2,3, P. Garrigue1,2,3, A. Moyon1,2,3, B. Louis1,3, L. Balasse1,3, S. Fernandez1,3, G. Hache1,2,3, D. Taïeb1,2,3, B. Guillet1,2,3; 1Aix-Marseille University, Centre Européen de Recherche en Imagerie Médicale (CERIMED), Marseille, FRANCE, 2Assistance Publique-Hôpitaux de Marseille, CHU La Timone, CHU Nord, Nuclear medicine department, Marseille, FRANCE, 3Aix-Marseille University, INSERM, INRA, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, FRANCE.

EPS-070Performance characterization of a multi pin-hole SPECT for preclinical imagingL. Irazola1, E. Prieto1, M. Collantes2, M. Ecay3, I. Peñuelas4, J. M. Martí-Climent1; 1Medical Physics, Clínica Universidad de Navarra, Pamplona, SPAIN, 2Translational Molecular Imaging Unit. Universidad de Navarra. IdiSNA & Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN, 32Translational Molecular Imaging Unit. Universidad de Navarra. IdiSNA, Pamplona, SPAIN, 4Translational Molecular Imaging Unit. Universidad de Navarra. IdiSNA & Unidad de Radiofarmacia. Clínica Universidad de Navarra. IdiSNA, Pamplona, SPAIN.

EPS-071Extensive in vitro and in vivo evaluation of SSTR2-mediated uptake and biodistribution of radiolabeled somatostatin analogues after treatment with HDAC inhibitor valproic acidM. Klomp, L. J. Hofland, L. van den Brink, P. M. van Koetsveld, F. Dogan-Oruç, L. W. de Kreij - de Bruin, C. M. de Ridder, D. C. Stuurman, M. de Jong, S. U. Dalm; Erasmus MC, Rotterdam, NETHERLANDS.

EPS-072Validation of [18F]-(2S,4R)-4-Fluoroglutamine in Multiple Myeloma Mouse ModelsS. Valtorta1,2, M. Chiu3, D. Toscani3, A. Sartori4, A. Coliva2, A. Brevi5,6, G. Taurino3, M. Grioni5, L. Ruffini7, F. Vacondio4, F. Zanardi4, M. Bellone5, R. M. Moresco1,2,8, O. Bussolati3, N. Giuliani3; 1Department of Medicine and Surgery and Tecnomed Foundation - University of Milano - Bicocca, Monza, ITALY, 2Department of Nuclear Medicine, San Raffaele Scientific Institute, IRCCS, Milan, ITALY, 3Department of Medicine and Surgery, University of Parma, Parma, ITALY, 4Department of Food and Drug, University of Parma, Parma, ITALY, 5Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute IRCCS, Milan, ITALY, 6Università Vita-Salute San Raffaele, Milan, ITALY, 7Nuclear Medicine; “Azienda Ospedaliero-Universitaria di Parma”, Parma, ITALY, 8IBFM-CNR, Segrate, ITALY.

EPS-075Preclinical investigation of a novel luteinizing hormone-releasing hormone antagonist for triple negative breast tumor-bearing model by SPECT/CT imagingM. Weng, S. Lo, S. Wang, Y. Shih, M. Weng, C. Ho, S. Farn; Institute of Nuclear Energy Research, Taoyuan City, TAIWAN.

EPS-076Simultaneous Biodistribution Studies of 99mTc/131I Labeled Antibody with HPGe Gamma SpectrometryM. Tassano1, M. Cabrera1, X. Camacho1, M. Fernandez1, M. Garcia1, J. Gambini2,3, P. Cabral1; 1Facultad de Ciencias - Universidad de la Republica, Montevideo, URUGUAY, 2Facultad de Medicina - Universidad de la República, Montevideo, URUGUAY, 3CUDIM – Centro Uruguayo de Imagenología Molecular, Montevideo, URUGUAY.

EPS-077Radioactive and near-infrared fluorescence in vivo imaging of Non-Hodgkin Lymphoma using 99mTc/Cy7-Fab(Bevacizumab)X. Camacho1, C. Perroni1, C. Carneiro2, M. Junqueira2, D. Faria2, M. García1, M. Fernández1, C. Buchpiguel2, H. Cerecetto1, R. Chammas3, E. Riva4, P. Cabral1, J. Gambini5; 1Universidad de la República-Facultad de Ciencias-Centro de Investigaciones Nucleares-Area de Radiofarmacia, Montevideo, URUGUAY, 2Universidade de Sao Paulo-Nuclear Medicine Medical Investigation Laboratory LIM43-Hospital das Clínicas da Faculdade de Medicina, Sao Paulo, BRAZIL, 3Universidade de Sao Paulo-Laboratório de Oncologia Experimental, Faculdade de Medicina, Sao Paulo, BRAZIL, 4Universidad de la República-Clínica Hematológica. Hospital de Clínicas-Facultad de Medicina, Montevideo, URUGUAY, 5Universidad de la República-Centro de Medicina Nuclear e Imagenología Molecular-Hospital de Clínicas-Facultad de Medicina, Montevideo, URUGUAY.

EPS-078Comparison Study of [111In]In-DTPA-HL, [68Ga]Ga‐NOTA‐HL and [18F]AlF-NOTA-HL for Imaging of asialoglycoprotein receptor in MiceH. Yu, C. Chan, C. Yang, K. Lin, C. Chien, C. Kuo, M. Wang; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EPS-079Syntheses of the 11C-labeled thymine-carborane conjugates for PET imaging-guided boron neutron capture therapy (BNCT)Z. Zhang1,2, M. Suzuki2,3; 1RIKEN Center for Biosystems Dynamic Research, Kobe, JAPAN, 2RIKEN Center for Molecular Imaging Science, Kobe, JAPAN, 3National Center for Geriatrics and Gerontology, Nagoya, JAPAN.

912


e-Poster Presentation Session 6: Molecular Brain Imaging

EPS-080The effect of reduced administered activity and image reconstruction on SUVR quantification in [18F]flutemetamol amyloid PET-MR scanningJ. Anton Rodriguez1,2, K. Herholz3, S. F. Carter4,5, J. C. Matthews2; 1The Christie NHS Foundation Trust and University of Manchester, Manchester, UNITED KINGDOM, 2Division of Informatics, Imaging and Data Sciences, MAHSC, Manchester, UNITED KINGDOM, 3Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health-University of Manchester, Manchester, UNITED KINGDOM, 4WMIC, University of Manchester, UK, Manchester, UNITED KINGDOM, 5Deparment of Psychiatry, University of Cambridge, Cambridge, UNITED KINGDOM.

EPS-081Model Based Data Driven Attenuation Correction for Brain Imaging with High Resolution Multifocal CollimatorX. Ding1, F. Massanes1, G. Platsch2, M. Reymann2, H. Vija1; 1Siemens Medical Solutions USA Inc., Molecular Imaging, Hoffman Estates, IL, UNITED STATES OF AMERICA, 2Siemens Healthcare GmbH, Molecular Imaging, Forchheim, GERMANY.

EPS-082Hypometabolism and Atrophy Patterns Associated with Niemann-Pick type CJ. Silva-Rodríguez1, C. Castro1, J. Cortés2, M. Arias3, J. Gascón4, M. Sobrido5, P. Aguiar6; 1Health Research Institute of Santiago de Compostela, Santiago de Compostela, SPAIN, 2Nuclear Medicine Department, University Hospital of Santiago de Compostela, Santiago de Compostela, SPAIN, 3Neurology Department, University Hospital of Santiago de Compostela, Santiago de Compostela, SPAIN, 4Neurology Department, Hospital Universitari de Bellvitge, Barcelona, SPAIN, 5Neurology Department, University Hospital of A Coruña, A Coruña, SPAIN, 6University of Santiago de Compostela, Santiago de Compostela, SPAIN.

EPS-083Amyloid PET imaging: impact on Alzheimer’s Disease Diagnostic Work-up and patient managementC. Ferrari, P. Caputo, A. R. Pisani, A. Branca, G. Rubini; Section of Nuclear Medicine, DIM, University of Bari “Aldo Moro”, Bari, ITALY.



177176

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-084Machine Learning Radiomics for Prediction of Cognitive Deficits by Using Amyloid Pet ImagesG. Giovacchini, E. Giovannini, V. Duce, S. Pastorino, O. Ferrando, F. Foppiano, C. Passera, A. Mannironi, A. Tartaglione, A. Ciarmiello; S. Andrea Hospital, La Spezia, ITALY.

EPS-085Differential Diagnosis of Atypical Parkinson Disorders from Parkinson’s Disease using dual-phase F-18 FP-CIT PET/CTM. Cheon, S. Kim, S. Ha, J. Yoo; VHS Medical Center, Seoul, KOREA, REPUBLIC OF.

EPS-086Regional Brain Amyloid Load Assessed by 11C-PIB PET/CT and Cognitive Performance in Patients with Mild Cognitive Impairment: A Longitudinal StudyJ. Jiménez-Bonilla1, M. De Arcocha-Torres1, J. Martín-Arroyo2, O. Cuenca1, I. Martínez-Rodriguez1, A. Sánchez-Salmón1, N. Martínez-Amador1, F. Gómez-De la Fuente1, S. Ruiz-Llama1, A. Pozueta2, M. Gómez2, S. López-García2, C. Lage2, E. Rodríguez2, P. Sánchez-Juan2, R. Quirce1; 1Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Research Group-IDIVAL. University of Cantabria, Santander, SPAIN, 2Neurology Service. Marqués de Valdecilla University Hospital., Santander, SPAIN.

EPS-087Optimal Cut-off Value for Automated Semiquantitative Analysis of 123I-beta-CIT SPECT in the Diagnosis of Idiopathic Parkinson’s DiseaseT. Laitinen1,2, J. Miettinen1, N. Vartiainen2, H. Gröhn2, T. M. Laitinen2; 1University of Eastern Finland, Kuopio, FINLAND, 2Kuopio University Hospital, Kuopio, FINLAND.

EPS-088Additional value of 2-[18F]FDG PET/CT in detection of malignancy in patients with paraneoplastic neurological syndromes having negative results of conventional radiological imagingM. Opalinska1, A. Sowa-Staszczak2, K. Wężyk3, A. Słowik4, A. Hubalewska-Dydejczyk2; 1Nuclear Medicine Unit, Endocrinology Department, University Hospital in Krakow, Krakow, POLAND, 2Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND, 3Department of Neurology , University Hospital, Krakow, POLAND, 4Chair and Department of Neurology, Jagiellonian University Medical College, Krakow, POLAND.

EPS-089A meta-analysis of brain glucose hypo-metabolism in patients with disorders of consciousnessA. Sala1,2, B. Kaan Ok1,3, A. Thibaut1,2, O. Gosseries1,2, S. Laureys1,2, J. Annen1,2; 1University of Liège, Liège, BELGIUM, 2Centre du Cerveau2, University Hospital of Liege, Liege, BELGIUM, 3Kadir Has University, Istanbul, TURKEY.

EPS-090Association of periodontitis with Intracerebral Beta-Amyloid Plaque Deposition measured by 18F-Florbetaben PET/CTM. Rashki1, E. Triviño-Ibáñez1, T. Rudolphi Solero1, M. Gerez Muñoz2, I. Gómez Cartes2, M. Gómez-Río1; 1Department of Nuclear Medicine, University Hospital Virgen de las Nieves, Granada, SPAIN, 2School of Dentistry, Granada Biohealth Research Institute, Granada, SPAIN.

EPS-091Perfusion-like images based on [18F]florbetaben PET correlate well with brain metabolism in patients with inherited transthyretin-related amyloidosisS. Ferreira1,2,3, P. Alves4,5, I. Conceição4,5, I. P. Martins4,5, F. Oliveira1, M. Silva1, N. Matela3, D. C. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 2Philips Portuguesa S.A, Lisbon, PORTUGAL, 3Institute of Biophysics and Biomedical Engineering, Faculty of Sciences of the University of Lisbon, Lisbon, PORTUGAL, 4Department of Neurosciences, CHULN, Hospital de Santa Maria, Lisbon, PORTUGAL, 5Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, PORTUGAL.

EPS-092The role of amyloid PET-CT with 18F-Flutemetamol in patients with mild cognitive impairment: Identification of the group at risk of developing Alzheimer’s DiseaseL. Rodriguez-Bel1, M. Martínez de Bourio-Allona1, J. Campdelacreu-Fumado2, R. Reñé-Ramírez2, I. Rico-Pons3, P. Notta1, J. Vercher-Conejero1, G. Reynés-Llompart1, J. Fernandez-Barrionuevo1, M. Cortés-Romera1; 1PET Unit, Department of Nuclear Medicine-IDI. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN, 2Department of Neurology. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN, 3Neuropsychology Unit. Department of Neurology. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN.

EPS-093Texture Quantification Parameters for Alzheimer’s disease diagnosis measured by 11C- (R)- PK11195 PET imagesM. Lapo Pais1,2, L. Jorge1,2, R. Martins1,2, N. Canario1,2,3, C. Xavier1,2, A. Abrunhosa1,2, I. Santana3,4, R. Bernardes1,2,3, M. Castelo-Branco1,2,3; 1Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), University of Coimbra, Coimbra, PORTUGAL, 2Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, PORTUGAL, 3Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, 4Department of Neurology, Coimbra University Hospital, Coimbra, PORTUGAL.

EPS-09418F-FDOPA PET/CT diagnostic accuracy study in suspected brain tumors recurrenceD. Lisei Coscia, C. Salvat Dávila, C. Vigil Díaz, B. Fernández Llana, M. Domínguez Grande, M. López Carballo, A. Laverde Mächler, N. Martín Fernández, F. Gonzalez García; HUCA, Oviedo, SPAIN.

EPS-095Technical improvements implemented in a PET dedicated to the brain (CaremiBrain) in its technical validation phaseP. Nespral Torres1, A. Abadía-Ruiz1, A. Delgado-Cano1, M. Cabrera-Martín1, G. González-Pavón2, C. Morera-Ballester2, M. Sanchís-Hernández2, J. Matías-Guiu3, J. Carreras-Delgado1; 1Nuclear Medicine Department, Health Research Institute of Hospital Clínico San Carlos. Madrid, SPAIN, 2Oncovision, General Equipment for Medical Imaging S.A., Madrid, SPAIN, 3Neurology Department, Health Research Institute of Hospital Clínico San Carlos. Madrid, SPAIN.

EPS-096F-18-FET and F-18-choline PET/CT imaging in primary diagnosis of low-grade gliomas with impact on therapyA. Golubic1, M. Hodolic2,3, A. Misir Krpan4, M. Zuvic1, M. Baucic4, G. Mrak5,6, J. Nemir5, D. Huic1,6; 1Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, CROATIA, 2Nuclear Medicine Department, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, CZECH REPUBLIC, 3Nuclear Medicine Research Department IASON, Graz, AUSTRIA, 4Department of Oncology, University Hospital Centre Zagreb, Zagreb, CROATIA, 5Department of Neurosurgery, University Hospital Centre Zagreb, Zagreb, CROATIA, 6University of Zagreb School of Medicine, Zagreb, CROATIA.

1012


e-Poster Presentation Session 7: An Overview on Endocrine Disease

EPS-097Frequency of Malignancy in Incidental Thyroid Nodules Detected by F-18 FDG PET/CTS. Kesim, H. T. Turoglu, S. Ozguven, S. Inanir, C. O. Sahin, N. Filizoglu, K. Niftaliyeva, T. N. Kissa, Z. C. Balaban Genc, F. Dede, K. Oksuzoglu, F. Sen, T. Ones, T. Y. Erdil; Marmara University School of Medicine, Istanbul, TURKEY.

EPS-09818F-FDG thyroid incindental uptakes: can semiquantitative and volumetric parameters predict the final diagnosis?F. Dondi1, A. Mazzoletti1, P. Bellini1, A. Calabrò1, M. Gregorelli1, D. Albano1, R. Rinaldi1, M. Gazzilli2, E. Cerudelli2, L. Camoni2, R. Giubbini1, F. Bertagna1; 1Università degli Studi di Brescia, Brescia, ITALY, 2Spedali Civili di Brescia, Brescia, ITALY.

EPS-099BRAFV600E mutational status in thyroid carcinoma patients - single center studyT. Makazlieva1, N. Manevska1, S. Stojanoski1, A. Jankulovska1, B. Stoilovska1, A. Eftimov2, R. Jovanovic2; 1Institut of pathophysiology and nuclear medicine, Skopje, NORTH MACEDONIA, 2Institut of pathology, Skopje, NORTH MACEDONIA.

EPS-100Postoperative basal serum thyroglobuline (TG) prior to radioiodine therapy as a predictive factor of recurrence in patients with differentiated thyroid cancer (DTC)R. Núñez Muñoz, Y. Carreres Ortega, M. A. Astudillo Sarmiento, R. Valverde Jorge, M. Nevares Herrero, J. Genollá Subirats, J. Santamaría Sandi, M. Badiola Molinuevo; Osakidetza, Bilbao, SPAIN.

EPS-101Low Radioiodine Dose in Postoperative Ablation of Residual Thyroid Tissue in Patients with Differentiated Thyroid CarcinomaO. Bourogianni1, N. Kapsoritakis1, A. Tsaroucha1, M. Stahaki1, E. Papadaki1, S. Koukouraki2; 1University Hospital of Crete, Heraklion, GREECE, 2School of Medicine, University of Crete, Heraklion, GREECE.



179178

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-102The efficacy of radioactive iodine with cumulative activities over 600 mCi for the treatment of Differentiated Thyroid CarcinomaA. Mazzoletti, D. Albano, F. Dondi, P. Bellini, A. Calabrò, M. Gregorelli, F. Bertagna, R. Giubbini; ASST Spedali Civili of Brescia, University of Brescia, Brescia, ITALY.

EPS-103131I-SPECT/CT at the first radioiodine ablation and during follow-up in patients with differentiated thyroid carcinoma (DTC)S. Nuvoli, A. Marongiu, I. Gelo, M. Luciana, M. L. Stazza, M. Rondini, A. Spanu, G. Madeddu; University of Sassari, Sassari, ITALY.

EPS-104Our Experience in the Use of Iodine-123 in the Diagnosis and Monitoring of Thyroid CancerM. Atalay1, B. Ural1, A. Yıldırım1, B. Okudan Tekin1,2; 1Ankara City Hospital, Ankara, TURKEY, 2University of Health Sciences, Ankara, TURKEY.

EPS-10568Ga-FAPI PET/CT Accuracy In Patients With Recurrent Medullary Thyroid CarcinomaU. Elboga, Z. Sayıner, E. Sahin, S. Ozturk, Y. Cayirli, Y. Celen, E. Akarsu; Gaziantep University, Gaziantep, TURKEY.

EPS-106Knowing like the Back of one’s Hand the 99mTc-sestamibi Uptake Mechanism: Could a Simple Parathyroid Scan Be an Essential Tool for Studying BAT?W. Jalloul1, I. Roata2, C. Archip2, A. Tarca2, R. Tibu2, S. Chiper1, I. Grierosu1,2, T. Ionescu1, C. Stolniceanu1, M. Gutu1,2, V. Ghizdovat1, M. Moscalu1, A. Naum1,3, C. Stefanescu1,2; 1University of Medicine and Pharmacy U.M.F „Grigore T. Popa”, Iasi, ROMANIA, 2Nuclear Medicine Laboratory, County Emergency Hospital „Sf. Spiridon”, Iasi, ROMANIA, 3Nuclear Medicine Laboratory, Regional Institute of Oncology, Iasi, ROMANIA.

EPS-107The role of parathyroid hormone and neck ultrasound in predicting positivity of parathyroid scintigraphyD. Bezzi1, E. Tabacchi2, A. Scrivo3, A. Cingolani3, L. Calderoni1, R. Bonfiglioli2, C. Malizia2, S. Fanti1,2; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 3Nephrology, Dialysis and Transplantation, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY.

EPS-108Accuracy of Choline PET/CT vs Tc 99m Sestamibi SPECT/CT Parathyroid Imaging in Comparison to Histopathology in the Diagnosis of Parathyroid Adenoma: A Meta-AnalysisB. Tecson; Philippine Heart Center, Quezon City, PHILIPPINES.

EPS-109Kinetic analysis of [18F]CETO in subjects with adrenocortical pathologies and validation of simplified quantification methodsL. O’Sullivan1, M. Lubberink2, I. Silins2, A. Sundin2, M. Gurnell3, F. Aigbirhio4, M. Brown5, A. Wall2, T. Åkerstrom2, S. Roslin6, P. Hellman2, G. Antoni6; 1Medical Physics, Uppsala University Hospital, Uppsala, SWEDEN, 2Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 3Department of Medicine, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UNITED KINGDOM, 4Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UNITED KINGDOM, 5Clinical Pharmacology, William Harvey Heart Centre, Queen Mary University of London, London, UNITED KINGDOM, 6Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN.

EPS-110Relation between Striatal to Pancreatic Dopaminergic Activity Ratio and Glycated Hemoglobin in Diabetic and Non-diabetic PatientsP. Kalmar1, C. Gstettner1, G. Schwantzer2, R. M. Aigner1; 1Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA, 2Institute for Medical Informatics, Statistics and Documentation, Graz, AUSTRIA.

EPS-111Concomitant lithium increases radioiodine uptake and absorbed doses per volume-adjusted administered activity in Graves’ disease: Comparison of conventional versus lithium-augmented radioiodine therapyF. Khreish1, A. Schaefer-Schuler1, L. Roth1, F. Rosar1, H. Aladwan1, A. Sabet2, M. Schreckenberger3, S. Ezziddin1; 1Department of Nuclear Medicine , Saarland University, Homburg, GERMANY, 2Department of Nuclear Medicine Goethe University, Frankfurt am Main, GERMANY, 3Department of Nuclear Medicine, University of Mainz, Mainz, GERMANY.

EPS-112Lutetium-177 Labelled MAA Imaging and Therapy in Cystic and Solid Thyroid NodulesS. Sager, A. Aygün, E. Karayel, H. Pehlivanoğlu, M. Abuqbeitah, K. Sönmezoğlu; Istanbul University-Cerrahpasa, Istanbul, TURKEY.

EPS-113Yttrium-90 Radiation Synovectomy in Knee-Activated Osteoarthritis: A Prospective Evaluation of almost a decade follow-up (115 months)I. Iakovou1, J. Kotrotsios1, K. Badiavas2, M. Potoupnis1; 1Aristotle University, Thessaloniki, GREECE, 2Papageorgiou Hospital, Thessaloniki, GREECE.

1112


e-Poster Presentation Session 8: Imaging in Recurrent Prostate Cancer

EPS-114Predictive value of 68GA-PSMA PET/CT in men with biochemical relapse after radical prostatectomy, undergoing salvage radiotherapyF. Serani1, H. Lanzafame2, A. Farolfi1, C. Malizia1, R. Mei1, F. Medici3,4, G. Aluisio5, S. Fanti1; 1Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 2Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY, 3Radiation Oncology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 4Radiation Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5Radiation Oncology, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, ITALY.

EPS-115Role of 18F-fluorocholine PET/CT for guiding and monitoring response in oligometastatic recurrence prostate cancer patients treated with stereotactic body radiotherapyE. Noriega-Álvarez1, L. García Zoghby1, M. Amo-Salas2, L. Calahorra Fernández3, P. V. Rios4, M. de Cabo Ripoll5, F. Leal Hernández6, M. V. Villas Sánchez7, M. J. Donate Moreno8, A. M. García Vicente1, Á. M. Soriano Castrejón1; 1Nuclear medicine physician. University Hospital of Ciudad Real, Ciudad Real, SPAIN, 2Department of Mathematics, University of Castilla-La Mancha, Ciudad Real, SPAIN, 3Urologist University General Hospital, Ciudad Real, SPAIN, 4Radiation Therapy Oncologist. University Hospital of Ciudad Real, Ciudad Real, SPAIN, 5Urologist Virgen de la Luz Hospital, Cuenca, SPAIN, 6Urologist University General Hospital, Guadalajara, SPAIN, 7Radiation Therapy Oncologist. University General Hospital, Albacete, SPAIN, 8Urologist University Hospital of Ciudad Real, Albacete, SPAIN.

EPS-116Utility of 18F-choline PET/CT images in real-time transrectal US-guided prostate biopsyA. Laverde Mächler, M. Domínguez Grande, G. Fernández Rivero, D. Lisei Coscia, B. Fernández Llana, C. Vigil Díaz, J. Suárez Fernández, J. Maraña González, A. Álvarez, L. Rodríguez Díaz, N. Martín Fernández, F. González García; HUCA, Oviedo, SPAIN.

EPS-11718F-fluciclovine PET/CT in recurrent prostate cancer: detection rate, image interpretation using PROMISE staging system and impact on clinical managementL. Filippi1, A. Fontana2, P. Basile1, G. Spinelli3, O. Bagni2; 1Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, ITALY, 2Department of Radiotherapy, Santa Maria Goretti Hospital, Latina, ITALY, 3Oncology Unit, AUSL Latina (District 1) Sapienza University of Rome, Aprilia, ITALY.

EPS-118Comparison of 18F-Fluciclovine and 18F-Flurocholine PET/CT diagnostic performance in recurrent prostate cancer patientsC. Ferrari, A. G. Nappi, V. Lavelli, P. Mammucci, N. C. Merenda, G. Rubini; Section of Nuclear Medicine, DIM, University “Aldo Moro”, Bari, ITALY.

EPS-11918F-DCFPyL PET/CT in biochemically recurrent prostate cancer with low prostate specific antigen (PSA) rates (<1.1 ng/mL). Searching for a suitable lower cut-offP. Plaza López1, B. Domenech Brasero1, P. Pifarre1, N. Romera1, F. Racca1, O. Coronil1, M. Suarez-Piñera2, J. Torices Caballero1; 1Hospital Quironsalud Barcelona, Barcelona, SPAIN, 2Hospital del Mar Barcelona, Barcelona, SPAIN.

EPS-120Impact of 68Ga-PSMA PET-CT on radiotherapy planning in recurrent prostate cancer after radical prostatectomyC. Varela Pinto, B. Martins, V. Sousa, T. Antunes, C. Loewenthal; Hospital da Luz Lisboa, Lisbon, PORTUGAL.

EPS-121Diagnostic accuracy of [18F]-PSMA-1007 PET/CT in biochemical recurrent prostate cancer patients - a retrospective analysisC. Mingels, J. Hünermund, K. P. Bohn, A. Rominger, A. Afshar-Oromieh, I. L. Alberts; Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.



181180

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-122Diagnostic performance of 68Ga-P16-093 PSMA PET/CT compared to 18F-fluciclovine PET/CT and 99mTc-MDP scintigraphy in prostate cancer: a pilot studyH. Lee1, M. Daube-Witherspoon1, J. Scheuermann1, A. Young1, R. Doot1, E. Schubert1, D. Alexoff2, H. Kung2, D. Pryma1; 1University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, UNITED STATES OF AMERICA, 2Five Eleven Pharma Inc., Philadelphia, PA, UNITED STATES OF AMERICA.

EPS-123Incidental finding of Ga68-PSMA uptake in covid-19 induced pneumoniaA. Aghaei1, S. Soltani2, S. Zakavi1, N. Norouzbeigi3, M. Esmatinia1, G. Gholami1, H. Dadgar3, A. Masoudifard1; 1Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 2Uro-oncology research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 3Nuclear medicine research center, Razavi international university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EPS-124Diagnostic performance of 18F-Fluciclovine PET/CT in biochemical recurrent prostate cancer patients with low PSA valuesV. Lavelli, A. G. Nappi, C. Ferrari, N. C. Merenda, G. Santo, C. Scaltrito, G. Rubini; Section of Nuclear Medicine, DIM, University “Aldo Moro”, Bari, ITALY.

EPS-125Influence of Initial Treatment in the Performance of [11C]Choline PET/CT in the Follow-up of Prostate CancerF. Gomez-De La Fuente, I. Martínez-Rodríguez, O. Cuenca-Vera, A. Sánchez-Salmón, M. de Arcocha-Torres, S. Ruiz-Llama, N. Martínez-Amador, J. Jiménez-Bonilla, J. Andrés-Pacheco, R. Quirce; Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria., Santander, SPAIN.

EPS-126Retrospective analysis of PET / CT with 18F-Choline for the evaluation of recurrence in prostate cancerM. Cruz, J. Rodríguez-Rubio Corona, M. de Bonilla Candau, Y. Santaella Guardiola, M. Pajares Vinardell, J. Freire Macías; Hospital Puerta del Mar, Cádiz, SPAIN.

EPS-127Impact of Ga68-PSMA11 PET/CT on the Treatment of Patients with Recurrent Prostate Cancer After Radical Prostatectomy: a Single Center ExperienceS. Grimaldi1, S. Dall’Armellina1, G. Rovera2, F. Ceci3, V. Chiofalo1, G. Iorio1, I. Bonavero1, R. Parise1, S. Bartoncini1, V. Richetto1, B. Lillaz1, M. Oderda1, P. Gontero1, A. Guarneri1, U. Ricardi1, D. Deandreis3; 1AOU Città della Salute e della Scienza, Turin, ITALY, 2Università Cattolica del Sacro Cuore, Rome, ITALY, 3Università degli Studi di Torino, Turin, ITALY.

EPS-128Evaluation of 68Ga-PSMA PET/CT in patients with Biochemical Recurrence of Prostate CancerM. Dyankova1,2, T. Stoeva1, Z. Dancheva1, T. Yordanova1, S. Chausheva1, B. Chaushev1, A. Klisarova1; 1Medical University Varna “Prof. Dr. Paraskev Stoyanov”, Department of Nuclear Medicine, Varna, BULGARIA, 2St Marina University Hospital, Varna, BULGARIA.

EPS-129A Preliminary Retrospective Experience on 18F-DCFPYL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate CancerV. Lopez Prior, F. Manchón-Adsuar, R. Díaz-Expósito; Valencian Oncologic Institution (IVO), Valencia, SPAIN.

EPS-130First clinical application of a novel PSMA-11-derived hybrid molecule for preoperative PET/CT imaging and fluorescence-guided surgery of prostate cancerA. Eder1,2,3, M. A. Omrane1,2,3, S. Stadlbauer4,5, M. Roscher4,6, W. Y. Khoder7, C. Gratzke7, K. Kopka4,5,8, M. Eder1,2,3, P. T. Meyer1,9, C. A. Jilg7, J. Ruf1,9; 1Department of Nuclear Medicine, University Medical Center Freiburg, Freiburg, GERMANY, 2Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, GERMANY, 3German Cancer Research Center, Heidelberg, GERMANY, 4Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, GERMANY, 5Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY, 6Division of Radiooncology/Radiobiology, German Cancer Research Center, Heidelberg, GERMANY, 7Department of Urology, University Medical Center Freiburg, Freiburg, GERMANY, 8German Cancer Consortium (DKTK), partner site Dresden, Dresden, GERMANY, 9German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, GERMANY.

1212


e-Poster Presentation Session 9: Imaging in Primary Prostate Cancer

EPS-13168Ga-PSMA-PET/CT for staging high risk prostate cancer patients suitable for radical treatments: effective clinic implication and preliminary diagnostic performanceF. Mattana1, L. Bianchi2, E. Balestrazzi2, F. Costa2, R. Mei1, A. Farolfi1, M. Droghetti2, A. Morganti3, R. Schiavina2, E. Brunocilla2, P. Castellucci1, S. Fanti1; 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Metropolitan Nuclear Medicine, Bologna, ITALY, 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, ITALY, 3IRCCS Azienda Ospedaliero-Universitaria di Bologna, Radiation Oncology Department, Bologna, ITALY.

EPS-132Preoperative Evaluation of Prostate Cancer by Positron Emission Tomography / Computed Tomography (PET-CT) with PSMA-68Ga: Correlation with Prostate Magnetic Resonance and Histopathological FindingsC. Stachera Stasiak1,2, A. Cardillo3, S. Altino de Almeida1, D. B. Parente1,2, R. Souza Rodrigues1,2, P. Rosado-de-Castro1,2; 1Instituto D’Or de Ensino e Pesquisa - IDOR, Rio de Janeiro, BRAZIL, 2Universidade Federal do Rio de Janeiro, Rio de Janeiro, BRAZIL, 3Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, BRAZIL.

EPS-133Comparing Q.Clear & OSEM algorithms in detecting biochemical recurrence of prostate cancer in68Ga-PSMA PETCTP. Tansey1, A. Nasoodi2; 1Center for Advanced Medical Imaging (CAMI), St James’s Hospital & Trinity College, Dublin, IRELAND, 2St James’s Hospital Nuclear Medicine department, Dublin, IRELAND.

EPS-134Ga 68 PSMA PET/CT at the initial staging of high-risk patients with prostate cancerT. Pipikos, M. Vogiatzis, J. Andreou, D. Kechagias, V. Fillipi, E. Oikonomou, K. Gogos, S. Merisoglou, D. Papoutsani, K. Dalianis, R. Efthimiadou, V. Prassopoulos; PET/CT Department, Hygeia hospital, Athens, GREECE.

EPS-135Ga68 PSMA PET/CT in the restaging of patients with prostate cancer. Correlation to PSA levelsT. Pipikos, J. Andreou, M. Vogiatzis, D. Kechagias, V. Fillipi, E. Oikonomou, K. Gogos, K. Dalianis, S. Merisoglou, D. Papotsani, R. Efthimiadou, V. Prassopoulos; PET/CT Department, Hygeia hospital, Athens, GREECE.

EPS-136Effective dose of for medical workers operating in a PET/CT with the use of synthesis moduleK. Dalianis1, K. Gogos1, G. Kollias1, R. Efthimiadou2, V. Prassopoulos2; 1Medical Physics Deparment, Hygeia Hospital, Athens, Marousi, GREECE, 2PET/CT Deparment, Hygeia Hospital, Athens, Marousi, GREECE.

EPS-137[68Ga]PSMA-11 PET findings in intermediate/high risk prostate cancer patients at stagingA. Scarale1, S. Capitanio1, A. Franchini2, M. A. Potami1, M. Longoni1, S. Tappero1, E. Gay1, G. Cabrini1, M. Milella1, P. Dell’Oglio1, A. Galfano1, A. M. Bocciardi1, C. Rossetti1; 1ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY, 2University of Milano-Bicocca, Milan, ITALY.

EPS-138A Randomised Controlled Diagnostic Trial Comparing [18F]PSMA-1007 PET/CT with Conventional Imaging in Primary Staging of Prostate CancerK. Buch-Olsen1, M. H. Vilstrup1, S. Hansen2, S. Hess3, P. C. Holdgaard4, M. H. Poulsen5, J. H. Dam1, S. S. Madsen6, M. G. Hildebrandt1; 1Department of Nuclear Medicine, OUH Odense, Odense, DENMARK, 2Department of Oncology, OUH Odense, Odense, DENMARK, 3Department of Nuclear Medicine, Hospital South West Jutland, Esbjerg, DENMARK, 4Department of Nuclear Medicine, Hospital Lillebaelt, Vejle, DENMARK, 5Department of Urology, OUH Odense, Odense, DENMARK, 6Department of Urology, Hospital South West Jutland, Esbjerg, DENMARK.

EPS-139Association Between Prostate-Specific Antigen (PSA) Levels And Metabolic Findings In Bone Scintigraphy (BS) In Prostate Adenocarcinoma. Stratification In Groups According To PSA LevelsJ. Badell, F. Gomez-Caminero, E. Martin, S. Lopez, J. Cañadas, A. C. Peñaherrera, J. G. Villanueva, B. Lucas, E. Martin, L. Diaz, P. Garcia-Talavera, C. Riola, P. Tamayo; Hospital Universitario de Salamanca, Salamanca, SPAIN.



183182

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-14168Ga-PSMA PET/CT in primary staging of prostate cancer (PC) patients: risk of metastatic diseaseM. Dyankova1,2, T. Stoeva1, Z. Dancheva1, T. Yordanova1, S. Chausheva1, B. Chaushev1, A. Klisarova1; 1Medical University Varna “Prof. Dr. Paraskev Stoyanov”, Department of Nuclear Medicine, Varna, BULGARIA, 2St Marina University Hospital, Varna, BULGARIA.

EPS-142Is there an ideal tracer for pre-surgical nodal staging primary PCa? Monocentric experience of [68Ga]PSMA and [18F]Fluciclovine performance in two high-risk populationsF. Mattana1, L. Bianchi2, E. Balestrazzi2, F. Costa2, A. Farolfi1, R. Mei1, C. Malizia1, M. Droghetti2, P. Castellucci1, R. Schiavina2, E. Brunocilla2, L. Zanoni1, S. Fanti1; 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Metropolitan Nuclear Medicine, Bologna, ITALY, 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, ITALY.

EPS-143The impact of (68Ga)-Ga-PSMA-11 PET/CT in primary staging of prostate cancerF. Weitzer, B. Pernthaler, E. Plhak, R. Riedl, R. M. Aigner; Medical University of Graz, Graz, AUSTRIA.

EPS-144Correlation of Intraprostatic Malignant Lesions Using F18-Prostate Specific Membrane Antigen Positron Emission Tomography (F-18 PSMA1007 PET/CT) with Magnetic Resonance Imaging (MRI) and Transrectal Ultrasound (TRUS) Biopsy Results in Initial Staging of Prostate Cancer, Single Institution ExperienceA. Sadeq, W. Moftah, A. Esmail, F. Marafi, M. Alfeeli; Jaber AlAhmad center for Molecular Imaging, Shuwaikh Medical area, KUWAIT.

EPS-145Gallium-68 [68Ga] labeled prostate specific membrane antigen (PSMA)-11 PET/CT in primary nodal and distant staging of prostate cancer (PC) patients compared to conventional imaging modalities ( CT, MRI, bone scintigraphy): a retrospective single center studyM. Dyankova1,2, Z. Dancheva1, T. Stoeva1, T. Yordanova1, S. Chausheva1, B. Chaushev1, A. Klisarova1; 1Medical University Varna “Prof. Dr. Paraskev Stoyanov”, Department of Nuclear Medicine, Varna, BULGARIA, 2St Marina University Hospital, Varna, BULGARIA.

EPS-146The Role of PSMA PET/CT in Primary Staging of Prostate Cancer according PSMA-RADS scale and correlation with prognostic staging from AJCC 8th

S. Medina-Ornelas, F. Garcia-Pérez, E. Gomez-Argumosa, J. Vargas-Ahumada; Instituto Nacional de Cancerologia, Mexico City, MEXICO.

EPS-14718F-Florastamin PET/CT for the initial staging of patients with high-risk prostate cancerW. H. Choi1, S. Boo1, Y. Choi2, H. Kim2, S. Lee2; 1Department of Nuclear Medicine, College of Medicine, The Cathoic University of Korea, Seoul, KOREA, REPUBLIC OF, 2Department of Urology, College of Medicine, The Cathoic University of Korea, Seoul, KOREA, REPUBLIC OF.

1312


e-Poster Presentation Session 10: Lymphoma and Other Hematological Diseases

EPS-148Prognostic role of end-of-treatment Fluorine-18 Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in diffuse large B cell lymphoma (DLBCL): a pilot study application of neural networks to predict time-to-eventE. Triumbari1, S. Annunziata2,1, A. Pelliccioni3, S. Hohaus4,5, E. Maiolo5, A. Giordano1,2; 1Section of Nuclear Medicine, University Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, Rome, ITALY, 2Nuclear Medicine Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY, 3INAIL-DiMEILA, Monte Porzio Catone, Rome, ITALY, 4Section of Hematology, University Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, Rome, ITALY, 5Hematology Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY.

EPS-14918F-FDG PET/CT Volumetric and Radiomic Features predict Histological Types of Bulky Mediastinal LymphomaE. Abenavoli1, F. Linguanti1, B. Puccini2, F. Mungai3, S. Cristin4, I. Romano2, V. Miele4, R. Sciagrà1,5, V. Berti1,5; 1Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Firenze, ITALY, 2Lymphoma unit,Hematology department, Careggi Hospital and University of Florence, Firenze, ITALY, 3Department of Radiology, Azienda Ospedaliero-Universitaria Careggi, Firenze, ITALY, 4Department of Radiology, Azienda Ospedaliero-Universitaria Careggi, L, Firenze, ITALY, 5Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, Firenze, ITALY.

EPS-150Predicting Time to Treatment in Follicular Lymphoma on Watchful Waiting using Baseline Metabolic Tumor BurdenD. Maccora1, L. Leccisotti1,2, R. Malafronte3, F. D’Alò3, S. Annunziata2, S. Hohaus3, V. Rufini1,2; 1Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, ITALY, 2Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, 3Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

EPS-152Can 18F-FDG PET/CT early detect treatment-related cardiotoxicity in patients with lymphomaM. Wei, T. Yuan, X. Chen, X. Wang; Peking university cancer hospital, BeiJing, CHINA.

EPS-153Impact of 18F-FDG-PET / TC for Assessing Response to Chimeric Antigen Receptors T Cell Therapy (CAR-T Cells) in the Treatment of Refractory Non-Hodgkin LymphomaJ. Ardila Mantilla, I. Gómez Fernández, M. Baquero Oliveros, A. Rotger Regí, J. Orcajo Rincón, C. Durán Barquero, M. Kwon, M. Bastos Oreiro, M. Toscano Sánchez, J. Alonso Farto; Hospital General Univeristario Gregorio Marañón, Madrid, SPAIN.

EPS-154Utility of serial PET imaging by Peking criteria to prospectively predict prognosis in patients with diffuse large B-cell lymphomaT. Yuan, M. Wei, X. Chen, X. Wang; Peking University Cancer Hospital & Institute, Beijing, CHINA.

EPS-155Quantification of whole-body [18F]FDG avid lymphoma lesions: advantages of semiautomatic over manual segmentationC. S. Constantino, S. Leocádio, F. Oliveira, M. Silva, C. Oliveira, J. C. Castanheira, Â. Silva, S. Vaz, R. Teixeira, M. Neves, P. Lúcio, C. João, D. C. Costa; Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL.

EPS-156Role of 18F-FDG-PET / TC in Predicting the Adverse Effects of Chimeric Antigen Receptors T Cell Therapy (CAR-T Cells) In The Treatment of Refractory Non-Hodgkin LymphomaI. Gomez Fernandez, J. Ardila Mantilla, M. Baquero Oliveros, A. Rotger Regí, J. Ardila Manjarrez, Y. Henao Celada, D. Zamudio Rodríguez, M. Kwon, M. Bastos Oreiro, M. Toscano Sánchez, J. Alonso Farto; HGU Gregorio Marañon, Madrid, SPAIN.

EPS-157Series interim 18F-FDG PET/CT stratify the prognosis of patients with Hodgkin lymphoma:based on Peking CriteriaM. Wei, X. Chen, T. Yuan, X. Wang; Peking university cancer hospital, BeiJing, CHINA.



185184

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-158Evaluation of the volumetric parameters calculated with the 2-[18F]FDG PET/CT and the molecular characteristics in patients with diffuse large B cell lymphoma, not otherwise specifiedS. Guzmán Ortiz1,2, J. Mucientes Rasilla1, J. A. Vargas Nuñez1,2, J. L. Rodriguez Carrillo1, A. Dotor de Lama1, M. B. Navarro Matilla1, M. Mitjavila Casanovas1; 1Puerta de Hierro University Hospital, Madrid, SPAIN, 2Autonoma University of Madrid, Madrid, SPAIN.

EPS-159The role of 18F-FDG PET/CT in Erdheim-Chester DiseaseM. Pudis1, A. Palomar-Muñoz1, K. López-Aldabe2, X. Solanich-Moreno2, J. J. Robles-Barba1, E. Llinares-Tello1, I. E. Sánchez-Rodríguez1, L. Rodríguez-Bel1, S. Bondía-Bescos1, M. Cortés-Romera1; 1Nuclear Medicine-PET (IDI) department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, 2Internal Medicine department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN.

EPS-160[18F]-FDG PET-CT in the diagnosis and management of plasma cell disordersM. Muzaffar, A. Hassan, B. Ahsan, T. Zafar; Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, PAKISTAN.

1412


e-Poster Presentation Session 11: Neuroendocrine and Lymphoma

EPS-161Concordance between baseline 68Ga-DOTATOC PET/CT and first post-dose 177Lu-oxodotreotide SPECT/CT (177Lu-DOTATATE-SPECT/CT) images in patients with neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)A. Cardozo Saavedra, M. Simó-Perdigó, A. García-Burillo, D. Villasboas-Rosciolesi, J. Hernando, J. Capdevila, S. Menéndez-Sánchez, R. Bellviure-Meiró, F. Dellepiane-Clarke, S. Aguadé-Bruix; Hospital Universitari Vall d’Hebron, Barcelona, SPAIN.

EPS-162Assessment of PRRT Response from SUV-SPECT & PET, Personal Dosimeter and Biochemical MetricsT. Alkahtani1,2,3, L. Livieratos1,2, V. Lewington1,2; 1King’s College London, London, UNITED KINGDOM, 2Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London, UNITED KINGDOM, 3Princess Nourah bint Abdulrahman University, Riyadh, SAUDI ARABIA.

EPS-163Dynamic changes of SUVs in 68Ga-somatostatin analogue PET/CT in response to PRRT as a predictive factor in patients with neuroendocrine tumoursM. Opalinska1, A. Sowa-Staszczak2, A. Kania-Kuc1, I. Al Maraih1, K. Morawiec-Sławek2, A. Hubalewska-Dydejczyk2; 1Nuclear Medicine Unit, Endocrinology Department, University Hospital in Krakow, Krakow, POLAND, 2Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND.

EPS-164Evaluation of 177Lu-DOTATATE treatment in patients with metastasic or unresectable paragangliomas and pheochromocytomasJ. Cañón Sánchez, S. G. Prado Wohlwend, P. Bello Arques, J. C. Bernal Vergara, A. Utrera Costero; Hospital Universitario I Politécnico La Fe, Valencia, SPAIN.

EPS-165Role of Interim CT Scan in Patients with Neuroendocrine Tumors (NETs) Treated with 177Lu-oxodotreotide (177Lu): Love it or List itS. Menendez-Sanchez, A. Garcia-Burillo, J. Hernando, D. Villasboas-Rosciolesi, A. Cardozo-Saavedra, M. Simo, J. Capdevila, S. Aguade; Hospital Universitario Vall d’Hebron, Barcelona, SPAIN.

EPS-166Evaluation and improvements of small VOI method for kidney dosimetry in patients undergoing radionuclide targeted therapy with 177Lu-DOTATATEJ. Khan1, T. Rydèn2, M. Van Essen3, J. Svensson4, P. Bernhardt5; 1Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN, 21Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN, 3Department of Clinical Physiology, Sahlgrenska University Hospital,, Gothenburg, SWEDEN, 43Department of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, 5Department of Medical Radiation Sciences, Institute of Clinical Gothenburg Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN.

EPS-167Evaluation of thyroid function in patients receiving Lu-177 DOTATATE treatmentA. Kibar, B. Ince, A. Nazari, K. N. Toplutas, S. Bilgic, S. Asa, R. L. Uslu Besli, M. S. Sager, H. B. Sayman, K. Sonmezoglu; Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, TURKEY.

EPS-168Simulation of selective ablation of liver metastases in neuroendocrine tumor patientsV. Santoro-Fernandes1, B. Schott1, D. Huff1, T. Perk2,3, A. Deatsch1, S. Perlman4, R. Jeraj1,5,6; 1University of Wisconsin-Madison, Department of Medical Physics, Madison, WI, UNITED STATES OF AMERICA, 2University of Wisconsin-Madison, Department of Radiology, Madison, WI, UNITED STATES OF AMERICA, 3AIQ Global, Inc., Madison, WI, UNITED STATES OF AMERICA, 4University of Wisconsin School of Medicine and Public Health, Department of Radiology, Section of Nuclear Medicine and Molecular Imaging, Madison, WI, UNITED STATES OF AMERICA, 5University of Wisconsin-Madison, Carbone Cancer Center, Madison, WI, UNITED STATES OF AMERICA, 6University of Ljubljana, Institute of Physics, Ljubljana, SLOVENIA.

EPS-169Toxicity evaluation of 177Lu-DOTATATE for advanced neuroendocrine tumorsJ. Bonilla Plaza, A. Martinez Lorca, T. Navarro Martinez, O. Ajuria Illarramendi, I. Lopez Villar, P. Azpeitia Hernandez, M. Gutierrez Guerrero, P. Paredes Rodriguez, M. Orduña Diez; Hospital Ramón y Cajal, Madrid, SPAIN.

EPS-170Extended field imaging in F-18 FDG PET/CT in Multiple Myeloma; is it necessary?Z. Koc, P. P. Özcan, A. Akdeniz, Z. S. Sağlam; Mersin University, Mersin, TURKEY.

EPS-171Importance of non attenuation corrected 18F PET/CT images in multilple myeloma (MM) vertbroplasty treated patients to avoid false positive reported imagesM. Agolti, L. Solari; Centro de Medicina Nuclear Clinica Modelo, Parana, ARGENTINA.

EPS-172Image quality assessment of [68Ga]-Gallium-CXCR4-PET/CT in multiple myeloma and diffuse large B-cell lymphomaA. Lambertini1, P. Hartrampf1, A. Haug2, A. K. Buck1; 1Department of Nuclear Medicine - Würzburg University Hospital, Würzburg, GERMANY, 2Division of Nuclear Medicine - Medical University of Vienna, Vienna, AUSTRIA.

EPS-173Correlation of histopathological and 18F-FDG-PET/CT data in patients with symptomatic multiple myelomaM. Türk1, C. Sachpekidis2, S. Sauer3, J. Hillengass4, A. Dimitrakopoulou-Strauss2; 1Ruprecht Karl University of Heidelberg, Heidelberg, GERMANY, 2German Cancer Research Center (DKFZ), CCU Nuclear Medicine, Heidelberg, GERMANY, 3University Hospital Heidelberg, Department of Hematology, Oncology and Rheumatology, Heidelberg, GERMANY, 4Roswell Park Comprehensive Cancer Center, Buffalo, NY, UNITED STATES OF AMERICA.

1612


e-Poster Presentation Session 12: Head Neck / Breast / Lung

EPS-174Comparison of FDG PET/CT and MRI Imaging in the Evaluation of the Treatment Response in Patients with Head and Neck CancerM. Engin1, F. Aydin1, A. Arcay1, C. Dundar Caglayan1, E. Tezel2, K. Karaali2, A. Tatli3, M. Genc Ozay4; 1Akdeniz university faculty of medicine nuclear medicine department, Antalya, TURKEY, 2Akdeniz university faculty of medicine radiology department, Antalya, TURKEY, 3Akdeniz university faculty of medicine medical oncology department, Antalya, TURKEY, 4Akdeniz university faculty of medicine radiation oncology department, Antalya, TURKEY.

EPS-176Clinical Effectiveness Of Sentinel Node Biopsy In Early Oral Cavity CarcinomaY. Herrera-Martinez, Á. De Bonilla-Damiá, V. Pachón-Garrudo, R. Álvarez-Pérez, J. Jiménez-Hoyuela; Hospital Universitario Virgen del Rocío, Seville, SPAIN.

EPS-177The utility of multiparametric imaging with 18F-FDG PET and MRI in predicting survival outcome of patients with nasopharyngeal carcinomaS. Chan1, C. Yeh2, S. Ng2, J. T. Chang2; 1Hualien Tzu Chi Hospital, Hualien, TAIWAN, 2Linkou Chang Gung Memorial Hospital, Taoyuan, TAIWAN.



187186

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-178Delayed complete metabolic response assessed with 18F-FDG-PET/CT in two time-points in patients with malignant epithelial head and neck tumor after radiotherapy with or without systemic chemotherapy- three clinical casesT. Yordanova, A. Klisarova, T. Stoewa, S. Chausheva, M. Dyankova, Z. Dancheva, B. Chaushev; Medical University Prof. dr. P. Stoyanov, Deparment of nuclear medicine, Varna, BULGARIA.

EPS-179Quantitative assessment of bone metastases in breast cancer patientsM. Mutuleanu, A. Lazar, I. Irimescu, M. Gherghe; National Institute of Oncology “Prof.Dr.Alexandru Trestioreanu”, Bucharest, ROMANIA.

EPS-180Metabolic Parameters By FDG PET-CT As Predictor Of Poor Prognosis In Breast Cancer PatientsS. Ali1, M. ELahmadawy1, H. Fathy2; 1National Cancer institute, Cairo, EGYPT, 2National Cancer Institute, Cairo, EGYPT.

EPS-181Incidental detection of breast cancer on [18F]fluorocholine PET/CT: a retrospective analysisA. Androjna1, M. Hocevar2,3, S. Rep1,4, K. Zaletel1,3, L. Lezaic1,3; 1Department for Nuclear medicine, University medical centre Ljubljana, Ljubljana, SLOVENIA, 2Oncological Surgery, Oncology institute Ljubljana, Ljubljana, SLOVENIA, 3Faculty of medicine, Ljubljana, SLOVENIA, 4Faculty of health sciences, Ljubljana, SLOVENIA.

EPS-182Differences between supine and prone images in 18F-PET/CT in restaging breast cancer. Development of a soft material device to acquire prone images with better resolutionM. Agolti, L. Solari; Centro de Medicina Nuclear Clinica Modelo, Parana, ARGENTINA.

EPS-183Submandibular gland involvement, as an unusual and the only site of breast cancer metastasis, detected in FDG PET/CT studyA. Aghaei1, G. Gholami1, F. Nesari1, F. Emami2, B. Rasoulian3, H. Dadgar2; 1Nuclear medicine research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 2Razavi Cancer research center, Razavi Hospital, Imam Reza international University, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 3Sinus and surgical Endoscopic research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EPS-184FDG Uptake in Breast Cancer and Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Association with Histopathological, Hormonal Status, and Clinical FeaturesG. Alçin, E. Arslan, T. Aksoy, T. F. Çermik; University of Health Sciences, Istanbul Training and Research Hospital, Clinic of Nuclear Medicine, Istanbul, TURKEY.

EPS-18518F-FDG PET/CT In The Characterization Of The Different Histological Subtypes Of Pulmonary Neuroendocrine Tumors And Its Prognostic ValueA. Peñaherrera Cepeda, P. García-Talavera San Miguel, J. Villanueva Curto, J. Cañadas Salazar, S. López Puche, J. Badell Martínez, C. Riola Parada, B. Lucas Velazquez, F. Gómez-Caminero López, P. Tamayo Alonso; Complejo Asistencial Universitario de Salamanca, Salamanca, SPAIN.

EPS-186Dynamic whole-body 18F-FDG PET/CT in patients with unclear lung tumors - evaluation of multiparametric dynamic imaging in a clinical settingM. Weissinger1, M. Atmanspacher2, H. Dittmann2, S. Gatidis1, L. Zender3, C. la Fougère2; 1Department of Radiology, University Hospital Tuebingen, Tuebingen, GERMANY, 2Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, GERMANY, 3Internal Medicine VIII, University Hospital Tuebingen, Tuebingen, GERMANY.

EPS-187Incidental Renal Mass on PET/CT in Lung Cancer Patients, Evaluation With Histopathological Radiological And Clinical Findings: Pearls, Pittfals and False PositivitiesB. Özdemir1, S. Soyluoglu1, U. Korkmaz1, B. Gunay2, B. Uslu2, G. Durmus-Altun1; 1Trakya University Department of Nuclear Medicine, Edirne, TURKEY, 2Trakya University Department of Radiology, Edirne, TURKEY.

EPS-188Evaluation of Two Thoracic Dedicated Imaging Techniques for Lung CT Stabilisation Applied to PET/CT in Lung Nodule Assessment: High-Frequency Non-Invasive Ventilation (HF-NIV) and Breath-Hold (BH)M. Jreige, E. Darçot, M. Pappon, M. Nicod-Lalonde, N. Schaefer, C. Beigelman-Aubry, J. O. Prior; Lausanne University Hospital, Lausanne, SWITZERLAND.

EPS-189Predictive value of quantitative metabolic tumor volume and metabolic index analysis in lung cancer stereotactic radiotherapy with F-18 FDG PET / CTF. Aras1, A. Olmezoglu2; 1Celal Bayar University, School of Medicine, Department of Nuclear Medicine, Manisa, TURKEY, 2Celal Bayar University, School of Medicine, Radiation oncology, Manisa, TURKEY.

EPS-190 Renal metastasis of primary lung carcinoma is associated with death and progression predicted by F-18 FDG PET/CTZ. Koc, P. P. Özcan, V. Erçolak, Y. Karabulut; Mersin University, Mersin, TURKEY.

1712


e-Poster Presentation Session 13: Image Acquisition / Reconstruction / Processing 1

EPS-191Determination of Partial-Volume Effect in Patient-Individual Kidney Phantoms for Tc-99m SPECT/CTA. Grings, T. Kuwert, P. Ritt; Clinic of Nuclear Medicine, Erlangen, GERMANY.

EPS-192Patient-Specific Phantoms for Tc-99m Brain Perfusion Imaging with SPECT/CTA. Grings1, M. Reymann2, A. H. Vija3, T. Kuwert1, P. Ritt1; 1Clinic of Nuclear Medicine, University Hospital, Erlangen, GERMANY, 2Siemens Healthineers GmbH, Forchheim, GERMANY, 3Siemens Medical Solutions USA, Inc., Molecular Imaging, Hoffman Estates, IL, UNITED STATES OF AMERICA.

EPS-193The potential of 18F-FDG PET/CT for monitoring disease progression of malignant PEComaA. Martini1,2, A. Coppola1, A. Arena1, M. Dona1, G. Baldi3, S. Sestini1; 1Hospital Santo Stefano, Nuclear Medicine Unit, Prato, ITALY, 2University of Florence, AUOC Careggi Nuclear Medicine Department, Florence, ITALY, 3Hospital Santo Stefano, Oncology Unit, Prato, ITALY.

EPS-194Application of PET/CT Studies in Radiotherapy Using Deformation AlgorithmsS. Pena Vaquero, Á. del Castillo Belmonte, M. Martín Veganzones, C. Andrés Rodríguez, M. Agulla Otero, A. Hurtado Romero, N. Álvarez Mena, I. Conles Picos, D. Miguel Pérez, L. Gómez Heras, D. Alonso Hernández, J. de Frutos Baraja, R. Torres Cabrera; Hospital Clínico Universitario, Valladolid, SPAIN.

EPS-195Dynamic PSMA PET/MRI imaging: initial resultsM. Gammel, I. Rauscher, M. Eiber, W. A. Weber, S. G. Nekolla; TU München, München, GERMANY.

EPS-197How refinements in the DROP-IN design improve surgical dexterity and surgical decision-making during radioguided surgeryS. Azargoshasb1, S. van Alphen2, L. J. Slof2, G. Rosiello3, S. Puliatti4, S. I. van Leeuwen2, K. M. Houwing2, M. Boonekamp5, J. Verhart5, P. Dell’Oglio6, J. van der Hage7, M. N. van Oosterom2, F. W.B. van Leeuwen2; 1Leiden University Medical Center, Leiden, NETHERLANDS, 2Interventional Molecular Imaging-Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, 3Department of Urology and Division of Experimental Oncology, Urological Research Institute IRCCS San Raffaele Scientific Institute, Milan, ITALY, 4Department of Urology, University of Modena and Reggio Emilia, Via del Pozzo, Modena, ITALY, 5Instrumentele zaken ontwikkeling, facilitair bedrijf, Leiden University Medical Center, Leiden, NETHERLANDS, 6Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY, 7Department of Surgery, Leiden University Medical Center, Leiden, NETHERLANDS.

EPS-198Dexterity and performance analysis in PET-navigated biopsiesI. Boekestijn, S. Azargoshasb, L. Pronk, A. R. van Erkel, M. N. van Oosterom, F. W. van Leeuwen, D. D. Rietbergen; Leiden University Medical Center, Leiden, NETHERLANDS.



189188

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-199Selective sentinel lymph node biopsy (SLNB) in infiltrating breast cancer and neoadjuvant therapyS. Perez Quiros, L. Fuentes Moreno, A. Prieto Soriano, M. Ramírez Medina, G. Silvestre Egea, J. Cardona Arboniés, S. Guzmán Ortíz, V. Spinelli René, M. Mitjavila Casanovas; Hospital Universitario Puerta de Hierro, Majadahonda, SPAIN.

EPS-2003D digital reconstruction of anatomical models integrating PET/CT data for pre-operative planning in gynecologic oncology surgery: a preliminary studyL. Muraglia1,2, P. Castellucci2,1, B. Bortolani3, S. Lodi3, P. De Iaco4,1, M. Perrone4,1, L. Cercenelli3, E. Marcelli3, S. Fanti2,1; 1Università di Bologna, Bologna, ITALY, 2Metropolitan Nuclear Medicine, IRCCS Policlinico Sant’Orsola-Malpighi, Bologna, ITALY, 3eDIMES Lab - Laboratory of Bioengineering, Department of experimental, diagnostic and specialty medicine (DIMES), Università di Bologna, Bologna, ITALY, 4Department of Obstetrics and Gynecology, Unit of Oncologic Gynecology, IRCCS Policlinico Sant’Orsola-Malpighi, Bologna, ITALY.

EPS-201Semi-Automated Analysis Of Amyloid-PET Images Allows To Shorten Acquisition Time With Accuracy ComparableTo Standard TimeP. Guglielmo, M. Scarlattei, G. Baldari, G. Serreli, S. Migliari, A. Sammartano, A. Pennacchio, L. Ruffini; University Hospital of Parma, Parma, ITALY.

EPS-202Optimization of cardiac atrial metabolism quantitative analysis with digital TOF-PET/CTM. Hesse, S. Marchandise, B. Gerber, R. Lhommel, V. Roelants; Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.

EPS-203Motion Correction in 15O-water Cardiac PETN. Christensen1, J. Nordström2, M. Lubberink3, L. Poulsen Tolbod1; 1Department of Nuclear Medicine & PET, Aarhus University Hospital, Aarhus N, DENMARK, 2Centre for Research & Development , Gävleborg, Gävle, SWEDEN, 3Department of Surgical Sciences/Nuclear Medicine & PET, Uppsala University, Uppsala, SWEDEN.

EPS-204Adaptive Regularized Reconstruction Enabling High Resolution Brain PET Images from Whole Body FOV PET/CT ImagingY. Hsieh1, K. Binzel1, C. L. Wright1, B. Zhang2, P. Maniawski2, M. V. Knopp1; 1The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA, 2Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EPS-205Using prone position to reduce motion induced artefacts during SPECT myocardial perfusion imagingI. Polycarpou1,2, G. Charitou3, S. Panagi3,4, D. Kaolis5, I. G. Petrou6, Y. Parpottas3,4; 1European University Cyprus, Nicosia, CYPRUS, 2E.U.C. Research Center, Nicosia, CYPRUS, 3Frederick Research Center, Nicosia, CYPRUS, 4Frederick University, Nicosia, CYPRUS, 5Department of Medical Physics, State Health Services Organisation, Nicosia, CYPRUS, 6Department of Nuclear Medicine, Nicosia General Hospital, State Health Services Organisation, Nicosia, CYPRUS.

EPS-206Development and Validation of a novel image software for automatic semiquantitative analysis Tc-99m Trodat-1 SPECT in patients with suspicious Parkinsion’s DiseaseC. Hung1, P. Kao2,3, J. Weng3, K. Lin4, R. Liu5; 1Department of Occupational Therapy and Graduate Institute of Behavioral Sciences, College of Medicine, Chang Gung University, Taoyuan, TAIWAN, 2School of Medicine, Chung Shan Medical University, Taichung, TAIWAN, 3Department of Nuclear Medicine, Chung Shan Medical University Hospital, Taichung, TAIWAN, 4Department of Electrical Engineering, Chung Yuan Christian University, Taoyuan, TAIWAN, 5School of Medicine, Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, TAIWAN.

EPS-207Putamen-to-caudate (P/C) ratio is a parameter not affected of different methods of Dopamine transporter (DAT) brain SPECT quantificationJ. Koutsikos, S. Giourgouli, V. Pantzou, M. Stathopoulou, T. Petropoulos; Nuclear Medicine Department, Henry Dunant Hospital Center, Athens, GREECE.

1812


e-Poster Presentation Session 14: Image Acquisition / Reconstruction / Processing 2

EPS-208On the Combination of a Dedicated HF Readout Circuit and the TOFPET2 ASIC to Push the Timing Performance of PET SystemsV. Nadig1, S. Gundacker1, H. Radermacher1, D. Schug1,2, B. Weissler1,2, V. Schulz1,2,3; 1Department of Physics of Molecular Imaging Systems, Institute of Experimental Molecular Imaging, RWTH Aachen University, Aachen, GERMANY, 2Hyperion Hybrid Imaging Systems GmbH, Aachen, GERMANY, 3Fraunhofer Instiute for Digital Medicine MEVIS, Aachen, GERMANY.

EPS-2093D-printed Source Holder for Dose Calibrators Enables Quantification of the Geometrical Effect of Source Position in Activity MeasurementsT. Miettinen1, S. Pekkarinen1, L. Koivula1, V. Reijonen1, E. Hippeläinen2; 1Department of Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND, 2Clinical Physiology and Nuclear Medicine, HUS Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND.

EPS-210Australian preclinical PET QA audit: a pilot studyA. Scott1, G. Cowin2, K. Mardon2, T. Hung3, W. Lakshantha4, M. DeVeer5, G. Angelis6, H. Hamze7, A. Narayaran2, G. O’Keefe1, C. Dixson2, S. Meikle6; 1Austin Health, ONJCRI, La Trobe Uni and University of Melbourne, Melbourne, AUSTRALIA, 2Queensland NIF node, University of Queensland, Brisbane, AUSTRALIA, 3UNSW NIF node, University of New South Wales, Sydney, AUSTRALIA, 4SAHMRI NIF node, South Australian health and medical research institute, Adelaide, AUSTRALIA, 5Monash NIF node, Monash University, Melbourne, AUSTRALIA, 6University of Sydney-ANSTO NIF node, University of Sydney, Sydney, AUSTRALIA, 7University of Sydney-ANSTO NIF node, ANSTO, Sydney, AUSTRALIA.

EPS-211Evaluation of Inter-user Variability and Time-savings for a Semi-automated Segmentation Method of Planar Gallbladder and Renal ExamsK. Krawiec1, J. Taylor2, T. Martin2, S. McGurk2, S. Whitmarsh3, A. S. Nelson1; 1MIM Software Inc, Cleveland, OH, UNITED STATES OF AMERICA, 2Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UNITED KINGDOM, 3Beth Israel Deaconess Medical Center, Boston, MA, UNITED STATES OF AMERICA.

EPS-212Dose Reduction Strategies for Optimizing [89ZR]Zr-Df-IAB22M2C PET Scans Using Virtual Reconstruction (VR) TechniquesR. Korn1, A. Abbott1, J. Sunderland2, I. Wilson1, W. Le1; 1ImaginAB, Inglewood, CA, UNITED STATES OF AMERICA, 2University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA.

EPS-213Assessing quantitative threshold with FES PET/CT imaging in metastatic breast cancerL. Ferrer1,2, B. Maucherat1, T. Carlier3,2, M. Lacombe4, S. Girault4, A. Leduc-Pennec5, F. Kraeber-Bodéré3,2,6, C. Rousseau1,2,6; 1ICO René Gauducheau, St Herblain, FRANCE, 2CRCINA UMR 1232 INSERM, Nantes, FRANCE, 3University Hospital, Nantes, FRANCE, 4ICO Paul Papin, Angers, FRANCE, 5University Hospital, Brest, FRANCE, 6Nantes University, Nantes, FRANCE.

EPS-214A new fully automated method for lung segmentation using low-dose CTS. Urbán1, E. Szabó2, Z. Mikó1, J. Csirik2, Z. Besenyi1, L. Pávics1; 1Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY, 2Institute of Informatics, University of Szeged, Szeged, HUNGARY.

EPS-215Evaluation of Tumour Volume and Activity using New Tumour Modelling Method: Application to Non-Hodgkin’s LymphomaR. Fedrigo1,2, R. Coope3, I. Bloise1, C. Gowdy4, A. Hart5, A. Rahmim1,2,6, C. Uribe2,6; 1BC Cancer Research Institute, Vancouver, BC, CANADA, 2University of British Columbia, Vancouver, BC, CANADA, 3Genome Science Institute, Vancouver, BC, CANADA, 4BC Children’s Hospital, Vancouver, BC, CANADA, 5University of Victoria, Vancouver, BC, CANADA, 6BC Cancer, Vancouver, BC, CANADA.

EPS-216Comparison of atlas-based and manual segmentation versus simple ROI placement for quantification of liver and spleen metabolism in FDG-PET/CTT. Kotwal, G. Krokos, A. Malaih, S. F. Barrington, P. Marsden, B. M. Fischer; King’s College London, London, UNITED KINGDOM.

EPS-217Social Media for Scientific Research: a preliminary evaluation of the impact of Publicization on Number of Citations of Medical Imaging PublicationsA. Forcina Barrero1, G. Converso1, S. Di Giorgio1, M. Grondelli1, B. Maizza1, S. Tarchi1, M. Sollini1,2, N. Gozzi2, A. Chiti1,2; 1Department of Biomedical Sciences, Humanitas University, Milan, ITALY, 2IRCCS Humanitas Research Hospital, Milan, ITALY.



191190

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EPS-218An automated bladder/lesion separation method using 99mTc-PSMA SPECT/CT imagesS. Urbán1, V. Rácz2, I. Farkas1, J. Csirik2, Z. Besenyi1, L. Pávics1; 1Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY, 2Institute of Informatics, University of Szeged, Szeged, HUNGARY.

EPS-219Effects of dedicated uniformity map for narrow energy windowR. Hirvilammi1,2, M. Seppänen1,3, T. Noponen1,2; 1Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, FINLAND, 2Department of Medical Physics, Turku University Hospital, Turku, FINLAND, 3Turku PET Centre, Turku University Hospital, Turku, FINLAND.

EPS-220[123I]FP-CIT SPECT reconstruction: FBP versus OSEM with resolution recovery - a quantitative and qualitative comparisonR. Teixeira1, J. Castanheira1, Â. Silva1, S. Vaz1, M. Silva1,2, A. Canudo1,2, R. Oliveira1,2, J. Correia1,2, H. Delgado1,2, M. Andrade1,2, B. Freitas1,2, S. Teixeira1,2, V. Vieira1,2, M. Machado1, C. Constantino1, F. Oliveira1, D. C. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 2Mercurius Health, Oeiras, PORTUGAL.

EPS-221Validation of PET data resampling methods to simulate lower injected doses on a multimodality PET-MR scannerJ. Anton Rodriguez1,2, T. W. Deller3, J. C. Matthews2; 1The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, 2Division of Informatics, Imaging and Data Sciences, MAHSC, Manchester, UNITED KINGDOM, 3GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.

EPS-222Effect of Attenuation Correction CT Parameters on PET Image Quality and QuantificationK. Binzel, C. L. Wright, M. V. Knopp; The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA.

EPS-223Key considerations when undertaking PSF acquisitions for use in I-131 post-therapy planar imaging deconvolutionW. Turner1, F. Barrack2, J. Scuffham2, D. McGowan1; 1Oxford University Hospitals, Oxford, UNITED KINGDOM, 2Royal Surrey County Hospital, Guildford, UNITED KINGDOM.

EPS-224Towards Automatic Detection of Enlarged Parathyroid glands in 3D Images of 99mTc-MIBI / 99mTc-pertechnetate SPECT/CTI. Marikova1, L. Stablova1, J. Trnka1,2, M. Samal1, D. Zogala1; 1Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and the General University Hospital, Prague, CZECH REPUBLIC, 2Department of Radiation Protection, General University Hospital, Prague, CZECH REPUBLIC.

1904


Technologists’ e-Poster Presentation Session - Sharing Technologist’s Experience

TEPS-01Effective half-life, excretion and radiation exposure of 177 Lu PSMAY. Parlak, D. Goksoy, G. Mutevelizade, G. Gumuser, E. Sayit; Celal Bayar University, Manisa, TURKEY.

TEPS-02Reconstruction with 2 mm voxel size improves the detection of small parathyroid adenomas with [18F]fluorocholine PET/CTS. Rep1,2, M. Hocevar3,4, P. Tomse1, K. Zaletel1,4, A. Cuderman1, L. Lezaic1,4; 1Department for Nuclear medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of health sciences, Medical imaging and radiotherapy department, Ljubljana, SLOVENIA, 3Oncological Surgery, Institute of oncology, Ljubljana, SLOVENIA, 4Faculty of medicine, Ljubljana, SLOVENIA.

TEPS-03PET/CT reconstruction study using 2 mm voxel size for improved image qualityS. Rep1,2, P. Tomse1, L. Jensterle1, K. Zaletel1,3, L. Lezaic1,3; 1Department for Nuclear medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of health sciences, Medical imaging and radiotherapy department, Ljubljana, SLOVENIA, 3Faculty of medicine, Ljubljana, SLOVENIA.

TEPS-05Radiolabeling of a glucose derivative with technetium-99m for the diagnosis of brain cancerE. Stasyuk1, V. Skuridin1, A. Rogov1, E. Nesterov1, R. Zelchan2, V. Sadkin1, E. Shelikhova1; 1Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 2Tomsk National Research Medical Center, Tomsk, RUSSIAN FEDERATION.

TEPS-07Results Of The Initial Examinations With MIBITop 1 mg Freeze Dried KitS. Keresztes1, T. Mándoki1, G. Nagy2, S. Barna2, M. Antalffy1; 1Institute of Isotopes Co., Ltd., Budapest, HUNGARY, 2Scanomed Ltd., Debrecen, HUNGARY.

TEPS-08Fully-automated production of 68Ga-FAPI-46 in TRASIS mini AIO and quality control with TLC and HPLC methodsR. Shukurov1, Z. Dadashov1, M. Valiyev1, M. Balashov1, C. Isayev1, K. Eryilmaz1, F. Valla2, F. Novruzov1; 1Azerbaijan National Centre Of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, 2SOFIE, Totowa, NJ, UNITED STATES OF AMERICA.

TEPS-09Technical validation of myocardial flow reserve measurement using a dynamic cadmium-zinc-telluride cameraT. Niimi1, K. Unno1, S. Yoshida2; 1Nagoya Daini Red Cross Hospital, Nagoya, JAPAN, 2Nagoya University, Nagoya, JAPAN.

TEPS-10Influence of low counts on clinical images of brain perfusion SPECTA. Sugiura1,2, M. Onoguchi1, T. Shibutani1, T. Aoki2, Y. Kouno2; 1Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, JAPAN, 2Department of Radiological Technology, Kariya Toyota General Hospital, Kariya, JAPAN.

TEPS-12Optimization of becquerel calibration factor for quantitative bone SPECT without attenuation and scatter correction in the lumbar spine: Head-to-head comparison with attenuation and scatter correctionH. Ichikawa1,2, M. Onoguchi2, T. Shibutani2, T. Ito3, H. Shimada1; 1Toyohashi Municipal Hospital, Toyohashi, JAPAN, 2Department of Quantum Medical Technology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, JAPAN, 3Department of Radiological Technology, Faculty of Medical Technology, Teikyo University, Itabashi-ku, JAPAN.

TEPS-13Post COVID-19 vaccination reactive lymphadenopathy on 18F-FDG PETA. Nasr, A. Akbari, J. Hagerman; Skåne University Hospital, Lund, SWEDEN.

TEPS-14Investigation of Optimal Reconstruction Conditions Using the Bayesian Penalized-Likelihood Algorithm in [18F]fluciclovine PET Imaging for Brain TumorsK. Tsuzura1,2,3, K. Wagatsuma3, N. Yokotsuka2, K. Miwa4, Y. Kamitaka3, K. Tanimoto1, R. Nishii5, K. Ishii3; 1QST Hospital, Chiba, JAPAN, 2Teikyo University, Tokyo, JAPAN, 3Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, 4Fukushima Medical University, Fukushima, JAPAN, 5Institute for Quantum Medical Science, Chiba, JAPAN.

TEPS-15The Imaging Performance of 89Zr in TOF PET/CT systemY. Parlak1, D. Goksoy1, C. Sezgin1, I. Medine2, G. Gumuser1, O. Aras3, E. Sayit1; 1Departmant of Nuclear Medicine, Celal Bayar University, Manisa, TURKEY, 2Department of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir, TURKEY, 3Department of Radiology, Memorial Sloan Kettering Cancer, New York, NY, UNITED STATES OF AMERICA.

TEPS-16Hand-foot contamination monitoring in hospital radiopharmacy laboratory: 2020 follow-up dataK. Levänen1, C. Lehtinen1, M. Kullberg1, J. Ketola2, J. Heikkinen2; 1Department of Radiology and Nuclear Medicine, Social and healtcare joint authority of South Savo, Mikkeli, FINLAND, 2Department of Medical Physics, South Savo Social and Health Care Authority, Mikkeli, FINLAND.



193192

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

1912


e-Poster Presentation Session 15: AI and Radiomics

EPS-225Comparison of cross-combinations between feature selection and machine-learning classifier methods based on 18F-PET/CT radiomic features for prediction of the metabolic response in metastatic breast cancerO. Gomez Lopez, J. López Herraiz, J. Udías Moinelo; Complutense University of Madrid, Madrid, SPAIN.

EPS-226Reproducibility of a semi-automatic gradient-based segmentation approach for lymphoma PETF. Yousefirizi1, I. Bloise2, P. Martineau2, D. Wilson2, F. Benard2, T. Bradshaw3, A. Rahmim1,4, C. Uribe2,4; 1BC Cancer Research Institute, Vancouver, BC, CANADA, 2BC Cancer, Vancouver, BC, CANADA, 3Department of Radiology, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA, 4Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

EPS-227Integrating gene mutation mutual exclusion logic and radiomics to improve the efficacy of predicting EGFR mutation in non-small cell lung cancerJ. Wang, F. Kang, J. Wang; Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, CHINA.

EPS-228Methodological Framework for AI-assisted diagnosis of Active Aortitis using Radiomic Analysis of FDG PET-CTL. Duff1,2, A. Scarsbrook3,4, S. Mackie5,6, M. Bailey1,7, R. Frood3,4, A. Morgan1,8, C. Tsoumpas1,9,10; 1University of Leeds, LICAMM, Leeds, UNITED KINGDOM, 2University of Leeds, CDT TERM iMBE, Leeds, UNITED KINGDOM, 3University of Leeds, Leeds Institute of Medical Research, Leeds, UNITED KINGDOM, 4St. James University Hospital, Department of Radiology, Leeds, UNITED KINGDOM, 5University of Leeds, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UNITED KINGDOM, 6NIHR Leeds, Biomedical Research Centre, Leeds Teaching Hospitals NHS trust, Leeds, UNITED KINGDOM, 7Leeds General Infirmary, The Leeds Vascular Institute, Leeds, UNITED KINGDOM, 8NIHR Leeds, Biomedical Research Centre, Leeds Teaching Hospitals NHS trust, Leeds, UNITED KINGDOM, 9Icahn School of Medicine at Mount Sinai, Biomedical Engineering and Imaging Institute, New York, NY, UNITED STATES OF AMERICA, 10Invicro, London, UNITED KINGDOM.

EPS-229Prognostic value of radiomic parameters derived from initial PET/CT in head and neck cancersC. Latappy1, N. Antonorsi1,2, F. Trousset1, A. Filali1, R. Perdrisot1, O. Tankyevych1,2, C. Cheze-Le Rest1,2; 1CHU de Poitiers, Department of Nuclear Medicine, Poitiers, FRANCE, 2INSERM UMR 1101, LATIM, Brest, FRANCE.

EPS-230Prediction of CT radiomic features using PET radiomic features and vice versaA. Jha1,2,3, S. Mithun1,2,3, U. B. Sherkhane1,2, V. Jaiswar2, G. Mehta2,3, A. Nautiyal2,3, N. Purandare2,3, V. Rangarajan2,3, A. Dekker1, L. Wee1; 1Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical, Maastricht, NETHERLANDS, 2Tata Memorial Hospital, Mumbai, INDIA, 3Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.

EPS-231Understanding omics data of lung cancer patients: Correlations between metabolomics and radiomicsL. Mesotten1,2, L. Deckers2, R. Truyens2, E. Derveaux1,2, P. Adriaensens2, M. Thomeer1,2, R. Boellaard3; 1ZOL, Genk, BELGIUM, 2Uhasselt, Hasselt, BELGIUM, 3Amsterdam UMC, Amsterdam, NETHERLANDS.

EPS-232Diagnostic value of baseline FDG PET/CT skeletal features in follicular lymphomaJ. Faudemer1, N. Aide1, G. Damaj1, A. Gac1, J. Vilque2, C. Lasnon2; 1CHU de Caen, Caen, FRANCE, 2Centre François Baclesse, Caen, FRANCE.

EPS-233The Effect of Increasing the Number of Iterations on the Stability of PET Radiomic Features: A Phantom StudyE. Alsyed1, R. Smith2, L. Bartley2, C. Marshall2, E. Spezi1; 1Cardiff University, Cardiff, UNITED KINGDOM, 2Wales Research & Diagnostic PET Imaging Centre, Cardiff, UNITED KINGDOM.

EPS-234Phantom with Heterogenous Tumour Inserts to Explore the Impact of Varying Number of OSEM Subsets on PET Radiomic FeaturesE. Alsyed1, R. Smith2, L. Bartley2, C. Marshall2, E. Spezi1; 1Cardiff University, Cardiff, UNITED KINGDOM, 2Wales Research & Diagnostic PET Imaging Centre, Cardiff, UNITED KINGDOM.

EPS-235Feasibility and Optimization of Radiomic Settings for Differentiation of HC and AD using 18F-FDG and 11C-PIB PET ScansD. Peretti1, G. Kolinger1, E. Pfaehler1, F. Reesink1, B. de Jong1, P. De Deyn1,2, R. Dierckx1, D. Vállez García3,1, R. Boellaard3,1; 1University Medical Center Groningen, Groningen, NETHERLANDS, 2University of Antwerp, Antwerp, BELGIUM, 3Amsterdam University Medical Center, Amsterdam, NETHERLANDS.

EPS-236Robustness of Radiomic Features against Reconstruction Settings in [18F]FET and [18F]GE180 PET Imaging of GliomasA. J. Zounek, A. Holzgreve, F. Vettermann, J. Brosch-Lenz, A. Gosewisch, G. Böning, P. Bartenstein, N. L. Albert, S. Ziegler, L. Kaiser; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY.

EPS-23718F-FDG PET radiomics predicts pathological data and survival of intrahepatic cholangiocarcinomaF. Fiz1, C. Masci2, M. Sollini1, G. Costa1, G. Torzilli1, F. Ieva2, A. Chiti1, L. Viganò1; 1Humanitas Clinical and Research Center - IRCCS, Milan, ITALY, 2MOX - Modelling and Scientific Computing Lab, Department of Mathematics, Politecnico di Milano, Milan, ITALY.

EPS-238Effect of change of gross tumour volume on CT radiomic featuresG. Mehta1,2, A. K. Jha1,2,3, S. Mithun1,2,3, V. Jaiswar1, U. B. Sherkhane1,3, N. Purandare1,2, V. Rangarajan1,2, A. Dekker3, L. Wee3; 1Tata Memorial Hospital, Mumbai, INDIA, 2Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA, 3Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, NETHERLANDS.

EPS-239Non-invasive prognostic assessment of patients with NET liver metastases treated with PRRT: a 68Ga-DOMITATE PET-based radiomics evaluationG. Centurioni, C. la Fougère, F. Fiz; Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, GERMANY.

EPS-240Artificial Intelligence Applications in SSTR Targeted PET/CT Images: Prediction of Response Assessment in GEP-NETs Undergoing PRRT with [177Lu]DOTATOCR. Laudicella1,2,3, A. Vento1, A. Spataro1, A. Comelli2, A. Stefano4, L. Crocè1, S. Baldari5, M. Bambaci6, D. Arico’6, M. Ippolito5, M. Gaeta7, I. A. Burger3,8, F. Minutoli1, S. Baldari1; 1Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY, 2Ri.MED Foundation, Palermo, ITALY, 3Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Zurich, SWITZERLAND, 4Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Cefalu’, ITALY, 5Nuclear Medicine Department, Cannizzaro Hospital, Catania, ITALY, 6Department of Nuclear Medicine, Humanitas Oncological Centre of Catania, Catania, ITALY, 7Section of Radiological Sciences, Department of Biomedical Sciences and Morphological and Functional Imaging, University of Messina, Messina, ITALY, 8Department of Nuclear Medicine, Kantonsspital Baden, Baden, SWITZERLAND.

EPS-241 Evaluation of Parametrial Infiltration in Cervical Cancer by Radiomics Analysis of 18F-FDG PETZ. Tan1, F. Shang1, T. Wang2, X. Tang1, H. Sun2, S. Liu1; 1School of Life Science, Beijing Institute of Technology, Beijing, CHINA, 2Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, CHINA.

EP-01

Wednesday, October 20 - Saturday, October 23, 2021e-Poster Area, release on Wednesday, October 20 at 09:00

Preclinical Studies -> Medical Preclinical -> Preclinical Oncology

EP-001Pioglitazone sensitises human breast cancer cells to the TRAIL-induced cell deathY. Zhao, M. Marx, M. Zuhayra, U. Lützen; Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein, Kiel, GERMANY.

EP-002Evaluation of amino acid PET imaging in a head and neck cancer modelJ. Verhoeven, S. Piron, B. Descamps, C. Vanhove, I. Goethals; Ghent university, Ghent, BELGIUM.



195194

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-003Targeting CD-20 antigen expression in Melanoma with 99mTechnetium-labeled RituximabC. Perroni1, X. Camacho1, M. Tassano1, M. García1, M. Cabrera1, M. Fernández1, J. Benech2, H. Cerecetto1, J. Gambini3, P. Cabral1; 1Centro de Investigaciones Nucleares-Facultad de Ciencias-Universidad de la República, Montevideo, URUGUAY, 2Laboratorio de Señalización Celular y Nanobiología, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, URUGUAY, 3Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY.

EP-004Evaluation of Radiotherapy associated with Temozolomide plus Metformin in a GBM immunocompetent microenvironmentD. Salvatore1,2, S. Valtorta1,2, G. Bertoli3, S. Todde1,3, M. Iannone1, A. Coliva2, E. Toninelli2, A. Spinelli4, F. Zerbetto5, S. Villa5, N. Di Muzio5, R. Moresco1,2,3; 1Department of Medicine and Surgery and Tecnomed Foundation, University of Milano—Bicocca, Monza, ITALY, 2Nuclear Medicine Department, San Raffaele Scientific Institute (IRCCS), Milan, ITALY, 3Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Segrate, ITALY, 4Experimental Imaging Centre, San Raffaele Scientific Institute (IRCCS), Milan, ITALY, 5Department of Radiation Oncology, San Raffaele Scientific Institute (IRCCS), Milan, ITALY.

EP-02


Preclinical Studies -> Medical Preclinical -> Preclinical Therapy

EP-005Efficacy of 18F-fluorothymidine and 18F-fluorodeoxyglucose Positron Emission Tomography in Determining a Radiotherapy EffectT. Otani, H. Ikushima, Y. Bando, K. Kuwahara, H. Otsuka, K. Kondo, H. Miyoshi; Tokushima University, Tokushima, JAPAN.

EP-006Evaluation of treatment process in reducing retinoblastoma tumor size using iodine-125 plaque brachytherapy in animal model of rabbitS. Moradi1, S. Sheibani1, M. Mokhtari Dizaji2, F. Ghassemi3, F. Asadi Amoli4, M. Arjmand3; 1Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 4Department of Pathology, Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-03


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Breast

EP-007[18F]Sodium fluoride-PET/MRI monitoring of chemotherapy response in breast cancer bone metastases- Proof of conceptM. Zia, E. Lundström, J. Mårtensson, M. Lubberink, A. Sundin; Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.

EP-008Utility of 18F-FDG PET-CT metrics predicting lymph node involvement in locally advanced breast cancerQ. Pitalua Cortes1, O. Garcia Perez1, L. Torres Agredo2, N. Esparza Arias1; 1Instituto Nacional de Cancerologia, Mexico city, MEXICO, 2Universidad Autónoma de Bucaramanga, Bucaramanga, COLOMBIA.

EP-04


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Lung (including Mesothelioma)

EP-009FDG PET/CT vs. PET/MRI with zero-echo time (ZTE): Comparing the capability of detection of lung metastasis and differentiating it from other lesions and the precision in fused imagesJ. Inukai1, M. Nogami2, F. Zeng2, M. Tachibana1, K. Kubo2, T. Kurimoto3, T. Murakami1; 1Kobe University Graduate School of Medicine, Kobe, JAPAN, 2Kobe University Hospital, Kobe, JAPAN, 3GE Healthcare, Hino, JAPAN.

EP-010Perfusion only SPECT CT only as a surrogate for VQ imaging in the COVID-19 era; a single centre experienceT. Hussain, M. Vadrucci; Barts Health NHS Trust, London, UNITED KINGDOM.

EP-011Prognostic and predictive value of radiomic parameters in 18F-FDGPET/CT in non-small cell lung cancer patients treated with immunotherapyF. Trousset1, N. Antonorsi1,2, A. Filali Razzouki1, C. Latappy1, O. Tankyevych1,2, C. Cheze-Le Rest1,2; 1CHU de Poitiers, Poitiers, FRANCE, 2INSERM U1101 Latim, Brest, FRANCE.

EP-012 Serial change of functional volume of non-transplanted lung before and after unilateral lung transplantationS. Nagamachi1, T. Shiraishi2, S. Miyahara2, R. Waseda2, K. Yochimitsu1; 1Department of Radiology, Faculty of Medicine, Fukuoka University, Fukuoka Prefecture, JAPAN, 2Department of Thoracic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka City, JAPAN.

EP-013Correlation between bone scintigraphy and HE4 serum values with bone metabolism in lung cancer patientsJ. Weissensteiner1, E. Babusikova2; 1Department of Nuclear Medicine, Hospital Poprad, Poprad, SLOVAKIA, 2Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Department of Medical Biochemistry, Martin, SLOVAKIA.

EP-01418F-FDG in suspected non-small cell lung carcinoma recurrenceP. García-Talavera San Miguel1, M. Mellado2, F. Gómez-Caminero1, B. Lucas1, J. G. Villanueva1, C. Peñaherrera1, C. Riola1, M. E. Martín1, P. Tamayo1; 1Nuclear Medicine department. Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN, 2Universidad de Salamanca, Salamanca, SPAIN.

EP-05


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Gastro-Intestinal (including Liver and Non-Endocrine Pancreas)

EP-015The Value of Future Remnant Liver Function Assessment in Pediatric Patients Before Extended Liver ResectionE. Kireeva, K. Chaurasiya, D. Akhaladze, Y. Likar; Dmitry Rogachev National Research Center of pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.

EP-06


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Neuroendocrine (Pancreatic and Others)

EP-016Significance of [68Ga]Ga-DOTA-NOC uptake in the pancreatic tailD. Fraga, R. Sousa, M. Silvestre, D. Ferraz, I. Vitorino, D. Rombo, M. R. Carvalho, F. Brandão, I. P. Carvalho, P. Ratão, T. C. Ferreira, L. Salgado; Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, PORTUGAL.



197196

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-017Impact of Different βlevels Q.Clear Reconstructions on [68Ga]Ga-DOTANOC PET/CT Image Quality in Overweight NEN Patients: Preliminary ResultsG. Argalia1, E. Fortunati1, L. Zanoni2, V. Allegri2, C. Malizia2, D. Calabrò1, S. Civollani2, D. Campana3,4, S. Fanti1,2, V. Ambrosini1,2; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 3Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 4DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-018Modified TGR: a new strong radiological marker to accurately predict early response to PRRT in GEPNETsF. Scalorbi, G. Calareso, E. Garanzini, G. Argiroffi, V. Fuoco, A. Marchianò, E. Seregni, M. Maccauro; Istituto Nazionale Tumori Milano, Milan, ITALY.

EP-019New 99mTc Exendin (9-39)/Tyr3-Octreotide radioligand improves sensitivity and specificity for the diagnosis of benign and malignant insulinomas, in comparison to 111In-pentetreotideE. Cortes-Mancera1, J. Gonzalez Díaz2, J. Soto Andonaegui2, G. Ferro Flores3, B. Ocampo García3; 1Hospital Angeles del Pedregal, Mexico City, MEXICO, 2UMAE Hospital de Especialidades. Centro Médico Nacional Siglo XXI, Mexico City, MEXICO, 3Instituto Nacional de Investigaciones Nucleares (ININ), Mexico City, MEXICO.

EP-020 Radiomic Model Discriminating Low Grade Pancreatic Neuroendocrine Tumours Assessed by Biopsy of the Primary LesionG. Argalia1, E. Fortunati1, D. Calabrò1, S. Malavasi2,3, D. Campana4,5, R. Casadei6,5, C. Ricci6,5, A. Bevilacqua2,7, S. Fanti1,8, V. Ambrosini1,8; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Advanced Research Center for Electronic Systems (ARCES), University of Bologna, Bologna, ITALY, 3Research Institute on Global Challenges and Climate Change (Alma Climate), University of Bologna, Bologna, ITALY, 4Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 6Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 7Department of Computer Science and Engineering (DISI), University of Bologna, Bologna, ITALY, 8Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-021[68Ga]Ga-DOTANOC PET/CT in Neuroendocrine Tumours: Results of Data Collection in a Three-Years Electronic ArchiveE. Fortunati1, G. Argalia1, L. Zanoni2, S. Telo1, D. Calabrò1, D. Campana3,4, R. Casadei5,4, C. Ricci5,4, C. Mosconi6, S. Fanti1,2, V. Ambrosini1,2; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 3Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 4DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 6Radiology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-07


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Colorectal

EP-022FDG PET/CT and Diffusion-Weighted MRI in Primary Staging of Rectal CancerA. Arçay1, F. Aydın1, A. Keven2, Z. G. Kıprak1, M. N. Engin1, C. N. Dündar Çağlayan1, A. Boz1; 1Akdeniz University Hospital, Department of Nuclear Medicine, Antalya, TURKEY, 2Akdeniz University Hospital, Department of Radiology, Antalya, TURKEY.

EP-023Quantitative Parameters of 18F-FDG PET/CT as a biomarker of KRAS expression in Metastatic Colorectal CancerS. Moustafa1, S. Khallaf2, A. Rayan3, A. Tawakol4, M. Makawy1, N. M. Mostafa1; 1Assiut university. Clinical Oncology and Nuclear medecine, Assiut, EGYPT, 2Medical clinical Oncology, SECI. South Egypt cancer Institute, Assiut, EGYPT, 3Assiut university. Clinical Oncology, Assiut, EGYPT, 4Cairo University. Clinical Oncology and Nuclear medecine, Cairo, EGYPT.

EP-024Evaluation of incidental gastrointestinal accumulations in 18F-FDG PET to differentiate malignant lesions from benig onesD. Dezso, K. Zámbó, Z. Ritter, Z. Bán, Z. Szabó, E. Schmidt; University of Pécs, Medical School, Department of Medical Imaging Diagnostic, Division of Nuclear Medicine, Pécs, HUNGARY.

EP-08


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Prostate Other

EP-025Effect of cold intervention on 68Ga-PSMA uptake of salivary glandsF. Görtan, N. Coşkun, N. C. Gülaldı; Turkish Ministry of Heath, Ankara City Hospital, Department of Nuclear Medicine, Ankara, TURKEY.

EP-026Impact of the 18F-PSMA PET/CT in the evaluation of response to androgen deprivation therapy in prostate cancer, a single center experienceS. Medina-Ornelas, F. Garcia-Pérez, M. Alvarez-Avitia, N. Sobrevilla-Moreno, M. Jimenez-Rios; Instituto Nacional de Cancerologia, Mexico City, MEXICO.

EP-027Discrepancy between serum PSA and tumour burden in PSMA PET/CT: can we find an explanation?L. Lemos1, P. Soeiro1, R. Silva1,2, R. Ferreira1,2, G. Costa1,3, J. Pedroso de Lima1,2,3; 1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 2Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL, 3Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL.

EP-028The cause of high [18F]PSMA-1007 uptake in the urinary bladder in some of the [18F]PSMA-1007 patients: an explorative, retrospective studyY. Allach, B. Privé, W. van Gemert, M. Schilham, L. R. Perk, M. Gotthardt, J. Nagarajah, M. Janssen; Radboudumc, Nijmegen, NETHERLANDS.

EP-029Radiopharmaceutical Biodistribution and the Factors Affecting Biodistribution in Ga68-PSMA PET/CTA. Arçay Öztürk, A. Boz, M. Erkılıç, G. G. Bural, F. Aydın; Akdeniz University Hospital, Department of Nuclear Medicine, Antalya, TURKEY.

EP-030[11C]C-Choline, [68Ga]Ga-PSMA, [18F]F-FACBC PET/CT in Castration Resistant Prostate Cancer Patients: Which Is the Most Suitable To Assess the Therapy Response?G. Argalia1, E. Tabacchi2, S. Vichi3, C. Malizia2, F. Massari4, V. Mollica4, V. Di Nunno5, E. Nobili4, C. Nanni2, S. Fanti2,1; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 3Clinical Engineering Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 4Medical Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5Medical Oncology, Azienda USL/Institute of Neurological Sciences of Bologna, Bologna, ITALY.

EP-031Predictors of 68Ga-PSMA-11 PET/CT tumour burden in castration resistant prostate cancer patients: a single center experienceS. Telo1, L. Vetrone1, A. Giordano1, C. Malizia2, A. Farolfi2, L. Calderoni1, S. Mattoni1, R. Mei1, P. Castellucci2, S. Fanti3; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Italy, Bologna, ITALY, 3Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna;Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Italy, Bologna, ITALY.

EP-032Response assessment to second-line systemic therapies in advanced prostate cancer using 68Ga-PSMA-11 PET/CTL. Calderoni1, A. Farolfi2, P. Castellucci2, F. Serani2, S. Telo2, S. Mattoni2, F. Mattana1, R. Mei2, E. Maietti3, S. Fanti2; 1Nuclear Medicine University of Bologna DIMES, Bologna, ITALY, 2Nuclear Medicine University of Bologna IRCCS, Bologna, ITALY, 3Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, ITALY.

EP-033Influence of 68Ga-PSMA-11-PET/CT on Clinical Management in Castration Resistant Prostate Cancer Patients: a Single Centre ExperienceL. Vetrone1, S. Telo1, A. Giordano1, A. Spagnoletti2, A. Farolfi3, L. Calderoni1, R. Mei1, P. Castellucci3, S. Fanti1,3; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Medical Oncology Department 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY, 3Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.



199198

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-034Assessing correlation between 68Ga-PSMA-11 renal PET parameters and renal function testsJ. Schierz1, I. Sarikaya2, A. Albatineh3, A. Sarikaya4; 1Municipal Hospital Dresden, Department of Radiology, Dresden, GERMANY, 2Kuwait University Faculty of Medicine, Department of Nuclear Medicine, Kuwait City, KUWAIT, 3Kuwait University, Faculty of Medicine, Department of Community Medicine and Behavioral Sciences, Kuwait City, KUWAIT, 4Trakya University, Faculty of Medicine, Department of Nuclear Medicine, Edirne, TURKEY.

EP-03568Ga-PSMA-11 PET/CT for Bone Lesions in Early Castration Resistant Prostate Cancer Patients: a Single Centre ExperienceL. Vetrone1, S. Telo1, A. Giordano1, A. Spagnoletti2, A. Farolfi3, L. Calderoni1, S. Mattoni1, R. Mei1, P. Castellucci3, S. Fanti1,3; 1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Medical Oncology Department 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY, 3Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-036Incidentalomas on PET-CT with 68Ga-PSMAC. Varela Pinto, B. Martins, V. Sousa, C. Loewenthal; Hospital da Luz Lisboa, Lisbon, PORTUGAL.

EP-037True nmCRPC in high-risk patients on 18F-Choline PET/MRI as compared with diagnostic imaging techniques accepted in international guidelinesJ. Garcia, A. Compte, P. Bassa, S. Mourelo, S. Ortiz, M. Soler, M. Buxeda, E. Valls, A. Blanch, E. Riera; CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN.

EP-038Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High Risk Prostate Cancer StagingK. De Man1, S. Piron2, N. Van Laeken1, L. Delrue1, V. Fonteyne1, N. Lumen1, B. Van den Broeck1, K. Kersemans1, P. Ost1, V. Schelfhout1; 1University Hospital Ghent, Ghent, BELGIUM, 2Laboratory of Radiopharmacy, Ghent, BELGIUM.

EP-09


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Thyroid

EP-039Possibly coexistence of Hashimoto thyroiditis (HT) and papillary thyroid carcinoma (PTC): data from two instituteK. Zaplatnikov1, V. Sukhov2; 1MVZ Nuklearmedizin Mögeldorf, Nürnberg, GERMANY, 2Nikiforov Russian Center for Emergency and Radiation Medicine, St Petersburg, RUSSIAN FEDERATION.

EP-040The use of FDG PET/CT in patients with recurrent differentiated thyroid cancerO. Ekmekcioglu; University of Health Sciences, Sisli Etfal Education and Research Hospital, Nuclear Medicine Dept., Istanbul, TURKEY.

EP-041Health-related quality of life analysis in differentiated thyroid carcinoma patients: a Tunisian studyS. Mensi1, M. Ben Fredj1, M. Ben Rejeb2, T. Dardouri1, A. Ezzine1, K. Chatti1; 1Departement of nuclear medecine, Sousse, TUNISIA, 2Department of Community Health and Epidemiology, Sousse, TUNISIA.

EP-10


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Gynaecological

EP-042Can Delayed Pelvic FDG PET/CT Scan Improve Lesion Detection and Differentiation?K. Afanasenka, D. Vaitkiene, I. Kulakiene, S. Sediene, I. Simeliunaite; Lithuanian University of Health Sciences, Kaunas, LITHUANIA.

NO

W A

VA

ILA

BLE

:N

OW

EA

RL

.EA

NM

.OR

G

Shared Audit and SupplierAssessment Initiative

AV

AA

VA

AV

ILA

BLE

:A

BLE

:A

BLE

ABX reports available now, place your order on ourwebsite

OUT NOW



201200

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-043 Breast and Bilateral Axillary Lymph Nodes Metastases from Serous Ovarian Carcinoma and Treatment Response Demonstrated on 18F-FDG PET/CTC. Sahin, S. Ozguven, T. Y. Erdil, N. Filizoglu, S. Kesim, K. Niftaliyeva, T. N. Kıssa, Z. C. Balaban, K. Oksuzoglu, F. Sen, T. Ones, H. T. Turoglu, S. Inanir; Marmara University Pendik Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TURKEY.

EP-044Valuing 18-FDG PET/CT Efficiency in Examining Patients with Cervical CancerJ. Stojanovic, I. Grozdic Milojevic; Centre for Nuclear medicine, Clinical Center of Serbia, Faculty od Medicine University of Belgrade, Belgrade, SERBIA.

EP-11


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Lymphoma

EP-045Prognostic Value of 18F-FDG PET/CT biomarkers in patients with diffuse large B-cell lymphoma treated with Chimeric Antigen Receptor T Cell Therapy, preliminary resultsJ. Cañadas Salazar, L. G. Díaz González, J. G. Villanueva Curto, F. Gomez-Caminero López, P. García-Talavera San Miguel, A. C. Peñaherrera Cepeda, C. Riola Parada, B. Lucas Velázquez, S. López Puche, J. Á. Badell Martínez, E. Martín Gómez, C. Montes Fuentes, L. Granado Alonso, M. E. Alonso Sarasquete, M. D. Caballero Barrigon, A. Martin Garcia-Sancho, P. Tamayo Alonso; Sacyl, Salamanca, SPAIN.

EP-046Prognostic value of interim18F-FDG PET/CT evaluation methods in peripheral T-cell lymphoma: a prospective, diagnostic accuracy studyT. Yuan, Y. Zhang, X. Chen, M. Wei, X. Wang; Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-047 Metabolic tumor burden and cytokine release syndrome (CRS) in patients with diffuse large cell B lymphoma (DLCBL) treated with CTL019 chimeric antigen receptor -T-cell (CAR-T): preliminary experienceC. Mantarro1, M. Donegani2, M. Bauckneht3, S. Raffa2, S. Chiola4, A. A. Miceli2, F. Lanfranchi2, F. D’Amico2, G. Sambuceti2, A. Raiola5, C. Ghiggi6, E. Angelucci7, S. Morbelli2;

1Department of Biomedical and Dental Sciences and Morphological ad Functional Images, University of Messina, Messina, ITALY, 2Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY, 3IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 4Humanitas Clinical and Research Center–IRCCS, Milan, ITALY, 5UOC Ematologia e Trapianto di Midollo Osseo, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 6Hematology and Transplant Center Division, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 7Hematology, Ospedale Policlinico San Martino, Genoa, ITALY.

EP-048Prognostic significance of FDG-PET derived conventional and textural parameters in high grade B cell lymphomaZ. Ritter1, K. Zámbó1, D. Dezső1, Z. Szabó1, Z. Bán1, K. Szigeti2, D. Szöllősi2, D. Veres2, K. Farkas3, Á. Szomor4, D. Máthé2, A. Hussain4, E. Schmidt1; 1University of Pécs Clinical Centre, Department of Medical Imaging, Division of Nuclear Medicine, Pécs, HUNGARY, 2Semmelweis University Faculty of Medicine, Department of Biophysics and Radiation Biology, Budapest, HUNGARY, 3University of Pécs Institute of Bioanalysis, Pécs, HUNGARY, 4University of Pécs 1st Department of Internal Medicine, Pécs, HUNGARY.

EP-049Association between Baseline Total Metabolic Tumor Volume, Interim Deauville 5-Point Scale and Progression Free Survival in Patients with Diffuse Large B-Cell LymphomaP. Kalmar1, S. Hatzl2, E. Schulz2, T. Schwarz1, P. Neumeister2, C. Beham-Schmid3, C. Gstettner1, R. M. Aigner1; 1Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA, 2Department of Internal Medicine, Division of Hematology, Graz, AUSTRIA, 3Institute of Pathology, Graz, AUSTRIA.

EP-050The role of 18F-FDG PET/CT in evaluation of bone marrow involvement in patients with diffuse large B-cell lymphomaC. Sandoval Moreno, B. Manzarbeitia Arroba, M. De la Rubia Marcos, M. Tagliatori Nogueira, M. Álvarez Moreno, P. García Alonso, A. Herrero Muñoz, A. Ortega Valle, M. Balsa Bretón; Hospital Universitario de Getafe, Getafe, SPAIN.

EP-051The Utility of Metabolic Parameters on Baseline F-18 FDG PET/CT in Predicting Survival in Paediatric Lymphoma: A Preliminary ReviewJ. Reed1,2, A. Masenge3, M. Vorster1,2, M. Sathekge1,2; 1University of Pretoria, Pretoria, SOUTH AFRICA, 2Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA, 3Department of Statistics, University of Pretoria, Pretoria, SOUTH AFRICA.

EP-052Prognostic Value of [18F]FDG PET/CT at the End of Treatment in Follicular LymphomaC. Soldevila Lozano1, M. Cortés-Romera1, E. Llinares-Tello1, A. Palomar-Muñoz1, S. Mercadal-Vílchez2, E. González-Barca2; 1PET/CT Unit (IDI)- Department of Nuclear Medicine. Hospital Universitari de Bellvitge, L’Hospitalet De Llobregat, SPAIN, 2Department of Hematology. ICO. Hospital Duran i Reynals-IDIBEL, L’Hospitalet De Llobregat, SPAIN.

EP-053Efficacy of 18F-FDG PET/CT in evaluation of Bone marrow involvement in patients with non Hodgkin Lymphoma and the influence of analytic parametersC. Sandoval Moreno, M. De la Rubia Marcos, M. Tagliatori Nogueira, B. Manzarbeitia Arroba, M. Álvarez Moreno, P. García Alonso, A. Herrero Muñoz, C. Paniagua Correa, M. Balsa Bretón; Hospital Universitario de Getafe, Getafe, SPAIN.

EP-054Role of [18F]FDG PET/CT in the evaluation of bone marrow at the initial staging of Non-Hodgkin Lymphoma patientsM. Calderón Calvente, M. Falgás Lacueva, L. De la Cueva Barrao, N. Canchumanya Huatuco, G. Guzmán Prudencio, L. Del barco Diez Canseco, M. Sangrós Sahún, P. Navarro Beltrán, S. Álvarez Ruiz, D. Abós Olivares; Hospital Universitario Miguel Servet, Zaragoza, SPAIN.

EP-12


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Melanoma

EP-055The Role of 18F-FDG PET-CT for the Follow up of Tumor Response to Immunotherapy with Checkpoint Inhibitors in Patients with Advanced MelanomaI. Kostadinova; Clinic of nuclear medicine, University Hospital Acibadem City Clinic, Mladost, Sofia, BULGARIA.

EP-13


Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Any Other Malignant (including Primary of Unknown Origin)

EP-056The potential added value of SPECT/CT in the management of patientsD. Grigolato, S. Rossetto, A. De Lucchi, U. Tebano, G. Napoli, N. Luca, M. Gabbani, F. Fiorica; Azienda Scaligera Verona, Ospedale Mater Salutis Legnago, ITALY.

EP-14


Imaging Clinical Studies -> Other Oncological Clinical Study -> Radioguided Surgery and Radiation Therapy Planning

EP-057ROLL with Freehand-SPECT for assessment of surgical margins in breast cancerJ. Orozco Cortés, Á. Badenes Romero, G. Garrigos, Á. Esteban Hurtado, M. Navas de la Cruz, I. Latorre Agraz, E. Martinez Lopez, P. Abreu Sánchez, T. Mut Dolera, D. Reyes Ojeda, B. Cueto Cañadas, D. Balaguer Muñoz, N. Estelles, R. Martinez Garcia, E. Caballero Calabuig; Hospital Universitario Dr Peset, Valencia, SPAIN.

EP-058Long term follow-up of patients with Small Intestine Neuroendocrine Tumors submitted to Ex Vivo Beta-Radioguided Surgery with Y-90-DOTATOCC. Grana1, M. Colandrea1, M. E. Ferrari1, E. Bertani1, F. Collamati2, R. Faccini3, S. Morganti2, S. Papi1, N. Fazio1, F. Spada1, L. Funicelli1, E. Pisa1, E. Solfaroli-Camillocci2, U. Fumagalli Romario1; 1European Institute of Oncology, IRCCS, Milan, ITALY, 2Istituto Nazionale di Fisica Nucleare, Rome, ITALY, 3Dipartimento di Fisica, Universita` di Roma Sapienza, Rome, ITALY.

EP-059Utilization of radioguided occult lesion localization (ROLL) method in thyroid and parathyroid surgeryA. Jankulovska, S. Stojanoski, N. Manevska, T. Makazlieva, V. Majstorov, D. Miladinova; Institute of pathophysiology and nuclear medicine, Faculty of Medicine, Skopje, NORTH MACEDONIA.



203202

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-060Lung shunt fraction (LSF) evaluation in microspheres liver radioembolization pre-therapy Technetium 99mTc albumin aggregated (99m-Tc MAA): comparison between planar scintigraphy, SPECT/CT and post-therapy Yttrium-90 microspheres PET/CT (90Y PET/CT)F. Serani1, G. Della Gala2, M. Santoro2, G. Paolani2, S. E. Prisco1, N. Bonazzi1, G. Battisti1, S. Strolin2, E. Tabacchi3, L. Calderoni1, L. Strigari2, S. Fanti1,3; 1Nuclear Medicine- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Medical Physics Department, IRCCS Azienda Ospedaliera Universitaria Bologna, Bologna, ITALY, 3Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-061Targeted Axillary Dissection by marking the positive lymph node with 99mTc-MAA and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. Initial experienceM. Pudis1, A. Benítez-Segura1, J. G. Reyes-Junca1, M. T. Bajén-Lázaro1, A. García-Tejedor2, R. Ortega-Martínez3, C. Soldevila-Lozano1, A. Petit-Montserrat4, M. Cortés-Romera1; 1Nuclear Medicine-PET (IDI) department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, 2Gynecology department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, 3Radiology department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, 4Pathology department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN.

EP-15


Imaging Clinical Studies -> Other Oncological Clinical Study -> Sentinel Node

EP-062Reduction of anxiety in patients undergoing lymphoscintigraphy for breast cancer without adequate information from the surgeonL. Burroni, D. Luconi, D. Celani, G. Scuppa, C. Lucarini, M. Damico; Nuclear Medicine, Ancona, ITALY.

EP-063Are magnetic nanoparticles combined with ICG a valuable alternative to ICG-99mTc-nanocolloid in sentinel lymph node surgery? - introduction of intraoperative 3D freehand magnetic particle imagingS. Azargoshasb1, L. Molenaar2, G. Rosiello3, T. Buckle4, D. M. van Willigen4, M. M van de Loosdrecht5, M. M. Welling4, L. Alic6, F. W.B. van Leeuwen4, A. Winter7, M. N. van Oosterom4; 1Leiden University Medical Center, Leiden, NETHERLANDS, 2Magnetic Detection & Imaging group, Technical Medical Centre, University of Twente, Enschede, NETHERLANDS, 3Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 4Interventional Molecular Imaging-Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, 5Magnetic Detection & Imaging group, Technical Medical Centre, University of Twent, Enschede, NETHERLANDS, 6Magnetic Detection & Imaging group, Technical Medical Centre, University of Twente, Enschede, NETHERLANDS, 7University Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, GERMANY.

EP-064Value of sentinel lymph node biopsy in vulvar cancerA. Sainz Esteban, P. Turbay Eljach, N. Álvarez Mena, F. Sebastián Palacid, C. García García, C. Gamazo Laherrán, B. Pérez López, M. Gónzalez Soto, R. Ruano Pérez; Hospital Clinico Universitario, Valladolid, SPAIN.

EP-065Sentinel lymph node in endometrial cancer and its impact on clinical practiceY. Saker Diffalah, A. Roteta Unceta Barrenechea, P. Razola Alba, T. Escalera Temprado, A. Andrés Gracia, M. Delgado Castro, L. Tardín Cardoso, E. Prats Rivera, M. Abós Olivares; Hospital Clínico Universitario Lozano Blesa, Zaragoza, SPAIN.

EP-066Concordance Between FREEHAND-SPECT and Conventional Scintigraphy for Sentinel Node Detection in Breast CancerJ. Orozco Cortés, Á. Esteban Hurtado, M. Navas de la Cruz, Á. Badenes Romero, I. Latorre Agraz, P. Abreu Sánchez, T. Mut Dólera, D. Reyes Ojeda, D. Balaguer Muñoz, B. Cueto Cañadas, A. Abella Tarazona, C. Plancha Mansanet, E. Caballero Calabuig; Hospital Universitario Dr Peset, Valencia, SPAIN.

EP-067Is the sentinel lymph node biopsy (SLNB) an adequate technique for axillary staging in patients with locally advanced breast cancer (LABC)?J. Espejo Niño, R. Valverde Jorge, M. Nevares Herrero; Hospital Universitario Cruces, Barakaldo, SPAIN.

EP-068Non-Identification of Sentinel Lymph Nodes in Head and Neck Melanoma: Clinical Predictors and OutcomeM. Punda, M. Romić, M. Pastorčić Grgić, D. Vagić, I. Jakšić, T. Jukić, A. Fröbe; UHC Sestre Milosrdnice, Zagreb, CROATIA.

EP-069Re-injection of the tracer in cases of no sentinel node visualization in lymphoscintigraphy for breast cancer, increases the detection rate of sentinel nodes and therefore high number of unnecessary axillary lymph node dissections can be avoidedA. Aghaei1, R. Sadeghi1, E. Soltani2, S. Jangjoo1, M. Asadi2, V. Dabbagh1; 1Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 2Onco-surgery research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-070Challenging visualization of sentinel lymph nodes in upper urinary tract urothelial carcinomaW. Cytawa, W. Polom, A. Polom, M. Frankiewicz, E. Szurowska, P. Lass, M. Matuszewski; Medical University of Gdansk, Gdansk, POLAND.

EP-071Inguinal Lymph Node Relapse in Vulvar Carcinoma After Negative Sentinel Lymph Node BiopsyC. Soldevila Lozano1, M. Bajén-Lázaro1, J. Mora-Salvadó1, A. Benítez-Segura1, J. Suils-Ramón1, E. Llinares-Tello1, I. Sánchez-Rodríguez1, G. Reyes-Junca1, M. Martí-Cardona2, L. Fernández-Romero1, M. Cortés-Romera1; 1Nuclear Medicine-PET (IDI). Hospital Universitari de Bellvitge, L’Hospitalet De Llobregat, SPAIN, 2Department of Gynecology and Obstetrics. Hospital Universitari de Bellvitge, L’Hospitalet De Llobregat, SPAIN.

EP-072Detection of disseminated prostate cancer cells in sentinel lymph node by dielectrophoretic technology: proof-of-conceptC. Rousseau1, E. Moranton2, D. Cochonneau2, G. Aillet3, T. Rousseau4, A. Morel-Thierry2, D. Heymann5; 1ICO René Gauducheau, F-44800 Saint-Herblain; Université de Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, FRANCE, 2ICO René Gauducheau, F-44800, Saint Herblain, FRANCE, 3Institut d’HistoPathologie, F-44000, Nantes, FRANCE, 4Urologic Clinic Nantes-Atlantis, F-44800, Saint Herblain, FRANCE, 5ICO René Gauducheau, F-44800 Saint-Herblain; Université de Nantes, F-44000, Saint Herblain, FRANCE.

EP-073Performance of lymphoscintigraphy and intraoperative sentinel node mapping in patients with prior breast surgeryL. Ferreira, V. Alves, J. Pereira; Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-074Initial experience from a multicentre clinical trial evaluating the safety and performance of a drop-in gamma probe for sentinel lymph node biopsy in prostate cancerL. Fumadó Ciutat1, J. Walz2, B. Hadaschik3, J. Adshead4, W. Everaerts5, K. Goffin5, M. Grootendorst6, F. Oldfield6, A. Mestre Fusco7, S. Vidal-Sicart1, J. Abascal Junquera1; 1Hospital del Mar, Barcelona, SPAIN, 2Institut Paoli-Calmettes Cancer Centre, Marseille, FRANCE, 3University Hospital Essen, Essen, GERMANY, 4The Lister Hospital, Stevenage, UNITED KINGDOM, 5KU Leuven, Leuven, BELGIUM, 6Lightpoint Medical Ltd., Chesham, UNITED KINGDOM, 7Hospital University Dr Josep Trueta, Girona, SPAIN.

EP-075Lymphoscintigraphy in the Time of COVID-19: Effect of Molybdenum-99 Shortage on Feasibility of Sentinel Node MappingR. Sadeghi, K. Sadri, V. Dabbagh, A. Mahdi; Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-076The accuracy of sentinel node biopsy by99mTc-sodium phytate in patients with pancreatic cancerR. Sadeghi, M. Aliakbarian, S. Hamed, B. Memar; Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-077Radioactive and Fluorescence (Hybrid) Imaging in Breast Sentinel Node ProceduresJ. Gambini1, E. Silvera1, F. Portugal1, R. J. Ortega1, G. Yang2, T. Quinn3, J. C. Hermida1, O. Alonso1, P. Cabral1; 1Centro De Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Montevideo, URUGUAY, 2Shanghai Jiao Tong University, Shanghai, CHINA, 3University of Missouri, Columbia, Missouri., MO, UNITED STATES OF AMERICA.



205204

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-16


Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Perfusion

EP-078Myocardial Perfusion SPECT Defects and Left Ventricular Ejection Fraction AccuracyI. Lopo1, R. Silva1,2, M. Cunha1, P. Lapa1,3, G. Costa1,3, J. Pedroso de Lima1,3,2; 1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 2Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL, 3Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-079Higher negative predictive value on seven years follow up of normal gated myocardial perfusion imaging in diabetic patients with HBA1c ≤7.3N. Fatima1, M. Zaman1, S. Zaman2, A. Zaman2; 1Aga Khan University, Karachi, PAKISTAN, 2Dr Ruth Pfau (CHK), Karachi, PAKISTAN.

EP-080Prevalence and Age-related Differences in the Occurence and Severity of Adverse Effects to Vasodilators Used in Myocardial Perfusion ImagingJ. Momodu, A. Ayeni, K. Purbhoo, M. Vangu; University of Witwatersrand, Parktown, SOUTH AFRICA.

EP-081The role of stress-rest myocardial scintigraphy in patients who are candidate to organ transplantationL. Vendramin1, C. Sarais2, P. Artioli3, S. Padoan3, D. Cecchin3, L. Evangelista3; 1University of Padua, Padua, ITALY, 2Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, ITALY, 3Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, Padua, ITALY.

EP-082Higher cardiac events with impaired exercise tolerance (METS <7) and lower ejection fraction <45% in patients with medium to large size fixed perfusion defect(s) on gated myocardial perfusion scintigraphy with prior coronary revascularizationM. Zaman1, N. Fatima1, S. Zaman2, A. Zaman2; 1AKUH, Karachi, PAKISTAN, 2Dr Ruth Pfau (CHK), Karachi, PAKISTAN.

EP-083 Aspects of myocardial gated-SPECT in dextrocardia with situs inversus totalisH. Haba1, A. Chirilă2, D. Piciu1, L. Strîmbu2; 1“Prof. Dr. Ion Chiricuta” Institute of Oncology, Cluj-Napoca, ROMANIA, 2“Niculae Stăncioiu” Heart Institute, Cluj-Napoca, ROMANIA.

EP-084The evaluation of myocardial perfusion of dynamic SPECT CZT in patients with non-obstructive coronary artery disease: comparison with blood lipid levelsA. Maltseva, K. Kopeva, A. Mochula, S. Belyaeva, E. Grakova, K. Zavadovsky; Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EP-085Incidence of Pathological Morphological Findings on Myocardial Perfusion SPECT/CTS. Kesim, H. T. Turoglu, S. Ozguven, S. Inanir, N. Filizoglu, C. O. Sahin, K. Niftaliyeva, T. N. Kissa, Z. C. Balaban Genc, K. Oksuzoglu, F. Sen, T. Ones, T. Y. Erdil; Marmara University School of Medicine, Istanbul, TURKEY.

EP-17


Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Heart Failure (including Sarcoidosis and Amyloidosis)

EP-086Utility of 99mTc-Diphosphonates scintigraphy in the diagnosis of cardiac amyloidosis by transthyretine: experience in our hospitalM. Negre1, N. Ferran1, A. Mestre1, C. Tapias1, V. Pineda2, A. Armengou3, P. Vilardell4, E. Torrent1, A. Rubió1; 1IDI-Nuclear Medicine Department. Hospital Universitari de Girona Dr. Josep Trueta, Girona, SPAIN, 2IDI-Radiology Department. Hospital Universitari de Girona Dr. Josep Trueta, Girona, SPAIN, 3General Internal Medicine Department. Hospital Universitari de Girona Dr. Josep Trueta, Girona, SPAIN, 4Cardiology Department. Hospital Universitari de Girona Dr. Josep Trueta, Girona, SPAIN.

EP-087Myocardial uptake in patients with malignant prostate neoplasia: Is there a relationship with transthyretin cardiac amyloidosis?A. Roteta Unceta Barrenechea1,2, A. Andrés Gracia1,2, L. Tardin Cardoso1, Y. Saker Diffalah1, T. Escalera Temprado1, M. Delgado Castro1, P. Razola Alba1, J. Melero Polo3,2, P. Revilla Marti3,2, M. Aibar Arregui3,2, A. Gracia Gutierrez4,2, E. Bueno Juana3,2, I. Moreno Gázquez3, R. Pérez Palacios2, S. Atienza Ayala3,2, C. Lahuerta Pueyo3,2, S. Menao Guillén3,2, E. Prats Rivera1, M. Abós Olivares5; 1UCMHMNA - Clinic Hospital “Lozano Blesa”, Zaragoza, SPAIN, 2IIS-Aragón, Zaragoza, SPAIN, 3Clinic Hospital “Lozano Blesa”, Zaragoza, SPAIN, 4Hospital General de la Defensa de Zaragoza, Zaragoza, SPAIN, 5UCMHMNA, Zaragoza, SPAIN.

EP-088Cardiac Uptake of 99m-Tc DPD as a Predictive Factor of Left Ventricular Wall Thickness in Patients with Transthyretin Cardiac AmyloidosisN. Martínez-Amador, O. Cuenca-Vera, J. Andres-Pacheco, A. Gutierrez-Gonzalez, M. Pombo-Lopez, A. Bota-Bota, F. Gomez-De La Fuente, J. Jimenez-Bonilla, I. Martinez-Rodriguez, A. Sanchez-Salmon, M. De Arcocha-Torres, S. Ruiz-Llama, R. Quirce; Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN.

EP-089Diagnostic performance of 99mTc-DPD scintigraphy for ATTR cardiac amyloidosis: single center experience and integration in the diagnostic workflowB. Martins, C. V. Pinto, V. Sousa, L. Raposo, C. Loewenthal; Hospital da Luz, Lisbon, PORTUGAL.

EP-090Diagnosis of Transthyretin Cardiac Amyloidosis by 99mTc-diphosphonate ScintigraphyM. Pudis1, L. M. Gràcia-Sánchez1, A. Palomar-Muñoz1, P. C. Notta1, M. Buaki-Sogo2, G. Reynés-Llompar3, C. Díez-López4, S. Bondía-Bescos1, M. Cortés-Romera1; 1Nuclear Medicine-PET (IDI) department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, 2Radiopharmacy department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, 3Medical Physics department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, 4Cardiology department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN.

EP-09199mTc-HDMP scintigraphy detects transthyretin-related cardiac amyloidosis; a substitute for biopsy?A. Cimino, E. Rizza, L. Luongo, A. Mita; Nuclear Medicine Unit, Lecce, ITALY.

EP-092Incidental findings of extra osseous Tc99m DPD uptake, in unselected patients undergoing bone scintigraphyA. Doumas1, F. Spyroglou1, E. Papanastasiou1, G. Gerasimou1, E. Giannoula1, D. Boundas2, I. Iakovou1; 1Aristotle University, AHEPA hsp, Thessaloniki, GREECE, 2Ippokratis, Nucl Med Centre, Thessaloniki, GREECE.

EP-093Absolute in vivo SPECT-CT quantification of myocardial amyloid ATTR deposit in patients with a positive 99mTc-DPD scanF. Sebastián Palacid, N. Álvarez Mena, B. Pérez López, C. Gamazo Laherrán, P. Turbay Eljach, M. Alonso Rodríguez, A. Sáinz Esteban, C. F. García García, M. J. González Soto, M. Á. Ruiz Gómez, R. Ruano Pérez; Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-18


Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Other Cardiovascular Imaging (including Plaque)

EP-094Differentiation ST-elevation from non-ST-elevation myocardial infarction on cardiac end-systolic Fluoro-18-fluorodeoxyglucose PET images using insulin intravenous preparationY. Chen; Quanzhou 1st hospital, Quanzhou, CHINA.


207

SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-19


Imaging Clinical Studies -> Endocrinological Imaging Clinical Study -> Endocrinology (including Thyroid Benign)

EP-095Evaluation of single only sestamibi positive foci in patients with secondary hyperparathyroidismA. Aktas, A. Gencoglu, G. Moray, M. Haberal; Baskent University, Ankara, TURKEY.

EP-096Thyrotropin value reached 20 days after levothyroxine withdrawal in Follow-up of Differentiated Thyroid CancerM. Torres Negreira1, G. Sierra1, P. Orellano1, G. dos Santos2, J. Hermida2, B. Mendoza1, O. Alonso2; 1Endocrinology and Metabolism Centre, Hospital de Clínicas, Montevideo, URUGUAY, 2Molecular Imaging Centre, Hospital de Clínicas, Montevideo, URUGUAY.

EP-097Usefulness of Elastography in the Assessment of Cold Solid Thyroid NodulesA. Štrok1, K. Bajuk Studen1, E. Pirnat1, N. Bedernjak Bajuk1, S. Gaberšček1,2, K. Zaletel1,2; 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

EP-098[18F]-Fluorocholine PET/CT in primary hyperparathyroidism: Initial experienceJ. Fernández Fernández, M. Muros de Fuentes, E. Triviño Ibañez, M. Lopez de la Torre Casares; Virgen de las Nieves University Hospital, Granada, SPAIN.

EP-099Scintigraphic features of atypical parathyroid adenomaA. Aktas1, N. Torun2, G. Nursal2, A. Gencoglu1, H. Ozdemir1; 1Baskent University, Ankara, TURKEY, 2Baskent University, Adana, TURKEY.

EP-20


Imaging Clinical Studies -> Infection and Inflammation -> Vasculitis and Endocarditis

EP-100The additional role of 18F-FDG PET/CT in the evaluation of suspected prosthetic valve infective endocarditisC. Ferrari, R. Ruta, F. Iuele, A. Sciacqua, C. Altini, A. Gaudiano, G. Rubini; Section of Nuclear Medicine, DIM, University “Aldo Moro”, Bari, ITALY.

EP-101Variations of myocardial uptake suppression and infective endocarditis detectability between a first conventional fasting-based FDG-PET and a second one scheduled on the next day after an Atkins dietM. Germaini, C. Boursier, F. Goehringer, C. Selton-Suty, B. Lefevre, V. Roch, L. Imbert, M. Claudin, E. Chevalier, P. Marie; CHRU Nancy, Nancy, FRANCE.

EP-21


Imaging Clinical Studies -> Infection and Inflammation -> Other Infections and Inflammatory Diseases

EP-102The role of 18F-FDG PET/CT in patients with IgG4 related disease. Our experienceC. Sandoval Moreno, B. Manzarbeitia Arroba, M. Tagliatori Nogueira, M. De la Rubia Marcos, M. Álvarez Moreno, L. Castillejos Rodríguez, A. Ortega Valle, M. Balsa Bretón; Hospital Universitario de Getafe, Getafe, SPAIN.

EP-22


Therapy Clinical Study -> Oncological Therapy Clinical Study -> Neuroendocrine Therapy

EP-103Adverse Prognostic Factors in Patients Refractory Pheochromocytoma and Paraganglioma After 131I-metaiodinebenzylguanidine (131I-mIBG) TherapyT. Hiromasa, H. Wakabayashi, D. Kayano, A. Inaki, A. Toratani, N. Akatani, S. Watanabe, T. Yamase, Y. Kunita, H. Mori, S. Saito, A. Takata, S. Kinuya; Kanazawa University Hospital, Kanazawa, JAPAN.

EP-104177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: a joint analysis of phase II prospective clinical trialsA. Bongiovanni1, S. Nicolini2, F. Foca3, T. Ibrahim1, M. Sansovini2, I. Grassi2, C. Liverani1, N. Riva1, M. Bocchini1, A. Moretti4, F. Matteucci2, L. Fabbri3, M. Signoretti5, C. A. Pacilio6, R. Galassi7, G. Paganelli2, S. Severi2; 1Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ITALY, 2Nuclear Medicine and Radiometabolic Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ITALY, 3Unit of Biostatistic and clinical trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ITALY, 4Nuclear Medicine Unit, Morgagni Pierantoni Hospital, Forli, ITALY, 5Unit of Gastroenterology and Digestive Endoscopy, Forli-Cesena Hospital, AUSL Romagna, Forli, ITALY, 6General and Oncology Surgery, Morgagni-Pierantoni Hospital, Forli, ITALY, 7Nuclear Medicine Unit, Morgagni Pierantoni Hospital, Forli, ITALY.

EP-105Associated with PRRT change of corrected SUVs max values in NET metastatic lesions assessed on [68Ga]Ga-DOTA-TATE PET/CTM. Opalinska1, A. Sowa-Staszczak2, A. Kania-Kuc1, I. Al Maraih1, M. Buziak-Bereza2, A. Hubalewska-Dydejczyk2; 1Nuclear Medicine Unit, Endocrinology Department, University Hospital in Krakow, Krakow, POLAND, 2Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND.

EP-106Body mass index and prior therapy lines conditioning response to [177Lu]Lu-DOTATATE therapy in neuroendocrine tumoursJ. Fernández Fernández, M. Muros de Fuentes, E. Triviño Ibañez, M. Lopez de la Torre Casares, E. Gonzalez Flores; Virgen de las Nieves University Hospital, Granada, SPAIN.

EP-23


Therapy Clinical Study -> Oncological Therapy Clinical Study -> Prostate Cancer Therapy

EP-107Combined bone scintigraphy and 18F-fluorocholine PET/CT predicts response of bone metastases to radium-223 treatment in patients with castration-resistant prostate cancerF. Volpe1, M. Klain1, V. Gaudieri1, M. Petretta2, E. Zampella1, C. Nappi1, G. Storto3, R. Gallicchio3, L. Piscopo1, M. Manganelli1, V. Parisella1, L. Pace4, M. Schlumberger1, A. Cuocolo1; 1Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, 2IRCCS SDN, Diagnostic Imaging, Naples, ITALY, 3Nuclear Medicine Unit, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, ITALY, 4Dipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”/DIPMED, Salerno, ITALY.

EP-108The value of osteoblastic activity from prostate cancer in efficacy and safety of radium-223 dichloride therapyI. Lopo1, P. Lapa1,2, G. Costa1,2, J. Pedroso de Lima1,2,3; 1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 2Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL, 3Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL.

EP-109[68Ga]FAPI-46, [18F]FDG and [68Ga]PSMA-11 PET/CT findings in advance stage castration resistant metastatic prostate carcinoma treated with tandem radionuclide [225Ac]/[177Lu]PSMA-617: Two case reportsF. Novruzov1, E. Mehdi1, Z. Dadashov1, M. Moore2, F. Valla2, T. Tahirov3, F. Giammarile4,1, F. Guliyev5, J. Aliyev6; 1Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, 2SOFIE, Totowa, NJ, UNITED STATES OF AMERICA, 3The National Centre of Oncology, Department of Medical Oncology, Baku, AZERBAIJAN, 4International Atomic Energy Agency, Vienna, AUSTRIA, 5Azerbaijan National Centre of Oncology, Department of Uro-Oncology, Baku, AZERBAIJAN, 6Azerbaijan National Centre Of Oncology, Department of General Surgery, Baku, AZERBAIJAN.



209208

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-24


Therapy Clinical Study -> Oncological Therapy Clinical Study -> Thyroid Therapy

EP-110The Role of Early- and Late-Stimulated Thyroglobulin in Predicting Treatment Response One Year After RAIT in Low-Intermediate Risk DTCA. Calabro’, D. Albano, F. Dondi, A. Mazzoletti, P. Bellini, M. Gregorelli, F. Bertagna, R. Giubbini; ASST Spedali Civili of Brescia, University of Brescia, Brescia, ITALY.

EP-111Postoperative outcome in patients with low-risk differentiated thyroid cancer treated without radioactive iodine ablationP. Dong, L. Wang, L. Xiao, L. Yang, R. Huang, L. Li; West China Hospital of Sichuan University, Chengdu, CHINA.

EP-25


Therapy Clinical Study -> Oncological Therapy Clinical Study -> Other Oncological Treatments

EP-112Feasibility and Therapeutic Potential of 177Lu-rituximab for patients with histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma: A preliminary studyM. Assadi1, S. Rekabpour1, H. Ahmadzadehfar2, R. Nemati1, E. Jafari1, N. Jokar1; 1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF, 2Department of Nuclear Medicine, Klinikum Westfalen, Dortmund, GERMANY.

EP-26


Technical Studies -> Radiation Protection -> Radiation Exposure and Protection

EP-113Establishment of National DRL for CT (PET) Hybrid Imaging Studies for Kuwait Population “The Second Phase National Dose Audit -2020”M. Masoomi1, I. Al-Shammeri1, L. Al-Kandari1, H. Elrahman1, J. Al-Shammeri2; 1Medical Imaging Department, ADAN Hospital - MOH, Hadiya, KUWAIT, 2Department of Nuclear Medicine, Faculty of Medicine, Kuwait University, Jabriya, KUWAIT.

EP-114Assessment of extremitiesand eye doses to staff involved in radionuclide therapy procedures in KuwaitM. Alnuaimi; Kuwait Cancer Control Center, AL Sabah Medical Area - Shweikh, KUWAIT.

EP-115Estimation of radiation exposure of workers in radionuclide therapy using 131I and 177LuJ. Hudzietzova1, M. Fülöp2, J. Sabol3, A. Vondrák4, O. Kraft5; 1Czech Technical University in Prague, Kladno, CZECH REPUBLIC, 2ABRS, s.r.o., Samorin, SLOVAKIA, 3Faculty of Security Management PACR in Prague, Prague, CZECH REPUBLIC, 4IZOTOPCENTRUM, s.r.o., Nitra, SLOVAKIA, 5Department of Nuclear Medicine, University Hospital Ostrava, Ostrava, CZECH REPUBLIC.

EP-116Relative Contributions to Patient Effective Dose in SPECT-CT Hybrid ImagingJ. Dixon, J. Dennis, A. Nicol; NSH Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

EP-27


Technical Studies -> Dosimetry and Radiobiology -> Preclinical Dosimetry and Radiobiology

EP-117Evaluation of a custom-made software to calculate I-131 dose for ablation of small sizes of thyroid remnants from diagnostic I-123 SPECT/CT imagesI. Iakovou1, S. Frangos2, I. Petrou3, A. Hadjiconstanti4, K. Michael5,6, T. Leontiou5,4, E. Ttofi5,7, E. Kyriacou5,4, M. Lyra4, Y. Parpotas5,4; 1Aristotle University, Thessaloniki, GREECE, 2Department of Nuclear Medicine, Bank of Cyprus Oncology Center, Nicosia, CYPRUS, 3Department of Nuclear Medicine, Nicosia General Hospital, State Health Services Organisation, Nicosia, CYPRUS, 4Frederick Research Center, Nicosia, CYPRUS, 5Frederick University, Nicosia, CYPRUS, 6Department of Medical Physics, Bank of Cyprus Oncology Center, Nicosia, CYPRUS, 7Department of Medical Physics, German Oncology Center, Limassol, CYPRUS.

EP-118Biodistribution and dosimetry after intraperitoneal injection of 224Ra-labeled microparticles in ratsS. Westrøm1, J. Fonslet2, C. H. Nielsen2, C. Stokke3,4, T. B. Bønsdorff1; 1Oncoinvent AS, Oslo, NORWAY, 2Minerva Imaging ApS, Ølstykke, DENMARK, 3Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, 4Department of Physics, University of Oslo, Oslo, NORWAY.

EP-119Development of a digital three-dimensional rodent model for production of small laboratory animal phantomsI. Miloichikova1,2, A. Bulavskaya1, Y. Cherepennikov1, E. Gargioni3, A. Grigorieva1, S. Stuchebrov1, M. Wegner3,4; 1Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 2Cancer Research Institute of Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION, 3University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, 4Hamburg University of Technology, Hamburg, GERMANY.

EP-28


Technical Studies -> Dosimetry and Radiobiology -> Clinical Dosimetry

EP-120Comparison of 3D dosimetry methods in hepatic radioembolisation with 90Y microspheresN. Carrasco Vela1, N. Tejedor2, P. Bello2, F. Blazquez3, C. Olivas2, V. Gimenez-Gomez4, B. Luna5, D. Perez-Enguix2, I. Torres-Espallardo2; 1Hospital Universitario Dr. Peset, Valencia, SPAIN, 2Hospital Universitario y Politecnico La Fe, Valencia, SPAIN, 3Hospital Universitario y Politécnico La Fe, Valencia, SPAIN, 4Universidad de Valencia, Valencia, SPAIN, 5Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, SPAIN.

EP-121Determination of effective intra-renal half-life in radioligand therapy with 177Lu-PSMA-617: Comparison of different approachesC. Happel, L. Völler, W. T. Kranert, B. Bockisch, D. Gröner, N. Mader, A. Sabet, F. Grünwald; University Medical Center Frankfurt, Frankfurt, GERMANY.

EP-122Dosimetry of Metastases in Treatments with 177Lu-DOTATATE - Comparison Between two Calculation SoftwareT. Monserrat Fuertes1, N. Montenegro Iglesias1, D. Álvarez Llorente1, D. San José Olmedo1, C. Arroyo Sánchez1, M. A. Peinado Montes1, P. Mínguez Gabiña2; 1Hospital Universitario Central de Asturias, Oviedo, SPAIN, 2Hospital Universitario Cruces/Gurutzeta, Bilbao, SPAIN.

EP-123A Monte Carlo Based Tool for Skin Dose Assessment in 188Re Treatment of Non-Melanoma Skin CancerS. Vichi1, F. Zagni2, M. Ruscillo3, L. Vetrone4, A. Farina4, D. Mostacci3, F. Savoia5, P. Castellucci6, S. Fanti6,4, L. Strigari2; 1Clinical Engineering Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 2Medical Physics Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 3Department of Industrial Engineering, University of Bologna, Bologna, ITALY, 4Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 5Dermatology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 6Nuclear Medicine Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.



211210

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-29


Technical Studies -> Radiopharmacy/Radiochemistry -> New Radiopharmaceuticals - SPECT

EP-124Evaluation of new 99mTc-labeled enrofloxacin derivatives as potential infection- or tumor-specific imaging agentsD. Papagiannopoulou1, G. Tzovas1, L. Papadopoulou1, M. Kakafika1, I. Iakovou2; 1Aristotle University of Thessaloniki, School of Pharmacy, Thessaloniki, GREECE, 2Aristotle University of Thessaloniki, Medical School, Thessaloniki, GREECE.

EP-30


Technical Studies -> Radiopharmacy/Radiochemistry -> New Radiopharmaceuticals - PET

EP-125Synthesis of 68-Ga-NOTA-(Fab’)2-Trastuzumab, New PET Radiopharmaceutical for Imaging of Breast Cancer Expressing HER-2 ReceptorB. Shetye1,2, S. Mithun1,2, M. Pathan1,2, P. Monteiro1,2, M. Kameshwaran1,2, S. Shah1,2, S. Gupta3,2, V. Rangarajan1,2; 1Dept of Nuclear Medicine and Molecular Imaging,Tata Memorial Hospital, Mumbai, INDIA, 2Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA, 3Department of Medical Oncology, Advanced Centre for Treatment Research & Education in Cancer, Tata Memorial Centre, Navi, Mumbai, INDIA.

EP-126Preparation and preclinical studies of 64Cu-NOTA-antiCD20 for clinical use in PET imaging of B-cell Non-Hodgkin’s LymphomaB. Alirezapour1, S. Shahhosseini2, E. Aslani2, M. Hashemizadeh3, H. Yousefnia1, G. Aslani1; 1Nuclear Science and Technology Research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF, 2School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-31


Technical Studies -> Radiopharmacy/Radiochemistry -> Radiopharmaceutical Preparation and Quality Control

EP-127In vitro stability assessment of in-house labeled [68Ga]Ga-EDTAK. Chitnis1,2, A. K. Jha1,2, S. Mithun1,2, A. Nautiyal1,2, P. Bhardwaj1,2, V. Rangarajan1,2; 1Tata Memorial Hospital, Mumbai, INDIA, 2Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.

EP-128Preparation and optimization of the radiolabeling method of111In-PSMA-INER-56S. Chen1, S. Lo2, S. Lo2, M. Li2, M. Chen2, W. Lo2, S. Li2; 1Institute of nuclear energy research, Taoyuan, TAIWAN, 2Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EP-129188Re-glucoheptonate for targeted radiotherapyM. Karamivand, M. Davarpanah; Pars Isotope, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-32


Covid Studies -> Clinical Study

EP-130Comparative Study Before And During The SARS-CoV-2 Pandemic In Breast Cancer With SLNB After Neoadjuvant ChemotherapyN. Alvarez Mena, F. Sebastián Palacid, P. Turbay Eljach, C. García García, B. Pérez López, C. Gamazo Laherrán, M. Alonso Rodríguez, A. Sainz Esteban, M. González Soto, M. Ruiz Gómez, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-13118F-FDG brain PET in post-SARS-CoV-2 infection with neurological involvement:time-dependent severity of hypometabolism after the acute infectionA. Martini1,2, G. Carli3, L. Kiferle4, P. Piersanti4, P. Palumbo4, S. Morbelli5, D. Perani3, S. Sestini1; 1Hospital Santo Stefano, Nuclear Medicine Unit, Prato, ITALY,

2University of Florence,AUOC Careggi Nuclear Medicine Unit, Florence, ITALY, 3University Vita Salute San Raffaele, Nuclear Medicine Unit Division of Neuroscience, Milan, ITALY, 4Hospital Santo Stefano Neurology Unit, Prato, ITALY, 5University of Genoa, Hospital San Martino, Genoa, ITALY.

EP-132Can FDG PET Predict Covid 19 Disease Severity and Discharge TimeF. Beytur1, S. Sager1, A. N. Aktaş2, R. Karaali2, A. Nazari1, F. Aghazada1, S. Asa1, L. Uslu-Beşli1, H. B. Sayman1, K. Sönmezoğlu1; 1Cerrahpasa Faculty of Medicine, Nuclear Medicine Department, Istanbul, TURKEY, 2Cerrahpasa Faculty of Medicine, Infectious Diseases Department, Istanbul, TURKEY.

EP-133Aspects of FDG-avid lymph nodes on FDG PET/CT following COVID-19 vaccinesP. Grecu1,2, H. Tissot1, A. M. Bettaieb1, T. Kamoun1, C. Garcia1; 1Nuclear Medicine Section, Diagnostic Imaging Department, Gustave Roussy, Villejuif, FRANCE, 2Nuclear Medicine Laboratory, “Sf. Spiridon” County Emergency Hospital, Iasi, ROMANIA.

EP-134Management of differentiated thyroid cancer through nuclear medicine facilities during Covid-19 emergency: the telemedicine challengeM. Manganelli, M. Klain, C. Nappi, E. Zampella, V. Gaudieri, S. Maurea, M. De Risi, F. Volpe, E. Caiazzo, D. De Lucia, R. Bologna, L. Piscopo, M. Schlumberger, A. Cuocolo; Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY.

EP-135Nuclear medicine lung perfusion imaging after COVID-19: review of a patient cohortB. Martins, C. V. Pinto, V. Sousa, C. Loewenthal; Hospital da Luz, Lisboa, PORTUGAL.

EP-136Molecular Imaging Findings Update on the NCI-NCTN Clinical Trial: Natural History of COVID-19 in Cancer PatientsM. Knopp1, C. Nealer1, P. Robson1, E. Huang2, B. Rini3, L. A. Korde4, L. K. Shankar4; 1The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA, 2National Cancer Institute, Rockville, MD, UNITED STATES OF AMERICA, 3Vanderbilt Ingram Cancer Center, Nashville, TN, UNITED STATES OF AMERICA, 4National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA.

EP-137GSMPI can predict early cardiac dysfunction in elderly high-risk DTC patients after TSH suppression treatmentY. Liu; Zhengzhou University, Zhengzhou, CHINA.

EP-33


Covid Studies -> Other Study (incl. Organisation)

EP-138Impact of COVID-19 pandemic on diagnostic Nuclear Medicine practice in Greece - a biannual survey (2019-2020)J. Koutsikos1,2, P. Georgoulias3, S. Koukouraki4, L. Lamprakos5, I. Iakovou6, S. Tsiouris7, D. Apostolopoulos8, T. Paschalis9, A. Fotopoulos7; 1Nuclear Medicine Department, 401 General Military Hospital, Athens, GREECE, 2Nuclear Medicine Department, Henry Dunant Hospital Center, Athens, GREECE, 3Nuclear Medicine Laboratory, University of Thessaly, University Hospital of Larissa, Larissa, GREECE, 4Department of Nuclear Medicine, School of Medicine, University of Crete, Heraklion, Crete, GREECE, 5Nuclear Medicine Department, Iatropolis Medical Center, Athens, GREECE, 62nd Department of Nuclear Medicine, Aristotle University, AHEPA hsp, Thessaloniki, GREECE, 7Nuclear Medicine Department, University Hospital of Ioannina, Ioannina, GREECE, 8Department of Nuclear Medicine, University Hospital of Patras, Rion Patras, GREECE, 9Greek National Organization for the Provision of Health Services, Strategic Planning Division, Athens, GREECE.

EP-34


Bone & Joint Malignant and Benign Diseases

EP-139Phase 1a intra-individual comparison trial of 10x ultrafast whole-body Na18F digital PET/CT for assessing non-malignant and malignant osteoblastic lesionsC. Wright, K. Binzel, Y. Hsieh, E. Folefac, D. A. Diaz Pardo, D. G. Stover, M. V. Knopp; The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA.

EP-140Prognostic value of quantitative [18F]FDG-PET features in patients with metastatic soft tissue sarcomaG. Kalisvaart, W. Grootjans, J. V. Bovée, H. Gelderblom, J. A. van der Hage, M. A. van de Sande, J. L. Bloem, L. de Geus-Oei; Leiden, Leiden University Medical Center, NETHERLANDS.



213212

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S SC

IEN

TIF

IC e

-P

OS

TE

RS

| FI

NA

L P

RO

GR

AM

ME

EP-141Myocardial Uptake As A Casual Finding In Tc-99m HMDP Bone Scintigraphy And Its Relationship With Pathological History, Analytical Parameters And Tumor MarkersS. Lopez Puche, G. Felipe, M. María Esther, C. José Cristobal, P. Andrea Carolina, B. José Ángel, V. Juan Gabriel, D. Luis, G. Paloma, L. Blanca, R. Cristina, T. Pilar; Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-142Normal Values of Skeletal Tc-99m-labelled Bisphosphonate Uptake in SPECT/CTP. Ritt, P. Heim, A. Grings, M. Beck, T. Kuwert; Clinic for Nuclear Medicine, Erlangen, GERMANY.

EP-143Asymptomatic Elastofibroma Dorsi: prevalence, morphological and metabolic characteristics of 18F-FDG PET/CT in oncological patientsG. Arsos, A. Georgiou, A. Kalaitzoglou, P. Exadaktylou, D. Katsampoukas, S. Georga, V. Mpalaris, M. Moralidis; 3rd Dept of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, GREECE.

EP-144Usefulness of bone metastasis evaluation by bone scintigraphy using AI diagnosis support system in plurality of cancersK. Nomura, M. Nakayama, A. Okizaki; Department of Radiology, Asahikawa Medical University, Asahikawa, JAPAN.

EP-145Asymptomatic Elastofibroma Dorsi : Detectability by diagnostic CT and 18F-FDG PET/CT in oncological patientsG. Arsos, A. Georgiou, P. Exadaktylou, A. Kalaitzoglou, D. Katsampoukas, S. Georga, V. Mpalaris, E. Moralidis; 3rd Dept. of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou Gen. Hospital, Thessaloniki, GREECE.

EP-146FDG PET / CT And MRI As Predictor Of Histological Response To Neoadjuvant Chemotherapy In Patients With Osteosarcoma And Ewing SarcomaZ. Kiprak, F. Aydin, A. Arçay Öztürk, A. Keven, E. Bilek, M. N. Engin, C. N. Dündar Çağlayan, A. N. Akınel, E. Güler; Akdeniz University, Antalya, TURKEY.

EP-147Skeletal metastasis detection with 99mTc-MDP bone scan and 18-F-FDG PET/CT scan in breast cancer patientsN. Manevska1, S. Besliev2, N. Bozinovska1, T. Makazlieva1, S. Stojanoski1, D. Miladinova1, A. Ugrinska1,2; 1Medical Faculty, Skopje, NORTH MACEDONIA, 2Institute of Positron Emission Tomography, Skopje, NORTH MACEDONIA.

EP-148Quantitative Assessment of Enthesis Patients with Ankylosing SpondylitisN. Dizdar1, M. Cagli2, A. Akbulut3, B. Duyur Çakit2, G. Koca3, H. Genc2, M. Korkmaz3; 1Department of Nuclear Medicine, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, TURKEY, 2Department of Physical Medicine and Rehabilitation, University of Health Sciences, Ankara Training and Research Hospital, Ankara, TURKEY, 3Department of Nuclear Medicine, University of Health Sciences, Ankara Training and Research Hospital, Ankara, TURKEY.

EP-149Clinical use of three-phase bone scintigraphy in identifying complications after knee replacement in patients with deforming osteoarthrosis with COVID-19P. Korol1, O. Shcherbina2, M. Kostylev1; 1Shalimov’s National Institute of Surgery of Transplantation, Kiev, UKRAINE, 2Shupik’s National University of Health of Ukraine, Kiev, UKRAINE.

EP-150Effectiveness of F18-FDG PET/CT in Initial Assessment of Necrotizing Otitis Externa (NOE) and Evaluation of Anti-Microbial ResponseA. Hussien, S. Ali, M. Kula, O. Sabra, W. Ibrahim; King Hamad University Hospital, Muharraq, BAHRAIN.

EP-151Relationship of F-18 FDG PET/CT Imaging Findings with Bone Trauma AgeS. Orun, U. Korkmaz, S. Soyluoglu, G. Durmus Altun; Trakya University, Edirne, TURKEY.

EP-152Evaluation of human anti-mouse antibodies prior to the administration of 99mTc-BesilesomabP. Guardia Jimena, R. Arenas Aguaza, M. Martínez del Valle Torres, D. Becerra García; Hospital Universitario Clínico San Cecilio, Granada, SPAIN.

EP-153Influence of tocilizumab therapy on osteoarticular inflammatory activity assessed by [18F]FDG PET/CT in patients with refractory polymyalgia rheumaticaI. Martínez-Rodríguez1, D. Prieto-Peña2, Á. Gutiérrez-González1, M. De Arcocha-Torres1, O. Cuenca-Vera1, J. Andrés-Pacheco1, F. Gómez-de la Fuente1, N. Martínez-Amador1, A. Sánchez-Salmón1, J. Jiménez-Bonilla1, S. Ruiz-Llama1, M. Pombo-López1, A. Bota-Bota1, M. A. González-Gay2, R. Quirce1; 1Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria., Santander, SPAIN, 2Rheumatology Service. Marqués de Valdecilla University Hospital. Genetics and atherosclerosis research group on systemic inflammatory diseases (IDIVAL)., Santander, SPAIN.

EP-35


General Isotopic Imaging

EP-159Quantification of Lung Ventilation/Perfusion SPECT (V/Q SPECT): A Helping Tool in Pulmonary EmbolismS. Menendez-Sanchez, R. Bellviure-Meiro, A. Cardozo-Saavedra, M. Boronat-Ferrater, S. Asadurova, F. Velazquez-Krisch, F. Dellepiane-Clarke, S. Aguade; Hospital Universitario Vall d’Hebron, Barcelona, SPAIN.

EP-160Clinical values of DMSA SPECT in follow-up evaluation of renal injuries after conservative managementS. Cho, S. Yu, H. Jang, J. Kim, K. Park, H. Song; Chonnam National University Hospital, Gwangju, KOREA, REPUBLIC OF.

EP-161Value of renal transplant scintigraphy: comparison with surgical occurrences and Doppler ultrasound resistive indexA. Marques, F. Abreu, J. Carvalho, S. Pintão; Centro Hospitalar de Lisboa Ocidental, Lisbon, PORTUGAL.

EP-162Role of follow-up quantitative bone SPECT-CT in active condylar hyperplasiaD. Cáceres Silva, L. Mohamed Salem, T. E. Rodríguez Locarno, T. Moreno Monsalve, A. S. De Agrela Serrao, A. M. Leiva Montejo, M. I. Castellón Sánchez, J. L. Navarro Fernández, L. Frutos Esteban, J. F. Contreras Gutiérrez, M. A. Claver Valderas; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-163Evaluation of clinical response to cholestyramine in patients affected by chronic diarrhoea undergoing 75-selenium homocholic acid taurine (sehcat) scintigraphy: preliminary resultsI. Bossert1, A. Schiepatti2,3, M. Cincotta4, D. D’Ambrosio5, A. Marchetto1, F. Lusetti3, F. Biagi2,3, G. Trifirò1; 1Nuclear Medicine Service, Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, ITALY, 2Gastroenterology Unit, Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, ITALY, 3Gastroenterology Unit, University of Pavia, Pavia, ITALY, 4University of Pavia, Pavia, ITALY, 5Medical Physics Unit, Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, ITALY.

EP-164Salivary Scintigraphy in the evaluation of xerostomia in patients treated with Intensity Modulated Radiotherapy for head and neck malignancyP. U N, V. G, K. Rishi, G. GV, B. Srinath, H. Mohan; Sri Shankara cancer hospital and Research center, Bangalore, INDIA.

EP-165Detection of Thromboembolic Pulmonary Disease using Lung Perfusion SPECT/CT in the time of COVID-19: Outcome AnalysisT. H. Tan, R. Ismail; Sunway Medical Centre, Bandar Sunway, MALAYSIA.

EP-166A novel, simple equation improving the accuracy of glomerular filtration rate (GFR) measurement with 99mTc-DTPA and two blood samplesG. Arsos, A. Kalaitzoglou, K. Lazaridis, D. Katsampoukas, E. Moralidis; 3rd Dept. of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou Gen. Hospital, Thessaloniki, GREECE.

EP-167Comparison of GFR measurement with two-blood sample technique using 99mTc-DTPA vs. MDRD4 and CKD-EPI equations in potential kidney donorsJ. Carvalho, A. B. Marques, F. Abreu, S. Pintão; Hospital de Santa Cruz - Centro Hospitalar de Lisboa Ocidental, Carnaxide, PORTUGAL.

EP-168Recommending bone scan with Tc99m-MDP as the missing link but an effective method in the initial staging of patients with muscle invasive bladder carcinomaA. Aghaei1, A. Masoudifard1, H. Ghorbani2, S. Soltani3, K. Aryana1, S. Zakavi1; 1Nuclear medicine research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 2Uro-oncology research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 3Urology research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-169Prognostic value of diuretic MAG3 renogram in acute kidney injuryD. Cáceres Silva, T. Rodríguez Locarno, T. Moreno Monsalve, A. Leiva Montejo, A. S. De Agrela Serrao, J. F. Contreras Gutiérrez, M. I. Castellón Sánchez, J. L. Navarro Fernández, L. Frutos Esteban, L. Mohamed Salem, M. A. Claver Valderas; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-170Evolution of Renal Function in Living Kidney Donors with99mTc-DTPAP. Azpeitia Hernández, J. A. Pérez Iruela, M. V. Gómez Martínez, J. Bonilla Plaza, M. Gutiérrez Guerrero, I. López Villar, A. Martínez Lorca, O. Ajuria Illarramendi, M. P. Orduña Diez; Hospital Universitario Ramón y Cajal, Madrid, SPAIN.


SA

TE

LL

ITE

SY

MP

OS

IA | F

IN

AL

PR

OG

RA

MM

E

215

Wednesday, October 20, 2021 10:15 – 11:00, Channel 3

GE HEALTHCAREHow do Innovations Support Theranostics?

Transition to Whole Body SPECT/CT Prof. Vineet Prakash, Royal Surrey County Hospital, Guildford, UK Alexander Smout, Royal Surrey Country Hospital, Guildford, UK

3D CZT SPECT/CT: First Clinical Experience with StarGuide Dr. Matthieu Bailly, Head of the Nuclear Medicine Department, NM Physician, Hospital of Orléans, France


SIRTEX HEALTHCARESIRT with SIR-Spheres® Y-90 resin microspheres – Best practice and realworld evidence

Follow the recommendation Dr. Arnaud Dieudonné

CIRT – Real world evidence that matters for patients Prof. Niklaus Schäfer

Q&A

SATELLITESYMPOSIA


214

FI

NA

L P

RO

GR

AM

ME

| S

CIE

NT

IFIC

e-

PO

ST

ER

S

EP-36


Technologist Digital ePoster

EP-171The eye can see what the mind knowsA. Ghilardi1, G. Medolago2, B. Ondei1; 1ASST-PG23, Bergamo, ITALY, 2Humanitas Gavazzeni, Bergamo, ITALY.

EP-172The usefulness of99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiterA. Tavellin, D. Carazzato, S. Rossetto, D. Grigolato; Ospedale Mater Salutis, Legnago, ITALY.

EP-173Analytical method validation tests for the development of a new radiopharmaceutical drug : 177Lu-PSMA-1P. Orhon1, M. Piquemal1, P. Bedouch2, J. Vuillez3, L. Djaileb3, M. Desruet1, J. Leenhardt1; 1Radiopharmacy, Grenoble Alpes University Hospital, Grenoble, FRANCE, 2Pharmacy department, Grenoble Alpes University Hospital, Grenoble, FRANCE, 3Nuclear Medicine, Grenoble Alpes University Hospital, Grenoble, FRANCE.

EP-174Yttrium microspheres irradiated at the IRT-T reactor for radioembolization of liver cancerV. Sadkin1, E. Nesterov1, A. Rogov1, E. Stasyuk1, K. Mayorov2, S. Getia2, N. Sashova2, N. Markov2; 1National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 2BEBIG, Moscow, RUSSIAN FEDERATION.

EP-175Dosimetry prior to I-131 therapy in hyperthyroidism using thyroid computed tomography valueH. Ikeda1, N. Fujita2, Y. Ochi1, M. Nishio1, Y. Asano1, S. Abe2, K. Kato1; 1Department of Integrated Health Science, Nagoya University Graduate School of Medicine, Nagoya, JAPAN, 2Nagoya University Hospital, Nagoya, JAPAN.

EP-176Radiation safety in PET-CT preparationT. Säilä1, S. Lahti1, T. Raita1, J. Husari2, T. Taatila2; 1Tampere University of Applied Sciences, Tampere, FINLAND, 2Tampere University Hospital, Tampere, FINLAND.

EP-177Operational Organization of a Clinical and Translational Research Environment using Today’s Digital TechnologiesL. Merrin1, A. Pippin1, M. M. Knopp2, M. Timko1, K. Binzel1, M. V. Knopp1; 1The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA, 2Technical University of Munich, Munich, GERMANY.

EP-178Contribution of Listening to Music in Reducing Anxiety in Bone ScintigraphyM. Boal1, E. Pereira2, D. Branco3, T. Guerreiro3, L. Vieira4; 1Instituto Superior de Engenharia de Lisboa/Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, PORTUGAL, 2NuclearMed, Hospital Particular de Almada, Almada, PORTUGAL, 3LASIGE, Faculdade de Ciências, Universidade de Lisboa, Lisbon, PORTUGAL, 4H&TRC and CIMOSM, Lisbon, PORTUGAL.

EP-37


Paediatrics

EP-154Analysis of Pediatric Patients Requiring PET/CT and Additional Other Nuclear Medicine Methods in the management of cancerS. Soyluoglu, U. Korkmaz; Trakya University, Medical School, Edirne, TURKEY.

EP-155Slope-intercept vs. single-sample glomerular filtration rate in childrenJ. Holness, A. Brink; University of Cape Town, Cape Town, SOUTH AFRICA.

EP-156Evaluate the efficiency of SPECT/CT in the diagnosis of mandibular unilateral active condylar hyperplasiaJ. Maraña González, J. Suárez Fernández, M. López Carballo, A. Laverde Mächler, L. Rodríguez Díaz, M. Domínguez Grande, N. Martín Fernández, D. Lisei Coscia, F. González García; HUCA, Oviedo, SPAIN.

EP-157Quantitative assessment of 123I-MIBG uptake in children in determining the unfavorable histological type of neuroblastomaM. Yadgarov1, N. Matveev2, K. Chaurasiya1, E. Kireeva1, Y. Likar1; 1Dmitry Rogachev National Medical Research Center, Moscow, RUSSIAN FEDERATION, 2Russian National Research Medical Univercity, Moscow, RUSSIAN FEDERATION.

EP-158Prognostic Factors in Children with Hydronephrosis and Urinary Tract InfectionI. Grierosu1,2, R. Tibu2, A. Tarca2, T. Ionescu1, C. Stolniceanu1, W. Jalloul1, A. Statescu2, M. Starcea1,3, R. Russu3, M. Munteanu3, V. Ghizdovat1,2, L. Teodoriu1,2, C. Stefanescu1,2; 1UMF “Grigore T. Popa”, Iasi, ROMANIA, 2County Emergency Hospital „Sf. Spiridon”, Iasi, ROMANIA, 3Hospital “Sf. Maria”, Iasi, ROMANIA.

FI

NA

L P

RO

GR

AM

ME

| S

AT

EL

LIT

E S

YM

PO

SIA



SA

TE

LL

ITE

SY

MP

OS

IA | F

IN

AL

PR

OG

RA

MM

E

217216


ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY Targeting PSMA in advanced prostate cancer: How will precision medicine evolve patient care?

Welcome and Introduction Joe O’Sullivan (Chair), UK

Revealing Gaps in the Advanced Prostate Cancer Treatment Landscape Noel Clarke, UK; Elena Castro, Spain

Precision Medicine: A New Era of Imaging-based Patient Selection Wim Oyen, The Netherlands

Radiopharmaceuticals in Advanced Prostate Cancer: Past and Future Joe O’Sullivan, UK

Panel discussion: Maximising MDT collaboration in clinical practice Led by Joe O’Sullivan, all

Wednesday, October 20, 2021 13:50 - 14:15, Channel 3

HERMES MEDICAL SOLUTIONS Innovations for personalized, fast and accurate dosimetry

Welcoming words Tom Francke, CEO, Assoc. Prof., Hermes Medical Solutions, Stockholm, Sweden

Impact of Dosimetry in Translational Research – Added Value for Probe Developments? Frederik L. Giesel, MD, Chairman of the Nuclear Medicine Department at the University Hospital Düsseldorf, Germany

Latest Innovation in Dosimetry Software Helena McMeekin, MSc. Clinical Applications Scientist, Hermes Medical Solutions, UK

Lu-177 PRRT Dosimetry in Clinical Practice Lydia Ram, Trainee Clinical Scientist, Queen Elizabeth Hospital, Birmingham, UK

Followed by a live Q&A with the speakers – 14:20– 14:40 CEST


ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANYAdvancing towards precision medicine with theranostics in oncology

Welcome and introduction Shaunak Navalkissoor

Moving towards precision medicine with RLT: Advances in imaging Vikas Prasad

Moving towards precision medicine with RLT: Advances in blood biomarkers Andrea Frilling

Moving towards precision medicine with RLT: Evolving theranostics in and beyond NETs Shaunak Navalkissoor

How can we make the best use of all tools available for optimal patient outcomes? Panel discussion

Summary and conclusion Shaunak Navalkissoor


TELIX PHARMACEUTICALSThe evolution of prostate cancer knowledge through PSMA

Session introduction Dr. Laura Ravasi, Telix Pharmaceuticals

Evolution of diagnostic imaging in prostate cancer: then and now Professor Louise Emmett, Director of Theranostics and Nuclear medicine at St Vincent’s Hospital Sydney, Australia

The evolution in patient’s management through PSMA Associate Professor Jochen Christoph Walz, Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre in Marseille, France

The evolution in therapeutic options as PSMA is an actionable target Professor Dr. Ken Herrmann, Director of Clinic of Nuclear Medicine at University Hospital of Essen, Germany

Closing remarks from Laura Ravasi

FI

NA

L P

RO

GR

AM

ME

| S

AT

EL

LIT

E S

YM

PO

SIA



SA

TE

LL

ITE

SY

MP

OS

IA | F

IN

AL

PR

OG

RA

MM

E

219218

# Thursday, October 21, 2021 09:00 - 09:45, Channel 3

GE HEALTHCAREDigital Technology: Impacts on Cardiac Imaging

Easy Patient Management with New Cardiac CZT Prof. Tali Sharir, MD, Director of Nuclear Cardiology, Assuta Medical Center, Tel Aviv, Israel

Modern Diagnosis in Cardiac Diseases with PET/CT Prof. Juhani Knuuti, MD, FESC, University of Turku and Turku University Hospital, Turku, Finland

Implementing Production of 13N-ammonia in an In-House PET Radiopharmacy Dr. Tom Christian Holm Adamsen, Ph. D., Chief Radiochemist / Head of Production Centre for Nuclear Medicine Haukeland University Hospital Bergen, Norway

Thursday, October 21, 2021 09:45 - 10:30, Channel 3

GE HEALTHCAREOvercoming the DLB Diagnosis Challenge: Perspectives for Neurologists and Nuclear Medicine Physicians

Prof. John O‘Brien, Professor of Old Age Psychiatry, University of Cambridge

Dr. George Petrides, Consultant Radionuclide Radiologist, Newcastle Upon Tyne Hospitals

Zulfiqar Haider (host), Global Medical Lead Neurology, GE Healthcare


GE HEALTHCAREHow do Innovations Support Theranostics?

The Future of Precision Diagnostics – Immune PET Prof. Rod Hicks, University of Melbourne, Australia Dr. Simon Williams D.Phil, Department of Biomedical Imaging, Genentech Inc., USA

The place of SPECT in Theranostics Prof. Michael C. Kreissl ,Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Germany

Prostate Cancer – the Role of PSMA PET Prof. Dr. Karolien Goffin, MD PhD, Nuclear Medicine & Molecular Imaging & PET-MR unit, University Hospital Leuven – KU Leuven, Belgium

How to Get your Clinic Ready for a Theragnostics Approach? Prof. Andrei Iagaru, MD, Professor of Radiology – Nuclear Medicine and Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University, USA


SIEMENS HEALTHINEERSEstablishing molecular imaging for tomorrow, with technology of today

Radiomics and Genomics – a match made in heaven? Prof. Dr. Alexander Haug, MD, PhD Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria

Quantification of myocardial 99mTc-HMDP uptake in patients with transthyretin- related cardiac amyloidosis: ready for clinical practice Prof. Alban Bailliez, MD, PhD and Nuclear Medicine Department-Humani TEP, Faculty of Medicine, Lille, France Dr. Dimitri Bellevre, MD, PhD student Nuclear Medicine Department-Humani TEP, Faculty of Medicine, Lille, France

Integrated intelligence in molecular imaging: today and tomorrow Bruce Spottiswoode, PhD Director, Clinical Applications Research, Siemens Healthineers Molecular Imaging, Knoxville, TN, USA Carl von Gall, MD Product Manager Clinical Applications Oncology, Siemens Healthineers Molecular Imaging, Knoxville, TN, USA


TERUMO INTERVENTIONAL SYSTEMSEstablishing Individualised SIRT dosimetry with The Holmium Platform

Upcoming EANM SIRT guidelines Dr. M.M. Weber (University Hospital Essen, Germany)

Starting with Holmium-166 SIRT in clinical practice Dr. A. Oliveira (São João Hospital, Portugal)

Individualized SIRT treatment planning & verification with the Holmium Platform: Practical aspects – PD Dr. R. Drescher (University Hospital Jena, Germany)

Latest Holmium data & The Clinical Roadmap Prof. Dr. M. Lam (UMC Utrecht, Netherlands)

Future Innovations of Holmium-166 SIRT: Real time MR guided SIRT UMC, The Netherlands)

FI

NA

L P

RO

GR

AM

ME

| S

AT

EL

LIT

E S

YM

PO

SIA



SA

TE

LL

ITE

SY

MP

OS

IA | F

IN

AL

PR

OG

RA

MM

E

221220

Thursday, October 21, 2021 16:50 – 18:20, Channel 3

PEERVOICECurrent and Emerging Radiopharmaceuticals for Prostate Cancer: Is There a Role for Both?

Welcome and Introduction Neal Shore, MD, FACs (Myrtle Beach, South Carolina, USA)

Evolving Radiotherapeutic Landscape in Metastatic Prostate Cancer Ken Herrmann, MD, MBA (Essen, Germany)

The Patient Journey and the Place of Radiotherapies: Understanding How Patient Profiles Align With Clinical Evidence Joe O’Sullivan, MD, FRCPI, FFRRCSI, FRCR (Belfast, Northern Ireland)

Sequencing Radiotherapeutics in mPC: What Does the Data Tell Us? Neal Shore, MD, FACs (Myrtle Beach, South Carolina, USA)

Cases in Practice: Identifying the Right Time for Radiopharmaceuticals in Men with mPC Panel

“Ask the Faculty” and Take-Home Messages Neal Shore, MD, FACs (Myrtle Beach, South Carolina, USA) and Ken Herrmann, MD, MBA (Essen, Germany)

Friday, October 22, 2021 09:00 – 09:45, Channel 3

GE HEALTHCAREIntegrating PET Innovations into Practice

Clinical Translation of Digital PET/CT innovations Dr. Martin W Hüellner, PD, Dr. med., Department of Nuclear Medicine University Hospital Zurich / University of Zurich, Switzerland

An Evaluation of the Effects of PET timing Resolution Versus NEC on Image Quality Dr. Paul E. Kinahan PhD, Professor and Vice-Chair for Radiology Research, University of Washington, Seattle, USA


GE HEALTHCAREUtility of Amyloid PET in the Diagnosis of Dementia

Prof. Renaud Lhommel, MD, Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium

Prof. Bernard Hanseeuw MD PhD, Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium

Gill Farrar PhD (host), Global Medical Director, Neurology GE Healthcare


SIRTEX HEALTHCARESIRT with SIR-Spheres® Y-90 resin microspheres – Case by Case

Patient Case 1 – Downsizing (mCRC) Dr. Macarena Rodríguez-Fraile

CIRT – Patient Case 2 – Bilobar Treatment (HCC) Dr. Julia Brosch-Lenz

Patient Case 3 – Super-selective Treatment (HCC) Dr. Mathias Zacherl


BOSTON SCIENTIFICFrom HCC to Liver mCRC, accelerating treatment standards with Y-90 glass microspheres

What have we learnt from treating HCC? Prof. Niklaus Schaefer, Medical Oncology & Nuclear Medicine, Lausanne University Hospital, Switzerland

EPOCH study design & result Dr Manuel Weber, Nuclear Medicine, Essen University Hospital, Germany

Dose response & dose toxicity relationship for Y-90 glass SIRT in CLM Prof. Marnix Lam, Nuclear Medicine, University Medical Centre Utrecht, Netherlands


SPECTRUM DYNAMICSInnovations That Transform SPECT ImagingCZT-based detector technology with unique scanner designs:

clinical transformation of workflow; image quality and quantitation

Cardiology Imaging• The significance of Emission Based Attenuation Correction in Myocardial Perfusion Imaging: an AI Application for routine implementation: TruCorr• CZT SPECT Myocardial Blood flow role and relevance: clinical experience

SPECT/CT Imaging• Localization and characterization: Role of the VERITON-CT SPECT/CT camera in the diagnosis of parathyroid adenomas• Beyond Total-Body NM/CT Imaging: In vivo imaging with dynamic 3600CZT SPECT/CT; SUV quantitation impact in SPECT.

FI

NA

L P

RO

GR

AM

ME

| L

IST

OF

EX

HIB

ITO

RS



LIS

T O

F E

XH

IBIT

OR

S | F

IN

AL

PR

OG

RA

MM

E

223222

EXHIBITORS &SPONSORS

ABX-CRO advanced pharmaceutical services

Advanced Accelerator Applications, a Novartis company

Bayer AG

Blue Earth Diagnostics Ltd.

Borchardt Logistics GmbH

Boston Scientific

Bruker BioSpin

Centre for Probe Development and Commercialization (CPDC)

Chelatec SAS

Comecer

Curium

Cyclomedica Europe Ltd.

Eckert & Ziegler Strahlen- und Medizintechnik AG

Eczacibasi-Monrol Nuclear Products Co.

GE Healthcare

Hermes Medical Solutions

IRE-ELiT

Isotopia Molecular Imaging Ltd.

ITM Isotopen Technologien München AG

JSC Isotope / Rusatom Healthcare

Jubilant DraxImage Inc, dba Jubilant Radiopharma

Medi-Radiopharma Ltd.

Mediso Medical Imaging Systems Ltd

MILabs B.V.

MIM Software

MR Solutions Ltd.

NRG

Oncobeta GmbH

OncoSil Medical Ltd

Pars Isotope

PeerVoice

PMB-ALCEN

Point BioPharma

ROTOP Pharmaka GmbH

Polatom

Siemens Healthineers

Sirtex Medical Europe GmbH

Spectrum Dynamics Medical Ltd.

Sumitomo Heavy Industries Ltd.

Telix Pharmaceuticals Ltd

Tema Sinergie S.p.A.

Terumo Interventional Systems

Triskem International

United Imaging Healthcare Poland Spolka z o.o.

U.S. Department of Energy Isotope Program

Waters Corporation

AIMN - Italian Association of Nuclear Medicine

ANZSNM - Australian and New Zealand Society of Nuclear Medicine

AOFNMB - Asia Oceania Federation of Nuclear Medicine and Biology

ASNC - American Society of Nuclear Cardiology

BELNUC - Belgian Society of Nuclear Medicine

BNMS - British Nuclear Medicine Society

EACVI - European Society of Cardiology

EIBIR - European Institute for Biomedical Imaging Research

ESTRO - European SocieTy for Radiotherapy and Oncology

HSNM&MI - Hellenic Society of Nuclear Medicine and Molecular Imaging

IAEA

ICPO Foundation

JSNM - Japanese Society of Nuclear Medicine

KSNM - Korean Society of Nuclear Medicine

OGNMB - Austrian Society of Nuclear Medicine & Molecular Imaging

ONCIDIUM

SNMMI - Society of Nuclear Medicine and Molecular Imaging

TSNM - Turkish Society of Nuclear Medicine

UEMS/EBNM - European Union of Medical Specialists/Section and European Board of Nuclear Medicine

WFNMB - World Federation of Nuclear Medicine and Biology

Springer Nature

EARL

ESMIT

SASAI

LIST OFSO CIET Y B O OTHS

COMPANYPROFILES

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

225224

ABX-CRO advanced pharmaceutical services Forschungsgesselschaft mbH

Blasewitzer Strasse 78-80 01307 Dresden, Germany

[email protected]

Welcome to ABX-CRO!

We are an international CRO with a strong focus on molecular imaging and internal radiotherapy clinical trials. In addition to conducting clinical trials, we provide specialised end-to-end services including consultancy for instance in pharmacokinetics and radiopharmacology and put our inhouse image core lab and data management department at the service of your demands. Find out how your project could benefit from our experience: Chat with us here or send a message to [email protected]. We’re looking forward to your ideas!

Presenting QDOSE: The next step in MRT dosimetry:

Founded on more than 20 years of experience, we proudly present QDOSE as the flexible stand-alone software tool for safe, efficient and productive internal dosimetry. Providing a one-stop solution for multiple workflows, QDOSE is ready for your daily clinical routine use. Come over for a live demo session and explore how QDOSE can enhance your workflow.

Advanced Accelerator Applications, a Novartis company

4, rue de la Tour de l’île, 1204 Genève, Switzerland

[email protected]

http://www.adacap.com

At Advanced Accelerator Applications (AAA), we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology.

Advancing Nuclear Medicine by NRG

Westerduinweg 3 1755 LE Petten, Netherlands

https://www.advancingnuclearmedicine.com/ en/field-lab

Advancing Nuclear Medicine

by NRG

FIELD-LAB, an innovative joint R&D centre for nuclear medicine

NRG meets the need to accelerate the development of new nuclear therapies, usually hindered by high costs and the restricted availability of proper facilities and isotopes. FIELD-LAB has been created together with renowned Dutch Academic Medical Centres and dedicated industry partners, and was presented to the international nuclear medicine society early 2019.

Now we take the next step by presenting the progress we have made on three innovative projects:

- Lu-177 n.c.a.: the isotope for targeted therapy

- Pt-195m: to increase effectivity of cisplatin chemotherapy

- Pb-212: promising alpha therapeutic isotope for targeted therapy

Each a hot-topic in the academic nuclear medicine world.

We expect various publication-ready topics by 2022. Physical construction of FIELD-LAB will start end of 2020 with supply of R&D testbatches expected by the beginning of 2023.

The initiative is financially supported by the European Regional Development Fund (EU) and the Province of North Holland (NL).

Interested in becoming a FIELD-LAB partner? Please contact us via our website.

NRG - Nuclear. For life.

American Society of Nuclear Cardiology

9302 Lee Highway, Suite 1210 22031 Fairfax, United States of America

[email protected]

www.asnc.org

The American Society of Nuclear Cardiology (ASNC) is the international leader in education, advocacy, and quality in cardiovascular imaging, with 4,000 members worldwide. We provide our members with a variety of continuing medical education programs related to nuclear cardiology and cardiovascular computed tomography (CT).· We promote accreditation and certification in nuclear cardiology. We establish standards and guidelines for training and practice.· We serve as a representative in health policy and the principal advocacy voice for professionals in the field. Founded in 1993 by a group of nuclear cardiology specialists who sensed the need for a professional society dedicated solely to the needs of those who perform these procedures. ASNC’s membership is composed of cardiologists, radiologists, physicians, scientists, technologists, imaging specialists, and other professionals dedicated to the science and practice of nuclear cardiology.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

227226

Associazione Italiana di Medicina Nucleare (AIMN)

Via Farini, 81 20159 Milano, Italy

[email protected]

https://www.aimn.it

The official Italian Association of Nuclear Medicine and Molecular Imaging It is composed by more than 900 members, mainly nuclear medicine physician. The scope of the association is to widespread the knowledge of nuclear medicine filed and to share all the information about the molecular imaging.

Australian and New Zealand Society of Nuclear Medicine

PO Box 6178 3133 Vermont South, Australia

[email protected]

http://www.anzsnm.org.au

Founded in 1969, the ANZSNM is the major professional society for those practising Nuclear Medicine in Australia and New Zealand. Our focus is promoting excellence in Nuclear Medicine through education, research and a commitment to the highest professional standards. The Society uniquely includes Technologists, Physicists, Radiopharmacists, Physicians, Nurses, Chemists and others interested in the practice of Nuclear Medicine. It has close ties with other professional groups in Nuclear Medicine, most particularly, the Australasian Association of Nuclear Medicine Specialists (AANMS) which represents all practicing medical doctors. Radiologists, Cardiologists, and Oncologists may also participate and be involved in this area of healthcare.

Belgian Society of Nuclear Medicine

Avenue Hippocrate 10 1200 Brussels, Belgium

[email protected]

https://www.belnuc.be/

With currently over 300 members, the Belgian Society of Nuclear Medicine (better known as BELNUC) was founded in 1978 and is the prime scientific multidisciplinary organization welcoming all individuals active in nuclear medicine in Belgium, including physicians, physicists, engineers, radiopharmacists/chemists, technologists, scientists and students.

The focus of BELNUC is mainly on (i) organizing regular scientific meetings and seminars, in particular encouraging research and development by young individuals, (ii) promoting quality improvement, (iii) partnering with authorities and (iv) fostering relationships with the professional society of nuclear medicine with regards to daily practice, regulations, and reimbursement issues. You can keep up-to-date with the all activities of BELNUC on www.belnuc.be, or by following our Facebook page www.facebook.com/BELNUC, or subscribing to our newsletter by contacting our office at [email protected].

Our next major international event will be the BELNUC ’22 Antwerp Symposium on 6-7-8th May 2022. The preliminary program is now available at www.belnuc22.be. See you in Antwerp!

Blue Earth Diagnostics Ltd

Magdalen Centre 1 Robert Robinson Avenue OX4 4GA Oxford, United Kingdoms

[email protected]

https://www.blueearthdiagnostics.com/

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is an international molecular imaging company on a growth trajectory to develop and commercialise innovative, well-differentiated diagnostic solutions that inform patient care and drive future therapies in cancer. Formed in 2014, the Company’s success is driven by its management expertise, supported by a proven track record of rapid development and commercialisation of positron emission tomography radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics’ expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialisation of precision radiopharmaceuticals for potential use in diagnostic imaging and therapy. For more information, please visit: www.blueearthdiagnostics.com.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

229228

Borchardt Logistics GmbH

Fasanenweg 7c 65451 Kelsterbach, Germany

[email protected]

http://www.borchardt-logistics.com

Ultra Sensitive Global Logistics, worldwide radioactive transports.

Boston Scientific

Rue René Caudron 2, Parc du Val St Quentin 78960 Voisins-le-Bretonneux, France

http://www.bostonscientific.eu/

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.eu and connect on Twitter and Facebook.

British Nuclear Medicine Society

Sir Colin Campbell Building, Triumph Rd NG7 2TU Nottingham, United Kingdom

[email protected]

http://www.bnms.org.uk

The British Nuclear Medicine Society (BNMS) established in 1966 is the only independent UK forum devoted to all aspects of Nuclear Medicine. The BNMS represents all craft groups in nuclear medicine and provides advice and guidelines for all those who practice nuclear medicine. The BNMS is concerned with promoting the clinical benefits of nuclear medicine and supporting the clinical practice, education, research and development of nuclear medicine within the UK. It is also active internationally in supporting our colleagues in all aspects of nuclear medicine practice. Membership is open to those who have a substantial interest and involvement in the provision of nuclear medicine services in the UK and overseas. The official journal of the Society is Nuclear Medicine Communications. Officers of the Society: Dr John Buscombe, President, Mrs Jilly Croasdale, Honorary Treasurer, Dr Richard Graham, President Elect, Dr Stewart Redman, Honorary Secretary. At the BNMS booth, delegates can find: • Information on BNMS membership - discount to new members signing up at the meeting. • Information about future meetings in the UK • BNMS Brochures and Publications • Answers to any other questions regarding the BNMS Pass by our stand for a chance to win free attendance at our Spring Meeting 2021 which will be held at the ICC Waterfront, Belfast in May 2021.

Bruker BioSpin GmbH

Rudolf-Plank-Str. 23 76275 Ettlingen, Germany

[email protected]

https://www.bruker.com/en/products-and-solutions/preclinical-imaging.html

Bruker BioSpin - Innovation with Integrity

Bruker offers advanced preclinical imaging solutions for a broad spectrum of application fields, such as oncology, neurology, cardiology, inflammation, infectious diseases, cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. Our range of techniques includes Magnetic Resonance Imaging (MRI), Nuclear Molecular Imaging with Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), micro-CT (Micro Computed Tomography), and Magnetic Particle Imaging (MPI). By combining our novel PET, proven micro-CT and outstanding MRI technologies, we make translational multi-modal imaging more accessible to the research community and offer optimal solutions for laboratories. All while keeping in mind that software, animal handling and lab workflow is a key part of any laboratory.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

231230

Centre for Probe Development and Commercialization (CPDC)

1280 Main St W, Hamilton ON L8S 4L8, Kanada

[email protected]

https://www.imagingprobes.ca/

At the Centre for Probe Development and Commercialization (CPDC), we discover, develop, and distribute radiopharmaceuticals. The CPDC was founded in 2008 as a non-for-profit Centre of Excellence for Commercialization and Research (CECR), specializing in radiopharmaceutical research and development. Since its inception, CPDC has gained expertise in GMP manufacturing of radiodiagnostics and radiotherapeutics and is now globally recognized as a leading GMP radiopharmaceutical manufacturing Contract Development and Manufacturing Organization (CDMO). CPDC uniquely offers the full range of scientific, technical, regulatory, logistics and business expertise combined with the full specialized infrastructure required to translate radiopharmaceuticals to the clinic and provide them to the commercial marketplace. With its superb experienced team and in collaboration with academic and pharma partners, CPDC has achieved several milestones including completion of over 30 radiopharmaceutical discovery, development, and manufacturing programs and translating over a dozen radiopharmaceuticals into clinical development, which currently support more than 25 clinical trials in 15 countries that span North America, Europe and Australia. CPDC succeeded in creating several companies in the radiopharmaceutical space, including Fusion Pharmaceuticals, and co-founded ARTMS and CanProbe with leading experts in the field. Currently, CPDC is transitioning towards a for-profit state of the art CDMO dedicated to clinical and commercial manufacturing of radiotherapeutics that will transform patients‘ lives by providing high quality drugs for the treatment of an array of diseases.

Chelatec

1 rue Aronnax 44800 Saint-Herblain, France

[email protected]

https://www.chelatec.com/

Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech.

With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.

Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package. All quality and non-clinical safety data required for translation of a radiopharmaceutical.

Our services cover/include:

- Bioconjugation

- Radioactive labeling

- Analytical controls (HPLC, iTLC/TLC, SDS-PAGE...)

- Stability studies (storage stability, plasma stability)

- In vitro assays (Binding affinity, IRF, internalization, cytotoxicity, autoradiography on tissue sections)

- In vivo investigations (Pharmacokinetics, biodistribution, efficacy, dosimetry).

COMECER

Via Maestri del Lavoro 90 48014 Castel Bolognese, Italy

[email protected]

https://www.comecer.com

Comecer, an ATS company, is a developer and manufacturer of high-tech systems in the field of Aseptic Processing and Containment for Pharmaceutical Industries. It operates in the Radiopharmaceutical sector through the production of shielding systems and equipment for special applications, both for large industrial groups and for research institutions.

Comecer designs and builds systems and equipment for the safe treatment of radioactive substances used in Nuclear Medicine, guaranteeing minimum exposure to the operator, total decontamination and inalterability in any working condition. In particular, Comecer excels in the field of radiochemistry where, on behalf of large industrial groups or research institutes, it manufactures shielding systems for special applications.

Comecer products, such as shielded hot cells, synthesis and dispensing isolators, solid target systems and radiopharma injectors, are used in the most advanced and prestigious research centres, universities, hospitals and pharmaceutical companies worldwide.

Curium

63, Avenue des Champs-Elysées 75008 Paris, France

[email protected]

Curium is the world’s largest nuclear medicine company with more than a century of industry experience. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.

To learn more, visit curiumpharma.com

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

233232

Cyclomedica Europe Ltd

Unit A5 Calmount Business Dublin 12 Ballymount, Ireland

[email protected]

http://www.cyclomedica.eu

Cyclomedica specialises in the diagnostic imaging field in lung health. It is known for the leading technology, the Technegas™ TechnegasPlus Generator.

Our vision, beyond PE drives our development from the diagnosis of pulmonary embolism, to embrace functional lung imaging through SPECT/CT to now emerge in the diagnostic contribution in clinical management of patients with airways diseases.

At Cyclomedica, our focus is to provide our customers with innovative Molecular Imaging solutions improving efficiency and effectiveness in patient care.

Our business is transforming and growing with the aim to explore new opportunities in order to deliver meaningful solutions and build our already strong service and product offering within the global market.

Eckert & Ziegler Medical

Robert-Roessle-Straße 10 13125 Berlin, Germany

http://www.medical.ezag.com

Eckert & Ziegler Medical is one of two business segments of the Eckert & Ziegler Group. With more than three decades of experience in the field, Medical represents our combined expertise in nuclear medicine, molecular imaging, radiation therapy and beyond, while always focusing customer success. We complement our wide-ranging portfolio of innovative high-quality technical solutions with the provision of versatile services such as development and contract manufacturing.

As a one-stop-shop for all your radiopharmaceutical needs our products include everything from hot cells to radiochemicals (e.g. Lu-177), radiopharmaceuticals (Yttriga, GalliaPharm®), radiosynthesis technology (Modular-Lab, KitLab) and radiochromatography equipment (e.g. AR-2000). Furthermore, we offer comprehensive solutions for LDR (IsoSeed®) and Ophthalmic Brachytherapy as well as X-ray therapy.

In addition the Eckert & Ziegler Group provides a wide range of sealed radiation sources for quality control in nuclear imaging, therapeutic radiology and biomedical applications.

Eczacibasi-Monrol Nuclear Products Co.

Rüzgarlıbahçe Mahallesi Kavak Sokak No.20 Beykoz İstanbul Turkey 34805 Istanbul, Turkey

[email protected]

https://www.monrol.com

Eczacıbaşı-Monrol Nuclear Products Co. is a leading developer, manufacturing, and distributor of radiopharmaceutical products in the Balkans, Middle East, North Africa and also Central & Eastern Europe. Eczacıbaşı-Monrol also carries out its expertise all around the world with its EU-GMP grade produced high-quality radiopharmaceuticals and unique logistics infrastructure.

Eczacıbaşı-Monrol has 7 world-class production facilities, 4 in Turkey, 2 in Europe and 1 in Egypt employing modern and environmentally responsible production technologies. The company also operates 7 cyclotrons in our affiliates. Eczacıbaşı-Monrol services regional nuclear medicine needs through 300 employees and more than 20 distributors, delivering high-quality and customer-oriented service to nuclear medicine centers in Turkey and more than 50 countries around the world.

European Association of Cardiovascular Imaging (EACVI)

European Heart House 06903 SOPHIA ANTIPOLIS Cedex, France

[email protected]

https://www.escardio.org/EACVI

The European Association of Cardiovascular Imaging (EACVI), a branch of the European Society of Cardiology, is a not-for-profit organisation. Everything we do is to support our 14,000 members worldwide and all healthcare professionals - cardiologists, technicians, nurses, basic scientists and allied professionals – specialising in cardiovascular imaging so they can deliver the best possible evidence-based care to patients.

Our activities are driven by volunteers who are renowned experts from across all imaging techniques: echocardiography, cardiovascular magnetic resonance, nuclear cardiology and cardiac computed tomography.

Our Mission: to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

235234

European Institute for Biomedical Imaging Research (EIBIR)

Am Gestade 1 1010 Vienna, Austria

[email protected]

www.eibir.org

The European Institute for Biomedical Imaging Research (EIBIR) is dedicated to the coordination of

research projects and aims to support the development of biomedical imaging technologies and the

dissemination of knowledge.

It is EIBIR’s mission to improve cooperation within the European biomedical imaging community,

and foster interoperability through research networking activities and common initiatives, with the

goal of improving the diagnosis, treatment, and prevention of diseases.

As a non-profit research organisation, EIBIR has helped scientists secure European funding for their

projects for 15 years offering professional research-related services from proposal preparation,

consortium building, to project management, communication, and dissemination. Over the years,

EIBIR has developed an excellent track-record in supporting international research consortia and

has helped scientists secure more than EUR 109 million in research funding.

European Society for Radiotherapy and Oncology (ESTRO)

Rue Martin V 40, 1200 Brussels, Belgium

[email protected]

https://www.estro.org/

About ESTRO

“Every cancer patient in Europe will have access to state of the art radiation therapy as part

of a multidisciplinary approach where treatment is individualised for the specific patient’s

cancer, taking account of the patient’s personal circumstances”

- ESTRO Vision 2030 –

The European Society for Radiotherapy and Oncology (ESTRO) is a non-profit and scientific organisation that fosters the role of Radiation Oncology in the multimodality treatment of cancer.

ESTRO promotes innovation, research and dissemination of science through its congresses, workshops, special meetings and peer-reviewed publications.

The Society also supports the professionals of Radiation Oncology in their educational development through a whole programme of teaching courses, online and onsite.

Do not miss on the virtual booth the announcements for ESTRO 2022, the next annual congress, the upcoming ICHNO-ECHNO 2022 conference and the Physics Workshop, the 2022 educational offer and our open access journals.

GE Healthcare

283, rue de la Minière 78 533 BUC, France

[email protected]

https://www.gehealthcare.co.uk

GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world. Visit our website www.gehealthcare.co.uk (EMEA zone) for more information.

Hellenic Society for Nuclear Medicine and Molecular Imaging (HSNM&MI)

44-46 Ippokratous street 10680 Athens, Greece

[email protected]

https://nuclear-medicine.gr/

Founded in 1968, by the renowned Honoured Member of the Academy of Athens for Sciences and Philosophy, Professor of Medicine Vassilios Malamos, HSNM&MI is one of the oldest European societies in Nuclear Medicine.

HSNM&MI aims:

• Scientific development of Nuclear Medicine and its biological applications.

• Contributing to research, study and optimization of Nuclear Medicine applications in Greece.

• Promoting Nuclear Medicine education in the context of continuing medical education

• Promoting cooperation of other disciplines in the field of Nuclear Medicine.

• Formulation, protection and compliance with radiation protection regulations, in accordance with the existing provisions, regarding handling, use and disposal of radioisotopes.

• Representation and cooperation of the Society’s representatives with the State, the European Union and international scientific bodies in general.

HSNM&MI has a total of 328 members, including Nuclear Medicine physicians and residents, Nuclear physicists, Technologists, Radiobiologists and Radiopharmacists.

HSNM&MI operates and acts as the main and only consultant for the Greek State, in any kind of issue including and interfering with Nuclear Medicine. Since the beginning, HSNM&MI has kept on collaborating worldwide with EANM, WFNMB and IAEA. In addition, HSNM&MI has a leading role concerning the promotion of Nuclear Medicine in the Balkan region, by contributing to the organization of BCNM congresses.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

237236

Hermes Medical Solutions

Strandbergsgatan 16 112 51 Stockholm, Sweden

[email protected]

https://www.hermesmedical.com/

At EANM 2021 Hermes Medical Solutions (HMS) is proud to show its latest products for visualisation, processing, remote and local reporting, management and storage of image data from multiple modalities within molecular imaging, nuclear medicine and radiology.

Visit us to find out you how you can:

Accelerate your PET/CT, PET/MR, and SPECT/CT reporting with the latest intuitive, fast and powerful Affinity Viewer®

Personalise the treatment of your patients with the most accurate and flexible CE-marked dosimetry software: HMS Dosimetry Suite includes Voxel Dosimetry® with Monte-Carlo dose simulation and theranostic dose prediction, single timepoint dosimetry, pre-and post-intervention dosimetry for SIRT, and organ dosimetry using OLINDA/EXM®.

Obtain superior quantification and image quality for any radionuclide and SPECT/CT camera with HMS’ latest SUV-SPECT® quantitative SPECT reconstruction, now with Bayesian noise suppression penalty factors, anatoImprove your lung analysis with HMS’ dedicated and automated tools for Lung VQ SPECT and Lung Lobe Quantification using CT-derived anatomical information.

HMS’ leadership within molecular imaging and NM is built upon 45 years of continual innovation, strong customer service and sound clinical expertise. HMS provides the most comprehensive independent, vendor-neutral software suite for diagnosis and treatment planning, making precision personalised medicine a reality.

ICPO Foundation

Humboldtstraße 29 65189 Garching / Munich, Germany

[email protected]

www.icpo.foundation

We enable cancer patients worldwide to gain access to highly effective theranostic treatments in Precision Oncology.

International Atomic Energy Agency

Wagramer Strasse 5 Vienna, Austria

https://www.iaea.org/

The International Atomic Energy Agency is the world‘s central intergovernmental forum for scientific and technical cooperation in the nuclear field. It works for the safe, secure and peaceful uses of nuclear science and technology, contributing to international peace and security. The IAEA’s aim is to help build Member States’ capacities to support them in establishing high-quality health care worldwide. Since the IAEA began its work in human health over 50 years ago, the use of nuclear techniques in nuclear medicine and radiology has become one of the most widespread peaceful applications of atomic energy. The IAEA assists Member States with the coordination of research projects, expert guidance, equipment, the development of internationally harmonized guidelines, training and knowledge exchange

IRE ELiT

Avenue de l’Espérance, 1 6220 Fleurus, Belgium

[email protected]

http://www.ire.eu

IRE ELiT is a radiopharmaceutical company founded in 2010 to develop radiopharmaceutical drugs used in molecular imaging and therapy.

IRE ELiT places quality, reliability and services at the center of all its concerns to secure the supply and easy use of radiopharmaceuticals for its customers worldwide. IRE ELiT’s portfolio of customer-oriented solutions includes radioisotopes for diagnosis or treatment purposes, as well as equipment dedicated to their preparation.

Our main product is a Ge-68/Ga-68 generator, Galli Ad, a simple and innovative PET imaging solution used, mainly, for NET tumors and recurrent prostate cancers. Galli Ad is a fully integrated and closed system to get rapidly highly concentrated and very pure radiopharmaceuticals preparations minimizing loss of activity. Its innovative design, specific for cold kits reconstitution, limits the risk of misuse and contamination. This generator can be used manually or connected to a synthesis module.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

239238

Isotopia Molecular Imaging

39 Alexander Yannai St. 4927735 Petah Tikva, Israel

[email protected]

https://isotopia.co.il/

Lifesaving radio pharma solutions for theragnostic purposes We understand that delivering the right treatment to the patient at the right time could be the tipping point in the patient’s care.That’s where our gold standard treatment and professional service make all the difference. We supply Lu -177 N.C.A and C.A tailor-made to your requirements, and work with you closely to devise the optimal solution to support your growth. Isotopia around the globe Isotopia has enhanced its external distribution across North America by partnering with the Canadian CPDC to build a local manufacturing site, designed to:

• Reduce complex logistics and customer costs.

• Upscale production, shorten delivery time and reduce material loss.

• Ensure timely and consistent delivery to all locations.

• Respond to changing demand.

We guarantee:

• Availability – a weekly supply of Lu-177 N.C.A and C.A all year round.

• Minimum material loss – thanks to our unique V-shaped vial.

• Maximum safety – while minimizing user exposure with a unique plexiglass insert.

We are committed to meeting your acute need for round-the-clock availability and responsiveness to solve problems in real-time. At the moment of truth, we are there! Instant communication (even with a 10-hour time difference) and NO middle man.

ITM Isotopen Technologien München AG

Walther von Dyck Strasse 4 85748 Garching, Germany

[email protected]

https://itm-radiopharma.com

ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline combining its superior radioisotopes with targeting molecules to create precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.

Japanese Society of Nuclear Medicine

NISSHIN Bldg. 3-1-17, Nishi-Azabu, Minato-ku, Tokyo 106-0031, JAPAN

[email protected]

http://jsnm.org/english/

The Japanese Society of Nuclear Medicine was established in 1964 which currently has over 3,600 members. The JSNM has been working hard to promote the development of nuclear medicine through the collaboration with the SNMMI, EANM, AOFNMB (Asia and Oceania Federation of Nuclear Medicine and Biology), ARCCNM (Asian Regional Cooperative Council for Nuclear Medicine), World Federation of Nuclear Medicine and Biology (WFNMB) and individual societies of many countries.

JSC Isotope (ROSATOM)

Pogodinskaya Str. 22 119435 Moscow, Russia

[email protected]

http://www.isotop.ru/en/

Founded in 1958, Isotope JSC (part of Rusatom Healthcare JSC group) is a leading supplier of isotope products for nuclear medicine, focused on increasing availability of medical isotopes worldwide. Located in Moscow, Isotope JSC is responsible for the distribution and marketing of isotope products manufactured by the enterprises of ROSATOM State Corporation. We offer high quality, cost-effective isotope-based products including radiopharmaceuticals and medicinal devices, as well as a wide range of raw materials (radioisotopes, stable isotopes). We supply over 20 critical medical isotopes to the international markets, among which are such core products as Mo-99, I-131, Lu-177, Ac-225, Ge-68/Ga-68 generators and others.

Isotope JSC is a major supplier of medical isotopes to Latin America and Asia and one of the active members of European isotope market. Over 100 foreign companies in 50 countries across the world and around 600 Russian companies including healthcare institutions, manufacturing facilities, and scientific & research organizations are among partners of Isotope JSC.

We set a key target to contribute to the development of the modern nuclear medicine treatments and technologies to improve patients’ quality of life.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

241240

Jubilant Radiopharma

16751 TransCanada Hwy H9H 4J4 Kirkland, Canada

[email protected]

http://www.jubilantradiopharma.com

Jubilant Radiopharma is an industry leading radiopharmaceutical company committed to driving the value of cardiac PET as a vital imaging modality, because they recognize the important role it plays in evaluating cardiac physiology and function. Whether you are looking to start a program or want to enhance your current practice; we are here to help you, every step of the way.

Partnering with Cyclomedica in the EEA, they will provide expanded access to the next-generation PET products to enhance the way patients with known or suspected coronary artery disease are both diagnosed and managed.

Korean Society of Nuclear Medicine

Gumhopalace BD #1705, Jibong-ro 29, Jongro-gu 03121 Seoul, South Korea

[email protected]

https://ksnm.or.kr/

The Korean Society of Nuclear Medicine (KSNM) was established in 1961.

The official bimonthly journal is ‘Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging)’ and publishes papers about nuclear medicine and related sciences.

The KSNM hosts Annual Spring and Autumn Meetings with academic symposiums, scientific sessions, award ceremonies, and training courses.

Currently, there are 130 institutions with nuclear medicine facilities in Korea. 395 board certified specialists and over 160 scientists dedicated to the field of nuclear medicine are members of the KSNM.

The KSNM works closely with the government and industry to promote progress of nuclear medicine in Korea.

Clinical practice and research applying molecular imaging and radiopharmaceuticals will continue to flourish, and the KSNM is proud to lead the advancement of the field of nuclear medicine in Korea..

Medi-Radiopharma Ltd.

Szamos u. 10-12. 2030 Érd, Hungary

[email protected]

https://mediradiopharma.com/

Medi-Radiopharma Ltd. (MRP) has more than 25 years of experience in developing, manufacturing and supplying radiopharmaceutical products to customers around the globe. MRP specialises in the production and supply of generic in-vivo kits for Tc-99m labelling used in nuclear medicine. By potentially enabling accurate early diagnosis and treatment of cancer, as well as heart, brain and bone diseases, our world-class products empower our cutomers with effective treatment and proven patient outcomes. MRP hold a diverse portfolio of proven products registered in 70 countries world-wide. We pride ourselves on our ability to deliver a steady supply of quality diagnositc and therapy solutions, with the highest standards of quality and safety assured at every stage. The company holds valid Manufacturer’s Authorisation, Certificate of GMP Compliance of a Manufacturer, Wholesale Distribution Authorization, Certificate of GDP Compliance of a Wholesaler Distributor, Good Laboratory Practice (GLP) Certificate, ISO certificate and relevant authorization for the manufacture and wholesale distribution of radiopharmaceuticals. MRP, together with its partner company, Radiopharmacy Laboratory Ltd., is also involved in the development of therapeutic radiopharmaceuticals. The company is open for requests and suggestions on new research and development projects in the field of nuclear medicine.

Mediso Medical Imaging Systems

Laborc str.3. 1037 Budapest, Hungary

https://mediso.com

Mediso works in the field of nuclear medicine since 1990 with a profile of development, manufacturing, selling and servicing molecular imaging multi-modality devices. It offers complete solutions from hardware design to evaluation and quantification software for clinical patient care and preclinical research.

With its 30-years expertise, 1,300+ clinical cameras, Mediso is within the leaders in clinical patient care. Besides a unique triple modality clinical SPECT-CT-PET hybrid system, Mediso launched the new AnyScan® TRIO family which has a triple head SPECT detector design and dedicated multipinhole collimation technology.

Mediso has a leader position in the preclinical nuclear imaging market with 250+ commissioned preclinical cameras around the world. Beyond the market leading nanoScan® PET/CT and SPECT/CT, Mediso launched the world’s first integrated PET/MRI and SPECT/MRI systems. Further on 3T and 7T cryogen-free magnets and PET insert have been added to the product line, resulting in the largest install base of integrated PET/MRI systems.

Products are sold directly or through a network of distributors with over 1500 imaging systems for clinical and preclinical imaging operating in 100+ countries around the globe.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

243242

MILabs

Duwboot 7a 3991 CD Houten, Netherlands

[email protected]

MILabs is a leading innovator in preclinical PET, SPECT, Optical, and X-ray CT imaging systems, available as stand-alone imaging devices or in any combination in a single integrated scalable platform. The scientific community recognizes all modalities for superior resolution and image quality. MILabs’ systems have received many international awards, and advanced preclinical imaging applications have been published by hundreds of satisfied users. By combining PET, SPECT, Optical, and CT on a single in-line platform, MILabs has introduced the first commercial system to exploit the many symbiotic strengths such as:

• Simultaneous Multi-isotope PET-PET and PET-SPECT imaging

• Sub-mm theranostic imaging including alpha- and beta-emitting radiotherapy isotopes

• Quantitative CT-guided Optical Tomography.

This single-pass in-vivo imaging platform with synergistic multi-modal capabilities paves the way for rapid translation of precision medicine from bench to bedside.

MIM Software Inc.

25800 Science Park Dr #180 44122 Beachwood, United States of America

[email protected]

https://www.mimsoftware.com/

MIM Software Inc. provides a broad range of applications and solutions that support Radiology and Nuclear Medicine’s role in improving patient care. MIM Software’s Nuclear Medicine Solutions empowers both physicians and technologists to work harmoniously through the use of a common platform and set of tools for PET/CT, SPECT, and MRI.

MIM Encore® provides advanced visualization, image registration, segmentation, and analysis tools that are well-equipped to manage the latest advances in theranostics and other fields. MIM SurePlan™ MRT offers tools to support the feasibility of Molecular Radiotherapy Dosimetry within the busy Nuclear Medicine workflow. Quantitative images are needed to calculate accurate dosimetry, and SPECTRA Quant® provides a vendor-neutral SPECT reconstruction method that pairs dynamically with existing SPECT/CT cameras.

With MIM Software’s Contour ProtégéAI™ solution, clinicians can standardize and expedite the normal organ segmentation workflow. Contour ProtégéAI features next-generation segmentation that utilizes machine learning algorithms.

MR Solutions Ltd

Ashbourne House The Guildway, Old Portsmouth Road GU3 1LR Guildford, United Kingdom

[email protected]

http://www.mrsolutions.com

MR SOLUTIONS GROUP develops and manufactures innovative MR, CT, PET and SPECT imaging solutions. All scanners are interchangeable between each other for multi-modality imaging.

The company is the worldwide leader in high-field cryogen-free MR and delivers systems up to 9.4T with a bore size up to 42 cm. This technology has exclusive features such as rotating the system to 90° and to change the field within few minutes. It doesn’t require pipes and heavy site building therefore the installation cost is extremely low.

PET/MR imaging is possible up to 9.4T simultaneously. PET and SPECT scanners are dissociable within a few minutes from the MR and pluggable onto the CT. It avoids duplicating the scanners for multi-modality imaging.

Oncidium foundation

Rue Emile Francqui 6 (boîte 5) 1435 Mont-Saint-Guibert, Belgium

[email protected]

https://www.oncidiumfoundation.org/

The Oncidium foundation is dedicated to supporting Radiotheranostics (RT) for cancer care in view of enhancing access, globally. It strives to connect patients, practitioners, and experts in the Nuclear Medicine field by raising awareness and improving access to cancer treatments and clinical trials worldwide. It also searches and provides answers to the questions of who, what, when, where, why, and how regarding RT.

Together, let’s commit to enhance Access | Education | Hope.

Access – Make Radiotheranostics available, globally.

Education – Raise awareness to promote precision medicine and the benefits of RT for cancer therapy.

Hope – When other cures are not an option and support RT by financing specific therapy costs and their development worldwide.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

245244

OncoBeta GmbH

Schleißheimer Str. 91 85748 München, Germany

[email protected]

http://www.oncobeta.com

OncoBeta® GmbH with its headquarters in Garching near Munich, is a privately held medical device and radiochemical company specialized in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. Since 2019 OncoBeta® GmbH produces tungsten (wolfram)-188/rhenium-188 (188W/188Re) Generators for commercial use.

OncoSil Medical

Suite 503, Level 5 15 Blue Street 2060 North Sydney, NSW, Australia

[email protected]

http://oncosil.com

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes for people living with cancer by utilising the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in combination with chemotherapy.

OncoSil is our brachytherapy device. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs1.

We believe in our technology and its ability to have a truly positive impact in Oncology.

Reference:

1. Skowronek J. J Contemp Brachytherapy 2017; 9: 581-589.

OGNMB - Austrian Society of Nuclear Medicine & Molecular Imgaing

Schmalzhofgasse 26, Top 5 1060 Vienna

[email protected]

https://www.ognmb.at

The OGNMB represents the field of nuclear medicine and molecular imaging in Austria with more than 250 individual and supporting members. It welcomes researchers and employees of all fields involved, including radiochemists, medical physicists, technologists, radiopharmacists and of course trained nuclear medicine specialists as well as those in training.

The annual congress of the OGNMB is organized 2022 the first time in Bad Ischl (Austria). You are cordially invited to attend the next International Austrian Winter Symposium, taking place from Jan 19 - 22, 2022. Please check the website (https://congress.ognmb.at/) for further information.

PARS ISOTOPE

No.88, west 23 St. Azadegan Blvrd. South Sheikh Bahaiee 1439955416 Tehran, Iran

[email protected]

http://www.parsisotope.com

Pars Isotope Co. is the leading producer and supplier of medical radioisotopes in the Middle East. With more than 50 products in the world of nuclear medicine, we supply different radiopharmaceuticals and solutions used in the treatment and diagnosis process. Based on our deep-seated knowledge and experience in radiopharmaceuticals production, we have succeeded to manufacture some unique radiopharmaceuticals and introduce different solutions to the international market. The most highly prized products in this range are PARSTEC (II) which is our TC-99m generator brand and PARS GalluGEN that is our Ge-68/Ga-68 generator.

To enhance the quality and quantity of medical products according to cGMP regulations Pars Isotope is involved in a project to implement new modern facilities for RRP, CKP, and PET in Iran.

Additionally, we are focused on the following activities according to our profession and capabilities:

– Production of 12 diverse types of Tc-99m cold kits.

– Production of 5 different types of Tc-99m peptide kits.

– Production of 5 types of radionuclide generators used in PET & SPECT.

– Production of 22 various ready-to-use radiopharmaceuticals in diagnostics and therapeutics.

– Production of 7 different types of radiochemicals used in the production of radiopharmaceuticals.

– Development and optimization of advanced methodologies in the production of radiopharmaceuticals.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

247246

PeerVoice

1, rue Hildegard von Bingen L-1282 , Luxembourg

http://www.peervoice.com

PeerVoice understands that today’s healthcare professionals are expected to stay up to date with the latest medical information and to demonstrate continual improvements in patient care, but are often challenged to find the time. We facilitate excellence in clinical practice through live and online education designed to positively impact patient care. You can trust us to provide:

– Education designed to eliminate specific knowledge and/or practice gaps

– Objective discussion of the best-available evidence and treatment guidelines

– Practical clinical perspectives from internationally-renowned faculty

– An easy-to-use online educational platform that allows you to control how, when and where you learn

PMB-Alcen

Route des Michels CD56 Chemin de la Corneirelle 13790 Peynier, France

[email protected]

https://www.imigine.com

Located near Aix-en-Provence, in France, PMB is a 130-employee SMB. With a strong expertise in brazing, the company designs and manufactures complex mechanical assemblies and components (ceramic-metal, radio-frequency…), linear particle accelerators and cyclotrons. PMB is part of the French industrial group ALCEN.

PMB has developed a cutting-edge, automated radiopharmaceutical production system for PET imaging, combining a cyclotron with a robotized radiochemistry room, complete with an automated quality control device. A 12 MeV superconducting cyclotron produces 18F, 11C and 68Ga radio-isotopes, which are used to label a targeting agent in a robotized radiochemistry room. Quality control is then carried out through an automated process to test the synthesized molecule.

iMiGiNE provides an unprecedented solution to current limitations in the radiopharmaceutical production and distribution process, by relocating the production close to the patient and expanding the spectrum of possibilities in the field of molecular imaging and theranostics. Furthermore, by allowing same-day diagnosis with multiple more specific radiopharmaceuticals, iMiGiNE improves patient care.

POINT Biopharma Inc

4850 West 78th Street 46268 Indianapolis, Indiana, United States of America

https://www.pointbiopharma.com/

POINT Biopharma Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), and manufacturing technology to revolutionize theragnostic drug development and radioligand commercialization.

ROTOP Pharmaka GmbH

Bautzner Landstraße 400 01328 Dresden, Germany

[email protected]

http://www.rotop-pharmaka.de

ROTOP Pharmaka is a leading German pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With more than 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships.

Our portfolio includes:

• ROTOP Pharmaka | GMP production of Tc-99m cold kits

• ROTOP Radiopharmacy | GMP production of radioactive radiopharmaceuticals

• ROTOP Innovation Center | Full CRO Services, incl. API and kit development

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

249248

Siemens Healthcare GmbH

Henkestraße 127 91052 Erlangen, Germany

https://www.siemens-healthineers.com

At Siemens Healthineers, our purpose is to drive innovation to help humans live healthier and longer. Through our products, services and solutions we help physicians, medical staff, and healthcare providers prevent illnesses from occurring and to correctly diagnose and determine the right treatments for people who do become ill – resulting in fewer complications, shorter hospital stays, and faster patient recovery.

Our mission is to enable healthcare providers to increase value by expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. With our comprehensive portfolio – from in-vitro diagnostics and imaging to therapy and follow-up care – we address the complete care continuum for many of the world’s most threatening diseases.

Every hour, more than 240,000 patients are touched by technologies provided by Siemens Healthineers. We are at the center of clinical decision making with almost three-quarters of all critical clinical decisions influenced by our solutions. We are a leading medical technology company with over 120 years of experience and more than 65,000 highly dedicated employees around the globe who are innovating every day, truly shaping the future of healthcare.

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33 53227 Bonn, Germany

[email protected]

http://www.sirtex.com

Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer.

Our current lead product is a targeted radiation therapy called SIR-Spheres® Y-90 resin microspheres.

SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

SIRT is a minimally invasive treatment that delivers high doses of high-energy beta radiation directly to the tumours.

For further information please visit www.sirtex.com.

Learn more about Sirtex in our interactive virtual booth https://www.sirtexvirtualbooth-emea.com

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

1850 Samuel Morse Dr. 20190 Reston, United States of America

[email protected]

www.snmmi.org

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI strives to be a leader in unifying, advancing and optimizing molecular imaging, with an ultimate goal of improving human health. With 14,000 members worldwide, SNMMI represents nuclear and molecular imaging professionals, all of whom are committed to the advancement of the field.

Spectrum Dynamics Medical

rue de Lausanne 31 1110 Morges, Switzerland

[email protected]

http://www.spectrum-dynamics.com

Spectrum Dynamics is spearheading the transformation of SPECT imaging systems from analog to digital detection technology, enabling hospitals and clinicians to provide superior healthcare services with improved image quality, efficiency and quantitative clinical applications.

Spectrum Dynamics launched the world first digital cardiac dedicated SPECT system – the D-SPECT® CARDIO system – in 2007.

The D-SPECT employs digital detectors made of Cadmium Zinc Telluride (CZT), which along with ingenious hardware design, proprietary software and algorithms, enables imaging of cardiac patients at unprecedented speed, at a low radiation dose, and with superior image quality. The D-SPECT is the platform for advanced clinical applications such as Dual Isotope Imaging, Dynamic Imaging and Emission Map Attenuation Correction for Myocardial perfusion imaging.

In 2018, Spectrum Dynamics launched its digital SPECT-CT system: VERITON-CT®, 80 cm bore, available in 16-slice or 64-slice configuration.

VERITON-CT is the first 360° ring-shaped digital SPECT/CT enabling total body 3D imaging at high speed, low radiation dose, and with significant improvement in image quality. With 360-CZT, routine planar clinical applications leap to 3D imaging, with significant benefits for patients and clinicians.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

251250

Springer Nature

Tiergartenstrasse 17 69121 Heidelberg, Germany

[email protected]

http://www.springernature.com

Springer Nature advances discovery by serving the whole research community. All the research we publish is robust and in the best possible format to be discovered, accessed, used, re-used and shared. Springer Nature is home to brands including Springer. Please visit springernature.com and @SpringerNature

Sumitomo Heavy Industries,Ltd.

ThinkPark Tower,1-1 Osaki 2-chome,Shinagawa-ku 141-6025 Tokyo, Japan

https://www.shi.co.jp/english/

Sumitomo Heavy Industries, Ltd. (“SUMITOMO”) is one of the largest heavy machinery companies in Japan and manufactures various machinery and equipment, such as VLCC tanker, power boiler, plastic machinery, power transmission equipment and accelerator.

In the field of accelerator, with long experiences, Sumitomo produces medical related equipment, i.e. proton therapy system and PET (“Positron Emission Tomography”) radio-tracer production system. Regarding PET radio-tracer production system, Sumitomo is the leading manufacture of cyclotrons as well as various synthesizers, hot cell and ancillary equipment with majority of market share in Asia. Sumitomo has an experience of delivering the PET cyclotron system over 30 years and delivered more than 200 PET systems in Asian countries, i.e. Japan, South Korea, China, Taiwan, Thailand, Malaysia, India, Philippines and Iraq.

Telix Pharmaceuticals

Rue de Hermée 255 4040 Herstal, Belgium

https://telixpharma.com/

Telix was created to deliver on the promise of nuclear medicine.

Nuclear medicine has historically suffered from a lack of commercial critical mass and commitment to late-stage product development. Molecularly-targeted radiation (MTR) potentially offers better-informed treatment decisions and truly personalised therapy. Our product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer.

We are an experienced team of drug developers, clinicians and executives, with a passion for radiation biology and oncology. Telix’s pipeline currently focuses on unmet needs in cancer care, specifically in prostate, renal (kidney) and glioblastoma (brain) cancer. We are also keenly interested in partnership and in-licensing opportunities to further expand our portfolio.

In December 2018, Telix acquired ANMI SA, a leader in the field of radiopharmaceutical development. The ANMI team brings a wealth of innovation and experience in the streamlined development and production of novel radiopharmaceuticals. For more information about ANMI, visit anmi.be.

We are focused on the development and commercialisation of clinical-stage oncology programs.

Telix Pharmaceuticals is focused on the development and commercialisation of several clinical-stage oncology assets in renal cancer, prostate cancer and brain cancer.

We are also actively exploring indication expansion opportunities for our programs and platforms.

Tema Sinergie

Via Malpighi, 120 48018 Faenza, Italy

[email protected]

http://www.temasinergie.com

Professionalism, proactivity, passion and business intelligence are features that have distinguished us every day since 1985.

Over 30 years of experience, together with continuous research, have allowed to develop a complete range of products and services that represent, both in Italy and worldwide, a fundamental landmark for all professionals dealing with ionizing radiations.

From synthesis and dispensing hot cells, to dose drawing systems, radiopharmaceutical injectors, monitoring systems and much more, Tema Sinergie is the ideal partner for each and every application within the field of Nuclear Medicine.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

253252

Terumo Interventional Systems

Interleuvenlaan 40 3001 Leuven, Belgium

https://www.terumo-europe.com/en-EMEA

Terumo is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Terumo Interventional Systems is working in partnership with Interventional Radiologists and Nuclear Medics within Interventional Oncology to ensure they have access to high quality tools for their patients. This partnership is based on Terumo’s comprehensive range of access to therapeutic technology and services to support healthcare professionals with their patient needs.

QuiremSpheres™ Holmium-166 microspheres, QuiremScout™ Holmium-166 microspheres and Q-Suite™ imaging software make up The Holmium Platform: three integrated products which aims to individualize SIRT at its full potential.

QuiremSpheres™ are the first Holmium-166 microspheres on the market which brings a wide range of benefits from higher dose rate, to optimized imaging capabilities.

QuiremSpheres™ are also the first SIRT microspheres to be designed with scout dose technology, QuiremScout™, which for the first time utilizes the same particle for the work up and the therapy, which aims to optimize patient selection and advance treatment planning using our Q-Suite™ imaging software. This CE-marked and in-house designed treatment planning software is also used for dose verification following the SIRT treatment to ensure you have delivered the dose you planned and will help to drive treatment efficacy and improve the outcomes for liver cancer patients.

TrisKem International

3 rue des Champs Géons 35170 Bruz, France

[email protected]

https://www.triskem-international.com/

TrisKem International develops, manufactures and commercializes selective resins for the separation and quality control of radionuclides for use in diagnosis and therapy such as Ga-67/8, Lu-177, Tb-161, Cu-61/4/7, Zr-89, Ge-68, alpha emitters, Ti-44/5, Sc-43/4/7 and many other radionuclides.

Further to its range of resins TrisKem also provides selective chromatography paper such as DGA Sheets (DGA,N & DGA,B) for quality control of radionuclides and generator effluents (Ra-223/Ac-225/Pb-212, Sr-90/Y-90, Ga-68,…), and other separation supports for rapid purifications and QC.

TrisKem’s resins are increasingly finding use in the production of radionuclides for radiopharmacy and nuclear medicine, and are employed by leading radionuclide manufacturers worldwide.

Our R&D team is constantly working on the development of new resins and methods in order to help you with your separation needs.

If you have a special separation need, you are willing to participate in a R&D project or you are looking for a partner to commercialize a new technology you have developed, please do not hesitate to contact us at [email protected].

Turkish Society of Nuclear Medicine (TSNM)

Cinnah Caddesi Pilot Sokak No: 10/12 0 6690 Ankara, Turkey

[email protected]

http://www.tsnm.org

The society organizes several scientific activities each year, national congresses in spring and a symposium dedicated on a different topic of interest in winter season and regular educational events called “School of Nuclear Medicine” designed for residents and young physicians by the experts of the scientific task groups involved within TSNM. Currently TSNM has 875 members including physicians, physicists, pharmacists and technologists. The official journal of TSNM is “Molecular Imaging and Radionuclide Therapy, MIRT” (http://mirt.tsnmjournals.org). MIRT is published in English and indexed in PubMed, PubMed Central, EBSCO and some other scientific indexes and provides open access to its content. The society also publishes an electronic journal, “Nuclear Medicine Seminars” which is in Turkish dedicated to educational articles on specific topics by the invited editors in each issue.

UEMS

24 Ruc de l’Industrie 1040 Brussles, Belgium

[email protected]

https://uems.eanm.org/

The European Union of Medical Specialists (UEMS) has existed for more than 50 years and is the political representative organisation for medical specialists in the European Union and associated countries. UEMS defined the basic principles in the field of training of European medical specialists to obtain a comparably high level of knowledge to allow free movement of specialists between member countries. Specialist Sections for each of the main disciplines practiced in the member states were created to coordinate and harmonise the specialist training and elaborate the criteria for the recognition of medical specialists. With successive enlargements of the European Union, the number of Specialist Sections gradually increased to 34. The UEMS created European “Boards”, working groups of the Specialist Sections, to guarantee optimal care by bringing the training of medical specialists to the highest possible level in the specialty concerned.

FI

NA

L P

RO

GR

AM

ME

| E

XH

IBIT

OR

PR

OF

ILE



O C T O B E R 2 0 - 2 3 , 2 0 2 1

EX

HIB

ITO

R P

RO

FIL

ES

| FI

NA

L P

RO

GR

AM

ME

255254

U.S. Department of Energy Isotope Program

1 Bethel Valley Road 37831 Oak Ridge, United States of America

[email protected]

http://www.isotopes.gov

The U.S. DOE Isotope Program supports the production and the development of production techniques of radioactive and stable isotopes that are in short supply for research and applications. Isotopes are high-priority commodities of strategic importance for the nation and are essential for energy, medical, and national security applications and for basic research. The goals of the program are to:

Produce and/or distribute radioactive and enriched stable isotopes that are in short supply, including valuable by-products and surplus materials, and perform related isotope services.

Maintain the infrastructure required to produce and supply isotope products and to perform related services.

Conduct R&D on new and improved isotope production and processing techniques that can make available new isotopes for research and applications.

The program also coordinates and supports isotope production at numerous universities, national laboratories, and commercial accelerator and reactor facilities throughout the nation to promote a reliable supply of domestic isotopes.

The National Isotope Development Center (NIDC) is funded by the DOE Isotope Program. It serves as an interface with the user community and manages the coordination of isotope production across the program facilities at Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge, and Pacific Northwest National Laboratories.ove the outcomes for liver cancer patients.

United Imaging Healthcare Poland Sp. z o.o.

ALEJE JEROZOLIMSKIE 142A/12/29 02-305 Warszawa, Poland

[email protected]

https://www.united-imaging.eu/

United Imaging Healthcare is dedicated to providing, developing and producing high-performance advanced medical imaging, radiotherapy equipment, and life science instruments, and offers intelligent digital solutions to customers worldwide. UIH was founded in 2011 and headquartered in Shanghai, with subsidiaries and R&D centers across China, the United States, United Arab Emirates, Australia, Poland, India and other parts of the world.

UIH has world-class talent including more than 140 scientists with global experience and more than 500 employees with rich R&D and management experience in the medical industry. 35% of our 5,800 employees are R&D personnel.

So far, 86 groundbreaking products have been launched, including a Total-Body PET/CT, HD TOF PET/MR, 3.0T MR and 640-Slice CT Scanner. All core technologies are developed in-house and have been globally or nationally recognized for world leading performance. Our products have been installed in 35 countries, including the U.S., Japan, Australia, New Zealand, Poland, Ukraine, India, UAE, Egypt, Morocco, South Africa, Argentina and Colombia.

With our mission “To Bring Equal Healthcare for All,” and our vision “Leading World Healthcare Innovation,” we are committed to creating more value for our customers and constantly improving the global accessibility of high-end medical equipment and services through in-depth cooperation with hospitals, universities, research institutions, and industry partners.

World Federation of Nuclear Medicine and Biology

San-Kanazawa Bldg.,1-14-29 920-0025 Kanazawa-shi, Ishikawa

[email protected]

http://www2.c-linkage.co.jp/wfnmb2022/

Welcome to the 13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB 2022) Booth.

WFNMB 2022 is now less than a year away. We are preparing to make a great conference for everyone, regardless of the infection status of COVID-19.

Let’s talk about the future of nuclear medicine and enjoy the Japanese “Omotenashi” in Kyoto and Kanazawa next September!

FI

NA

L P

RO

GR

AM

ME

| L

ET

TE

R O

F I

NV

ITA

TIO

NE A N M ’21 W O R L D L E A D I N G M E E T I N G

O C T O B E R 2 0 - 2 3 , 2 0 2 1

258

U S E F U L C O N T A C T S

SCIENTIFIC PROGRAMME EANM Executive Office

Ms. Susanne KoebeMr. Andreas Felser (Congress Manager)

Schmalzhofgasse 26/5, 1060 Vienna, Austria

Phone: +43 1 890 44 27

Fax: +43 1 890 44 27-9

Email: [email protected]

Web: eanm21.eanm.org

INDUSTRY EXHIBITION EANM Executive Office

Mr. Andreas Felser (Congress Manager)Mr. Alexander Berger Ms. Olga JoachimsthalSchmalzhofgasse 26/5, 1060 Vienna, Austria

Phone: +43 1 890 44 27

Fax: +43 1 890 44 27-9




REGISTRATION EANM Executive Office

Ms. Petra Neubauer

Schmalzhofgasse 26/5, 1060 Vienna, Austria

Phone: +43 1 890 44 27

Fax: +43 1 890 44 27-9



OPENING HOURS EANM Executive Office

October 20-23, 2021

08:00 to 18:00 CEST

USEFULCONTACTS

final programme - EANM 2021 - European Association of ...

Documents

Transcript of final programme - EANM 2021 - European Association of ...